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Background: Uncertainty about optimal red blood cell transfusion thresholds in cardiac surgery is reflected
in widely varying transfusion rates between surgeons and cardiac centres.
Objective: To test the hypothesis that a restrictive compared with a liberal threshold for red blood cell
transfusion after cardiac surgery reduces post-operative morbidity and health-care costs.
Design: Multicentre, parallel randomised controlled trial and within-trial cost–utility analysis from a
UK NHS and Personal Social Services perspective. We could not blind health-care staff but tried to blind
participants. Random allocations were generated by computer and minimised by centre and operation.
Setting: Seventeen specialist cardiac surgery centres in UK NHS hospitals.
Participants: Patients aged > 16 years undergoing non-emergency cardiac surgery with post-operative
haemoglobin < 9 g/dl. Exclusion criteria were: unwilling to have transfusion owing to beliefs; platelet,
red blood cell or clotting disorder; ongoing or recurrent sepsis; and critical limb ischaemia.
Interventions: Participants in the liberal group were eligible for transfusion immediately after
randomisation (post-operative haemoglobin < 9 g/dl); participants in the restrictive group were eligible for
transfusion if their post-operative haemoglobin fell to < 7.5 g/dl during the index hospital stay.
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Main outcome measures: The primary outcome was a composite outcome of any serious infectious
(sepsis or wound infection) or ischaemic event (permanent stroke, myocardial infarction, gut infarction or
acute kidney injury) during the 3 months after randomisation. Events were verified or adjudicated by blinded
personnel. Secondary outcomes included blood products transfused; infectious events; ischaemic events;
quality of life (European Quality of Life-5 Dimensions); duration of intensive care or high-dependency unit
stay; duration of hospital stay; significant pulmonary morbidity; all-cause mortality; resource use, costs
and cost-effectiveness.
Results: We randomised 2007 participants between 15 July 2009 and 18 February 2013; four withdrew,
leaving 1000 and 1003 in the restrictive and liberal groups, respectively. Transfusion rates after randomisation
were 53.4% (534/1000) and 92.2% (925/1003). The primary outcome occurred in 35.1% (331/944) and
33.0% (317/962) of participants in the restrictive and liberal groups [odds ratio (OR) 1.11, 95% confidence
interval (CI) 0.91 to 1.34; p= 0.30], respectively. There were no subgroup effects for the primary outcome,
although some sensitivity analyses substantially altered the estimated OR. There were no differences for
secondary clinical outcomes except for mortality, with more deaths in the restrictive group (4.2%, 42/1000 vs.
2.6%, 26/1003; hazard ratio 1.64, 95% CI 1.00 to 2.67; p= 0.045). Serious post-operative complications
excluding primary outcome events occurred in 35.7% (354/991) and 34.2% (339/991) of participants in
the restrictive and liberal groups, respectively. The total cost per participant from surgery to 3 months
postoperatively differed little by group, just £182 less (standard error £488) in the restrictive group, largely
owing to the difference in red blood cells cost. In the base-case cost-effectiveness results, the point estimate
suggested that the restrictive threshold was cost-effective; however, this result was very uncertain partly owing
to the negligible difference in quality-adjusted life-years gained.
Conclusions: A restrictive transfusion threshold is not superior to a liberal threshold after cardiac surgery.
This finding supports restrictive transfusion due to reduced consumption and costs of red blood cells.
However, secondary findings create uncertainty about recommending restrictive transfusion and prompt a
new hypothesis that liberal transfusion may be superior after cardiac surgery. Reanalyses of existing trial
datasets, excluding all participants who did not breach the liberal threshold, followed by a meta-analysis of
the reanalysed results are the most obvious research steps to address the new hypothesis about the
possible harm of red blood cell transfusion.
Trial registration: Current Controlled Trials ISRCTN70923932.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 60.
See the NIHR Journals Library website for further project information.
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Plain English summary
When patients lose blood during cardiac surgery, the oxygen-carrying capacity of the blood(haemoglobin) drops. Blood transfusion is thought to restore the oxygen-carrying capacity and a
patient’s haemoglobin usually guides doctors’ decisions about when to give a transfusion. However,
different hospitals and surgeons give transfusions at different levels of haemoglobin. The study investigated
whether or not giving fewer transfusions (by allowing the haemoglobin to fall lower) reduces the risk of
serious post-operative complications previously associated with transfusion.
Just over 2000 patients took part. They were allocated by chance into groups who were transfused at ‘low’
or ‘high’ haemoglobins. Almost all patients in the high group (92%), but only half of the patients in the low
group (53%), had a transfusion. Slightly more patients in the low group experienced serious complications
(infections, heart attacks, strokes, kidney and serious bowel problems) than in the high group (35% vs.
33%), but this was a small difference. However, more patients died in the low group than in the high group
(4.2% vs. 2.6%, respectively). We found no substantial differences between groups in other aspects
of patients’ recovery, including the duration of hospital stay, quality of life reported by patients or
lung complications.
Contrary to our original expectation, the trial showed that waiting to transfuse until lower haemoglobin is
reached might, in fact, be worse. It is particularly worrying that more patients died in the lower haemoglobin
group. We have recommended that more research be done to understand the reasons for this finding.
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Scientific summary
Background
Perioperative anaemia is common after cardiac surgery and is associated with an increased risk of morbidity
and mortality. Transfusion of allogeneic red blood cells is the preferred treatment for acute anaemia but
an ‘acceptable’ level of anaemia, and the risks and benefits of red blood cell transfusion, are unclear.
Defining what constitutes a safe and effective red blood cell transfusion strategy is important; observational
analyses suggest that reversing anaemia by transfusing red blood cells may worsen outcome, yet > 50%
of cardiac surgery patients are transfused. Randomised controlled trials (RCTs) have sought to answer the
question by comparing restrictive (lower haemoglobin) with liberal (higher haemoglobin) transfusion
thresholds. However, RCTs in cardiac surgery populations have had insufficient power and RCTs in
non-cardiac surgery populations, although generally supportive of restrictive practice, have recruited very low
proportions of patients with unstable cardiac disease. Transfusion guidelines increasingly recommend
restrictive transfusion but uncertainty about the safety of this strategy for cardiac surgery patients persists
and is reflected in large variations in transfusion practice.
Objective
The Transfusion Indication Threshold Reduction (TITRe2) RCT tested the hypothesis that a restrictive
threshold for red blood cell transfusion reduces post-operative morbidity and health-care costs compared
with a liberal threshold.
Methods
Study design
A multicentre parallel-group RCT with an economic evaluation.
Settings and participants
Seventeen specialist cardiac surgery centres in UK NHS hospitals took part. Patients aged > 16 years
undergoing non-emergency cardiac surgery were eligible if the haemoglobin fell < 9 g/dl post-operatively.
Exclusion criteria were: patients unwilling to have transfusion owing to beliefs; platelets, red blood cell or
clotting disorders; ongoing or recurrent sepsis; critical limb ischaemia; inability to give full informed
consent; and participation in another interventional research study. Participants gave written informed
consent before surgery and were only randomised after admission to intensive care units (ICUs) after
surgery, if the haemoglobin fell < 9 g/dl. Participants were followed up by post or telephone 3 months
after randomisation.
Interventions
Participants were randomised to a restrictive (transfuse if haemoglobin falls < 7.5 g/dl) or liberal threshold
(transfuse if haemoglobin falls < 9 g/dl), which was applied during hospitalisation after surgery. One red
blood cell unit was transfused, the haemoglobin rechecked and a second unit transfused only if the
haemoglobin remained below the relevant threshold. Physicians could transfuse, or refuse to transfuse, in
contravention of the allocated threshold but had to document the reason and the haemoglobin level.
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Randomisation and blinding
Randomisation was achieved with a secure internet-based system that generated the allocation using
cohort minimisation to balance allocations by centre and operation type, and concealed allocation until a
participant’s details were recorded. Physicians and nurses were not blinded to the allocation. We tried to
blind participants and tested whether or not this was successful by asking if they knew their allocation.
Outcomes
The primary outcome was a composite of a serious infectious (sepsis or wound infection) or ischaemic
event [permanent stroke, myocardial infarction, gut infarction or acute kidney injury (AKI)] in the 3 months
after randomisation.
Secondary outcomes were: red blood cells and other blood products transfused; infectious events;
ischaemic events; quality of life [European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L)]; duration of
ICU and high-dependency unit (HDU) stay; duration of hospital stay; significant pulmonary morbidity;
all-cause mortality; resource use, costs and cost-effectiveness.
Protocol adherence
Non-adherence was defined as (1) failing to transfuse red blood cells within 24 hours of breaching the
allocated threshold or (2) transfusing red blood cells when the haemoglobin level was above the allocated
threshold. Non-adherence was considered severe when it changed the classification of a participant as
transfused or not.
Sample size
The primary outcome frequency was estimated to be 17% and 11% in the liberal and restrictive groups,
respectively. A sample size of 1468 was required to detect this difference with 90% power and 5%
significance (two-sided test). The target sample size was inflated to 2000 to allow for uncertainty about
non-adherence, as higher than expected non-adherence would reduce power.
Statistical methods
All analyses were performed on an intention-to-treat basis and directed by a pre-specified analysis plan.
All outcomes were compared using mixed-effects methods, adjusting for operation type and centre. Binary
outcomes were analysed by logistic regression, time-to-event outcomes using Cox proportional hazards
models and EQ-5D-3L scores using mixed-effects mixed-distribution models.
Primary outcome frequencies in pre-specified subgroups were compared by estimating allocation by
subgroup interactions. Sensitivity analyses were performed for the primary outcome and for mortality.
Pre-specified observational analyses adjusting for potential confounding by conventional regression and
instrumental variable (IV) methods (using allocation as the instrument) investigated relationships between
number of red blood cells units transfused, minimum haemoglobin and red blood cell storage time with
morbidity and mortality.
A 5% significance level (two-sided) was applied for main treatment effects and subgroup analyses, and a
10% level for interactions between allocated group and time in longitudinal models. Likelihood ratio tests
were used. We did not adjust for multiple testing or a planned interim analysis.
Economic evaluation
A within-trial cost–utility analysis assessed the incremental cost and cost-effectiveness of a restrictive compared
with liberal transfusion threshold from the perspective of the UK NHS and Personal Social Services. The primary
outcome was quality-adjusted life-years (QALYs) estimated using the EQ-5D-3L. Resource use was collected
for all participants from surgery to 3 months postoperatively. The restrictive haemoglobin threshold was
considered as cost-effective if the incremental cost-effectiveness ratio fell below £20,000.
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Results
Trial cohort
Between July 2009 and February 2013, 11,483 patients were screened; 3565 consented to take part and
2007 were randomised. Four participants asked for their data to be excluded, giving an analysis population
of 2003 participants (1000 and 1003 in the restrictive and liberal groups, respectively). Treatment of
47 participants (28 and 19 in the restrictive and liberal groups, respectively) was discontinued. Twenty-five
participants (1.2%) could not be followed up.
Participant characteristics
Baseline characteristics were similar in the two randomised groups. Median age was 70.3 years
[interquartile range (IQR) 63.5–76.4 years] and 68.5% were men. Median European System for Cardiac
Operative Risk Evaluation was 5 (IQR 3–7). Most participants had undergone coronary artery bypass
grafting (CABG) (40.7%) or valve (30.5%) surgery. One-quarter of participants had a red blood cell
transfusion before randomisation (25.7%).
Success of blinding
At discharge, 15.1% of participants thought they knew their allocation, of whom 115 (75.6%) were
correct. At 3 months, more participants thought they knew their allocation (27.5%) but fewer (56.6%)
were correct.
Haemoglobin levels and transfusions
After randomisation, the mean nadir haemoglobin level was lower in the restrictive than the liberal group
by approximately 1 g/dl; 53.4% and 92.2% of participants in the restrictive and liberal groups, respectively,
were transfused after randomisation [risk ratio (RR) 0.58, 95% confidence interval (CI) 0.54 to 0.62;
p< 0.0001]. The median numbers of red blood cell units transfused were 1 unit (IQR 0–2 units) and 2 units
(IQR 1–3 units) in the restrictive and liberal groups, respectively. Use of other blood products was similar
across groups.
Non-adherence
One or more instance of non-adherence was documented in 30.0% and 45.2% of participants in the
restrictive and liberal groups, respectively. Severe non-adherence was reported for 9.7% and 6.2% in
the restrictive and liberal groups, respectively.
Primary outcome
The primary outcome occurred in 35.1% and 33.0% of participants in the restrictive and liberal groups,
respectively [odds ratio (OR) 1.11, 95% CI 0.91 to 1.34; p= 0.30]. Sensitivity analyses tested the
robustness of this result. When participants transfused before randomisation were excluded, the OR
increased (OR 1.23, 95% CI 0.97 to 1.54; p= 0.084). Including additional AKI events, identified from
routinely collected creatinine data, as primary outcome events increased the treatment effect (OR 1.20,
95% CI 1.00 to 1.44; p= 0.045). Two sensitivity analyses, excluding primary outcome events in the first
24 hours after randomisation and excluding AKI events not supported by a creatinine rise, did not change
the result. Restricting the primary outcome to serious events decreased the treatment effect (OR 0.99,
95% CI 0.77 to 1.27; p= 0.94). A further sensitivity analysis showed little heterogeneity between sites
(p= 0.65) and no indication that the OR tended to the null with increasing severe non-adherence. There
were no subgroup effects.
Secondary outcomes
There were more deaths in the restrictive than the liberal group [4.2% vs. 2.6%, respectively; hazard ratio
(HR) 1.64, 95% CI 1.00 to 2.67; p= 0.045]; two sensitivity analyses, excluding participants transfused before
randomisation and deaths within 24 hours of randomisation, shifted the HR away from the null. Percentages
of participants with significant pulmonary morbidity, duration of ICU/HDU and hospital stay and EQ-5D-3L
scores were similar across groups. Serious post-operative complications (excluding primary outcome events)
occurred in 35.7% (664 events) and 34.2% (648 events) of participants in the restrictive and liberal groups.
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Meta-analysis
A meta-analysis of mortality for TITRe2 and five earlier RCTs suggest an increased risk of death in the
restrictive group, of borderline statistical significance (RR 1.41, 95% CI 0.98 to 2.04).
Economic evaluation
Mean QALYs to 3 months were 0.18 in both groups (restrictive minus liberal difference= 0.0004, 95% CI
–0.0037 to 0.0045). The total costs from surgery up to 3 months were £17,945 and £18,127 in the
restrictive and liberal groups, respectively (mean difference –£182, 95% CI –£1108 to £744); the cost
difference was largely attributable to the difference in the costs of red blood cells. Several outliers
substantially influenced the average cost of participants in the liberal group, altering the direction of the
differences between groups when they were excluded.
In the base-case cost-effectiveness analysis, the point estimate suggested that the restrictive group was
more effective and less costly than the liberal group (i.e. dominant) and, therefore, cost-effective. However,
there was great uncertainty around these results partly owing to the negligible differences in QALYs gained.
Bootstrap replicates of the cost and QALY differences covered all four quadrants of the cost-effectiveness
plane, which shows that there is not a movement in one direction rather than another. There was a 43%
probability that the restrictive group dominated the liberal group but also a 20% probability of the reverse
scenario. There was a 65% chance that the restrictive group was cost-effective at a £20,000/QALY ceiling
ratio. One subgroup effect was significant; participants in the restrictive group with chronic pulmonary
disease or asthma gained a reduced number of QALYs compared with other participants (p= 0.003).
Observational analyses
A dose–response relationship between the number of red blood cell units transfused and occurrence of
the primary outcome or death was apparent in a conventional multivariable regression model (OR 1.19,
95% CI 1.06 to 1.35). However, an IV analysis contradicted this result (OR 0.89, 95% CI 0.75 to 1.06).
A multivariable regression model suggested that increasing haemoglobin level reduced the risk of primary
outcome or death, particularly for non-CABG patients (estimate for valve patients; OR 0.62, 95% CI 0.48
to 0.79). An IV analysis estimated a reduced effect for all surgery types (OR 0.83, 95% CI 0.64 to 1.08).
The third analysis investigating the effect of red blood cell storage time was infeasible.
Discussion
Main findings: study results
The frequency of the primary outcome did not differ between the restrictive and liberal groups. Subgroup
analyses showed no differences, contrary to beliefs that ‘at risk’ groups should be transfused at different
haemoglobin thresholds. More participants died in the restrictive group than the liberal group (4.2% vs.
2.6%, respectively). There were no differences in other secondary outcomes, including cost, between the
two groups. In the economic evaluation, differences in cost and effect between the two groups were
small. The cost-effectiveness result was very uncertain, although the restrictive threshold appeared to be
dominant (more effective and less costly).
Strengths and limitations
There was better than expected power with TITRe2 because the outcome frequency was higher than
expected. In addition, unlike previous trials, the trial only randomised participants who breached the liberal
threshold, preventing any dilution of the treatment effect by including similar numbers of untransfused
participants in both groups. TITRe2 was pragmatic and, therefore, should directly inform red blood cell
transfusion practice in cardiac surgery patients with haemoglobin levels< 9 g/dl in similar settings.
Transfusion thresholds were successfully implemented and there were few missing outcome data.
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The main limitation was our inability to blind health-care staff. However, the use of objective end points or
adjudication by blinded personnel protected against detection bias. The nature of protocol non-adherence
differed by group but only affected the overall transfusion rate in a small percentage of participants.
A second limitation was the unexpected way in which sepsis and AKI, less severe events, dominated the
primary composite outcome. A third limitation was that prospective data collection failed to identify AKI
events that were apparent from routinely collected serial creatinine data. The effects of the final two
limitations were investigated in sensitivity analyses.
Lessons for the future
The results of the trial lead us to reject the hypothesis that restrictive transfusion is superior to more liberal
transfusion in cardiac surgery. Our main analysis indicates no difference between the two strategies,
although, given the increased cost of more liberal transfusion, these results are still supportive of restrictive
practice. However, the results of our primary analysis notwithstanding, the secondary analyses create new
uncertainty about recommending restrictive transfusion after cardiac surgery. Importantly, the risk of death
was higher in the restrictive group and this finding strengthened in sensitivity analyses, although the trial
does not provide a clear explanation for this finding. Causes of death and severe adverse events that
preceded death did not suggest a mechanism. In addition to the mortality finding, a benefit from more
liberal transfusion was also suggested by sensitivity analyses of the primary outcome, excluding participants
who had received transfusion prior to randomisation and including AKI events based on serial creatinine
data. These findings do not lead us to recommend using a liberal threshold after cardiac surgery; however,
we believe that, collectively, they should lead to a new hypothesis that more liberal transfusion may
be beneficial.
This hypothesis is clinically plausible. Unlike previous trials, all participants in TITRe2 had symptomatic
cardiovascular disease, the principal indication for cardiac surgery, and a significant proportion will have
developed oxygen supply dependency in the immediate post-operative period. As cardiac surgery patients
are often at the limits of their cardiovascular reserve, they may constitute a high-risk group in whom more
liberal transfusion is beneficial.
Conclusion
A restrictive threshold is not superior to a liberal threshold after cardiac surgery.
Implications for health care
Our primary finding supports use of either transfusion threshold evaluated in the trial. In practice, it is likely
to lead to wider application of a restrictive strategy because this will reduce the consumption and cost of
allogeneic red blood cells.
Recommendations for research
Our findings show that transfusion is safe but uncertainty remains as to the correct haemoglobin threshold
or indication for transfusion at which the benefits outweigh the risks. We suggest that a more liberal
transfusion threshold of approximately 9 g/dl may benefit cardiac surgery patients and that this hypothesis
should be tested in a pragmatic trial. Identifying when the benefits of transfusion outweigh the risks is
not straightforward because red blood cell transfusion is inevitably associated with haemoglobin level and
the nadir haemoglobin level does not necessarily precede transfusion.
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Trial registration
This trial is registered as ISRCTN70923932.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Perioperative anaemia is strongly associated with adverse outcomes in cardiac surgery patients.1–3Transfusion of allogenic red blood cells is the preferred treatment to reverse acute anaemia and,
on average, > 50% of adult cardiac surgery patients receive a perioperative transfusion.4,5
Cardiac surgery consumes a substantial proportion of blood supplies – > 6% of all red blood cell use in the
UK occurs in cardiac surgery.6 Red blood cell transfusion is essential in some cardiac surgical patients for
the management of life-threatening haemorrhage. In most cases, however, decisions to give a red blood
cell transfusion are made because the haemoglobin concentration has fallen to a level or threshold at
which the physician is uncomfortable.2,7,8 The transfusion threshold varies across different cardiac surgery
units and between different surgeons, which contributes to the wide variation in blood usage observed in
cardiac surgical units (25% to 95%).4,5,9 The threshold variation stems from a lack of evidence regarding
what constitutes a safe level of anaemia following cardiac surgery.
Background and rationale
The clinical benefits of red blood cell transfusion beyond increasing circulating haemoglobin concentrations
are unclear. Observational analyses suggest that transfusion after cardiac surgery may not, in fact, improve
outcome where, in an apparent paradox, reversal of anaemia with transfusion has been shown to be
consistently associated with increased infection, low cardiac output state, acute kidney injury (AKI) and
death.2,10,11 In contrast, randomised controlled trials (RCTs) comparing a restrictive red blood cell transfusion
threshold (allowing a participant’s haemoglobin level to drop to a lower level before transfusing) with a more
liberal strategy (transfusing a participant at a higher haemoglobin level) have not demonstrated adverse effects
directly attributable to transfusion in patients undergoing major surgery or in the critically ill.12–14
The absence of harm from restrictive practice in RCTs combined with the evidence from observational
studies has been interpreted as being supportive of restrictive transfusion practice.15 Alongside the
well-documented risks of more liberal transfusion (including haemolytic and non-haemolytic transfusion
reactions and transfusion-associated lung injury,16 increasing demands on blood services17 as well as
additional and important cost implications associated with the storage, handling and administration of red
blood cell units18), this evidence has led to an emphasis on restrictive transfusion in contemporary blood
management guidelines19–21 and increasingly in health policy.22,23
The Transfusion Indication Threshold Reduction (TITRe2) trial was designed in 2006 and was prompted
by the widely varying transfusion thresholds that were being applied at the time and by a detailed
observational analysis of data from the hospital in which the triallists worked.2 Existing RCTs at the time
that had compared liberal with restrictive transfusion in cardiac surgery, including our own pilot trial, had
lacked sufficient statistical power to demonstrate clinical benefits attributable to restrictive transfusion.24–26
A contemporary systematic review of RCTs of liberal compared with restrictive transfusion, most of which
were not conducted in cardiac surgery, also concluded that there is uncertainty as to the benefits of more
restrictive transfusion in patients with unstable cardiac disease.12
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Aims and objectives
To address this uncertainty, we undertook the TITRe2 RCT. The trial was designed to test the hypothesis
that a restrictive threshold for red blood cell transfusion (haemoglobin 7.5 g/dl and/or haematocrit 22%)
would reduce post-operative morbidity and health service costs compared with a liberal threshold
(haemoglobin 9 g/dl and/or haematocrit 27%).
Specific objectives of the TITRe2 trial were:
l to estimate the difference in the risk of a post-operative infection or ischaemic event between
restrictive and liberal transfusion thresholds
l to compare the effects of restrictive and liberal transfusion thresholds with respect to a range of
secondary outcomes
l to estimate the cost-effectiveness of a restrictive compared with a liberal haemoglobin
transfusion threshold.
INTRODUCTION
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Chapter 2 Methods
Study design
The study was a multicentre RCT. The objectives were addressed by randomising participants to either a
restrictive (transfuse if post-operative haemoglobin dropped below 7.5 g/dl, or haematocrit below 22%)
or a liberal (transfuse if post-operative haemoglobin dropped below 9 g/dl, or haematocrit below 27%)
strategy for red blood cell transfusion. The trial is registered, number ISRCTN70923932.
Participants provided written, informed consent pre-operatively but only became eligible for randomisation
if their haemoglobin fell below 9 g/dl, or haematocrit below 27%, at some point postoperatively.
Therefore, postoperatively, haemoglobin/haematocrit levels were monitored according to usual care and if
the relevant threshold was breached at any time on the cardiac unit the participant was randomised as
soon as possible, at the latest within 24 hours. (Note: thresholds were expressed as haemoglobin or
haematocrit, and randomisation or transfusion was indicated if either value fell below the allocated
threshold. Hereinafter, haemoglobin should be interpreted as haemoglobin or haematocrit.) A UK NHS
Research Ethics Committee approved the study (08/H0606/125). Full details of all methods are
reported elsewhere.7
Changes to study design after commencement of the study
There were no major changes to the study design after commencement. Some changes were made to
eligibility criteria and outcomes, which are discussed in Changes to study eligibility criteria after
commencement of the study and Changes to study outcomes after commencement of the study, respectively.
Participants
Eligibility criteria
The study inclusion criteria were:
l adults of either sex, aged ≥ 16 years, undergoing cardiac surgery [defined as coronary artery bypass
grafting (CABG), heart valve replacement or repair, aortic surgery or surgical correction of congenital
cardiac disease]
l post-operative haemoglobin level < 9 g/dl at any stage during the patient’s post-operative hospital stay
[i.e. on cardiac intensive care unit (CICU) or cardiac surgical ward]
l written informed consent.
The exclusion criteria were:
l patients undergoing emergency cardiac surgery
l patients prevented from having blood and blood products according to a system of beliefs
(e.g. Jehovah’s Witnesses)
l patients with congenital or acquired platelet, red blood cell or clotting disorders
l patients with ongoing or recurrent sepsis
l patients with critical limb ischaemia
l patients unable to give full informed consent for the study (e.g. learning or language difficulties)
l patients already participating in another interventional research study.
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Changes to study eligibility criteria after commencement of the study
In April 2009 (before starting recruitment to the study), two exclusion criteria were removed:
l patients with a critical carotid artery stenosis (> 75%)
l patients with flow limiting (> 70% luminal stenosis) coronary artery disease not undergoing
complete revascularisation.
These exclusion criteria were included originally on the basis of the exclusion criteria used in the pilot study
for this trial.26 The pilot study used different thresholds, notably a lower haemoglobin threshold of 7 g/dl
for the restrictive group. At the time of designing the pilot study it was felt that, because patients entering
the pilot study could potentially experience haemoglobin levels as low as 7 g/dl, these exclusion criteria
were needed to avoid non-adherence by intensivists, who might consider such patients to be more at risk
of experiencing ischaemic adverse effects. TITRe2 used the higher haemoglobin level of 7.5 g/dl for the
restrictive threshold and this threshold was already used routinely at some centres for all patients.
Therefore, after discussing these exclusion criteria again, the study team believed they were not necessary
for TITRe2.
In August 2010, the previously stated upper age limit of 80 years for the inclusion of participants was
removed. This decision was a result of feedback from sites that they did not consider older age to be a
contraindication for randomisation to the study and that the exclusion would substantially limit the pool of
eligible patients for the study. After removal of this criterion surgeons were still able to refuse to include
patients aged > 80 years on a case-by-case basis.
Settings
Patients were recruited to the trial in 17 specialist cardiac surgery centres in UK NHS hospitals.
Interventions
The trial compared two thresholds for blood transfusion, liberal and restrictive. The thresholds were
defined as follows:
l Liberal group: participants randomised to this group were eligible for transfusion if their post-operative
haemoglobin level fell < 9 g/dl at any time during their post-operative hospital stay on the CICU or
cardiac surgical ward. Therefore, all participants in this group should have received one red blood cell
unit soon after randomisation. The objective was to maintain the haemoglobin level at or above 9 g/dl.
l Restrictive group: participants randomised to this group were eligible for transfusion if their
post-operative haemoglobin level fell < 7.5 g/dl at any time during their post-operative hospital stay on
the CICU or cardiac surgery ward. The objective was to maintain the haemoglobin level ≥ 7.5 g/dl.
The protocol specified that, in both groups, one red blood cell unit should be transfused, the haemoglobin
rechecked and a second unit transfused only if the haemoglobin remained below the relevant threshold.
Clinicians were allowed to transfuse, or refuse to transfuse, in contravention of the allocated threshold
but were required to document their reason for doing this and the haemoglobin level at the time.
Furthermore, a clinician could decide it was in the best interests of a participant to permanently
discontinue treatment according to the allocated group, which did not constitute a withdrawal and the
participant was followed up as normal. Other aspects of post-operative care were provided in accordance
with the institution’s usual care.
METHODS
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The duration of intervention in the trial was the duration of the participant’s care under the consultant
cardiac surgeon or a maximum of 3 months after the date of randomisation, whichever was shorter.
Almost always, the duration of care under the cardiac surgeon was the period of hospitalisation after
surgery. However, a few participants who developed serious complications were transferred to the care of
another consultant in the same hospital, at which time the interventional period for the study ended.
Outcomes
Primary outcome
The primary outcome was a binary composite outcome of any serious infectious (sepsis or wound
infection) or ischaemic event [permanent stroke, myocardial infarction (MI), gut infarction or AKI] in the
first 3 months after randomisation. The qualifying events listed in Table 1 were included; the table also
describes the manner in which each qualifying event was verified.
Events occurring after discharge only contributed to the primary outcome if the potentially qualifying event
resulted in admission to hospital or death. Wound infection identified as a result of adding post-discharge
information was the only exception to this rule. For example, information ascertained using the additional
treatment, serous discharge, erythema, purulent exudate, separation of deep tissues, isolation of bacteria,
and stay duration as inpatient (ASEPSIS) post-discharge surveillance assessment questionnaire (see Table 1),
when added to the ASEPSIS score derived for the index admission, sometimes resulted in a total ASEPSIS
score for the index admission that was > 20. Other suspected infectious events treated in the community
that did not cause readmission to hospital were not recorded as they could not be validated and are
less serious than perioperative infections.
Events suspected to qualify for the primary outcome but that were not supported by objective evidence
were referred to an independent adjudication committee. In practice, the adjudication committee only
considered suspected MIs because documentary objective evidence for sepsis, stroke, AKI and gut
infarction was verified by research nurses at the co-ordinating centre who were blinded to the random
allocation. The adjudication committee consisted of a cardiac surgeon, cardiologist and anaesthetist who
were blinded to allocation and each other’s assessments. They were required to classify a suspected MI as
definite or not based on participant’s medical history, echocardiograms (ECGs) (both pre-operatively and at
the time of the suspected MI) and troponin levels at the time of the suspected MI. Agreement between
at least two of the three specialists was required to reach a final adjudicated classification.
Death was not included as a component of the primary composite outcome because, if death occurred
following a qualifying event, the event would precede death itself. Deaths that occurred for other reasons
were not hypothesised to increase because of red blood cell transfusion.
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TABLE 1 Definition of serious infectious/ischaemic primary outcome events
Infectious events Definition/method of verification
Sepsis During index admission:
l Defined by the following two conditions: antibiotic treatment for suspected infection and the
presence of SIRS within 24 hours prior to the start of antibiotic treatment
l SIRS was defined as two or more of the following conditions: temperature > 38 °C or < 36 °C;
heart rate > 90 beats/minute; respiratory rate > 20 breaths/minute or PaCO2 < 32mmHg or
< 4.3 kPa; white blood cell count > 12,000mm3 or < 4000mm3
In follow-up period:
l Hospital admission for treatment with antibiotic therapy
Wound infection ASEPSIS score of > 20.27 Two scores were calculated and summed:
l An in-hospital score from assessment of wounds between one and three times during a
participant’s index hospital admission
A follow-up score derived from the in-hospital score and a questionnaire either posted for
self-completion or administered by telephone, at 3 months post randomisation28,29
Ischaemic events Definition/method of verification
Permanent stroke Clinical report of brain imaging (CT or MRI), in association with new onset focal or generalised
neurological deficit (defined as a deficit in motor, sensory or co-ordination function)
MI Elevated post-operative peak serum troponin I or T, verified by an adjudication committee. Further
details are given in Primary outcome
Gut infarction Documented reason for laparotomy or post-mortem report
AKI AKI network criteria for AKI, stage one, two or three:30
Stage one:
l Serum creatinine increase ≥ 0.3mg/dl (≥ 26.4 µmol/l), or
l > 1.5 and ≤ 2-fold serum creatinine increase compared with the pre-operative serum creatinine
(baseline) value, or
l urine output < 0.5ml/kg for 6 hours
Stage two:
l > 2 and ≤ threefold serum creatinine increase compared with the pre-operative serum
creatinine (baseline) value, or
l urine output < 0.5ml/kg for > 12 hours
Stage three:
l > threefold serum creatinine increase compared with the pre-operative serum creatinine
(baseline) value, or
l serum creatinine ≥ 4.0mg/dl (≥ 354 µmol/l) with an acute increase of at least 0.5mg/dl
(44 µmol/l), or
l urine output < 0.3ml/kg per hour for 24 hours or anuria for 12 hours, or
l need for RRT irrespective of AKI stage at time of RRT
l the AKI stage recorded was the highest stage reached by the participant after randomisation
CT, computerised tomography; MRI, magnetic resonance imaging; RRT, renal replacement therapy; SIRS, systemic
inflammatory response syndrome.
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Secondary outcomes
All secondary outcomes were collected in the time between randomisation and 3-month follow-up, unless
otherwise stated.
l Units of red blood cells and other blood components [fresh frozen plasma (FFP), platelets,
cryoprecipitate, activated factor VI (NovoSeven, Novo Nordisk) and Beriplex® (CSL Behring UK Ltd)]
transfused during a participant’s hospital stay. Red blood cells transfused pre-randomisation (either
intraoperatively or postoperatively but prior to randomisation) were collected and described separately.
However, it was only possible to collect information about other blood components transfused over the
pre-randomisation and post-randomisation periods combined.
l Occurrence of an infectious qualifying event, defined as sepsis or wound infection.
l Occurrence of an ischaemic qualifying event, defined as permanent stroke, MI, AKI or gut infarction.
l Quality of life measured using European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L),31 assessed
pre-operatively and at 6 weeks and 3 months post randomisation.
l Duration of intensive care unit (ICU) or high-dependency unit (HDU) stay; calculated as the total time
between randomisation and discharge from the cardiac unit that the participant was in either the
CICU, HDU or general ICU wards, including any periods of readmission to that area.
l Duration of hospital stay, calculated as the time between randomisation and discharge from the
cardiac unit.
l Significant pulmonary morbidity, comprising initiation of non-invasive ventilation [e.g. continuous
positive airway pressure (CPAP) ventilation], reintubation/ventilation or tracheostomy.
l All-cause mortality.
l Health and Personal Social Services resource use and their costs.
(Durations of ICU, HDU and hospital stay were originally specified as ‘postoperative’. We specified
randomisation as the time origin for these durations in the analysis plan, for consistency with the primary
and other secondary outcomes.)
Changes to study outcomes after commencement of the study
The following changes were made to study outcomes after the trial had commenced.
l In April 2009, before starting recruitment, there were some amendments made to the definitions of
infectious and ischaemic events that qualified for the primary outcome.
l In March 2010, an amendment was made to include troponin T in addition to troponin I in defining
MI. This amendment was required after discovering that some participating centres habitually used
troponin T rather than I. In addition, as part of this change, the troponin threshold for MI that was
previously stated was removed; the decision was made, instead, to collect the highest troponin reading
for all participants with suspected MI and to adjudicate suspected MIs (see Primary outcome).
l In March 2011, the secondary outcome ‘significant pulmonary morbidity’ was added. This was initially
named transfusion-associated circulatory overload and then subsequently renamed. The outcome was
added because information from the haematology community had highlighted pulmonary morbidity as
a potentially important outcome for patients receiving blood transfusions. The outcome was defined
with respect to data already being collected on the study case report forms (CRFs) before the
amendment so that the outcome could be identified consistently across the entire duration of the trial.
l Furthermore, in March 2011, ‘A&E [accident and emergency] admission’ was removed from the
primary outcome as qualifying event. This change arose from discussion with clinicians on the Trial
Steering Committee (TSC) who agreed that a participant experiencing any element of the primary
outcome would be admitted to hospital if they attended the emergency department (ED) within the
follow-up period.
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Adverse events
Expected adverse events (AEs) were specified in the study protocol and captured via the study CRFs, both
for the post-operative in-hospital period (serious and non-serious), and at the 3-month follow-up
(serious only).
A serious adverse events (SAE) is any untoward medical occurrence that either results in death, is
life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in
persistent or significant disability or incapacity, or results in a congenital anomaly/birth defect.
All other AEs were considered unexpected, any such events satisfying one or more criteria for classification
as serious were recorded in detail on purpose-designed SAE forms. Unexpected SAEs were coded using
the Medical Dictionary for Regulatory Activities version 14.1 (MedDRA; McLean, VA, USA) independently
by two research nurses blinded to randomised allocation. Any discrepancies were resolved by a consultant
cardiac surgeon also blinded to allocation.
Sample size
The trial was designed to answer superiority questions. The following steps were taken to calculate the
sample size.
l From observational data, we assumed that approximately 65% of patients would breach the threshold
of 9 g/dl and 20% would breach the 7.5 g/dl threshold.2 Therefore, with complete adherence to the
transfusion protocol, we assumed that transfusion rates should be 100% in the liberal group and
≈30% (0.20/0.65) in the restrictive group.
l In the observational analysis,2 63% of patients with a nadir haematocrit between 22.5% and 27%,
and 93% of patients with a nadir haematocrit below 22.5%, were transfused. Therefore, in
combination with the proportions of patients expected to breach the liberal and restrictive thresholds,
these figures were used to estimate conservative transfusion rates of 74% for the liberal group and
≤ 35% for the restrictive group. These percentages reflected the rates of transfusion documented in
the observational study (Figure 1) and assumed non-adherence with the transfusion protocol of
approximately 26% in the liberal group and 5% in the restrictive group.
l The observational frequencies of infectious and ischaemic events for transfused and non-transfused
patients were adjusted to reflect the estimated transfusion rates in the two groups (i.e. 74% and
≤ 35%), giving event rates for the proposed composite outcome of 17% in the liberal threshold group
and 11% in the restrictive threshold group. A sample size of 1468 was required to detect this risk
difference of 6% with 90% power and 5% significance (two-sided test), using a sample size estimate
for a chi-squared test comparing two independent proportions (applying a normal approximation
correction for continuity) in Stata version 9 (StataCorp LP, College Station, TX, USA).
l The target sample size was inflated to 2000 participants (i.e. 1000 in each group) to allow for
uncertainty about non-adherence and the estimated proportions of participants experiencing the
primary outcome. We regarded these parameter estimates as uncertain because (1) they were estimated
from observational data, (2) they were based on the red blood cell transfusion rate only in Bristol,
(3) they were based on routinely collected data, using definitions for elements of the composite primary
outcome which are not identical to those proposed for the trial, and (4) they were based on any
compared with no red blood cell transfusion, rather than on the number of units of red blood cells likely
to be transfused in participants who breach the liberal threshold. No adjustment was made for
withdrawals or loss to follow-up, as both rates were expected to be very low.
We expected approximately two-thirds of participants to breach the haemoglobin threshold for eligibility.2
Therefore, we predicted that we needed to register approximately 3000 participants into the study as a
whole to allow 2000 participants to be randomised into the main study.
METHODS
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The main outcome measure for the economic evaluation was quality-adjusted life-years (QALYs), which are
derived from EQ-5D-3L utilities measured on a continuous scale and time under observation. The analysis
of QALYs requires baseline utility to be modelled as a covariate; the correlation between baseline and
3-month EQ-5D-3L utilities was assumed to be ≥ 0.3. With a total sample size of 2000, the trial had more
than 95% power to detect a standardised difference in continuous outcomes between groups of 0.2 with
1% significance (two-sided test). This magnitude of difference is conventionally considered to be ‘small’.32
Interim analyses
One formal, pre-specified interim analysis was carried out in June 2012 after 50% of the participants had
been recruited and followed up for 3 months. Extreme criteria for stopping the trial (p≤ 0.001) were set
and, therefore, no adjustment was made to the sample size and statistical significance levels for this
interim analysis.
Randomisation
Participants were randomly allocated to either the liberal or restrictive transfusion strategies using cohort
minimisation to achieve balance across the two arms of the trial; minimisation factors were centre and
operation type (CABG, valve, CABG and valve combined, or other cardiac surgery). Participants were
Transfusion threshold
Nadir Hb 
<  7.5 g/dl
Nadir Hb
7.5 to <   9.0 g/dl
Total
Transfused 96% 62% 74%
Not 
transfused
Not 
transfused4% 38% 26%
Transfusion threshold
Nadir Hb 
<  7.5 g/dl
Nadir Hb
7.5 to <  9.0 g/dl
Total
Transfused 96% <  5% <  35%
4% >  95% >  65%
All cardiac surgery patients (100%)
Eligible patients who consent (28%)
Baseline data including EQ-5D-3L (28%)
Operation carried out (28%)
Nadir Hb <  9.0 g/dl (18%),
randomised to:
Transfusion threshold: Hb < 9.0 g/dl Transfusion threshold: Hb <  7.5 g/dl
Other exclusions/not approached/declined
to take part 
65.3%
Emergency operations 3.8%
Early post-operative 
deaths (very few)
0.3% 
Nadir Hb >  9.0 g/dl 9.6%
FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram summarising TITRe2 trial design.
Percentages are based on data from the cardiac surgery registry in Bristol for the period January to September
2007. An unknown percentage of patients are excluded by the exclusion criteria because the registry does not
contain sufficient detail to apply the definitions proposed for the trial. However, patients meeting one or more of
these criteria are extremely rare and we expected all of the exclusion criteria to account for a maximum of 5% of
cardiac surgery patients. Hb, haemoglobin.
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randomly assigned in a 1 : 1 ratio. Allocations were generated by computer and concealed using an
internet-based system provided by Sealed Envelope Ltd (London, UK). Staff in participating centres were
able to gain secure limited access to the system using a password and PIN (personal identification number).
Information to identify a participant uniquely and to confirm eligibility had to be entered before the system
assigned the randomised treatment allocation, ensuring concealment of allocations. Randomisation
occurred postoperatively and as soon as possible after the participant’s haemoglobin level fell below
9 g/dl (at the latest within 24 hours). If randomisation did not occur within 24 hours, the patient was
considered to have become ineligible and should not have been randomised unless the haemoglobin fell
below 9 g/dl again (when the clock for the ‘24 hour rule’ was restarted; see Non-adherence with
randomisation protocol).
Blinding
It was not possible to blind clinicians, research staff and other NHS staff caring for participants to the
randomised allocation. However, outcomes were defined on the basis of objective criteria as far as
possible, in order to minimise susceptibility to bias. Furthermore, both the research nurses reviewing the
documentary evidence relating to primary outcome events and the adjudication committee assessing MIs
were blinded to treatment allocation.
Every effort was made to blind participants to their allocation. The success of blinding was checked by
asking participants if they knew what their allocation was at the time of discharge from hospital and their
3-month post-randomisation follow-up.
Data collection
In-hospital data collection (see Appendix 4 for the CRFs) included the following elements.
l Screening log of all non-emergency patients having cardiac surgery
¢ distinguishing patients but without recording identifiable data electronically
¢ whether or not a patient information leaflet (PIL) was sent
¢ whether or not a patient was approached for the trial
¢ assessment of eligibility; if ineligible, reasons for ineligibility
¢ whether or not a patient was asked to give written informed consent for the trial.
l For all registered participants (randomised and non-randomised)
¢ pre-operative characteristics, including operation category
¢ a summary of blood products received
¢ daily haemoglobin levels to check compliance with protocol.
l For all randomised participants
¢ date and time when the haemoglobin fell below 9 g/dl
¢ operative details, including duration of surgery and use of any blood products
¢ observations required for the primary and secondary outcomes, including dates and times of
relevant events
¢ other key resource use
¢ any AEs
¢ information about whether or not a participant was blinded to allocation at discharge.
METHODS
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Research staff in participating centres collected data on the trial screening log and pre-printed CRFs. These
data were transferred promptly to a secure computerised database maintained on a NHS computer,
allowing data to be checked centrally. Queries about specific data items were listed on the database and
were immediately apparent to centre staff when they logged on.
Post-operative haemoglobin levels in consented participants were measured at regular intervals and the
lowest level observed on each post-operative day was recorded on the CRF. After randomisation, the
threshold to which a participant had been randomised was communicated to attending medical and
nursing staff and recorded on the CRF. Centres used varying methods to highlight to staff that a
participant had been randomised. Details of red blood cell transfusions were recorded and haemoglobin
levels continued to be monitored. If a non-adherent transfusion decision was made for a randomised
participant (i.e. a decision which did not adhere to the allocated protocol, see Non-adherence with
transfusion protocol), the attending doctor was required to give a reason for the decision. This reason was
documented on the CRF.
Data collection after hospital discharge consisted of the following elements.
l The EQ-5D-3L was posted to randomised participants at 6 weeks and 3 months after randomisation.
Participants who consented to the study but were not randomised also received a postal EQ-5D-3L
3 months after their operation.
l Three months after the operation, a questionnaire was posted for self-completion, or administered by
telephone (if a participant elected to be telephoned or failed to return the postal questionnaire), by
staff at the co-ordinating centre. The questionnaire was composed of items eliciting information about:
¢ AEs occurring after discharge, with further details of any event suspected to contribute to the
primary outcome or meet the definition of a SAE sought from either the admitting hospital or the
participant’s general practitioner (GP).
¢ surgical wound infections occurring after discharge (ASEPSIS post-discharge surveillance questionnaire).28,29
¢ resource use after discharge from hospital.
¢ a participant’s awareness of his/her random allocation.
l Occasionally data collection was delayed beyond the planned follow-up times; when this occurred the
following rules were used to determine whether or not data should be included in analyses:
¢ EQ-5D-3L – the time between questionnaire completion and operation date was examined by
group, blinded to allocation, separately for each time point. The distributions did not differ;
therefore, data corresponding to times that were extreme outliers (identified by eye) were excluded
but all other data included.
¢ Three-month telephone/postal questionnaire – questionnaire items were phrased specifically in
relation to the 3-month post-operative period and staff completing the telephone questionnaires
were trained only to record information regarding this period. Therefore, data from all
questionnaires were used.
Data collection is summarised in Table 2.
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Adherence
Non-adherence with randomisation protocol
Non-adherence with the randomisation protocol was defined as any of the following:
l Participant did not meet one or more of the pre-consent study eligibility criteria but was consented into
the study. Any randomised participant to whom this applies was classified as ‘randomised in error’ and
excluded from the analysis population.
l Participant consented and met the post-consent inclusion criteria (i.e. haemoglobin dropped below
9 g/dl) but was not randomised. Any randomised participant to whom this applies was not randomised
and, therefore, was excluded from the analysis population.
l Participant did not meet the post-consent eligibility criteria (i.e. haemoglobin did not drop below 9 g/dl)
but was randomised. Any randomised participant to whom this applies was classified as ‘randomised in
error’ and excluded from the analysis population.
l Participant was randomised more than 24 hours after meeting the post-consent inclusion criteria
(i.e. randomised more than 24 hours after haemoglobin dropping below 9 g/dl). Any participant to
whom this applies was classified as non-adherent with the randomisation protocol, but was included in
the analysis population.
Non-adherence with transfusion protocol
Measuring and assessing adherence with the transfusion protocol was identified as a critical element of
the study owing to the assumptions about adherence made in the sample size calculation.33 The Data
Monitoring and Ethics Committee (DMEC) also highlighted the importance of non-adherence, as they had
concern that doctors might otherwise make transfusion decisions in different ways in the two groups.
For example, a decision to transfuse in the liberal group could be delayed up to 24 hours without
contravening the protocol and such behaviour would have been missed if data about haemoglobin levels
measured during this period, their times and consequent actions had not been recorded.
Two types of non-adherence were defined: (1) a participant received a red blood cell transfusion outside of
protocol (‘extra’ transfusion) and (2) a participant was not given a red blood cell transfusion that,
according to the protocol, should have been given (‘withheld’ transfusion). Adherence was assessed for
the period from randomisation to hospital discharge so multiple instances of non-adherence could be
documented for a participant. If a participant withdrew or had their treatment according to their allocation
discontinued, adherence after the time of withdrawal/discontinuation was not assessed. For both of
the above types of non-adherence, instances were classified into mild, moderate or severe (Table 3).
Non-adherence was classified as severe only if the non-adherent instant changed the participant’s overall
classification as transfused or not.
TABLE 3 Non-adherence with the transfusion protocol
Non-adherence
type ‘Extra’ transfusion outside of protocol ‘Withheld’ transfusion according to protocol
Mild N/A A transfusion took place, but more than 24 hours
after the relevant breach of the transfusion threshold
Moderate Participant transfused outside of protocol,
but participant breached the threshold for
transfusion at least once postoperatively
Participant was not transfused following a breach,
but the participant had previously had at least one
post-randomisation transfusion
Severe Participant transfused outside of protocol
and participant did not breach the threshold
for transfusion at any point postoperatively
Participant was not transfused following a breach
and participant had no post-randomisation
transfusions
N/A, not applicable.
A participant could breach the relevant threshold for transfusion multiple times and so there could be more than one case
of non-adherence per participant.
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In addition to describing the amount of non-adherence, work has been done to further describe and
characterise non-adherence, including:
l characteristics of each instance of non-adherence (including reasons, haemoglobin levels and timing)
have been described
l logistic regression models were fitted to identify predictors of non-adherence
l non-adherence trends both by centre and over the course of the trial have been described.
Statistical methods
The analysis and safety populations consisted of all participants randomised into the study, excluding
participants who withdrew and who were unwilling for the data already collected to be used. All analyses
were performed on an intention-to-treat (ITT) basis and were directed by a pre-specified analysis plan.34
Continuous variables were summarised via the mean and standard deviation (SD), or median and
interquartile range (IQR) if distributions were skewed. Categorical data were summarised as a number
and percentage. Pre-randomisation characteristics were described by allocated treatment. Similarly,
pre-operative and intraoperative characteristics, transfusions, EQ-5D-3L scores and mortality of randomised
and non-randomised (but consented) participants were described but no formal comparisons made.
Comparisons of outcomes
All outcomes were analysed using mixed-effects regression models, adjusting for all factors included in the
cohort minimisation: operation type as a fixed effect and centre as a random effect (or a shared frailty
term in time-to-event models). The primary outcome and other binary outcomes (numbers of participants
experiencing infectious or ischaemic events, any transfusions of red blood cells and non-red blood cell
products and significant pulmonary morbidity) were analysed using logistic regression, with treatment
estimates presented as odds ratios (OR) and 95% confidence intervals (CI). For the analysis of the
transfusion of any red blood cells, treatment estimates were analysed using unadjusted logistic regression,
with results presented as a risk ratio (RR) and 95% CI, as the OR proved difficult to interpret and an
adjusted model did not converge. Time-to-event outcomes were analysed using Cox proportional hazards
models and treatment estimates presented as hazard ratios (HR) and 95% CI. Durations of ICU/HDU stay
and hospital stay were censored at the time of death if the participant died before discharge from hospital.
All-cause mortality was censored at the time of last follow-up for survivors. A secondary analysis of the
primary outcome, analysing the time to first occurrence of the primary outcome, was also undertaken
using a Cox proportional hazards model, censoring at the time of last follow-up or death.
Longitudinal data (EQ-5D-3L scores) were analysed using mixed-effects mixed-distribution models;35 this
method was used because the distribution of the data was non-monotonic, with many participants
scoring perfect health. Both types of score (utility and visual analogue scores) were dichotomised into less
than perfect health compared with perfect health. There were two-parts to each fitted model: (1) an
occurrence model, a logistic regression model for the occurrence of less than perfect health compared with
perfect health, and (2) an intensity model, a log-linear model for the score, conditional on a non-perfect
health score. Correlated participant-term random effects (for occurrence and intensity) were included in
each model to allow for the repeated measures. Separate parameter estimates were incorporated into
models for the mean baseline response across both treatment groups and for each treatment post
intervention, avoiding the necessity to either exclude cases with missing baseline measures or to impute
missing baseline values. A time by allocation interaction (post intervention) was added to each of the
models; an overall treatment effect is reported unless the interaction was statistically significant at
the 10% level, in which case separate treatment effects at each post-intervention time are given.
METHODS
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Safety data
The AEs and SAEs were described by allocated treatment but no formal comparisons made.
Subgroup analyses
Pre-planned subgroup analyses were specified because of clinical opinion that transfusion decisions should
be influenced by patients’ characteristics, notably that ‘at-risk’ patients should be transfused at a different
threshold. The subgroups defined in the protocol were: operation type (isolated CABG vs. other operation
types), age (< 75 years vs. ≥ 75 years), pre-operative diagnosis of diabetes (none vs. diet, oral medication
or insulin controlled), pre-operative diagnosis of lung disease (none vs. chronic pulmonary disease or
asthma), pre-operative renal impairment [estimated glomerular filtration rate (eGFR) > 60ml/minute vs.
eGFR ≤ 60ml/minute], sex (males vs. females) and ventricular function (good vs. moderate or poor). Such
analyses were implemented by adding a relevant treatment allocation by subgroup interaction term into
the primary outcome model; the hypothesis for all subgroup analyses was that there would be no
interaction. The pre-operative renal impairment subgroup analysis was defined in the study protocol as
pre-operative creatinine ≤ 177 µmol/l versus creatinine > 177 µmol/l. However, during the course of the
trial, use of pre-operative creatinine for risk stratification was superseded by estimated eGFR and,
therefore, the subgroup analysis for renal impairment was based on eGFR as described above (this change
was not covered by a protocol amendment).
Sensitivity analyses
A number of sensitivity analyses were pre-specified for the primary outcome in the analysis plan, although
such analyses were not specified in the study protocol.
(a) Examining treatment effect estimates for the primary outcome by site, ordering sites by rates of severe
non-adherence with the transfusion protocol. This was implemented by a forest plot displaying site-specific
treatment estimates. It provided a way of assessing the effect of non-adherence on the overall treatment
estimate for the primary outcome, without excluding non-adherent participants. (We considered that an
analysis excluding non-adherent participants would be inappropriate because it would be very likely to be
biased as non-adherent participants were hypothesised to be the sicker participants in the restrictive group
and the healthier participants in the liberal group.) As non-adherence represents a dilution of the allocated
intervention, we hypothesised that the treatment effect would tend towards the null with increasing
non-adherence.
(b) Excluding all events that occurred in the first 24 hours after randomisation. The rationale was that such
events could have an onset that actually preceded randomisation and, hence, be unrelated to the
intervention. Therefore, we hypothesised that the treatment effect would tend away from the null with
exclusion of these events.
(c) Excluding participants who were transfused before randomisation. The rationale was that transfusions
before randomisation, expected to occur with similar frequency in both groups, would dilute any
effect of a difference between groups in the number of transfusions after randomisation. Therefore,
we hypothesised that the treatment effect would tend away from the null with exclusion of
pre-randomisation transfusions.
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(d) In collecting AKI data it became apparent that prospective data collection by research nurses in centres
failed to identify AKI events that were apparent from routinely collected serial creatinine data. We
attribute this discrepancy to differences between centres in the ‘baseline’ creatinine value used to
define AKI, which can be confusing to implement as the specified creatinine rise should occur in a
48-hour period.30,36 However, highest daily creatinine levels were recorded separately, so the following
sensitivity analyses were planned:
¢ excluding AKI events when the clinical diagnosis was not verified by routinely recorded creatinine
levels. This analysis would exclude potentially ‘false’ AKI events, although AKI events in these
participants may have been ‘true’ events classified on the basis of urine output (which was not
documented routinely).
¢ including additional AKI events when the participant was reported not to have had AKI according
to clinical judgement but when highest daily creatinine levels supported a diagnosis of AKI. This
analysis would include AKI events that were missed, assuming that the creatinine levels recorded
for usual hospital care were accurately transcribed on to the CRF.
Assuming that false AKI events would arise in proportion to the incidence of true AKI events, they
would not bias the treatment effect. Therefore, we hypothesised that the effect in the first analysis
would reduce precision but not shift the estimate predictably either towards or away from the null.
Similarly, assuming that missed AKI events would arise in proportion to the incidence of true AKI
events, they would also not bias the treatment effect. Therefore, we hypothesised that the effect in the
second analysis would increase precision but not shift the estimate predictably.
(e) Including only ‘serious’ primary outcome events, defined as either stroke, MI, gut infarction, AKI stage
three events, pre-discharge sepsis plus organ failure [MI, stroke, laparotomy for gut infarction and
one or more of reintubation, acute respiratory distress syndrome (ARDS), low cardiac output and/or
tracheostomy] and/or post-discharge sepsis that required hospital readmission. This analysis arose from
the pre-planned interim analysis that showed a higher primary outcome event frequency than was
anticipated when the study was designed, with a large majority of qualifying events arising from sepsis
and AKI, which were considered to be clinically less serious. We considered that this sensitivity analysis
would better reflect our original intention in formulating the composite outcome and the outcome
events that were included in the observational analysis, which led to the superiority hypothesis for the
trial. This analysis would necessarily have less precision but we did not have a strong hypothesis about
the way in which the treatment effect might be affected. If transfusion were to have the same effect
on more and less serious events, the treatment effect should be unaltered; if transfusion were to have
a differential effect on more and less serious events, the treatment effect should be moved towards or
away from the null in a manner consistent with the differential effect.
Post-hoc analyses
In addition, a secondary post-hoc analysis of severe in hospital events was performed, which involved
refitting the primary outcome model with an outcome of death, severe sepsis [as defined in sensitivity
analysis (e) above], ARDS, tracheostomy, low cardiac output, MI, AKI stage three, gut infarction and/or
stroke. This analysis was performed because it was judged to be of key interest to hospital-based clinicians
caring for patients. As for analysis (e) above, it would necessarily have less precision but we did not
hypothesise that the treatment effect would be moved towards or away from the null.
Two further post-hoc sensitivity analyses were carried out for the secondary outcome of mortality; these
comprised analyses (b) and (c) above (i.e. excluding deaths within 24 hours of randomisation and
participants transfused before randomisation). These were suggested during the peer review process, on
account of the seriousness of the outcome, and we agreed that they were worthwhile. Our (post hoc)
hypotheses were the same as that for the corresponding sensitivity analyses of the primary outcome. These
were the only additional analyses requested in this way, the decision to perform them was made without
knowing the results and the results are fully reported.
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Observational analyses
Three observational analyses were pre-specified in the study protocol.
(a) Estimating the relationship between the number of red blood cell units transfused and the risk of
mortality and morbidity, stratified by trial arm.
(b) Investigating the relationship between percentage decline in haemoglobin from the pre-operative level
and the risk of primary and secondary outcomes, taking into account the number of red blood cell
units transfused.
(c) Investigating whether or not red blood cell age (i.e. time since donation and processing) is associated
with the risk of primary and secondary outcomes, achieved by linking batch numbers of all red blood
cells transfused to a blood bank database and determining the age of each unit donation and
transfusion dates.
For the purposes of these observational analyses, a composite outcome of the trial primary outcome or
death was defined in the statistical analysis plan (SAP). In addition, all red blood cell units transfused or
haemoglobin levels recorded after the time of the first occurrence of the primary outcome (or censoring)
were excluded to ensure the relevant exposure occurred before the outcome. (More complex methods
to deal with this issue were outlined in the SAP but these have not been attempted owing to the
complexity of the analyses.) For all three analyses, pre-operative and intraoperative characteristics and
trial outcomes were described by exposure [i.e. any red blood cells vs. no red blood cells, minimum
haemoglobin < 7.5 g/dl vs. ≥ 7.5 g/dl, and transfusion of any red blood cells aged over 21 days old
(median age) vs. only younger blood (< 21 days) vs. no red blood cell transfusions].
For analyses (b) and (c), the exposure definitions differ slightly from those used in the protocol/SAP. With
respect to analysis (b), the protocol stated that haemoglobin would be defined in terms of percentage
decline; however, exploratory analyses suggested this was not sensible (e.g. a participant with pre-operative
haemoglobin 12 g/dl and post-randomisation haemoglobin 6 g/dl would be treated in the same way as
a participant with pre-operative haemoglobin 18 g/dl and post-randomisation haemoglobin 9 g/dl,
as the percentage decline is 50% in both cases) and that it would be more informative to include both
pre-operative and post-randomisation haemoglobin levels in any analysis model. For analysis (c), various
methods of defining age of blood were described in the SAP (using the age of the ‘oldest’ red blood cell unit
given, the mean age of all red blood cells, the use of any red blood cells more than 14 days old, the number
or percentage of red blood cells given over 14 days old, the use of red blood cells older than the median
age of all red blood cells transfused) and it was stated that the age of the oldest unit would be used as the
primary analysis. Owing to the large volume of missing data for age of blood, it was decided instead only to
provide descriptive analyses by the receipt of any red blood cells older than the median age.
For parts (a) and (b), further analyses have been undertaken. Univariate analyses exploring the relationship
between exposures and the outcome were performed. Two separate adjusted models [one for analysis
(a) and one for analysis (b)] were then fitted adjusting for the following, if found to be potential
confounders: operation type, centre (as a random effect), European System for Cardiac Operative Risk
Evaluation (EuroSCORE), age, sex and pre-randomisation red blood cell transfusions [for analysis (a) only].
A model building strategy was used whereby variables were sequentially added to the model, at each step
including the variable that improved the model fit the most (as determined by a likelihood ratio test).
Variables were included in the model if they were (1) associated with both the exposure and the outcome
but did not lie on the causal pathway between the exposure and outcome, and (2) significantly contributed
to the relevant multivariate model (defined by a likelihood ratio p< 0.05 or modifying the effect estimate by
greater than 10%). If pairs of variables were considered to be collinear or strongly related (e.g. EuroSCORE
and age), only one of the pair was included. In addition, interaction terms were included in models if
significant at the 5% level. The parameterisation of the exposure variable (e.g. continuous linear, continuous
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including additional power terms, ordinal categorical or binary) was explored using fractional polynomial
models and likelihood ratio tests to compare nested models. Marginal plots were used to describe
interactions between continuous and categorical covariates graphically. Models were refitted separately
within each randomised group. Finally, instrumental variable (IV) methods were used to estimate the
associations of interest free from confounding, separately for analyses (a) and (b); models used the
multiplicative generalised method of moments estimation (the ivpoisson command in Stata).
Meta-analysis
A meta-analysis was performed analysing mortality from TITRe2 and all other RCTs that have compared
liberal and restrictive red blood cell transfusion strategies in patients undergoing cardiac surgery. This
analysis was undertaken to place the findings of TITRe2 in the context of the evidence base. Eligible
RCTs24–26,37,38 were identified from a previous review of RCTs comparing restrictive versus liberal transfusion
thresholds12 and an on-going review comparing RCT and observational evidence about the effects of red
blood cell transfusion in cardiac surgery patients.39 The previous Cochrane review searched multiple
databases including the Cochrane Injuries Group’s Specialised Register, the Cochrane Central Register of
Controlled Trials, MEDLINE, EMBASE and ISI Web of Science (both the Science and Conference Proceedings
Citation Indices). The review included RCTs with a concurrent control group in which participants were
assigned to groups with different transfusion triggers or thresholds, for which the thresholds were defined
by a haemoglobin or haematocrit level that a participant had to reach before a red blood cell transfusion
could be administered. For the purposes of the current meta-analysis, we included RCTs identified from
either review that were deemed to have taken place in the context of cardiac surgery. Therefore, we
included RCTs with different group-specific transfusion thresholds to those used in TITRe2 and which
included all participants, irrespective of whether or not the liberal threshold was breached (i.e. without the
post-operative eligibility criterion adopted in the TITRe2 trial). When writing the SAP, we also intended to
perform a meta-analysis for the primary outcome; however, outcomes were too dissimilar between included
RCTs. The meta-analysis was performed using standard meta-analysis methods for binary outcomes with
a random effects model.
Missing data
Missing data are indicated in all of the tables. Rules for imputing missing data were outlined in the analysis
plan, dependent on the level of missing data. However, the majority of outcomes had levels of missing
data below the defined thresholds in the plan (5% for outcomes measured at one time point and 20%
for longitudinal data) and imputation methods were not generally used. The first exception was for the
infectious events secondary outcome (5.6% missing), whereby separate estimates were made prior to
hospital discharge and overall. A second exception was the in-hospital component of the ASEPSIS score
from which wound infection events were identified; this was one of the rarer components of the primary
outcome but the in-hospital component of the score was the outcome data item that was most likely
to be missing. If the in-hospital ASEPSIS score was missing, the participant was assumed not to have
had a serious wound infection if the following criteria were met: participant did not have antibiotics for
suspected wound infection prescribed in hospital and follow-up was completed, and the participant
reported no problems with the healing of chest, leg and/or arm wound up to 3 months after
the operation.
Significance levels
For hypothesis tests, two-tailed p-values of < 0.05 were considered statistically significant, with the
exception of tests for interactions between group and time in longitudinal models when a 10%
significance level was used. Likelihood ratio tests were used in preference to Wald tests. No formal
adjustment was made for multiple testing. When interpreting the results, consideration has been given to
the number of tests performed and the consistency, magnitude and direction of estimates for different
outcomes.40 All data management and analyses were performed in SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA) or Stata version 12.1 or 13.1 (StataCorp LP, College Station, TX, USA).
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Health economics
Aims and objectives
The economic evaluation aimed to estimate the cost-effectiveness of the restrictive compared with the
liberal haemoglobin transfusion threshold as compared in TITRe2. Our main objective was to estimate the
incremental cost and the incremental cost-effectiveness of the restrictive compared with the liberal
haemoglobin transfusion threshold after cardiac surgery.
Economic evaluation methods overview
A cost–utility analysis was conducted, with outcomes measured using the EQ-5D-3L. The restrictive
haemoglobin threshold was considered as cost-effective if the incremental cost-effectiveness ratio (ICER)
fell below £20,000, which is generally considered as the threshold at which the National Institute for
Health and Care Excellence (NICE) considers an intervention to be cost-effective.41 Good practice guidelines
on the conduct of economic evaluations were followed for the economic evaluation.42–44 Table 4
summarises the methods for the economic evaluation, with further details provided in the text following
the table.
TABLE 4 Summary of methods used in the economic evaluation
Aspect of methodology Strategy used in base-case analysis
Form of economic evaluation Cost–utility analysis for comparison between restrictive and liberal transfusion
thresholds
Perspective NHS and Personal Social Services
Time horizon A within-trial analysis, taking a 3-month time horizon (up to the primary clinical
time point)
Population All randomised participants were included, except those randomised in error
Costs included in analysis Index admission
l Surgery
l Blood products
l Length of stay by ward type (including ICU and HDU)
l Medications
l Reoperations
l Investigations and treatments relating to complications, including renal
replacement therapy, and SAEs
Post discharge
l Readmissions to hospital
l Other hospital ED and outpatient visits (e.g. warfarin clinics)
l Community health and social care contacts
Utility measurement (primary
economic outcome)
EQ-5D-3L (administered pre-operatively and at 6 weeks and 3 months
postoperatively)
QALY calculations Assume that participants’ utility changes linearly between utility measurements
Adjustment for baseline utility Regression used to adjust QALY calculations for differences in baseline utility
Missing data Mean imputation and multiple imputation
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Form of analysis and primary outcome measure
The primary outcome measure for the economic evaluation was QALYs, as advocated by NICE.44 This
outcome combines quantity and quality of life into a single measure. Our evaluation took the form of
a cost–utility analysis in which the difference in mean costs between the two transfusion threshold
groups is divided by the difference in mean QALYs between the two groups to calculate an ICER and,
specifically, the incremental cost per QALY gained by switching from using a liberal threshold to using a
restrictive threshold.
Perspective
The primary perspective of the evaluation was that of the UK NHS and Personal Social Services, as
recommended by NICE.44 However, data were collected on some types of non-NHS costs including
expenditure incurred by a participant when travelling to hospital. We planned to include these costs in a
wider perspective in a sensitivity analysis, if resource use for these non-NHS costs differed between the trial
groups. The perspective for outcomes was that of the participants undergoing treatment.
Time horizon
A within-trial analysis, taking a 3-month time horizon, was conducted. It was anticipated that all major
resource use would occur within this timeframe and, therefore, be captured. The start of our analysis was
from the point of surgery. Surgery was chosen as the time origin, rather than the point of randomisation
as was the case with the analysis of effectiveness, in order to capture the resources that would be required
for the intervention from a decision-maker’s perspective, that is, to include all relevant costs (and effects)
involved in delivering an intervention. Our time horizon continued until 3 months postoperatively. Ideally,
the time point for baseline costs and outcomes should be the same; however, the EQ-5D-3L was collected
pre-operatively whereas detailed resource use collection began on the day of surgery.
Population
Our base-case analysis included all participants randomised into the trial except those randomised in error,
which is consistent with the main effectiveness analyses. Analyses were performed on an ITT basis.
Collection of resource use and cost data
Resource use data were collected on all significant health service resource inputs for the trial participants
up to the point of the 3-month follow-up. The main resource use categories that were costed are listed
in the first column of Table 5, along with the sources of information for both the resource use and unit
costs. Costing decisions (such as resource use assumed for complications) were made without knowledge
of the allocation of participants to trial groups.
Initial cardiac surgery and blood products
As the type of surgery itself was not the main factor being assessed within the trial, we used published
cardiac surgery costs rather than performing a detailed microcosting. We used cost figures from
the cardiac surgery Healthcare Resource Group (HRG) codes from the elective inpatient spreadsheet in
the National Reference Costs database45 and subtracted costs relating to length of stay (LOS) and blood
products to calculate the cost of the surgery itself.
The LOS in hospital was removed by using the average LOS associated with each HRG and each specialty
(cardiac surgery or cardiothoracic surgery) at a cost of £392 per day; this cost is a weighted average of
elective inpatient excess bed-days for relevant cardiac procedures (see Appendix 3, Table 60 for further
details). For valve surgery, there were HRG codes for single-valve procedures and for procedures on more
than one valve. The costs are higher for procedures involving more than one valve; 25% of the activity
reported in Reference Costs was for procedures involving multiple valves45 but in TITRe2 this proportion is
only 10%. To reflect this fact, we created a weighted average of the costs of single- and multiple-valve
procedures, with the weighting being according to the proportion of these types of participants recruited
to TITRe2.
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The costs of blood products (red blood cells, FFP and platelets) were removed from HRG costs by using
the average numbers of products reported to be used by CABG, valve, and CABG and valve patients in the
NHS Blood and Transplant (NHSBT) national audit in 2011,5 and valued using published NHSBT prices.
For our surgery category of ‘other’, the costs of average blood products were removed by applying the
information used for CABG and valve participants because the average operation time for ‘other’ was
lengthy and most similar to the CABG and valve group.
The total number of red blood cells transfused each day was recorded on the trial CRFs. The costs of
administering red blood cell transfusions were added to the costs of the units of red blood cells. The costs of
administering transfusions were based on primary data collection of the nursing time and consumables
associated with administering transfusions collected by the authors as part of another study (see Appendix 3,
Table 60 for more information).
Initial post-surgery hospital stay
In terms of hospital stay following the actual surgery, LOS was collected for CICU/HDU, general ICU and ward
during the trial. As time spent on CICU was not reported separately from time spent on HDU, and recognising
that these activities probably require a different level of resources, the time of extubation was used to
distinguish between time on CICU and time on HDU. Participants had an initial extubation date and time
recorded in the trial, along with the dates and times of any further intubations and extubations. If data
were missing on extubation date/time, we assumed that for those who died before discharge, that they were
intubated until death. For participants without a tracheostomy, and no indication that they were not extubated,
we assumed an average intubation duration, based on information from participants with available data. For
participants who went on to have a tracheostomy, we calculated their time to tracheostomy and time to
discharge and assumed the average intubation time for participants with intubation durations between these
two times. Similar assumptions were made for any reintubations. CICU and HDU costs were taken from NHS
Reference Costs.45 To cost time on a cardiac ward, an average bed-day cost was created by weighting the cost
of relevant cardiac procedures excess bed-day costs according to activity from the elective inpatient spreadsheet
in Reference Costs45 (see Appendix 3, Table 60 for further details).
TABLE 5 Resource use categories and sources of resource use and unit cost information
Resource category
Sources for resource use
informationa Sources for unit cost information
Initial cardiac surgery CRF C1 National Schedule of Reference Costs (2012–13);45
NHSBT National Comparative Audit of Blood
Transfusion;5 NHSBT price list46
Blood products CRFs B1, B2 NHSBT price list;46 primary data collection for the
costs of administering blood products (further details
in Appendix 3, Table 60)
Initial stay in hospital post
surgery
CRFs D1, H5 National Schedule of Reference Costs (2012–13)45
Medications CRF D2 eMIT;47 BNF48
Complications, including
re-operations; SAEs
CRFs C1, C2–C4, C5, C6,
C7, F1–F3, H5, X1
National Schedule of Reference Costs (2012–13);45
eMIT;47 BNF48
Hospital readmissions CRF X1, 3-month follow-up
questionnaire – section 2a
National Schedule of Reference Costs (2012–13)45
Outpatient attendances and
visits to ED
3-month follow-up questionnaire –
sections 2b, 2c
National Schedule of Reference Costs (2012–13)45
Community health and
social care contacts
3-month follow-up questionnaire –
section 3
National Schedule of Reference Costs (2012–13);45
Unit Costs of Health and Social Care49
BNF, British National Formulary; eMIT, electronic marketing information tool; NHSBT, NHS Blood and Transplant.
a B1–X1 are labels used to distinguish CRFs (see Appendix 4).
DOI: 10.3310/hta20600 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 60
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
Medications and fluids
Medications and fluids given during surgery or intensive care, such as inotropes, were costed for each
participant. Information on whether or not participants received these medications were collected on
pre-specified yes/no tick boxes on the trial CRFs (Form D2). In order to cost these interventions, a member of
the trial research team provided an estimate of the likely quantity of fluids a participant would receive. The
costs of antibiotics administered after surgery for an infection were summed during the period of initial
hospital stay post surgery and during any hospital stay after discharge if participants were readmitted (up to
3 months). The names of specific antibiotics were reported on the trial CRF (Form C5) as free text with the
route and duration of the course. We established the most likely dose with the TITRe2 research team. If
information was missing on the route of administration (oral or intravenous) or frequency of drugs, we
clarified this information with the trial research team and conducted sensitivity analyses around alternative
scenarios and drug costs for antibiotic treatment. The costs of antibiotics were included in the costs
of complications.
In addition, the regular medications that participants were taking, such as beta-blockers, statins and
warfarin, were recorded as on the medication or not by pre-specified tick boxes (yes/no) on CRF Form D2.
This was recorded for two time points: at baseline – on admission to the cardiac surgery unit – and at
discharge from the cardiac surgery unit. A member of the trial research team estimated the name, dose
and mode of delivery (oral or intravenous) for the regular medications that participants were taking at
baseline and discharge. We assumed that participants took any medications recorded at discharge for the
3-month follow-up and costed these medications for 3 months. In a separate analysis, we also costed the
regular medications participants were taking at baseline and at discharge for a period of one week.
Comparisons were then made between the costs of these medications taken at baseline and at discharge
from hospital, to determine whether or not there were significant changes in this resource before and
after surgery.
Treatment complications and serious adverse events
Primary outcome complications that were costed included serious infection, permanent stroke, MI, gut
infarction and AKI. Details of these complications were recorded on CRF Forms C5 and C6. We also
included the costs of any procedures or tests required to verify the complications, such as computerised
tomography (CT) or magnetic resonance imaging (MRI) scans for permanent stroke, laparotomy for gut
infarction and ECG for suspected MIs. For all participants suspected to have had a MI, the costs of
diagnostic investigations were included. The costs of all other post-operative complications recorded on
CRF C7 were calculated; examples include pacing (both temporary and permanent pacing), CPAP
ventilation, tracheostomy and transient ischaemic attack. Cardiac surgery reoperations were also included
in complication costs. Care was taken to avoid double counting of complication costs. For example,
resource use associated with both ARDS and reintubation was assumed to be a transoesophageal echo
and three chest X-rays. If a participant had both complications on the same day, only one echo and three
chest X-rays were costed to avoid probable double counting. The trial CRFs were used to gather the types
and amounts of complications the participants had experienced and also to capture resource use around
SAEs. SAEs were individually reviewed and additional resources were costed if not already captured in
complication costs, again to avoid double counting. Tables 64, 65, 67 and 68 in Appendix 3 show all the
complications, the corresponding diagnostic tests and treatments assumed, and their unit costs.
Hospital readmissions
The costs of hospital readmissions include all expected and unexpected cardiac surgery and transfusion
complications, in terms of AEs and SAEs, but excluded all unexpected unrelated complications. For example,
our analysis included the cost of readmissions for hypertension and angina, but excluded the cost of
readmissions for cancer treatment. Clinical opinion was sought to clarify whether unexpected complications
were possibly related or were unrelated to the index surgery. A bed-day cost for readmissions was created
by weighting the non-elective inpatient excess bed-days across all specialties according to activity. The cost
of an ED attendance was included if a participant was admitted via ED or referred by their GP (and assumed
to be admitted via ED). If participants travelled to hospital via ambulance, this was also costed.
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Outpatient attendances, emergency department visits and community health
and social care contacts
The type of outpatient appointment was recorded by pre-specified tick boxes on the trial follow-up
questionnaire [section 2(c)] which include cardiac surgery, cardiology (non-surgical), renal/dialysis unit,
stroke clinic or ‘other’. If participants specified ‘other’, we discussed with the trial research team whether
or not these were likely to be linked to the surgery, in order to avoid costing any outpatient visits that
were totally unlinked to the trial. Information on the number of ED visits related to the surgery and
the reasons for the visits was captured on the trial CRF [section 2(b) of the follow-up questionnaire]. The
reasons for visits recorded by participants were reviewed and any unrelated activity excluded. Information
was also collected on how the participant travelled to ED to ensure any ambulance costs were captured.
Primary care contacts with GPs and practice nurses, whether at the GP surgery or participant’s home,
were costed. Other NHS or social services visits at home or elsewhere, including any visits to cardiac
rehabilitation clinics or warfarin clinics, were also costed using information collected on the trial follow-up
questionnaires (see section 3 of the questionnaire).
Attaching unit costs to resource use
Unit costs for hospital and community health-care resource use were largely obtained from national
sources, for example, NHSBT price lists for blood products, the National Schedule of Reference Costs
for ICU, HDU and cardiac ward costs, MRI and CT scans and many complications, and Unit Costs of Health
and Social Care for community costs.45,46,49 Resources were valued in 2012/13 pounds sterling (£); if any
unit costs were in pre-2012/13 prices, they have been inflated to 2012/13 using the Hospital and
Community Health Services (HCHS) inflation index.49 Costs of drugs given in hospital were taken from
the electronic marketing information tool (eMIT)47 when possible, which provides the reduced prices paid
for generic drugs in hospital; other drug costs were taken from the British National Formulary (BNF).48
Tables 63 and 64 in Appendix 3 lists all the medications and their costs used for the trial; further details on
all unit costs and their source can be found in Appendix 3, Unit costs and resource use assumed
for complications.
Measurement of health-related quality of life and quality-adjusted life-years
Measurement of health-related quality of life
The EQ-5D-3L questionnaire, advocated for use in economic evaluations by NICE,44 was used to measure
health-related quality of life.31 The EQ-5D-3L is a generic measure of health outcome covering
five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Responses
recorded on the instrument are converted into a single-index value using the UK valuation set, valuations
from approximately 3000 members of the UK general population elicited using the time trade-off
method;50 scores are then used to facilitate the calculation of QALYs in health economic evaluations.
The EQ-5D-3L was used for TITRe2 as the 5-level version was not available at the start of the trial. Our trial
participants completed the EQ-5D-3L questionnaire at three time points: in hospital pre-operatively and by
post/telephone at 6 weeks and 3 months postoperatively.
Calculation of quality-adjusted life-years
The QALY profile for each participant up to 3 months postoperatively was estimated and the area under
the curve of utility measurements used to calculate the number of QALYs accrued by each participant.
QALYs were calculated assuming that each participant’s utility changed linearly between each of the time
points (pre-operatively, 6 weeks and 3 months postoperatively). For participants who died during the trial,
their utility was assumed to change linearly between the preceding time point and the time of death,
and a value of zero was given to participants from death onwards.
Total QALYs gained were calculated for each participant by adding together QALYs gained from baseline
to 6 weeks and from 6 weeks to 3 months. QALYs gained from baseline to 6 weeks were calculated by
averaging a participant’s EQ-5D-3L scores at baseline and 6 weeks and multiplying by 42 days (or number
of days until death if this was within 42 days). QALYs gained from 6 weeks to 3 months were calculated in
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a similar way. Once total QALYs gained were calculated for all participants, the average QALY gain for
participants in each group was calculated. Alternative assumptions regarding the analysis of QALYs were
investigated in sensitivity analyses, such as using the date of completion of the 6-week EQ-5D-3L rather
than assuming this was at 42 days.
Missing data
We first summarised descriptively the volume of missing data for both resource use and EQ-5D-3L scores,
which showed that 2.5% of resource use data were completely missing: 2.4% in the restrictive group and
2.5% in the liberal group. Overall, 10.7% of EQ-5D-3L scores were missing across the three time points
(pre-surgery, 6 weeks and 3 months); 10.9% in the restrictive group and 10.5% in the liberal group.
Although the level of missing data on resource use sounds small, because there are a large number of
resource use variables for the trial, any simple methods to deal with the missing data would work poorly.
For instance, using complete case analysis would leave only 61% of participants remaining for analysis.
Multiple imputation was used to handle this missing data.
When data were partially missing, for example for linked questions for which only the first part was
answered, mean imputation was used to handle such missing data. This occurred when a resource use
question was in two parts: if participants were asked to respond yes/no to whether or not they used a
particular resource (e.g. if they were readmitted to hospital) and then if yes, to record further details on the
volume of resource use (e.g. the number of days they were readmitted, or the number of visits). Further
details of mean and multiple imputation are described next.
Mean imputation for partially missing data
When data were partially missing, mean imputation was used. For example, if participants reported a
readmission to hospital, but information on the LOS was missing, a mean LOS across all readmissions was
calculated and this mean was then imputed if data were missing. Similarly if a participant reported GP
visits, but did not record the number of visits, the mean number of visits from other participants was
calculated and then imputed for those participants whose data were missing. This approach was also used
to complete some of the intubation durations.
There were a number of dates and times recorded on the CRFs for events such as extubation, reintubation
and re-extubation and movements between wards. If the exact time of an event was unknown, there was
provision on the CRFs to record an approximate time of morning, afternoon or overnight. If only an
approximate time was available, we used the same assumptions as were made in the effectiveness
analyses, which were based on discussions with the research nurses. For calculations involving the date
and time of hospital discharge, a discharge time of 18:00 was assumed (consistent with the
effectiveness analyses).
Multiple imputation for missing data
Multiple imputation using a series of chained regression equations was used to impute missing resource
use and EQ-5D-3L data. Following recent guidelines,51 multiple imputation using chained equations was
conducted using the mi command in Stata. Multiple imputation uses regression to predict m-values for
each missing data cell (m is often 5 and was here), and enables all variables used in the economic
evaluation and demographic data (both complete and incomplete) to be used to predict the values of
missing data cells.
Missing resource use data were imputed in two stages. First, the missing data within inpatient resource use
were imputed based on the available inpatient resource use data together with independent variables: centre,
sex, treatment group, age at operation and cardiac procedure (as four categories) in the regression equations;
second, all the post-discharge resource use with missing data were imputed on the same independent
variables with the addition of total LOS. All readmission variables, including ICU days, complications and SAEs,
were imputed conditional on readmission LOS being greater than zero; that is, only participants who had a
readmission could then have complications in the follow-up period. Indicator variables for SAEs included in the
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
imputation only counted participants for whom we attached a cost to their SAE. Missing EQ-5D-3L data were
imputed based on the available EQ-5D-3L scores at each of the three time points together with independent
variables: centre, sex, treatment group, age at operation, cardiac procedure and total costs. Finally, Rubin’s
Rule was used to summarise data across the m datasets.52 This approach accounts for the variability both
within and between imputed datasets and takes uncertainty in the estimated mean into account.
Adjustment for baseline utility
Given that baseline utility directly contributes to QALY calculations, it is important to control for any
potential imbalances in baseline utility in the estimation of the mean difference in QALYs between
treatment groups, to avoid introducing bias.53 Regression adjustment also allows for regression to the
mean and increases precision. Therefore, we adjusted our QALYs for baseline EQ-5D-3L. For each of
the five imputed datasets, we regressed total QALYs on treatment group and baseline EQ-5D-3L and
used the Stata command, mi estimate, to combine the five imputed datasets, and used Rubin’s Rule to
combine the standard errors (SEs) across the five imputations. This provided an estimate of the QALY
difference and its SE between the trial groups, adjusted for baseline EQ-5D-3L. The Stata command nlcom
was then used to combine regression coefficients to obtain the mean QALYs in each trial group, adjusted
for baseline EQ-5D-3L.
Within-trial statistical analysis of cost-effectiveness results
Most of the cost-effectiveness analyses were conducted in Stata version 12; some of the graphs and unit
cost calculations were conducted in Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA).
Initially, resource use, costs and health-related quality of life were summarised using means, SDs and SEs
of means, using both the central limit theorem and bootstrapping. ICERs were derived from the average
costs and QALYs gained in each trial group, producing an incremental cost per QALY gained by
implementing a restrictive threshold in place of a liberal threshold. Non-parametric bootstrapping of costs
and QALYs was then used to quantify the degree of uncertainty around the ICER. Bootstrapping was used
to avoid making parametric assumptions.
A thousand bootstrap samples were drawn for each of the five imputed datasets. For each bootstrap
sample for each imputation, total costs were regressed on treatment group and total QALYs were
regressed on treatment group and baseline EQ-5D-3L. The mean cost difference between the groups
(restrictive minus liberal) was calculated, as well as the mean QALY difference between the groups
adjusted for baseline EQ-5D-3L.
These 5000 bootstrap replicates of the mean difference in costs and QALYs between the groups were
used to represent graphically the uncertainty around the ICER on the cost-effectiveness plane. In order
that the points could be seen, only 1000 replicates were plotted (200 replicates for each of the
five imputations).
For each of the five imputations, the mean and SD of the 1000 cost and QALY differences were estimated.
These SDs are SDs of a column of means, so are actually SEs. Rubin’s Rule was then used to combine the
SEs across the five imputed datasets. CIs around the cost and QALY differences were then generated
based on these SEs rather than SEs based on parametric methods.
Results are expressed in terms of a cost-effectiveness acceptability curve (CEAC), which indicates the
likelihood that the restrictive threshold is cost-effective for different levels that health-care decision-makers
are willing to pay for health gain. All 5000 bootstrap replicates were used to generate the CEAC. The
restrictive threshold would be considered as cost-effective if the ICER falls below £20,000; however, the
ICERs and CEACs presented would allow decision-makers to assess cost-effectiveness at a willingness-to-pay
threshold of their choice.
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Discounting
Costs and effects were not discounted as our time horizon was < 12 months.
Sensitivity analysis
One-way sensitivity analysis was used to investigate the impact on the results of the cost and cost-effectiveness
analyses when varying key parameters or major cost drivers and also to investigate the impact of uncertainty on
the cost-effectiveness results. Factors that were examined in the sensitivity analysis for costing were:
l varying the unit costs of treatment of complications, ward stays, reoperations, expensive drugs, oral
versus intravenous drug administration and the source of medication unit costs (BNF vs. eMIT)
(see Appendix 3, Sensitivity analyses around unit costs)
l conducting the costing from the point of randomisation rather than the point of surgery as undertaken
in the baseline analysis (further details in Appendix 3, Costs from randomisation)
l exploring the impact of any high-cost participants (outliers) if the cost data are skewed.
Non-NHS costs were also considered and analyses were conducted to determine whether or not these
differed between the trial groups and hence whether or not there was a need to conduct a sensitivity
analysis from a wider societal perspective (instead of a NHS and Personal Social Services perceptive).
For the sensitivity analysis on outcomes, we varied the assumptions for calculating QALYs; the alternative
strategies examined were:
l not adjusting for baseline utility
l exploring the use of the last observation carried forward until death rather than assuming utility
changes linearly until death
l using the date of completion of the 6-week EQ-5D-3L rather than assuming it is completed at exactly
6 weeks
l calculating QALYs from the point of randomisation rather than surgery.
Finally, we carried out a sensitivity analysis examining life-years gained as a secondary outcome measure in
the economic evaluation. Previous economic evaluations conducted by the authors have often found that
EQ-5D-3L scores are similar across trial groups.54 Such a finding could reflect reality but could also be a
function of the 3-level version of the EQ-5D-3L not being sufficiently sensitivity to changes in quality of life,
or that quality-of-life improvements arise before EQ-5D-3L measurements (failing to capture periods of
lower quality of life), especially following SAEs.
Subgroup analysis
Subgroup analyses were conducted to investigate whether or not cost-effectiveness results varied between
participant subgroups. The pre-specified subgroups used for the effectiveness analyses were used for the
cost-effectiveness subgroup analyses:
l operation type (isolated CABG vs. other operation types)
l age at operation (< 75 years vs. ≥ 75 years)
l pre-operative diagnosis of diabetes (none vs. diet, oral medication or insulin controlled)
l pre-operative diagnosis of lung disease (none vs. chronic pulmonary disease or asthma)
l pre-operative renal impairment (eGFR ≤ 60ml/minute vs. eGFR > 60ml/minute)
l sex (males vs. females)
l pre-operative ventricular function (good vs. moderate or poor).
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The impact of subgroups was evaluated using ordinary least squares regression predicting total costs and
QALYs, conditional on treatment group, subgroup and an interaction between treatment group and
subgroup (and baseline EQ-5D-3L for QALYs only). A Bonferroni adjustment was made to allow for the
multiple tests conducted across the seven subgroups and two variables; statistical significance was
therefore evaluated at the 0.0036 level.
Patient and public involvement
At the time of formulating the research question for TITRe2 and deciding to apply for funding, information
about progress on the pilot study26 and the proposed trial was presented to the Research Advisory Group
of the Bristol Heart Institute. This group comprised members of the public who are stakeholders in the use
of, or delivery of, health care and health-care research, including patients and potential patients, those
who commission or deliver health-care services and a representative of the British Heart Foundation. The
group agreed that it was important for patients and the NHS to answer the research question and
supported our proposal for the trial.
The trial recruited patients who had moderate to high levels of anxiety before surgery because of the
life-threatening nature of their condition and the operation, and took place in a particularly acute care
setting. Although patients had full capacity when they were approached about the trial, about 90% were
randomised and first received the intervention when they were on the ICU or HDU, when they were likely to
be artificially ventilated or sedated. In terms of the conduct of the trial, most patient and public involvement
(PPI) occurred through the representative on the TSC, Karin Smyth. At the time of her appointment to the
TSC, she had recently been a non-executive director of Bristol North Primary Care Trust and a lay/patient
representative on the Research Advisory Group.
Information about the trial used when approaching patients to take part was developed with input from
patients who had had cardiac surgery previously, both initially and when the information was revised,
in order to try to better communicate the possible benefits and risks of withholding or giving extra
transfusions. We also consulted a group of past patients when we were considering the option of obtaining
follow-up information by postal questionnaire, as well as by telephone. This option was raised when staff
in the trials unit were having to spend large amounts of time carrying out telephone follow-ups. We had
not budgeted for such a large amount of time and there was a risk that either a backlog of follow-up
information would build up or other trial-related tasks would be delayed. We particularly valued the
involvement of this group of patients in endorsing the principle that postal follow-up would be an
acceptable alternative and in optimising the format of the questionnaire for self-completion by participants,
which we believe contributed to the completeness of follow-up information. We are currently involving
patients and lay representatives in disseminating information about the results of the trial to participants.
The lay representative of the TSC played an important role towards the end of the trial when there was
some concern about emerging findings from the trial based on the data available at the time. Having
reassurance from both lay and professional members of the TSC was vital at this time in ensuring
successful completion of the trial as planned.
We also would like to draw attention to the reciprocal benefits that PPI can contribute. With her
permission, we are reproducing comments that Karin Smyth made spontaneously about her membership
of the TSC.
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I wanted to put on record my appreciation of being involved in this trial. As I have found in my own
work the role of a ‘lay person’ is a peculiar and ill-defined one. When Gavin [Professor Murphy] asked
me to be involved it was as someone who had commissioning and health care management
experience but who was not, at that point, working in the NHS and could be a lay person. The science
has often been beyond my own understanding but I am grateful for your patience and explanation
when that was the case. I was made to feel a full part of the team.
Karin Smyth, reproduced with permission
Contractual and financial arrangements
When applying for funding, we chose to adopt a fee-per-participant payment model in order to reimburse
the research costs incurred by participating centres in taking part. These research costs arose primarily
from the need to collect data during participants’ index admissions but also from the time spent by local
research teams helping with collection of follow-up data, for example if a participant was readmitted to a
participating centre or a nearby referring hospital after discharge. We preferred this model to one in which
each participating centre is given a set amount of funding, for example to employ a part-time research
nurse, because it created an incentive for centres to recruit and randomise participants, and contained
local research costs.
We developed a spreadsheet to estimate the total locally incurred costs (i.e. for the total target sample
size), estimating the amount of a consultant’s, research nurse’s and clerical person’s time per participant
needed to identify, approach and consent patients and collect the data required. The spreadsheet took
into account the different numbers of patients/participants at each stage of the recruitment process;
we projected that 6000 patients would need to be identified, 5000 approached, 3000 consented and
registered, and 2000 randomised. Items in the spreadsheet were then classified as research or service
support activities. Most but not all of the activities prior to randomisation were considered to represent
service support (i.e. approaching and consenting patients, including discussion with a clinician). Therefore,
for simplicity, we estimated the fee-per-participant for randomised participants only (including the costs
of pre-randomisation tasks within this amount, averaged per randomised participant). The total came to
£260 per randomised participant, divided into £100 for service support costs and £160 for local research
costs. The latter total included 0.25 hours of consultant time (reviewing and signing SAE forms), 7.75 hours
of research nurse time (collecting data, communicating with the participants and usual-care staff and
responding to data queries from the coordinating centre) and 2.75 hours of clerical time (primarily entering
data into the database).
On the basis of our original assumption that a centre would randomise eight participants, on average,
per month, we expected the corresponding income [8 × 12 × (£160+ £100)= £24,960] to generate
sufficient research income to pay for approximately 0.6 full time equivalents of a research nurse and the
appropriate amounts of consultant and clerical time.
This payment structure was implemented through the contracts (using the model non-commercial
agreement) between the Sponsor (University Hospitals of Bristol NHS Foundation Trust) and sites.
(A separate contract was in place between the Sponsor and the University of Bristol, which held the grant.)
The contract specified that payments would be made in two parts: £120 ‘Upon receipt of complete and
accurate data following participant discharge, including documentary evidence of qualifying or suspected
qualifying events for the primary outcome as specified in the protocol and case report form’ and an
additional £40 ‘Upon receipt of additional data required as a result of 3-month-follow-up (e.g. response
to queries on follow-up or SAEs)’. The trial database kept track of data submitted, payments due and
payments already invoiced. A query was run quarterly to generate an itemised activity report for each site
detailing the payment due. This report formed the basis for an invoice to the University of Bristol, which
held the grant.
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Chapter 3 Trial cohort
Screened patients
Screening data were provided for 11,483 patients at 17 UK centres (Figure 2). A total of 7918 screened
patients were excluded from the study: 3055 were not sent a PIL; 1863 were not approached; 281 were
ineligible; and 2719 did not consent. In addition, there were 696 participants who were not sent a PIL and
118 participants who were not approached, as they were already deemed ineligible when they were screened.
Similarly, for 10 participants, the reason for non-consent was recorded as ineligibility and reasons are unknown
for these participants. The most common reasons for ineligibility were: congenital or acquired platelet, red
blood cell or clotting disorder (83 patients); and inability to give full informed consent (62 patients). Similarly,
the most prevalent reasons for not consenting were: wanting the standard procedure (1053 patients) and
personal reasons (678 patients). Therefore, 3565 participants (31.0% of those screened) consented to take
part in the study, of whom 94 were not considered for randomisation (for reasons see Figure 2). Of the
remaining 3471 participants, 2007 (57.8%) were randomised, 1004 to the restrictive group and 1003 to the
liberal group.
The numbers of patients screened, excluded from the study, consented and randomised are given in
Table 6, demonstrating a large variation in screening rates. The percentage of screened patients consented
into the study ranges from 11.1% to 90.0%, suggesting that quality in screening (or the completeness of
recording screened patients in the log) was very variable between centres. Two centres (site A, consent
rate 34.3%, and site H, consent rate 11.1%) were identified as using the screening log as intended,
suggesting centres with higher consent rates were perhaps not screening all non-trial patients and,
therefore, some of the variation is likely to have arisen from varying data completeness across centres up
to the point of consent.
Furthermore, the percentages of consented patients that were randomised ranged from 36.0% to 92.3%
(accepting that the latter percentage is based on a relatively small denominator). These differences are
likely to have arisen from differences in clinical practice and case mix of patients between centres, as well
as from the different strategies used by sites to target certain kinds of patient who were more likely to
be randomised (such targeting was encouraged by the trial management team to maximise the yield of
randomised participants among those who consented).
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Assessed for study (n = 11,483)a 
Exclusions (n = 94)
Participant withdrawal pre-surgery (n = 7), participant withdrawal post-surgery
but pre-randomisation (n = 1), clinician withdrawal pre-surgery (n = 17), clinician
withdrawal post-surgery but pre-randomisation (n = 16), surgery not performed/
participant died pre-surgery (n = 26), found to be ineligible post-consent (n = 9),
trial ended prior to surgery date (n = 9), participant missed on admission due to
staff error (n = 5), participant died in theatre (n = 4) 
    
Considered for randomisation (n = 3471)
Exclusions (n = 4863)a
Not approached (n = 1863)
No staff available (n = 693), insufficient time to read PIL (n = 102), missed due to staff error (n = 150), 
cancelled/transferred to theatre list of non-participating surgeon (n = 504), trial ended (n = 105),
ineligible (n = 118), patient too anxious/confused (n = 70), clinician decision not to include patient
(n = 73), other (n = 48) 
Ineligible (n = 281)
Age < 16 years (n = 6), prevented from having blood and blood products due to system of beliefs
(n = 7), congenital or acquired platelet, red cell or clotting disorder (n = 83), ongoing or recurrent
sepsis (n = 30), critical limb ischaemia (n = 46), emergency surgery (n = 0), participating in another
interventional research study (n = 43), unable to give full informed consent (n = 62), unknown (n = 10)  
Did not consent (n = 2719)
No reason given (n = 610), not enough time to consider study (n = 218), wants standard procedure
(n = 1053), personal reasons (n = 678), trial ended (n = 12), patient did not receive/read PIL (n = 54),
clinician decision not to include patient (n = 9), cancelled/transferred to another list (n = 17), 
staff/patient not available (n = 35), ineligible (n = 10), other (n = 23)   
PIL not sent (n = 3055)
Not eligible (n = 696), insufficient time (n = 1024), staff not available (n = 981), oversight/error (n = 38),
no contact details (n = 1), patient too anxious/confused or declined PIL (n = 159), clinician decision not to
include patient (n = 92), surgery no longer required (n = 18), other (n = 46) 
PIL sent and assessed for eligibility (n = 8428)a
Consented (n = 3565)
Randomised (n = 2007)
Not randomised (n = 1464)
Did not breach 9  g/dl threshold (n = 1288), randomisation missed 
(i.e. breached <  9 g/dl threshold) (n = 176)
FIGURE 2 Flow of participants.
a, These figures should be interpreted with caution owing to variable data quality between centres.
The proportion of screened patients consented into the study varied between centres (range 11–90%).
b, Only withdrawals in which participants were unwilling for data collected to be used or for follow-up to continue
were treated as exclusions. Some participants withdrew from treatment but were willing for data collection
to continue. (continued )
TRIAL COHORT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Allocated to restrictive group (n = 1004)
Participant withdrew consent for treatment (n = 4)
Treatment discontinued by clinician (n = 25)
Participant and clinician withdrawal (n = 3)
Allocated to liberal group (n = 1003)
Participant withdrew consent for treatment (n = 10)
Treatment discontinued by clinician (n = 19)
Participant and clinician withdrawal (n = 0)
Included in analysis population of data
at hospital discharge (n = 1003)
Included in analysis population of data
at hospital discharge (n = 1000)
Exclusions (n = 4)
Participant withdrew,b unhappy for 
data collected to be used (n = 4)
Exclusions (n = 0)
Participant withdrew,b unhappy for 
data collected to be used (n = 0)
Included in analysis population of data at
3-month follow-up (n = 992)
Questionnaire completed by participant (n = 916) 
Information obtained from participant GP (n = 32) 
Participant died, information obtained from death 
certificate (n = 42)
Information on hospital admissions provided by sites 
(n = 2)
Exclusions (n = 8)
Participant withdrewb/requested no 
further contact (n = 5)
Follow-up data not obtained (n = 3)
Exclusions (n = 17)
Participant withdrewb/requested no 
further contact (n = 12)
Follow-up data not obtained (n = 5)
Included in analysis population of data at
3-month follow-up (n = 986)
Questionnaire completed by participant (n = 940) 
Information obtained from participant GP (n = 18) 
Participant died, information obtained from death 
certificate (n = 26)
Information on hospital admissions provided by sites 
(n = 2)
EQ-5D-3L data
Pre-operative data collected (n=996)
6-week data collected (n = 793)
3-month data collected (n = 840)
EQ-5D-3L data
Pre-operative data collected (n = 999)
6-week data collected (n = 827)
3-month data collected (n = 854)
EQ-5D-3L data (non-randomised participants)
Pre-operative data collected (n = 1225)
3-month data collected (n = 891)
FIGURE 2 Flow of participants.
a, These figures should be interpreted with caution owing to variable data quality between centres.
The proportion of screened patients consented into the study varied between centres (range 11–90%).
b, Only withdrawals in which participants were unwilling for data collected to be used or for follow-up to continue
were treated as exclusions. Some participants withdrew from treatment but were willing for data collection
to continue.
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Recruitment
Participants were consented to the study between 13 July 2009 and 14 February 2013, and randomised
between 15 July 2009 and 18 February 2013. Follow-up data for the last participant were collected
21 August 2013. The 2007 randomised participants were recruited from 17 centres (see Table 6).
Actual cumulative recruitment compared with the original and revised targets are shown in Figure 3.
At the start of the study, recruitment was predicted as follows: (1) we expected two centres to start
recruiting in month one, with a further two centres opening per month thereafter until eight centres
were open; (2) we predicted five consented participants per month at centres in their first 2 months of
recruitment, 10 consented participants per month at centres in months three and four of recruitment and
19 consented participants per centre per month thereafter; and (3) we also predicted that two-thirds of
consented participants would be randomised.
As the trial progressed, it became clear that these estimates were optimistic: (1) it took 1 year to set up the
first eight sites to the point of starting recruitment instead of the 4 months we predicted, mainly due to
delays with contracts but also due to other site-specific reasons; (2) the predicted numbers of consented
participants per centre per month were not achieved at the majority of centres; and (3) the percentage of
consented participants who were randomised was substantially lower than the predicted 66% (at the end
of trial it was 56%). Extra centres (over the eight predicted) were opened to try to increase recruitment,
but the targets were still not achieved.
TABLE 6 Screening data by centre
Centre
Number
of months
recruiting
into study Screened
Excluded from study Consented
(% of
screened
patients)
Randomised
(% of
consented
patients)
PIL not
sent
Not
approached Ineligible
Did not
consent
Site A 44 1690 50 250 128 683 579 (34.3) 393 (67.9)
Site B 35 819 64 240 6 135 374 (45.7) 135 (36.1)
Site C 40 1077 213 274 1 209 380 (35.3) 142 (37.4)
Site D 9 20 0 1 0 1 18 (90.0) 8 (44.4)
Site E 40 282 34 12 7 91 138 (48.9) 76 (55.1)
Site F 41 902 7 259 40 256 340 (37.7) 224 (65.9)
Site G 27 271 37 54 6 94 80 (29.5) 47 (58.8)
Site H 30 3067 2232 150 24 320 341 (11.1) 179 (52.5)
Site I 35 531 0 130 4 78 319 (60.1) 147 (46.1)
Site J 32 844 243 121 8 222 250 (29.6) 157 (62.8)
Site K 28 284 38 24 4 64 154 (54.2) 134 (87.0)
Site L 21 228 2 2 2 72 150 (65.8) 54 (36.0)
Site M 22 283 1 54 8 123 97 (34.3) 56 (57.7)
Site N 25 774 70 112 35 312 245 (31.7) 183 (74.7)
Site O 14 328 32 163 7 55 71 (21.6) 51 (71.8)
Site P 2 30 11 2 1 3 13 (43.3) 12 (92.3)
Site Q 3 53 21 15 0 1 16 (30.2) 9 (56.3)
Total 44 11483 3055 1863 281 2719 3565 (31.0) 2007 (56.3)
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Therefore, in November 2010 an extension request was made to the National Institute for Health
Research (NIHR). This extension was based on actual cumulative recruitment to the end of October 2010
(399 randomised participants) and predicted that thereafter 60 randomised participants would be recruited
each month across all centres. This request was granted and the trial was extended with a revised end of
recruitment date of 31 January 2013. For the following 10 months, the new target was not met (a median
of 50 participants per month were randomised); however, in September 2011 recruitment took an upward
turn and the 60 randomised participants per month target was exceeded for the first time. Subsequently,
recruitment remained above target at a median of 63 participants per month for the remainder of the trial.
The highest monthly recruitment was achieved in August 2012 when 91 participants were randomised.
The last participant was recruited in mid February 2013, just 2 weeks behind target.
Recruited patients
Very few data were collected about patients who did not take part in the study (Table 7). On average,
patients who did not take part (for whatever reason) were older than participants who consented
[median 71 years (IQR 62–77 years) vs. 68 years (IQR 61–75 years)] and were less likely to be male
(66.7% vs. 75.4%).
Characteristics of (1) participants who consented but were not randomised and (2) randomised participants are
described in Table 8. As anticipated (because they were by definition not anaemic), non-randomised participants
were generally younger [median 66.5 years (IQR 59.5–73.1 years) vs. 70.3 years (IQR 63.5–76.4 years)], more
likely to be male (84.8% vs. 68.5%), with a lower risk of perioperative mortality [median EuroSCORE of 4
(IQR 2–5) vs. 5 (IQR 3–7)] and a higher pre-operative haemoglobin [mean 14.4 g/dl (SD 1.3 g/dl) vs. 13.3 g/dl
(SD 1.5 g/dl)]. Non-randomised participants were more likely to be having CABG surgery (54.6% vs. 40.6%) and
were less likely to be transfused red blood cells (8.1% vs. 79.4%) or other blood products (FFP 6.6% vs. 29.0%,
platelets 10.1% vs. 36.8%, cryoprecipitate 1.6% vs. 10.0%) intra-operatively and/or postoperatively. EQ-5D-3L
scores were similar. A higher proportion of non-randomised participants were alive at hospital discharge
(raw percentages, not taking differences in the composition of the subpopulations, were 99.3% vs. 97.9%).
Haemoglobin levels were considerably higher for non-randomised participants than randomised participants
(Figure 4), with differences being highest in the first 24 hours postoperatively.
TABLE 7 Characteristics of patients included and excluded in study
Characteristic
Excluded from study
Included in study
(N= 3565)
PIL not sent
(N= 3055)
Not approached
(N= 1863)
Ineligible
(N= 281)
Did not consent
(N= 2719)
Age (years),
median (IQR)
71.0 (62.0–78.0) 70.0 (61.0–76.0) 71.0 (61.0–77.0) 71.0 (63.0–77.0) 68.0 (61.0–75.0)
Males, n (%) 2077 (68.0) 1303 (69.9) 170 (60.5) 1730 (63.6) 2687 (75.4)
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TABLE 8 Characteristics of randomised and non-randomised participants
Characteristic
Consented not randomised
(N= 1464)
Randomised
(N= 2003)
Cardiac history
EuroSCORE,a median (IQR) 4.0 (2.0–5.0) 5.0 (3.0–7.0)
NYHA class, n/N (%)
I 420/1426 (29.5) 493/1951 (25.3)
II 683/1426 (47.9) 885/1951 (45.4)
III 301/1426 (21.1) 525/1951 (26.9)
IV 22/1426 (1.5) 48/1951 (2.5)
CCS class, n/N (%)
No angina 437/1430 (30.6) 718/1962 (36.6)
I 260/1430 (18.2) 362/1962 (18.5)
II 451/1430 (31.5) 526/1962 (26.8)
III 236/1430 (16.5) 281/1962 (14.3)
IV 46/1430 (3.2) 75/1962 (3.8)
Pacemaker, n/N (%)
No 1420/1464 (97.0) 1940/2002 (96.9)
Temporary 10/1464 (0.7) 10/2002 (0.5)
Permanent 34/1464 (2.3) 52/2002 (2.6)
Heart rhythm, n/N (%)
AF/flutter 165/1463 (11.3) 250/1998 (12.5)
Heart block 14/1463 (1.0) 43/1998 (2.2)
Sinus 1284/1463 (87.8) 1705/1998 (85.3)
Coronary disease, n/N (%)
None 365/1462 (25.0) 620/1991 (31.1)
Single vessel 162/1462 (11.1) 225/1991 (11.3)
Double vessel 213/1462 (14.6) 282/1991 (14.2)
Triple vessel 660/1462 (45.1) 805/1991 (40.4)
Not investigated 62/1462 (4.2) 59/1991 (3.0)
Disease in left main stem (> 50% stenosis),
n/N (%)
224/1450 (15.4) 304/1977 (15.4)
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TABLE 8 Characteristics of randomised and non-randomised participants (continued )
Characteristic
Consented not randomised
(N= 1464)
Randomised
(N= 2003)
Non-cardiac history
Age (years), median (IQR) 66.5 (59.5–73.1) 70.3 (63.5–76.4)
Males, n/N (%) 1241/1464 (84.8) 1373/2003 (68.5)
BMI (kg/m2),b mean (SD) 29.5 (4.8) 28.2 (4.9)
Urgent operative priority, n/N (%) 132/1464 (9.0) 245/2003 (12.2)
Diabetic, n/N (%)
No diabetes 1191/1464 (81.4) 1604/2003 (80.1)
Diet controlled 54/1464 (3.7) 69/2003 (3.4)
Insulin 61/1464 (4.2) 98/2003 (4.9)
Oral medication 158/1464 (10.8) 232/2003 (11.6)
Smoker, n/N (%)
Non-smoker 668/1464 (45.6) 928/2002 (46.4)
Ex-smoker (> 1 month) 652/1464 (44.5) 922/2002 (46.1)
Current smoker 144/1464 (9.8) 152/2002 (7.6)
Haemofiltration/dialysis, n/N (%) 4/1464 (0.3) 19/2001 (0.9)
CVA/TIA, n/N (%) 108/1464 (7.4) 163/2003 (8.1)
Pre-operative tests
Haemoglobin (g/dl), mean (SD) 14.4 (1.3) 13.3 (1.5)
eGFRb (ml/minute/1.73m2) median (IQR) 85.7 (69.2–108) 73.9 (56.8–93.2)
Medications
Intravenous nitrates until theatre, n/N (%) 12/1463 (0.8) 5/2002 (0.2)
Unfractionated intravenous heparin within 6 hours of surgery,
n/N (%)
17/1463 (1.2) 19/2002 (0.9)
Low-molecular-weight heparin within 12 hours
of surgery, n/N (%)
14/1463 (1.0) 23/2002 (1.1)
Inotropes until theatre, n/N (%) 7/1463 (0.5) 3/2002 (0.1)
Aspirin within 5 days of surgery, n/N (%) 302/1462 (20.7) 561/1999 (28.1)
Clopidogrel within 5 days of surgery, n/N (%) 32/1463 (2.2) 78/2000 (3.9)
Operative details
Cardiac procedure, n/N (%)
CABG only 800/1464 (54.6) 814/2003 (40.6)
Valve only 382/1464 (26.1) 597/2003 (29.8)
CABG and valve 189/1464 (12.9) 393/2003 (19.6)
Other 93/1464 (6.4) 199/2003 (9.9)
Alive at end of surgery, n/N (%) 1464/1464 (100) 2003/2003 (100)
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TABLE 8 Characteristics of randomised and non-randomised participants (continued )
Characteristic
Consented not randomised
(N= 1464)
Randomised
(N= 2003)
Transfusions (intra-operative and postoperative)
Red blood cells, n/N (%) 119/1464 (8.1) 1591/2003 (79.4)
FFP, n/N (%) 97/1464 (6.6) 581/2003 (29.0)
Platelets, n/N (%) 148/1464 (10.1) 738/2003 (36.8)
Cryoprecipitate, n/N (%) 23/1464 (1.6) 201/2003 (10.0)
Activated factor VII used, n/N (%) 3/1464 (0.2) 12/2003 (0.6)
Beriplex used, n/N (%) 52/1464 (3.6) 100/2003 (5.0)
EQ-5D-3L scores
Pre-operative utility,c median (IQR) 0.8 (0.7–1.0) 0.8 (0.7–1.0)
3-month post-operative utility,d median (IQR) 0.8 (0.7–1.0) 0.8 (0.7–1.0)
Pre-operative visual analogue score,e median (IQR) 75.0 (60.0–85.0) 70.0 (53.0–80.0)
3-month post-operative visual analogue score,f median (IQR) 80.0 (70.0–90.0) 80.0 (70.0–90.0)
Mortality
Alive at hospital discharge, n/N (%) 1454/1464 (99.3) 1961/2003 (97.9)
AF, atrial fibrillation; BMI, body mass index; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident;
NYHA, New York Health Association; TIA, transient ischemic attack.
a Missing for 19 consented not randomised participants and 38 randomised participants.
b Missing for one randomised participant.
c Missing for 243 consented not randomised participants and 20 randomised participants.
d Missing for 585 consented not randomised participants and 331 randomised participants.
e Missing for 247 consented not randomised participants and 19 randomised participants.
f Missing for 576 consented not randomised participants and 318 randomised participants.
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FIGURE 4 Daily mean nadir haemoglobin levels for randomised/non-randomised participants. The numbers
alongside the points are the numbers of participants contributing readings for that data point. The x-axis has an
origin of the day of surgery for both groups.
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Withdrawals
Participant withdrawals and clinician discontinuations of treatment are summarised in Table 9. Prior to
randomisation there were eight participants who withdrew consent, seven of whom did so pre-operatively.
There were also 33 pre-randomisation decisions by clinicians to discontinue treatment according to the
allocation, 17 of which occurred pre-operatively. The most common reason for discontinuation was the
participant’s condition (13 participants).
A further 17 participants (seven in the restrictive group and 10 in the liberal group) withdrew consent after
randomisation but before hospital discharge, of whom four were unhappy for data collected to be used (all in
the restrictive group) and a further three were unhappy for follow-up to continue. The most common reason for
TABLE 9 Participant withdrawals and clinician decisions to discontinue treatment
Pre-randomisation
Withdrawal/discontinuation of treatment type
Total consented
participants
(n= 3565)
Participant withdrawals 8 (0.2%)
Timing
Pre-surgery 7
Post surgery but pre-randomisation 1
Reason
After discussion with family decided to withdraw 2
Surgery rearranged and participant no longer
happy to take part
2
Participant decided to take part in another study 1
No reason given 3
Clinician treatment discontinuations 33 (0.9%)
Timing
Pre-surgery 17
Post surgery but pre-randomisation 16
Reason
Condition of participant 13
Complex procedure 4
Clinician wants haemoglobin at a specific level 5
Change of planned operation 5
Change of surgeon 6
Post randomisation but pre-hospital discharge
Withdrawl/discontinuation of treatment type
Randomised to
restrictive threshold
(n= 1004)
Randomised to
liberal threshold
(n= 1003)
Total randomised
participants
(N= 2007)
Participant withdrawals 7 (0.7%) 10 (1.0%) 17 (0.8%)
Participant happy for data already collected to be used 3 10 13
Participant happy to participate in follow-up 2 8 10
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TABLE 9 Participant withdrawals and clinician decisions to discontinue treatment (continued )
Post randomisation but pre-hospital discharge
Withdrawl/discontinuation of treatment type
Randomised to
restrictive threshold
(n= 1004)
Randomised to
liberal threshold
(n= 1003)
Total randomised
participants
(N= 2007)
Reason
Wants normal care 2a 0 2
Post-operative problems, does not want further
intervention
2 2 4
Unhappy with allocation 0 1 1
Does not want any more transfusions 0 6 6
Blood products given before and after surgery 1b 0 1
Ineligibility (discovered post randomisation) 1c 0 1
No reason given 1 1 2
Clinician treatment discontinuations 28 (2.8%) 19 (1.9%) 47 (2.3%)
Reason
Participant too unstable/unwell 16 6 22
Clinician does not want participant to have any
more blood
1b 7 8
Clinician wants participant to have more blood 1 0 1
Clinician wants to transfuse at higher haemoglobin 6a 0 6
Clinician wants to transfuse at lower haemoglobin 1 1 2
Participant already had many breaches of threshold 0 2 2
Reaction to blood 0 1 1
Continued participation would prolong hospital
stay
0 1 1
Ineligibility (discovered post randomisation) 1c 0 1
Clinical need (no further details given) 1 0 1
No reason given 1 1 2
Post-hospital discharge
Participant withdrawals 4 (0.4%) 10 (1.0%) 14 (0.7%)
Reason
Participant too ill/had complications 0 5 5
Participant not contactable as lives abroad 1 1 2
Requests no further questionnaires/contact 1 3 4
No reason given 2 1 3
a One participant withdrew because he/she wanted normal care and the clinician responsible discontinued treatment
because he/she wanted to transfuse the participant at a higher haemoglobin than the allocated threshold.
b One participant withdrew because of having already had blood products before and after surgery and the clinician
responsible discontinued treatment because he/she did not want the participant to have any further transfusions.
c One participant was withdrawn after randomisation because he/she was found to be ineligible on account of critical limb
ischaemia. This comorbidity was not apparent at the time of consent, but was documented after randomisation on the
basis of a Doppler blood flow investigation.
A total of 17 participants were included in the analysis dataset at hospital discharge but excluded prior to follow-up
(see Figure 2); the 14 participants who withdrew post discharge plus three participants who withdrew pre-discharge were
unhappy for follow-up to continue but happy for data collected so far to be used.
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withdrawal was that the participant did not want any more transfusions (six participants, all in the liberal group).
Clinicians decided to discontinue treatment according to the allocation after randomisation for 47 participants
(28 in the restrictive group and 19 in the liberal group), the most common reason being that the participant was
too unstable/unwell (22 participants, 16 in the restrictive group and six in the liberal group). Making such a
decision did not necessarily mean that the clinician had a definitive opinion about the transfusion needs of the
participant but, often, simply that the clinician considered the additional uncertainty or constraint created by
the randomised treatment allocation to be undesirable when managing some critically ill participants. Three
participants both withdrew and had their treatment discontinued (all in the restrictive group). A further
14 participants withdrew after hospital discharge (four in the restrictive group and 10 in the liberal group).
Participant follow-up
Follow-up data at 3 months post randomisation were obtained for 1978 participants (992 in the restrictive
group and 986 in the liberal group), 98.7% of the 2003 eligible participants (see Figure 2). The
questionnaire was completed by 1856 participants and by the research team from information supplied by
the participant’s GP for 50 participants. Relevant information was extracted from the death certificate for a
further 68 participants who died. For the remaining four participants, information on hospital admissions
only (which provided the required data to ascertain the primary outcome) was provided by sites. Of the
25 participants with no follow-up data, 17 had withdrawn consent or requested no further contact;
the remaining eight were lost to follow-up.
For randomised participants, EQ-5D-3L data were collected for almost all participants (1995/2003)
pre-operatively, for 1620/2003 (80.9%) at 6 weeks and 1694/2003 (84.6%) at 3 months post
randomisation (see Figure 2). Of the 1464 participants considered for randomisation who were not
randomised, EQ-5D-3L data were collected for 1225 participants (83.7%) pre-operatively and
891 participants (60.9%) at 3 months post randomisation.
Numbers analysed
The analysis population consisted of 2003 participants, that is the 2007 randomised participants excluding
four withdrawn participants who were unhappy for their data to be used. Primary outcome data were
available for 1906 participants (95.2%). For most of the secondary outcomes, very few data were missing
with the exception of the infectious event component of the primary outcome and the EQ-5D-3L
(see Participant follow-up). Post-operative complication data up to 3 months after randomisation were
complete for 1982 participants (99.0%).
Baseline data and operative characteristics
Baseline characteristics are summarised in Table 10 and intraoperative characteristics in Table 11. The median
additive EuroSCORE was 5 (IQR 3–7) and logistic EuroSCORE was 4.0 (IQR 2.2–7.2). The median age was
70.3 years (IQR 63.5–76.4 years) and 68.5% of participants were male. Just fewer than 20% of participants
were diabetic and 12.2% required urgent operations (i.e. urgent operative priority). Pre-operative haemoglobin
concentrations had a mean value of 13.3 g/dl (SD 1.5 g/dl) and the median eGFR was 73.8ml/minute/1.73m2
(IQR 56.8–93.2ml/minute/1.73m2). In terms of intraoperative characteristics, the median duration of operation
was 4.0 hours (IQR 3.3–5.0 hours) and 95.1% of operations were performed using cardiopulmonary bypass
(CPB). Most operations were either isolated CABG (40.7%) or valve (30.5%) procedures. Tranexamic acid was
used in 80.7% of procedures. All pre-operative and intraoperative characteristics were generally well balanced
between the two groups, although the logistic EuroSCORE was slightly higher in the liberal group than the
restrictive group [median 4.3 (IQR 2.4–7.5) vs. 3.8 (IQR 2.1–7.0)]. Pre-randomisation red blood cell transfusions
are described in Chapter 4 and EQ-5D-3L scores in Chapter 5.
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TABLE 10 Participant demography and past history
Characteristic
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
Cardiac history
Additive EuroSCORE,a median (IQR) 5.0 (3.0–7.0) 5.0 (3.0–7.0) 5.0 (3.0–7.0)
Logistic EuroSCORE,a median (IQR) 3.8 (2.1–7.0) 4.3 (2.4–7.5) 4.0 (2.2–7.2)
NYHA class, n/N (%)
I 235/997 (24.1) 258/974 (26.5) 493/1951 (25.3)
II 445/997 (45.5) 440/974 (45.2) 885/1951 (45.4)
III 268/997 (27.4) 257/974 (26.4) 525/1951 (26.9)
IV 29/997 (3.0) 19/974 (2.0) 48/1951 (2.5)
CCS class, n/N (%)
No angina 365/982 (37.2) 353/980 (36.0) 718/1962 (36.6)
I 169/982 (17.2) 193/980 (19.7) 362/1962 (18.5)
II 273/982 (27.8) 253/980 (25.8) 526/1962 (26.8)
III 139/982 (14.2) 142/980 (14.5) 281/1962 (14.3)
IV 36/982 (3.7) 39/980 (4.0) 75/1962 (3.8)
Pacemaker, n/N (%)
No 972/1000 (97.2) 968/1002 (96.6) 1940/2002 (96.9)
Temporary 7/1000 (0.7) 3/1002 (0.3) 10/2002 (0.5)
Permanent 21/1000 (2.1) 31/1002 (3.1) 52/2002 (2.6)
Heart rhythm, n/N (%)
AF/flutter 119/997 (11.9) 131/1001 (13.1) 250/1998 (12.5)
Heart block 18/997 (1.8) 25/1001 (2.5) 43/1998 (2.2)
Sinus 860/997 (86.3) 845/1001 (84.4) 1705/1998 (85.3)
Coronary disease, n/N (%)
None 310/993 (31.2) 310/998 (31.1) 620/1991 (31.1)
Single vessel 112/993 (11.3) 113/998 (11.3) 225/1991 (11.3)
Double vessel 132/993 (13.3) 150/998 (15.0) 282/1991 (14.2)
Triple vessel 403/993 (40.6) 402/998 (40.3) 805/1991 (40.4)
Not investigated 36/993 (3.6) 23/998 (2.3) 59/1991 (3.0)
Disease in left main stem (> 50% stenosis) 159/987 (16.1) 145/990 (14.6) 304/1977 (15.4)
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TABLE 10 Participant demography and past history (continued )
Characteristic
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
Non-cardiac history
Age (years), median (IQR) 69.9 (63.1–76.0) 70.8 (64.1–76.7) 70.3 (63.5–76.4)
Males, n/N (%) 693/1000 (69.3) 680/1003 (67.8) 1373/2003 (68.5)
BMI (kg/m2),b mean (SD) 28.2 (5.0) 28.2 (4.9) 28.2 (4.9)
Urgent operative priority, n/N (%) 126/1000 (12.6) 119/1003 (11.9) 245/2003 (12.2)
Diabetic, n/N (%)
No diabetes 802/1000 (80.2) 802/1003 (80.0) 1604/2003 (80.1)
Diet controlled 33/1000 (3.3) 36/1003 (3.6) 69/2003 (3.4)
Insulin 49/1000 (4.9) 49/1003 (4.9) 98/2003 (4.9)
Oral medication 116/1000 (11.6) 116/1003 (11.6) 232/2003 (11.6)
Smoker, n/N (%)
Non-smoker 461/1000 (46.1) 467/1002 (46.6) 928/2002 (46.4)
Ex-smoker (> 1 month) 472/1000 (47.2) 450/1002 (44.9) 922/2002 (46.1)
Current smoker 67/1000 (6.7) 85/1002 (8.5) 152/2002 (7.6)
Haemofiltration/dialysis, n/N (%) 7/999 (0.7) 12/1002 (1.2) 19/2001 (0.9)
CVA/TIA, n/N (%) 76/1000 (7.6) 87/1003 (8.7) 163/2003 (8.1)
Pre-operative tests
Haemoglobin (g/dl) mean (SD) 13.3 (1.5) 13.3 (1.5) 13.3 (1.5)
eGFRc (ml/minute/1.73m2) median (IQR) 74.5 (57.2–92.9) 72.8 (56.4–93.2) 73.8 (56.8–93.2)
Medications
Intravenous nitrates until theatre, n/N (%) 1/1000 (0.1) 4/1002 (0.4) 5/2002 (0.2)
Unfractionated intravenous heparin within 6 hours of
surgery, n/N (%)
10/1000 (1.0) 9/1002 (0.9) 19/2002 (0.9)
Low-molecular-weight heparin within 12 hours of
surgery, n/N (%)
13/1000 (1.3) 10/1002 (1.0) 23/2002 (1.1)
Inotropes until theatre, n/N (%) 2/1000 (0.2) 1/1002 (0.1) 3/2002 (0.1)
Aspirin within 5 days of surgery, n/N (%) 277/999 (27.7) 284/1000 (28.4) 561/1999 (28.1)
Clopidogrel within 5 days of surgery, n/N (%) 41/1000 (4.1) 37/1000 (3.7) 78/2000 (3.9)
AF, atrial fibrillation; BMI, body mass index; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular event;
NYHA, New York Health Association; TIA, transient ischaemic attack.
a Missing for 17 restrictive group participants and 21 liberal group participants.
b Missing for one liberal group participant.
c Missing for two liberal group participants.
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TABLE 11 Operative characteristics
Characteristic
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
Duration of operationa (hours) median (IQR) 4.0 (3.3–5.0) 4.0 (3.2–5.0) 4.0 (3.3–5.0)
Lowest haematocrit,b mean (SD) 25.5 (4.2) 25.6 (4.4) 25.6 (4.3)
CPB used, n/N (%) 950/999 (95.1) 953/1003 (5.0) 1903/2002 (5.1)
If yes: total bypass time (minutes), median (IQR) 97.0 (77.0–132) 95.0 (75.0–127) 96.0 (76.0–129)
If yes: cumulative cross-clamp timec (minutes),
median (IQR)
66.0 (48.0–92.0) 63.0 (46.0–86.0) 65.0 (47.0–90.0)
If yes: myocardial protection, n/N (%)
Blood 796/948 (84.0) 809/952 (85.0) 1605/1900 (84.5)
Crystalloid 107/948 (11.3) 110/952 (11.6) 217/1900 (11.4)
Other 30/948 (3.2) 22/952 (2.3) 52/1900 (2.7)
NA 15/948 (1.6) 11/952 (1.2) 26/1900 (1.4)
Operation type
Cardiac procedure, n/N (%)
CABG only 408/1000 (40.8) 408/1003 (40.7) 816/2003 (40.7)
Valve only 307/1000 (30.7) 304/1003 (30.3) 611/2003 (30.5)
CABG+ valve 195/1000 (19.5) 203/1003 (20.2) 398/2003 (19.9)
Major aortic procedure 54/1000 (5.4) 62/1003 (6.2) 116/2003 (5.8)
Other procedure 36/1000 (3.6) 26/1003 (2.6) 62/2003 (3.0)
Number of distal coronary anastomoses, n/N (%)
0 374/1000 (37.4) 369/1002 (36.8) 743/2002 (37.1)
1 114/1000 (11.4) 124/1002 (12.4) 238/2002 (11.9)
2 165/1000 (16.5) 137/1002 (13.7) 302/2002 (15.1)
3 234/1000 (23.4) 267/1002 (26.6) 501/2002 (25.0)
4 99/1000 (9.9) 92/1002 (9.2) 191/2002 (9.5)
5 14/1000 (1.4) 12/1002 (1.2) 26/2002 (1.3)
6 0/1000 (0.0) 1/1002 (0.1) 1/2002 (0.0)
Aortic valve replaced/repaired, n/N (%) 431/999 (43.1) 456/1003 (45.5) 887/2002 (44.3)
MV replaced/repaired, n/N (%) 154/999 (15.4) 143/1003 (14.3) 297/2002 (14.8)
TV replaced/repaired, n/N (%) 32/999 (3.2) 33/1003 (3.3) 65/2002 (3.2)
Pulmonary valve replaced/repaired, n/N (%) 7/999 (0.7) 3/1003 (0.3) 10/2002 (0.5)
Details of other cardiac procedures, n
Ablation for AF 1 0 1
Atrial septal defect closure 1 0 1
Atrial septal defect closure+ radiofrequency ablation
for AF
1 0 1
AVR+ biopsy of lesion of wall of heart 1 0 1
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TABLE 11 Operative characteristics (continued )
Characteristic
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
AVR, left atrial appendage occlusion+ pulmonary vein
isolation
0 1 1
AVR, Cox-Maze procedure+ left atrial appendage
occlusion
0 1 1
AVR, MVR, ablation for AF+ left atrial Cox-Maze
procedure
1 0 1
AVR, MVR, TV repair, left atrial appendage
removal+ radiofrequency ablation for AF
1 0 1
AVR, TV repair +/– MVR, ablation for AF+ left atrial
appendage occlusion
0 1 1
AVR +/– TV repair+Morrow procedure 0 1 1
CABG+ ablation for AF 1 0 1
CABG+ aneurysmectomy 3 0 3
CABG, AVR+ left atrial appendage occlusion 0 1 1
CABG, AVR, Cox-Maze procedure+ left atrial
appendage occlusion
1 0 1
CABG+ left atrial appendage occlusion 0 1 1
CABG+ left ventricular pacing lead 0 1 1
CABG+Cox-Maze procedure 3 0 3
CABG, MV repair+ ablation for AF 0 1 1
CABG, MV repair+ left ventricular lead placement 1 0 1
CABG, MV repair+Cox-Maze procedure 0 1 1
CABG, MV repair+myomectomy 1 0 1
CABG, MV repair, TV repair+Cox-Maze procedure 0 1 1
CABG, MVR+ left ventricular aneurysm 0 1 1
CABG, TV repair+ atrial septal defect closure 1 0 1
CABG, valve+Cox-Maze procedure 1 0 1
CABG, valve+ replacement of aneurysmal segment 0 1 1
CABG, valve replacement+ thymectomy 1 0 1
Excision of atrial myxoma 0 1 1
Left apical aneurysmectomy 0 1 1
MV repair+ ablation for AF 2 2 4
MV repair+ atrial septal defect closure+ tricuspid 0 1 1
MV repair, left atrial appendage occlusion+ patent
foramen ovale closure
1 0 1
MV repair+Cox-Maze procedure 0 1 1
MV repair, MV ring+ pulmonary vein isolation
ablation
0 1 1
MV repair+ TV repair 2 1 3
MVR+ ablation for AF 1 0 1
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TABLE 11 Operative characteristics (continued )
Characteristic
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
MVR+ artificial chordae 1 0 1
MVR+ patent foramen ovale closure 1 0 1
MVR+ TV repair 0 1 1
MVR, TV repair+ ablation for AF 2 0 2
MVR, TV repair+Cox-Maze procedure 1 0 1
MVR, TV repair+ left atrial appendage occlusion 0 1 1
MVR, TV repair+ patent foramen ovale closure 0 1 1
MVR, TV repair, patent foramen ovale closure+Cox-Maze
procedure
1 1 2
MVR +/– TV repair, patent foramen ovale closure,
left atrial appendage ligation +/– radiofrequency
ablation for AF
1 0 1
Reimplantation of anomalous right coronary artery 1 0 1
TV repair+ atrial septal defect closure 0 1 1
TV repair, Cox-Maze procedure, ablation for
AF+ excision of LATR
1 0 1
TV repair, MV repair, left atrial appendage
occlusion+ left sided Cox-Maze procedure
1 0 1
Valve+ ablation for AF 0 1 1
Valve+ radiofrequency ablation for AF 1 0 1
Graft conduit harvest sites
Right arm, n/N (%) 3/1000 (0.3) 3/1003 (0.3) 6/2003 (0.3)
Left arm, n/N (%) 40/1000 (4.0) 38/1003 (3.8) 78/2003 (3.9)
Right leg, n/N (%) 212/999 (21.2) 200/1003 (19.9) 412/2002 (20.6)
Left leg, n/N (%) 416/999 (41.6) 416/1003 (41.5) 832/2002 (41.6)
Left internal mammary artery, n/N (%) 488/1000 (48.8) 495/1003 (49.4) 983/2003 (49.1)
Right internal mammary artery, n/N (%) 19/1000 (1.9) 32/1003 (3.2) 51/2003 (2.5)
Other, n/N (%) 7/1000 (0.7) 10/1003 (1.0) 17/2003 (0.8)
Blood saving techniques
Tranexamic acid, n/N (%) 806/999 (80.7) 809/1002 (80.7) 1615/2001 (80.7)
Trasylol, n/N (%) 39/942 (4.1) 32/952 (3.4) 71/1894 (3.7)
Cell saver, n/N (%) 481/999 (48.1) 503/1003 (50.1) 984/2002 (49.2)
AF, atrial fibrillation; AVR, aortic valve replacement; MV, mitral valve; MVR, mitral valve replacement; NA, not applicable;
TV, tricuspid valve.
a Missing for one restrictive group participant.
b Missing for 280 restrictive group participants and 274 liberal group participants.
c Missing for one restrictive group participant and one liberal group participant.
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Post-operative characteristics that were not specified explicitly as primary or secondary outcomes are
summarised in Table 12 and Figure 5. The median haemoglobin at randomisation was 8.5 g/dl
(IQR 8.1–8.8 g/dl), the median time between end of surgery and randomisation was 4.9 hours
(IQR 1.7–17.7 hours) and the median post-randomisation ventilation time was 3.6 hours (IQR 0.0–10.2
hours). The majority of participants (88.2%) were discharged after cardiac surgery to their homes. There
did not appear to be any important difference between the two groups, although the total chest tube
drainage at 12 hours was slightly higher in the restrictive group than the liberal group [median 500ml
(IQR 325–790ml) vs. 475ml (IQR 300–750ml)].
TABLE 12 Post-operative characteristics
Characteristic
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
Medications used in theatre/postoperatively
Hydroxyethyl starch, n/N (%) 230/996 (23.1) 233/1002 (23.3) 463/1998 (23.2)
Human albumin solution (Zenalb, Bio Products
Laboratory Ltd), n/N (%)
79/996 (7.9) 90/1002 (9.0) 169/1998 (8.5)
Gelofusine, n/N (%) 839/996 (84.2) 834/1001 (83.3) 1673/1997 (83.8)
Inotropes, n/N (%) 620/995 (62.3) 612/1000 (61.2) 1232/1995 (61.8)
Randomisation
Haemoglobin at randomisation (g/dl), median (IQR) 8.5 (8.1–8.8) 8.5 (8.1–8.8) 8.5 (8.1–8.8)
Time from surgery to randomisationa (hours),
median (IQR)
5.0 (1.7–17.8) 4.8 (1.7–17.4) 4.9 (1.7–17.7)
Post-operative details
Total chest tube drainage at 4 hours (ml),b median
(IQR)
250 (150–425) 240 (150–400) 250 (150–425)
Total chest tube drainage at 12 hours (ml),b
median (IQR)
500 (325–790) 475 (300–750) 480 (320–760)
Post-operation cell salvage used, n/N (%) 55/989 (5.6) 45/989 (4.6) 100/1978 (5.1)
Post-randomisation ventilation time (hours),c
median (IQR)
3.6 (0.0–11.0) 3.6 (0.0–9.5) 3.6 (0.0–10.2)
Duration of post-randomisation ward stay (hours),d
median (IQR)
102 (74.1–164) 104 (75.1–152) 103 (75.0–152)
Discharged from cardiac surgery unit to, n/N (%)
Another unit in hospitale 9/1000 (0.9) 18/1003 (1.8) 27/2003 (1.3)
Home 882/1000 (88.2) 885/1003 (88.2) 1767/2003 (88.2)
Other hospital 74/1000 (7.4) 74/1003 (7.4) 148/2003 (7.4)
Other 35/1000 (3.5) 26/1003 (2.6) 61/2003 (3.0)
a Missing for 1 restrictive group participant.
b Missing for 2 restrictive group participants and 1 liberal group participant.
c There were 341 restrictive group participants and 351 liberal group participants with a post-randomisation ventilation
time of zero. 32 restrictive group participants and 29 liberal group participants had censored observations. 63 restrictive
group participants were re-intubated (59 once, 2 twice, 1 three times and 1 four times) and 60 liberal group participants
(50 once, 7 twice and 3 three times).
d There were 44 restrictive group participants and 44 liberal group participants with a post-randomisation ward stay of
zero. 2 restrictive group participants and 2 liberal group participants had censored observations. 18 restrictive group
participants were readmitted to the ward (14 once, 3 twice and 1 three times) and 19 liberal group participants
(18 once and 1 three times).
e The median LOS in the other unit in the hospital was 6 days (IQR 3–26 days) in the restrictive group and 14 days
(IQR 3–32 days) in the liberal group.
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Success of blinding
At discharge, 152 participants of the 1007 questioned thought they knew which group they were
allocated to (15.1%), of whom 115 (75.7%) were correct (Table 13). At the 3-month follow-up more
participants thought they knew which group they were allocated to (459/1669; 27.5%) but
proportionately fewer participants (260/459; 56.6%) were correct. More participants thought that being in
the liberal group would be better than the restrictive group, although the proportion was higher at
discharge (864/1003; 86.1%) than at follow-up (172/278; 61.9%).
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FIGURE 5 Daily highest creatinine levels for randomised/non-randomised participants. The numbers alongside the
points are the numbers of participants contributing readings for that data point. The x-axis has an origin of the
day of randomisation for both groups.
TABLE 13 Success of blinding
Described by treatment group
Aspect of blinding
Randomised to
restrictive threshold
(n= 1000)
Randomised to
liberal threshold
(n= 1003)
Overall
(n= 2003)
At hospital discharge
Did the participant think being in one group would be
better, if so whicha
Restrictive 74 65 139
Liberal 422 442 864
Did not know 1 3 4
Did the participant think they knew which group they were
in, if so whicha
Restrictive 51 21 72
Liberal 16 64 80
Did not know 430 425 855
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TABLE 13 Success of blinding (continued )
Described by treatment group
Aspect of blinding
Randomised to
restrictive threshold
(n= 1000)
Randomised to
liberal threshold
(n= 1003)
Overall
(n= 2003)
At 3-month follow-up
Did the participant think being in one group would be
better, if so whichb
Restrictive 65 41 106
Liberal 86 86 172
Thought one group was better, did not specify which 12 8 20
Did not think one group was any better 553 612 1165
Did the participant think they knew which group they were
in, if so whichc
Restrictive 158 99 257
Liberal 54 102 156
Thought knew which group, did not specify which 21 25 46
Did not know which group they were in 581 629 1210
Description of data at hospital discharge vs. data at 3-month follow-up
Hospital discharge
At 3-month follow-up
Restrictive Liberal
Thought one group
was better, did not
specify which
Did not think
one group was
any better
Did not
answer
question
Did the participant think being in
one group would be better, if so
which
Restrictive 16 21 3 77 22
Liberal 38 69 6 547 204
Did not know 0 1 0 1 2
Unavailable to answer questions 52 81 11 540 312
Restrictive Liberal
Thought knew
which group, did
not specify which
Did not think
one group was
any better
Did not
answer
question
Did the participant think they knew
which group they were in, if so
which
Restrictive 31 5 4 25 7
Liberal 10 23 4 41 2
Did not know 102 50 14 576 113
Unavailable to answer questions 114 78 24 568 212
a 503 restrictive group participants and 493 liberal group participants were unavailable to answer questions at
hospital discharge.
b 284 restrictive group participants and 256 liberal group participants did not answer question.
c 186 restrictive group participants and 148 liberal group participants did not answer question.
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Summary
There is some uncertainty about screening data and there were recruitment challenges throughout the
trial. However, a significant upturn in recruitment in late 2011 led to the trial completing recruitment just
2 weeks behind the revised target date. Data completeness is excellent and withdrawals and drop-out
rates were few; over 98% of participants were followed up 3 months after randomisation. Baseline
characteristics were well balanced between the groups.
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Chapter 4 Process outcomes
Haemoglobin levels
Haemoglobin levels at the time of randomisation were similar [median 8.5 g/dl (IQR 8.1–8.8 g/dl)] in both
the restrictive and liberal groups (see Table 12). After randomisation the groups diverged, daily nadir
haemoglobin levels were lower in the restrictive group than the liberal group by approximately 1 g/dl
(Figure 6). Day three was pre-specified in the SAP to be used as an overall summary measure; at this time
the mean haemoglobin was 8.66 g/dl (SD 1.03 g/dl) in the restrictive group and 9.55 g/dl (SD 1.01 g/dl) in
the liberal group.
Red blood cell transfusions
Red blood cell transfusions both before and after randomisation are given in Figure 7 and Table 14. Before
randomisation, 25.7% of participants were transfused one or more units, with approximately equal
numbers of transfused participants in each group. Most of the pre-randomisation red blood cell
transfusions were administered intraoperatively and the remaining were given either postoperatively but
pre-randomisation or during a reoperation. After randomisation, 53.4% of participants in the restrictive
group and 92.2% in the liberal group were transfused one or more units (RR 0.58, 95% CI 0.54 to 0.62;
p< 0.0001). The median numbers of red blood cell units transfused after randomisation in the restrictive
and liberal groups were 1 unit (IQR 0–2 units) and 2 units (IQR 1–3 units), respectively, and 1494 units
were transfused in the restrictive group and 2494 units in the liberal group in total. Most red blood cell
units were transfused according to the trial protocol; a small number were given either during a
reoperation (when the trial protocol was suspended), after treatment according to allocation was
discontinued, or in breach of the protocol. During the entire index admission (i.e. pre-randomisation and/or
post randomisation), 63.7% of participants in the restrictive group and 94.9% in the liberal group were
transfused. The median numbers of units transfused in the index admission was 1 (IQR 0–3) in the
restrictive group and 2 (IQR 1–4) in the liberal group.
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FIGURE 6 Mean daily nadir haemoglobin. The error bars are SDs (calculated independently at each time point).
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FIGURE 7 Secondary outcome: pre-randomisation and post-randomisation red blood cell transfusions.
(a) Pre-randomisation red blood cell transfusions.
(b) Post-randomisation red blood cell transfusions.
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TABLE 14 Red blood cell transfusions
Outcome
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
RRa
(95% CI) p-value
Pre-randomisation transfusions
Total units transfused
pre-randomisation,
n/N (%)
Median (IQR) units 0.0 (0.0–0.5) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Not transfused 750/1000 (75.0) 739/1003 (73.7) 1489/2003 (74.3)
1 unit 90/1000 (9.0) 109/1003 (10.9) 199/2003 (9.9)
2 units 89/1000 (8.9) 79/1003 (7.9) 168/2003 (8.4)
3 units 32/1000 (3.2) 33/1003 (3.3) 65/2003 (3.2)
4 units 16/1000 (1.6) 21/1003 (2.1) 37/2003 (1.8)
≥ 5 units 23/1000 (2.3) 22/1003 (2.2) 45/2003 (2.2)
Total units transfused 587 589 1176
Intraoperative
transfusions, n/N (%)
Not transfused 816/1000 (81.6) 823/1003 (82.1) 1639/2003 (81.8)
1 unit 69/1000 (6.9) 69/1003 (6.9) 138/2003 (6.9)
2 units 71/1000 (7.1) 67/1003 (6.7) 138/2003 (6.9)
3 units 18/1000 (1.8) 18/1003 (1.8) 36/2003 (1.8)
4 units 14/1000 (1.4) 18/1003 (1.8) 32/2003 (1.6)
≥ 5 units 12/1000 (1.2) 8/1003 (0.8) 20/2003 (1.0)
Post-operative
pre-randomisation
transfusions, n/N (%)
Not transfused 911/1000 (91.1) 894/1003 (89.1) 1805/2003 (90.1)
1 unit 45/1000 (4.5) 68/1003 (6.8) 113/2003 (5.6)
2 units 26/1000 (2.6) 22/1003 (2.2) 48/2003 (2.4)
3 units 10/1000 (1.0) 10/1003 (1.0) 20/2003 (1.0)
4 units 7/1000 (0.7) 4/1003 (0.4) 11/2003 (0.5)
≥ 5 units 1/1000 (0.1) 5/1003 (0.5) 6/2003 (0.3)
Transfusions during a
pre-randomisation
reoperation, n/N (%)
Not transfused 986/1000 (98.6) 992/1003 (98.9) 1978/2003 (98.8)
1 unit 6/1000 (0.6) 2/1003 (0.2) 8/2003 (0.4)
2 units 3/1000 (0.3) 5/1003 (0.5) 8/2003 (0.4)
3 units 3/1000 (0.3) 3/1003 (0.3) 6/2003 (0.3)
4 units 2/1000 (0.2) 1/1003 (0.1) 3/2003 (0.1)
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TABLE 14 Red blood cell transfusions (continued )
Outcome
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
RRa
(95% CI) p-value
Post-randomisation transfusions
Total units transfused
post randomisation,
n/N (%)
Median (IQR) units 1.0 (0.0–2.0) 2.0 (1.0–3.0) 1.0 (0.0–3.0)
Not transfused 466/1000 (46.6) 78/1003 (7.8) 544/2003 (27.2) 0.58
(0.54 to 0.62)
< 0.0001
1 unit 193/1000 (19.3) 341/1003 (34.0) 534/2003 (26.7)
2 units 152/1000 (15.2) 262/1003 (26.1) 414/2003 (20.7)
3 units 66/1000 (6.6) 141/1003 (14.1) 207/2003 (10.3)
4 units 50/1000 (5.0) 62/1003 (6.2) 112/2003 (5.6)
≥ 5 units 73/1000 (7.3) 119/1003 (11.9) 192/2003 (9.6)
Total units transfused 1494 2494 3988
Transfusions during a
post-randomisation
reoperation, n/N (%)
Not transfused 963/1000 (96.3) 969/1003 (96.6) 1932/2003 (96.5)
1 unit 15/1000 (1.5) 9/1003 (0.9) 24/2003 (1.2)
2 units 11/1000 (1.1) 13/1003 (1.3) 24/2003 (1.2)
3 units 6/1000 (0.6) 4/1003 (0.4) 10/2003 (0.5)
4 units 1/1000 (0.1) 3/1003 (0.3) 4/2003 (0.2)
≥ 5 units 4/1000 (0.4) 5/1003 (0.5) 9/2003 (0.4)
Transfusions after
treatment according to
protocol discontinued,
n/N (%)
Not transfused 980/1000 (98.0) 993/1003 (99.0) 1973/2003 (98.5)
1 unit 4/1000 (0.4) 2/1003 (0.2) 6/2003 (0.3)
2 units 4/1000 (0.4) 2/1003 (0.2) 6/2003 (0.3)
3 units 2/1000 (0.2) 0/1003 (0.0) 2/2003 (0.1)
4 units 2/1000 (0.2) 0/1003 (0.0) 2/2003 (0.1)
≥ 5 units 8/1000 (0.8) 6/1003 (0.6) 14/2003 (0.7)
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Transfusion of blood products other than red blood cells
Platelets were the most common other blood product transfused (36.8% of participants). FFP was
transfused in 29.0% of participants, cryoprecipitate in 10.0% and Beriplex and activated factor VII in only
5.0% and 0.6% of participants, respectively (Figure 8 and Table 15). Use of all other products was similar
between the two groups over the duration of the index admission.
TABLE 14 Red blood cell transfusions (continued )
Outcome
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
RRa
(95% CI) p-value
Transfusions in breach
of protocol, n/N (%)
Not transfused 727/1000 (72.7) 896/1003 (89.3) 1623/2003 (81.0)
1 unit 135/1000 (13.5) 85/1003 (8.5) 220/2003 (11.0)
2 units 72/1000 (7.2) 10/1003 (1.0) 82/2003 (4.1)
3 units 34/1000 (3.4) 5/1003 (0.5) 39/2003 (1.9)
4 units 17/1000 (1.7) 3/1003 (0.3) 20/2003 (1.0)
≥ 5 units 15/1000 (1.5) 4/1003 (0.4) 19/2003 (0.9)
Transfusions per
protocol, n/N (%)
Median (IQR) units 0.0 (0.0–1.0) 2.0 (1.0–3.0) 1.0 (0.0–2.0)
Not transfused 577/1000 (57.7) 87/1003 (8.7) 664/2003 (33.2)
1 unit 256/1000 (25.6) 362/1003 (36.1) 618/2003 (30.9)
2 units 93/1000 (9.3) 265/1003 (26.4) 358/2003 (17.9)
3 units 46/1000 (4.6) 147/1003 (14.7) 193/2003 (9.6)
4 units 13/1000 (1.3) 56/1003 (5.6) 69/2003 (3.4)
≥ 5 units 15/1000 (1.5) 86/1003 (8.6) 101/2003 (5.0)
a RR from an unadjusted logistic regression model comparing any transfusions with no transfusions (models adjusting for
cardiac procedure and/or centre would not converge).
Shading denotes outcomes for which there was no pre-specified plan to estimate the RRs.
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FIGURE 8 Use of (a) FFP, (b) platelets and (c) cryoprecipitate; pre-randomisation and post-randomisation use have
been combined.
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TABLE 15 Use of blood products other than red blood cells (pre and post randomisation combined)
Outcome
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Overall
(N= 2003)
Estimatea
(95% CI) p-value
FFP transfusions,
n/N (%)
Not transfused 703/1000 (70.3) 719/1003 (71.7) 1422/2003 (71.0)
1 unit 12/1000 (1.2) 11/1003 (1.1) 23/2003 (1.1) OR 1.08
(0.88 to 1.33)
0.45
2 units 129/1000 (12.9) 113/1003 (11.3) 242/2003 (12.1)
3 units 32/1000 (3.2) 30/1003 (3.0) 62/2003 (3.1)
4 units 82/1000 (8.2) 92/1003 (9.2) 174/2003 (8.7)
≥ 5 units 42/1000 (4.2) 38/1003 (3.8) 80/2003 (4.0)
Platelet transfusions,
n/N (%)
Not transfused 624/1000 (62.4) 641/1003 (63.9) 1265/2003 (63.2)
1 unit 196/1000 (19.6) 177/1003 (17.6) 373/2003 (18.6) OR 1.08
(0.89 to 1.31)
0.42
2 units 130/1000 (13.0) 133/1003 (13.3) 263/2003 (13.1)
3 units 29/1000 (2.9) 25/1003 (2.5) 54/2003 (2.7)
4 units 11/1000 (1.1) 20/1003 (2.0) 31/2003 (1.5)
≥ 5 units 10/1000 (1.0) 7/1003 (0.7) 17/2003 (0.8)
Cryoprecipitate
transfusions, n/N (%)
Not transfused 901/1000 (90.1) 901/1003 (89.8) 1802/2003 (90.0)
1 unit 23/1000 (2.3) 22/1003 (2.2) 45/2003 (2.2) OR 0.99
(0.72 to 1.35)
0.95
2 units 58/1000 (5.8) 69/1003 (6.9) 127/2003 (6.3)
3 units 6/1000 (0.6) 4/1003 (0.4) 10/2003 (0.5)
4 units 7/1000 (0.7) 5/1003 (0.5) 12/2003 (0.6)
≥ 5 units 5/1000 (0.5) 2/1003 (0.2) 7/2003 (0.3)
Activated factor VII
used, yes (%)
7/1000 (0.7) 5/1003 (0.5) 12/2003 (0.6) RR 1.41
(0.45 to 4.45)
0.56
Beriplex used, yes (%) 52/1000 (5.2) 48/1003 (4.8) 100/2003 (5.0) OR 1.21
(0.73 to 2.03)
0.46
a Estimates from adjusted logistic regression models (adjusting for cardiac procedure as a fixed effect and centre as a
random effect) comparing any blood product with no blood product. For activated factor VII, estimates are from an
unadjusted logistic regression model (there were not enough events to deem adjustment appropriate) with a log-link
function to enable a RR to be estimated.
Shading denotes outcomes for which there was no pre-specified plan to estimate the ORs or RRs.
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Adherence
Non-adherence with the randomisation protocol
There were nine participants consented to the trial who were later found to be ineligible, although none
of these participants were randomised (Table 16). Of the 1464 non-randomised participants, 176 (12.0%)
met the post-consent eligibility criterion (haemoglobin < 9 g/dl) but were not randomised. All of the 2003
randomised participants breached the 9 g/dl threshold. However, randomisation was delayed (i.e. occurred
later than 24 hours after the threshold breach occurred) for 65 participants (3.2%) and these instances
were classified as non-adherent with respect to the randomisation protocol.
Non-adherence with the allocated transfusion threshold
Non-adherence with the allocated transfusion threshold is described in Table 17. There were 1813
deviations from the protocol occurring in 37.6% of participants; 635 deviations in 30.0% of participants in
the restrictive group and 1178 deviations in 45.2% of participants in the liberal group. As anticipated,
TABLE 16 Non-adherence with randomisation protocol
Non-adherence type Consented (N= 3565)
Participant was randomised more than 24 hours after meeting post-consent eligibility criteria
(haemoglobin < 9 g/dl),a n/N (%)
9/3565 (0.2)
Considered for randomisation, but not randomised (n = 1464)
Participant consented and met post-consent eligibility criterion (haemoglobin < 9 g/dl) but was
not randomised, n/N (%)
176/1464 (12.0)
Randomised (n = 2003)
Participant did not meet the post-consent eligibility criteria (haemoglobin < 9 g/dl) but was
randomised, n/N (%)
0/2003 (0.0)
Participant was randomised more than 24 hours after meeting post-consent eligibility criteria
(haemoglobin < 9 g/dl) but was not randomised,b n/N (%)
65/2003 (3.2)
a None of these participants went on to be randomised. The one patient who was found to be ineligible after
randomisation (see Footnote c, Table 9) was not known to be ineligible at the time of obtaining consent.
b Median time between meeting the criteria and randomisation for these participants was 2 days (IQR 2–3 days, range
1–13 days).
TABLE 17 Non-adherence with the allocated transfusion threshold
Non-adherence type
Randomised to restrictive
threshold
Randomised to liberal
threshold Overall
Events
(n)
Participants
(N= 1000)
(n/N) %
Events
(n)
Participants
(N= 1003)
(n/N) %
Events
(n)
Participants
(N= 2003)
(n/N) %
Any protocol deviation 635 300/1000 30.0 1178 453/1003 45.2 1813 753/2003 37.6
Any severe protocol
deviation
186 97/1000 9.7 116 62/1003 6.2 302 159/2003 7.9
Extra transfusion 573 273/1000 27.3 161 107/1003 10.7 734 380/2003 19.0
Moderate 391 180/1000 18.0 161 107/1003 10.7 552 287/2003 14.3
Severe 182 93/1000 9.3 0 0/1003 0.0 182 93/2003 4.6
Withheld transfusion 62 55/1000 5.5 1017 390/1003 38.9 1079 445/2003 22.2
Mild 34 30/1000 3.0 546 204/1003 20.3 580 234/2003 11.7
Moderate 24 22/1000 2.2 355 167/1003 16.7 379 189/2003 9.4
Severe 4 4/1000 0.4 116 62/1003 6.2 120 66/2003 3.3
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extra transfusions (i.e. given outside of protocol) were more common in the restrictive group (573 in
27.3% of participants vs. 161 in 10.7% of participants) and withheld transfusions were more common in
the liberal group (1017 in 38.9% of participants vs. 62 in 5.5% of participants). Approximately one-sixth
of all deviations were classified as severe; 24.8% of extra transfusions and 11.1% of withheld transfusions.
Therefore, severe protocol deviations were more common in the restrictive group than the liberal group
(186 in 9.7% of participants vs. 116 in 6.2% of participants).
Characteristics of each instance of non-adherence are reported in Table 18. Extra transfusions tended to
be given either for the clinical reasons listed on the CRF (36.5%) or for ‘other’ reasons (42.7%), which
were generally clinical reasons not listed as specific options on the CRF. The most common reason for a
withheld transfusion was ‘oversight/error’ (67.2%). Extra transfusions tended to occur earlier than withheld
transfusions and were more likely to occur overnight. There were no clear trends in time of year for either
type of non-adherence.
Separate logistic regression models were fitted for (1) extra transfusions and (2) withheld transfusions to
identify any characteristics (both at an adherence level and participant level) that predicted non-adherence
(Table 19). The odds of an extra transfusion reduced by 3% with each post-operative day and reduced by
22% at weekends. However, the odds of a withheld transfusion increased by 3% with each post-operative
day and increased by 79% at weekends. Both types of non-adherence were much more likely in the ICU
than on the ward. Centre recruitment rate was important for predicting both types of non-adherence,
which was most common in relatively slow recruiting centres (3–4 participants per month). Participants
having more complex operation types (CABG and valve and valve-alone surgery) were more likely to have
an extra transfusion, as were participants transfused pre-randomisation. Participants with a longer period
of time between operation end and randomisation were more likely to have a withheld transfusion, and
the odds of a withheld transfusion decreased by 1% with each year of age.
TABLE 18 Characteristics of instances of non-adherence with transfusion protocol
Characteristic
Extra transfusions Withheld transfusions
Restrictive
group
(N= 573)
Liberal
group
(N= 161)
Overall
(N= 734)
Restrictive
group
(N= 62)
Liberal
group
(N= 1017)
Overall
(N= 1079)
Section Aa
Reason for non-adherence,
n/N (%)
Excessive blood loss 128/558
(22.9)
55/149
(36.9)
183/707
(25.9)
N/A N/A N/A
Sepsis 18/558
(3.2)
2/149
(1.3)
20/707
(2.8)
N/A N/A N/A
Physiological indicators of
oxygen debt
54/558
(9.7)
1/149
(0.7)
55/707
(7.8)
N/A N/A N/A
Clinical preference N/A N/A N/A 8/48
(16.7)
167/815
(20.5)
175/863
(20.3)
Oversight/error 98/558
(17.6)
49/149
(32.9)
147/707
(20.8)
26/48
(54.2)
554/815
(68.0)
580/863
(67.2)
Other 260/558
(46.6)
42/149
(28.2)
302/707
(42.7)
14/48
(29.2)
94/815
(11.5)
108/863
(12.5)
continued
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TABLE 18 Characteristics of instances of non-adherence with transfusion protocol (continued )
Characteristic
Extra transfusions Withheld transfusions
Restrictive
group
(N= 573)
Liberal
group
(N= 161)
Overall
(N= 734)
Restrictive
group
(N= 62)
Liberal
group
(N= 1017)
Overall
(N= 1079)
If, clinical reason/other level of
clinician making decision, n/N (%)
Consultant 203/340
(59.7)
34/71
(47.9)
237/411
(57.7)
5/10
(50.0)
79/174
(45.4)
84/184
(45.7)
Registrar 125/340
(36.8)
32/71
(45.1)
157/411
(38.2)
5/10
(50.0)
70/174
(40.2)
75/184
(40.8)
Junior doctor 9/340
(2.6)
5/71
(7.0)
14/411
(3.4)
0/10
(0.0)
14/174
(8.0)
14/184
(7.6)
Nurse practitioner 3/340
(0.9)
0/71
(0.0)
3/411
(0.7)
0/10
(0.0)
11/174
(6.3)
11/184
(6.0)
Haemoglobin levels at time of
non-adherence (g/dl), median
(IQR)
Any non-adherenceb 7.8
(7.6–8.4)
9.0
(8.2–9.5)c
8.0
(7.6–8.8)
7.2
(7.0–7.4)
8.6
(8.3–8.8)
8.6
(8.3–8.8)
Mild N/A N/A N/A 7.1
(7.0–7.4)
8.6
(8.3–8.8)
8.6
(8.1–8.8)
Moderated 7.8
(7.5–8.3)
9.0
(8.2–9.5)c
8.1
(7.6–8.9)
7.2
(7.1–7.4)
8.6
(8.4–8.8)
8.6
(8.3–8.8)
Severee 8.0
(7.6–8.5)
N/A 8.0
(7.6–8.5)
7.3
(7.2–7.4)
8.7
(8.5–8.8)
8.7
(8.4–8.8)
Time between operation end and
non-adherence (days), median
(IQR)
Any non-adherence 2.0
(0.4–7.0)
0.7
(0.3–4.2)
1.8
(0.3–6.1)
3.0
(1.8–5.4)
3.7
(1.8–8.0)
3.7
(1.8–7.9)
Mild N/A N/A N/A 2.8
(1.5–7.2)
3.0
(1.4–8.6)
3.0
(1.4–8.5)
Moderate 2.7
(0.5–11.2)
0.7
(0.3–4.2)
2.0
(0.4–8.2)
3.7
(2.7–4.6)
4.8
(3.4–9.8)
4.8
(3.2–9.6)
Severe 0.9
(0.3–3.7)
N/A 0.9
(0.3–3.7)
1.9
(1.1–2.8)
3.0
(1.0–4.6)
2.9
(1.0–4.4)
Time of day, n/N (%)
Weekday 09:00 to 17:00 153/573
(26.7)
34/161
(21.1)
187/734
(25.5)
13/57
(22.8)
163/923
(17.7)
176/980
(18.0)
Weekday evenings/overnight 262/573
(45.7)
93/161
(57.8)
355/734
(48.4)
18/57
(31.6)
348/923
(37.7)
366/980
(37.3)
Weekend 09:00 to 17:00 65/573
(11.3)
6/161 (3.7) 71/734
(9.7)
8/57
(14.0)
92/923
(10.0)
100/980
(10.2)
Weekend evenings/overnight 93/573
(16.2)
28/161
(17.4)
121/734
(16.5)
18/57
(31.6)
320/923
(34.7)
338/980
(34.5)
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TABLE 18 Characteristics of instances of non-adherence with transfusion protocol (continued )
Characteristic
Extra transfusions Withheld transfusions
Restrictive
group
(N= 573)
Liberal
group
(N= 161)
Overall
(N= 734)
Restrictive
group
(N= 62)
Liberal
group
(N= 1017)
Overall
(N= 1079)
Section Bf
Day of week, n/N (%)
Sunday 56/1334
(4.2)
10/1333
(0.8)
66/2667
(2.5)
8/1334
(0.6)
166/1333
(12.5)
174/2667
(6.5)
Monday 63/1428
(4.4)
20/1431
(1.4)
83/2859
(2.9)
8/1428
(0.6)
124/1431
(8.7)
132/2859
(4.6)
Tuesday 76/1489
(5.1)
40/1491
(2.7)
116/2980
(3.9)
4/1489
(0.3)
97/1491
(6.5)
101/2980
(3.4)
Wednesday 108/1552
(7.0)
36/1524
(2.4)
144/3076
(4.7)
3/1552
(0.2)
105/1524
(6.9)
108/3076
(3.5)
Thursday 103/1609
(6.4)
19/1586
(1.2)
122/3195
(3.8)
7/1609
(0.4)
138/1586
(8.7)
145/3195
(4.5)
Friday 106/1558
(6.8)
22/1569
(1.4)
128/3127
(4.1)
12/1558
(0.8)
132/1569
(8.4)
144/3127
(4.6)
Saturday 61/1437
(4.2)
14/1440
(1.0)
75/2877
(2.6)
15/1437
(1.0)
161/1440
(11.2)
176/2877
(6.1)
Time of year, n/N (%)
February to April 88/2291
(3.8)
42/2368
(1.8)
130/4659
(2.8)
13/2291
(0.6)
204/2368
(8.6)
217/4659
(4.7)
May to July 129/2210
(5.8)
41/2311
(1.8)
170/4521
(3.8)
7/2210
(0.3)
221/2311
(9.6)
228/4521
(5.0)
August to October 227/3031
(7.5)
27/2847
(0.9)
254/5878
(4.3)
18/3031
(0.6)
264/2847
(9.3)
282/5878
(4.8)
November to January 129/2875
(4.5)
51/2848
(1.8)
180/5723
(3.1)
19/2875
(0.7)
234/2848
(8.2)
253/5723
(4.4)
Level of care, n/N (%)
ICU 460/4318
(10.7)
137/4184
(3.3)
597/8502
(7.0)
40/4318
(0.9)
708/4184
(16.9)
748/8502
(8.8)
Ward 113/6089
(1.9)
24/6190
(0.4)
137/12279
(1.1)
22/6089
(0.4)
309/6190
(5.0)
331/12,279
(2.7)
N/A, not applicable.
a Denominators in this section are the numbers of relevant non-adherent deviations.
b Missing for 112 extra transfusions in the restrictive group and 22 extra transfusions in the liberal group.
c The lower quartile is < 9 g/dl because, although extra transfusions occurred less often in the liberal group, a substantial
proportion of them arose from prescribing 2 units at once without rechecking haemoglobin concentrations.
d Missing for 80 extra transfusions in the restrictive group and 22 extra transfusions in the liberal group.
e Missing for 32 extra transfusions in the restrictive group.
f Denominators in this section are the numbers of patient days in the trial.
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Adherence by centre is given in Figure 9, which demonstrates wide variation between centres with no
obvious relationship to total recruitment or average recruitment rates.
Non-adherence was monitored carefully over the course of the trial and various measures were put in
place to try and improve non-adherence rates.33 Some of these measures are described in Table 20.
There was no improvement in non-adherence rates over the course of the study despite these measures
(Figure 10). In the early stages, rates of non-adherence fluctuated somewhat but by the time that half of
the participants had been recruited, rates remained fairly constant.
TABLE 19 Multiple logistic regression models to identify predictors of non-adherence
Characteristic
Extra transfusions Withheld transfusions
OR (95% CI) p-value OR (95% CI) p-value
Adherence characteristics
Time from operation end (days) 0.97 (0.95 to 0.98) p< 0.001 1.03 (1.01 to 1.04) p< 0.001
Weekend vs. weekday 0.78 (0.63 to 0.95) p= 0.013 1.79 (1.54 to 2.09) p< 0.001
ICU vs. ward 4.68 (3.76 to 5.83) p< 0.001 3.07 (2.55 to 3.69) p< 0.001
Participant characteristics
Centre recruitment rate
≥ 6 participants per month Reference group p< 0.001 Reference group p= 0.022
4–6 participants per month 1.04 (0.77 to 1.39) 0.84 (0.61 to 1.15)
3–4 participants per month 2.23 (1.62 to 3.05) 1.39 (0.99 to 1.96)
< 3 participants per month 1.54 (0.97 to 2.44) 0.71 (0.41 to 1.22)
Time between operation end and randomisation 1.15 (1.07 to 1.25) p< 0.001
Age (years) 0.99 (0.97 to 1.00) p= 0.029
Cardiac procedure p< 0.001
CABG only Reference group
CABG+ valve 1.36 (1.01 to 1.83)
Valve only 1.75 (1.27 to 2.40)
Other 1.04 (0.66 to 1.65)
Transfused pre-randomisation 1.49 (1.15 to 1.93) p= 0.003
Shading denotes outcomes for which there was no pre-specified plan to estimate the ORs or RRs, or analyses that were not
pre-specified.
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FIGURE 9 Adherence by centre.
(a) Percentage of participants with any severe/non-severe non-adherence by centre.
(b) Percentage of participants having extra and withheld transfusions. Sites are ordered by the average number of
participants recruited per month.
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TABLE 20 Methods implemented to monitor feedback and/or provide training on adherence
Methods implemented by trial management team across all sites
For site research teams For clinical staff For clinical and site research staff
Regular newsletters were sent to sites
to try to motivate staff to improve
adherence and maintain interest in
study
Regular teaching slots about the trial
for new and existing staff, the timing
of which was frequently aimed to
coincide with the start of residents’
rotations
Colour-coded labels provided for
research and clinical staff to add to
participants’ notes and charts (to clearly
identify TITRe2 participants and
allocated group)
Mid-study site visits included analysis
and discussion of non-adherence with
local research teams to try to identify
site-specific barriers to adherence and
potential solutions
Nurses’ manuals at nursing stations
containing trial-specific information
and summaries of the protocol for the
restrictive and liberal groups
Daily haemoglobin transfusion checks
by research nurses to monitor
adherence with the protocol for
randomisation and treatment according
to allocated group and to record
instances of non-adherence. These
checks were usually done Monday
to Friday (owing to research nurse
working patterns). These checks
provided a useful additional avenue of
communication if the clinical team had
any trial-related queries and provided a
physical presence of the trial on the
cardiac units
Reports were fed back to sites, both
at mid-study visits and thereafter on a
quarterly basis, describing site-specific
non-adherence over time and
non-adherence in relation to other
sites
Adherence competitions were trialled
but found to be difficult to implement
logistically. However, informal prizes
were handed out at meetings of study
investigators to commend sites that
achieved high adherence rates
Trial branded stationery produced to
remind staff to check and react to
haemoglobin concentrations
Methods for avoiding non-adherence
adopted by sites with better
adherence were shared at meetings
of study investigators. Research nurses
were primary contributors at these
meetings
Study posters in staff rooms
Methods implemented by sites themselves
Careful ‘handover’ between nursing shifts, highlighting the need to monitor the haemoglobin of a participant carefully and
to randomise/transfuse in the event of breaching the allocated threshold (site A)
Additional plastic wrist band/tag identifying that the patient was taking part in the trial; this band was alongside another
band with the participant’s identification details, which doctors and nurses had to check when prescribing/administering a
red blood cell transfusion (site E)
Adding coloured covers to the participant’s paper medical records highlighting that the patient was taking part in research
(site C)
Out of hours/weekend reminder calls to ICU/ward (for participants known to be at risk of breaching their allocated
threshold) to ask whether or not a participant’s haemoglobin had been checked
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Summary
The proportion of participants with any non-adherence was relatively high (37.6%). However, only 7.9%
of participants had non-adherence that was classified as severe and which, by definition, affected overall
transfusion rates. This percentage was consistent with the assumptions made when designing the trial.
Therefore, we managed to achieve good separation between the groups in terms of both haemoglobin
levels (approximately 1 g/dl difference) and transfusion rates (53.4% in the restrictive group vs. 92.2% in
the liberal group). Finally, the proportions of participants transfused prior to randomisation, and the
proportions given other blood products, were similar in the two groups.
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FIGURE 10 Change over time in proportions of non-adherent participants. Lines represent cumulative
non-adherence rates; triangles represent the number of centres in the study.
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Chapter 5 Primary and secondary outcomes
Primary outcome
Primary analysis
The primary outcome occurred in 35.1% of participants in the restrictive group and 33.0% in the liberal
group (Table 21). This difference was not statistically significant, OR 1.11 (95% CI 0.91 to 1.34; p= 0.30).
The most common element of the primary outcome was sepsis (21.6%), followed by AKI (13.2%) and
wound infection (5.4%); all other components were relatively rare (< 2%). There were 27.1% participants
who experienced the primary outcome before hospital discharge and 10.8% after hospital discharge
(some participants experienced qualifying events both in hospital and after discharge). The small excess of
primary outcome events in the restrictive group appeared to be mainly driven by AKI events. Most of the
AKI events occurred before hospital discharge (96.6%) and AKI events had similar frequencies in each
of the three AKI stages (34.4% stage one, 28.6% stage two and 37.1% stage three).
Most participants experiencing the primary outcome encountered their first component event in the first
10 days after randomisation (Figure 11). A planned secondary analysis using a Cox proportional hazards
model gave HR 1.09 (95% CI 0.93 to 1.27; p= 0.29) which is very similar to the OR obtained from logistic
regression in Table 21.
TABLE 21 Primary outcome
Outcome
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003) Estimate (95% CI) p-value
At any time,a n/N (%)
Overall 331/944 (35.1) 317/962 (33.0) OR 1.11 (0.91 to 1.34) 0.30
Infectious event 238/936 (25.4) 240/954 (25.2) OR 1.02 (0.83 to 1.26) 0.83
Sepsisb 210/982 (21.4) 214/983 (21.8)
Wound infection 55/921 (6.0) 46/936 (4.9)
Ischaemic event 156/991 (15.7) 139/991 (14.0) OR 1.16 (0.90 to 1.49) 0.26
Permanent strokec 15/989 (1.5) 17/985 (1.7)
MI 3/987 (0.3) 4/981 (0.4)
Gut infarctiond 6/987 (0.6) 1/982 (0.1)
AKIe 140/989 (14.2) 122/989 (12.3)
Stage one 49/989 (5.0) 40/989 (4.0)
Stage two 39/989 (3.9) 35/989 (3.5)
Stage three 50/989 (5.1) 46/989 (4.7)
continued
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TABLE 21 Primary outcome (continued )
Outcome
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003) Estimate (95% CI) p-value
Pre-discharge, n/N (%)
Overall 282/988 (28.5) 253/984 (25.7)
Infectious event 184/983 (18.7) 175/983 (17.8)
Sepsis 178/990 (18.0) 167/993 (16.8)
Wound infection 17/990 (1.7) 15/990 (1.5)
Ischaemic event 146/1000 (14.6) 134/1003 (13.4)
Permanent stroke 11/1000 (1.1) 14/1003 (1.4)
MI 1/1000 (0.1) 3/1003 (0.3)
Gut infarction 5/1000 (0.5) 1/1003 (0.1)
AKI 134/1000 (13.4) 121/1003 (12.1)
Post discharge, n/N (%)
Overall 104/924 (11.3) 98/938 (10.4)
Infectious event 94/924 (10.2) 92/937 (9.8)
Sepsis 49/987 (5.0) 55/981 (5.6)
Wound infection 55/921 (6.0) 46/936 (4.9)
Ischaemic event 15/987 (1.5) 6/981 (0.6)
Permanent stroke 5/987 (0.5) 3/981 (0.3)
MI 2/987 (0.2) 1/981 (0.1)
Gut infarction 1/987 (0.1) 0/981 (0.0)
AKI 7/987 (0.7) 2/981 (0.2)
a This table does not include any pre-randomisation events. 46 restrictive group participants and 44 liberal group
participants experienced an event pre-randomisation: infectious events for 22 restrictive group participants and 24 liberal
group participants (all sepsis); ischaemic events for 31 restrictive group participants and 26 liberal group participants
(two strokes, one MI and 28 AKI in the restrictive group, and one stroke, three MIs and 23 AKI in the liberal group).
b Sites of sepsis events: respiratory – 134 restrictive group and 128 liberal group, wound – 47 restrictive group and
49 liberal group, blood – 23 restrictive group and 32 liberal group, and other – 49 restrictive group and 53 liberal group.
c Verification methods of strokes: CT scan only – 10 restrictive group and 16 liberal group, MRI only – none, and CT and
MRI – two restrictive group and one liberal group.
d Verification methods of gut infarctions: laparotomy only – three restrictive group and three liberal group, post-mortem
only – one restrictive group, and laparotomy and post-mortem – two restrictive group.
e AKI stage is the most severe stage reached.
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The combinations of primary outcome components occurring are described in Table 22. Four hundred and
eighty participants experienced one component, of which sepsis alone was the most common (240/480,
50%); 151 participants experienced two components (of which sepsis and AKI was the most common
combination; 72/151, 47.7%) and 17 participants experienced three components (of which sepsis, wound
infection and AKI was the most common combination; 11/17, 64.7%). More participants in the restrictive
group had AKI alone than the liberal group (7.2% vs. 5.9%), but fewer had AKI and sepsis (3.1% vs. 4.1%).
Sensitivity analyses
Sensitivity analyses were pre-specified in the SAP, but not the study protocol; several of these were planned
during data collection in response to knowledge about limitations of the study (e.g. non-adherence) or
accruing data (e.g. inconsistency in data characterising renal function) but without any knowledge about
how the sensitivity analyses would impact on the findings. The rationale and hypotheses for the sensitivity
analyses have been explained previously (see Chapter 2, Sensitivity analyses).
The effect of non-adherence was assessed by estimating centre-specific treatment effects and ordering
sites by rates of severe non-adherence (Figure 12). The hypothesis that estimates would tend towards the
null with increasing non-adherence was not supported either visually, from the forest plot, or statistically in
that a test for heterogeneity suggested no significant differences between sites (p= 0.65).
Excluding primary outcome events occurring in the first 24 hours after randomisation did not substantially
alter the estimated treatment effect (Table 23), which did not support the hypothesis that the effect
would tend away from the null. Excluding participants who received transfused red blood cells prior
to randomisation caused the treatment effect estimate to increase (OR 1.23, 95% CI 0.97 to 1.54;
p= 0.084), which was consistent with the hypothesis. Excluding AKI events without the relevant creatinine
rise did not alter the treatment effect estimate; however, including additional AKI events not picked up
via clinical assessment (anticipated to be milder events) caused the treatment effect estimate to increase
(OR 1.20, 95% CI 1.00 to 1.44; p= 0.045) and the distribution of AKI events across AKI stages also became
more pyramidal, consistent with adding in extra mild events. We had not hypothesised an increase in the
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FIGURE 11 Kaplan–Meier estimates of time from randomisation to the primary outcome.
The HR is not adjusted for cardiac procedure (as was planned) because the proportional hazards assumption was
violated if this term was included, and the first events occurring were sepsis (169 restrictive group and 171 liberal
group), wound infection (21 restrictive group and 26 liberal group), stroke (12 restrictive group and 12 liberal
group), MI (one restrictive group and four liberal group), gut infarction (four restrictive group) and AKI (126 in
restrictive group and 105 in liberal group).
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TABLE 22 Combinations of primary outcome events
Number of
elements Sepsis
Wound
infection Stroke MI
Gut
infarction AKI
Randomised
to restrictive
threshold
(N= 1000)
Randomised
to liberal
threshold
(N= 1003)
n (%) n (%)
None 613 (61.3) 645 (64.3)
No No No No No No 613 (61.3) 645 (64.3)
One 244 (24.4) 236 (23.5)
Yes No No No No No 120 (12.0) 120 (12.0)
No No No No No Yes 72 (7.2) 59 (5.9)
No Yes No No No No 20 (2.0) 24 (2.4)
Yes Missing No No No No 14 (1.4) 14 (1.4)
No No Yes No No No 6 (0.6) 6 (0.6)
No Missing No No No Yes 2 (0.2) 3 (0.3)
No No No Yes No No 1 (0.1) 3 (0.3)
Missing Missing Yes Missing Missing Missing 1 (0.1) 2 (0.2)
Missing No No No No Yes 3 (0.3) 0 (0.0)
Yes Missing Missing Missing Missing Missing 1 (0.1) 2 (0.2)
Yes No Missing Missing Missing Missing 1 (0.1) 1 (0.1)
Missing Missing Missing Missing Missing Yes 0 (0.0) 1 (0.1)
Missing Missing Yes No No No 0 (0.0) 1 (0.1)
Missing No Yes Missing Missing Missing 1 (0.1) 0 (0.0)
Missing No Yes No No No 1 (0.1) 0 (0.0)
No No No No Yes No 1 (0.1) 0 (0.0)
Two 76 (7.6) 75 (7.5)
Yes No No No No Yes 31 (3.1) 41 (4.1)
Yes Yes No No No No 19 (1.9) 17 (1.7)
Yes Missing No No No Yes 6 (0.6) 4 (0.4)
No Yes No No No Yes 7 (0.7) 2 (0.2)
Yes No Yes No No No 2 (0.2) 4 (0.4)
Yes Missing Missing Missing Missing Yes 2 (0.2) 3 (0.3)
No No Yes No No Yes 3 (0.3) 1 (0.1)
Yes No No No Yes No 2 (0.2) 0 (0.0)
Missing Missing Yes Missing Missing Yes 0 (0.0) 1 (0.1)
Missing Yes No No No Yes 1 (0.1) 0 (0.0)
No No No No Yes Yes 1 (0.1) 0 (0.0)
No No No Yes No Yes 1 (0.1) 0 (0.0)
Yes Missing No No Yes No 1 (0.1) 0 (0.0)
Yes Missing No Yes No No 0 (0.0) 1 (0.1)
Yes No Missing Missing Missing Yes 0 (0.0) 1 (0.1)
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TABLE 22 Combinations of primary outcome events (continued )
Number of
elements Sepsis
Wound
infection Stroke MI
Gut
infarction AKI
Randomised
to restrictive
threshold
(N= 1000)
Randomised
to liberal
threshold
(N= 1003)
n (%) n (%)
Three 11 (1.1) 6 (0.6)
Yes Yes No No No Yes 8 (0.8) 3 (0.3)
Yes No Yes No No Yes 1 (0.1) 1 (0.1)
Yes Missing Missing Missing Yes Yes 0 (0.0) 1 (0.1)
Yes No No No Yes Yes 1 (0.1) 0 (0.0)
Yes No No Yes No Yes 1 (0.1) 0 (0.0)
Yes No Yes Missing Missing Yes 0 (0.0) 1 (0.1)
Missing 56 (5.6) 41 (4.1)
No Missing No No No No 45 (4.5) 26 (2.6)
Missing Missing Missing Missing Missing Missing 5 (0.5) 8 (0.8)
Missing No No No No No 2 (0.2) 6 (0.6)
Missing No Missing Missing Missing Missing 2 (0.2) 1 (0.1)
Missing Missing No No No No 2 (0.2) 0 (0.0)
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FIGURE 12 Sensitivity analysis: primary outcome OR estimates by site, ranked by severe non-adherence rates.
The grey vertical lines represent the overall treatment estimate (solid line) and 95% CI (dashed lines) of the
primary outcome for the entire analysis cohort. The sizes of the point estimates reflect the centre sizes. Test for
heterogeneity between sites; p= 0.65. Estimates have not been calculated for three sites with fewer than
20 participants with complete primary outcome data.
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treatment effect for this analysis but it was consistent with the observation that the small difference in
the primary outcome frequency arose mainly from AKI events (see Table 23) and with the last planned
sensitivity analysis, including only serious primary outcome events, which unexpectedly reduced the
treatment effect estimate to unity (OR 0.99, 95% CI 0.77 to 1.27; p= 0.94).
Finally, the post-hoc analysis of severe in-hospital events (death, severe sepsis, ARDS, tracheostomy, low
cardiac output, MI, AKI stage three, gut infarction and/or stroke) showed that this composite outcome
occurred in 94/995 (9.5%) participants in the restrictive group and 90/993 (9.1%) in the liberal group
(OR 1.05, 95% CI 0.77 to 1.43; p= 0.75).
Subgroup analyses
Subgroup analyses pre-specified in the study protocol are summarised in Figure 13. The subgroup analysis
showing the largest difference between strata contrasted the treatment effect for participants with
and without chronic obstructive pulmonary disease or asthma. The analysis suggested that the liberal
transfusion strategy might be beneficial for participants with pulmonary comorbidity, although few
participants had this comorbidity and the effect is not statistically significant. There was no other evidence
of any subgroup effects.
TABLE 23 Sensitivity analyses
Sensitivity analysis
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003) OR (95% CI) p-value
Excluding primary outcome events
occurring in the first 24 hours after
randomisation, n/N (%)
293/943 (31.1) 284/956 (29.7) 1.08 (0.88 to 1.31) 0.47
Excluding participants who were
transfused red blood cells
pre-randomisation, n/N (%)
229/707 (32.4) 202/712 (28.4) 1.23 (0.97 to 1.54) 0.084
Excluding AKI events without relevant
creatinine rise,a n/N (%)
328/944 (34.8) 315/962 (32.7) 1.10 (0.91 to 1.34) 0.33
Including additional AKI events identified
from routinely collected creatinine data,b
n/N (%)
477/959 (49.7) 440/970 (45.4) 1.20 (1.00 to 1.44) 0.045
Including only ‘serious’ primary outcome
events, n/N (%)
Any serious event 145/985 (14.7) 147/987 (14.9) 0.99 (0.77 to 1.27) 0.94
Sepsis 102/982 (10.4) 110/983 (11.2)
Stroke 15/989 (1.5) 17/985 (1.7)
MI 3/987 (0.3) 4/981 (0.4)
Gut infarction 6/987 (0.6) 1/982 (0.1)
AKI 50/989 (5.1) 46/989 (4.7)
a Excluding events that were classified as AKI according to clinical judgement but the recorded creatinine levels did not
verify this.
b Including events for which the participant was classified as not having AKI according to clinical judgement, but a
creatinine increase in line with AKI criteria was recorded. New AKI event rates are as follows: restrictive group 342/991
(34.5%), liberal group 303/993 (30.5%).
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Secondary outcomes
Primary analyses
Infectious and ischaemic events
Infectious and ischaemic events are summarised in Table 21. Infectious events occurred equally often in the
two groups, 25.4% in the restrictive group and 25.2% in the liberal group (OR 1.02, 95% CI 0.83 to 1.26;
p= 0.83). However, as the number of missing data was over 5% (mainly due to missing post-hospital
discharge data), a treatment effect was estimated separately for pre-hospital discharge infections only,
as specified in the SAP (OR 1.07, 95% CI 0.85 to 1.36; p= 0.55). Ischaemic events were slightly more
common in the restrictive group (15.7%) than the liberal group (14.0%; OR 1.16, 95% CI 0.90 to 1.40;
p= 0.26). This small difference appears to arise mainly owing to AKI events – 14.2% in the restrictive
group and 12.3% in the liberal group.
Other clinical outcomes
There were significantly more deaths from any cause in the restrictive group (4.2%) than the liberal group
(2.6%; HR 1.64, 95% CI 1.00 to 2.67; p= 0.045) (Table 24 and Figure 14). Causes of death and other
SAEs that preceded death are given in Table 25. There are no clear causes of death contributing to the
excess in the restrictive group; the common causes were cardiac disorders (21 participants), infections/
infestations (13 participants) and general disorders and administration site conditions (10 participants). The
primary outcome was experienced before death by 65% of participants. With respect to SAEs preceding
death, 55% of the deaths in the restrictive group were preceded by an ischaemic SAE, whereas 58% of
the deaths in the liberal group were preceded by an infectious SAE.
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FIGURE 13 Subgroup analyses. The grey vertical lines represent the overall treatment estimate (solid line) and
95% CI (dashed lines) of the primary outcome for the entire analysis cohort. The sizes of the point estimates reflect
the sizes of the subgroups.
COPD, chronic obstructive pulmonary disease; LV, left ventricular; mod, moderate.
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TABLE 24 Other clinical outcomes
Outcome
Randomised to restrictive
threshold (N= 1000)
Randomised to liberal
threshold (N= 1003)
Effect
(95% CI) p-value
All-cause mortality, n/N (%) 42/1000 (4.2) 26/1003 (2.6) HR 1.64
(1.00 to 2.67)
0.045
Significant pulmonary
morbidity, n/N (%)
127/979 (13.0) 116/982 (11.8) OR 1.11
(0.85 to 1.45)
0.45
Initiation of non-invasive
ventilation
88/989 (8.9) 77/984 (7.8)
Re-intubation/ventilation 50/975 (5.1) 53/973 (5.4)
Tracheostomy 30/988 (3.0) 32/988 (3.2)
Duration of ICU/HDU stay
(hours),a median (IQR)
49.5 (21.9–99.7) 45.9 (20.1–94.8) HR 0.97
(0.89 to 1.06)
0.53
Duration of hospital stay
(days),b median (IQR)
7.0 (5.0–10.0) 7.0 (5.0–10.0) HR 1.00
(0.92 to 1.10)
0.94
a Post-randomisation stay only, which was (1) zero for 63 restrictive group participants and 61 liberal group participants,
and (2) censored for 23 restrictive group participants and 15 liberal group participants. In addition, 37 restrictive group
participants had more than one ICU/HDU admission (33 had two admissions and four had three admissions) and
32 liberal group participants (31 had two admissions and one had four admissions). A sensitivity analysis investigating
the potential effect of informative censoring, assuming all censored patients had the maximum observed (i.e. not
censored) duration of ICU/HDU stay, gave an estimated HR 0.94 (95% CI 0.86 to 1.03; p= 0.20).
b Post-randomisation stay only, which was (1) zero for four restrictive group participants and two liberal group participants,
and (2) censored for 25 restrictive group participants and 17 liberal group participants. A sensitivity analysis investigating
the potential effect of informative censoring, assuming all censored patients had the maximum observed (i.e. not
censored) duration of hospital stay, gave an estimated HR 0.98 (95% CI 0.90 to 1.07; p= 0.71).
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FIGURE 14 Kaplan–Meier estimates of time from randomisation to all-cause mortality.
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TABLE 25a Further information on death: causes of death
Causes of deatha
Randomised to restrictive
threshold
Randomised to liberal
threshold
Events Participants (n= 42) Events Participants (n= 26)
Blood and lymphatic system disorders 0 0 1 1
Coagulopathy 0 0 1 1
Cardiac disorders 10 10 11 11
Arrhythmia 4 4 1 1
Cardiac arrest 1 1 0 0
Cardiac failure 3 3 1 1
Cardiac failure acute 0 0 2 2
Cardiac failure congestive 1 1 4 4
Left ventricular failure 1 1 1 1
Left ventricular hypertrophy 0 0 1 1
Pericardial haemorrhage 0 0 1 1
GI disorders 6 6 1 1
Duodenal ulcer perforation 1 1 0 0
GI haemorrhage 0 0 1 1
Intestinal infarction 1 1 0 0
Intestinal ischaemia 3 3 0 0
Peritonitis 1 1 0 0
General disorders and administration site
conditions
7 7 3 3
Multiorgan failure 7 7 3 3
Hepatobiliary disorders 1 1 0 0
Hepatic necrosis 1 1 0 0
Infections and infestations 8 8 5 5
Bronchopneumonia 1 1 2 2
Empyema 0 0 1 1
Endocarditis 1 1 1 1
Lower respiratory tract infection 1 1 0 0
Pneumonia 3 3 1 1
Sepsis 2 2 0 0
Neoplasms benign, malignant and unspecified 1 1 0 0
Brain cancer metastatic 1 1 0 0
Nervous system disorders 3 3 2 2
Cerebral haemorrhage 1 1 0 0
CVA 1 1 2 2
Haemorrhage intracranial 1 1 0 0
Renal and urinary disorders 1 1 0 0
Renal failure 1 1 0 0
Respiratory, thoracic and mediastinal disorders 4 4 0 0
ARDS 1 1 0 0
Hypoxia 1 1 0 0
Pulmonary oedema 2 2 0 0
continued
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TABLE 25a Further information on death: causes of death (continued )
Causes of deatha
Randomised to restrictive
threshold
Randomised to liberal
threshold
Events Participants (n= 42) Events Participants (n= 26)
Surgical and medical procedures 3 3 3 3
Cardiac operation 3 3 2 2
Ventriculocardiac shunt 0 0 1 1
Vascular disorders 1 1 3 3
Aortic aneurysm rupture 1 1 1 1
Haemorrhage 0 0 2 2
CVA, cerebrovascular accident; GI, gastrointestinal.
a Six participants have two primary causes of death listed: three participants in the restrictive group (participant 1,
duodenal ulcer perforation and peritonitis; participant 2, multiorgan failure and sepsis; and participant 3, hypoxia and
pulmonary oedema) and three participants in the liberal group (participant 1, endocarditis and ventriculocardiac shunt;
participant 2, bronchopneumonia and empyema; and participant 3, bronchopneumonia and coagulopathy).
TABLE 25b Further information on death: SAE preceding death
SAEs preceding deatha
Randomised to restrictive
threshold
Randomised to liberal
threshold
Events, n
Participants (N= 42),
n/N (%) Events
Participants (N= 26),
n/N (%)
Primary outcome 26/40 (65) 17/26 (65)
Sepsis 11/40 (28) 15/26 (58)
Wound infection 2/42 (5) 0/26 (0)
Permanent stroke 3/42 (7) 0/26 (0)
MI 0/42 (0) 1/26 (4)
Gut infarction 4/42 (10) 0/26 (0)
AKI 16/42 (38) 12/26 (46)
Transient ischaemic attack 0 0/42 (0) 1 1/26 (4)
GI complications 2 2/42 (5) 8 7/26 (27)
Post-operative haemorrhage 1 1/42 (2) 1 1/26 (4)
Cardiac tamponade 0 0/42 (0) 0 0/26 (0)
Pulmonary complications 23 14/41 (34) 29 10/26 (38)
Arrhythmias 15 12/42 (29) 9 7/26 (27)
Re-operation 12 11/42 (26) 4 4/26 (15)
Thromboembolic complications 1 1/42 (2) 0 0/26 (0)
Low cardiac output 6 6/42 (14) 10 6/26 (23)
Wound dehiscence 0 0/42 (0) 6 4/26 (15)
Other (unexpected event) 5 5/42 (12) 1 1/26 (4)
Cardiac arrest 1 1/42 0 0/26
Cardiac failure 3 3/42 0 0/26
Cardiac failure congestive 0 0/42 1 1/26
Compartment syndrome 1 1/42 0 0/26
GI, gastrointestinal.
a Excluding causes of death.
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In the restrictive group, 13.0% of participants experienced significant pulmonary morbidity compared with
11.8% participants in the liberal group (OR 1.11, 95% CI 0.85 to 1.45; p= 0.45). The median duration of
post-randomisation ICU/HDU stay was 49.5 hours (IQR 21.9–99.7 hours) in the restrictive group and
45.9 hours (IQR 20.1–94.8 hours) in the liberal group (see Table 24). This difference was not statistically
significant (HR 0.97, 95% CI 0.89 to 1.06; p= 0.53). Durations of total post-randomisation hospital stay
were very similar in both groups [medians and IQRs for both groups were 7 days and IQR 5–10 days
(HR 1.00, 95% CI 0.92 to 1.10; p= 0.94)].
Quality of life
Crude responses to the five EQ-5D-3L component questions show no clear trends between the treatment
groups (Table 26), although there was some suggestion of slightly improved scores on the mobility and
usual activities domains in the restrictive compared with the liberal group post randomisation. No formal
statistical comparisons were performed and the usual activities domain was also slightly imbalanced at
baseline. The median utility and visual analogue scale (VAS) scores were similar in the two groups at all
three time points (Table 27). Modelling the utility score demonstrated that participants in the restrictive
group were slightly less likely to experience a score representing imperfect health than the liberal group,
although this difference was not statistically significant (OR 0.89, 95% CI 0.71 to 1.12; p= 0.33). Scores
for those participants with imperfect health were similar in the group groups [geometric mean ratio (GMR)
0.99, 95% CI 0.95 to 1.12; p= 0.68). For the VAS, the occurrence model suggested very little difference
between the groups in the proportions of participants experiencing imperfect health (OR 1.11, 95% CI
0.57 to 2.15; p= 0.76). Of those with imperfect health on the VAS score, the average score was slightly
higher (representing better health) for the restrictive group (GMR 0.97, 95% CI 0.92 to 1.02; p= 0.21).
There was no evidence of a treatment by time interaction for either measure, implying that any difference
between groups did not change between 6 weeks and 3 months after randomisation.
Sensitivity analyses
The two sensitivity analyses outlined for the primary outcome that could be applied to the secondary
outcome of mortality were performed on a post-hoc basis. The results are shown in Table 28. The
treatment effects for both analyses, excluding deaths occurring in the first 24 hours after randomisation
and excluding participants who had red blood cells transfused before randomisation, were shifted further
away from unity, as was hypothesised.
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TABLE 26 European Quality of Life-5 Dimensions-3 Level component questions
EQ-5D-3L component
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
Mobility, n/N (%)
Pre-operative
I have no problems walking about 586/995 (58.9) 583/996 (58.5)
I have some problems walking about 400/995 (40.2) 410/996 (41.2)
I am confined to bed 9/995 (0.9) 3/996 (0.3)
6 weeks post randomisation
I have no problems walking about 524/790 (66.3) 521/823 (63.3)
I have some problems walking about 261/790 (33.0) 299/823 (36.3)
I am confined to bed 5/790 (0.6) 3/823 (0.4)
3 months post randomisation
I have no problems walking about 572/833 (68.7) 549/850 (64.6)
I have some problems walking about 259/833 (31.1) 300/850 (35.3)
I am confined to bed 2/833 (0.2) 1/850 (0.1)
Self-care, n/N (%)
Pre-operative
I have no problems with self-care 901/996 (90.5) 923/997 (92.6)
I have some problems with self-care 90/996 (9.0) 71/997 (7.1)
I am unable to wash and dress myself 5/996 (0.5) 3/997 (0.3)
6 weeks post randomisation
I have no problems with self-care 648/792 (81.8) 664/824 (80.6)
I have some problems with self-care 136/792 (17.2) 152/824 (18.4)
I am unable to wash and dress myself 8/792 (1.0) 8/824 (1.0)
3 months post randomisation
I have no problems with self-care 722/833 (86.7) 728/849 (85.7)
I have some problems with self-care 108/833 (13.0) 117/849 (13.8)
I am unable to wash and dress myself 3/833 (0.4) 4/849 (0.5)
Usual activities, n/N (%)
Pre-operative
I have no problems with doing my usual activities 549/995 (55.2) 513/996 (51.5)
I have some problems with doing my usual activities 372/995 (37.4) 418/996 (42.0)
I am unable to perform my usual activities 74/995 (7.4) 65/996 (6.5)
6 weeks post randomisation
I have no problems with doing my usual activities 263/787 (33.4) 257/822 (31.3)
I have some problems with doing my usual activities 455/787 (57.8) 485/822 (59.0)
I am unable to perform my usual activities 69/787 (8.8) 80/822 (9.7)
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TABLE 26 European Quality of Life-5 Dimensions-3 Level component questions (continued )
EQ-5D-3L component
Randomised to
restrictive threshold
(N= 1000)
Randomised to
liberal threshold
(N= 1003)
3 months post randomisation
I have no problems with doing my usual activities 455/835 (54.5) 423/850 (49.8)
I have some problems with doing my usual activities 349/835 (41.8) 394/850 (46.4)
I am unable to perform my usual activities 31/835 (3.7) 33/850 (3.9)
Pain/discomfort, n/N (%)
Pre-operative
I have no pain or discomfort 609/995 (61.2) 573/995 (57.6)
I have moderate pain or discomfort 356/995 (35.8) 393/995 (39.5)
I have extreme pain or discomfort 30/995 (3.0) 29/995 (2.9)
6 weeks post randomisation
I have no pain or discomfort 265/791 (33.5) 279/823 (33.9)
I have moderate pain or discomfort 516/791 (65.2) 528/823 (64.2)
I have extreme pain or discomfort 10/791 (1.3) 16/823 (1.9)
3 months post randomisation
I have no pain or discomfort 418/836 (50.0) 432/850 (50.8)
I have moderate pain or discomfort 400/836 (47.8) 392/850 (46.1)
I have extreme pain or discomfort 18/836 (2.2) 26/850 (3.1)
Anxiety/depression, n/N (%)
Pre-operative
I am not anxious or depressed 683/994 (68.7) 687/996 (69.0)
I am moderately anxious or depressed 278/994 (28.0) 284/996 (28.5)
I am extremely anxious or depressed 33/994 (3.3) 25/996 (2.5)
6 weeks post randomisation
I am not anxious or depressed 602/791 (76.1) 592/823 (71.9)
I am moderately anxious or depressed 181/791 (22.9) 215/823 (26.1)
I am extremely anxious or depressed 8/791 (1.0) 16/823 (1.9)
3 months post randomisation
I am not anxious or depressed 635/836 (76.0) 640/850 (75.3)
I am moderately anxious or depressed 186/836 (22.2) 196/850 (23.1)
I am extremely anxious or depressed 15/836 (1.8) 14/850 (1.6)
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Adverse events
All expected and unexpected SAEs (excluding the primary outcome and mortality) occurring after
randomisation are summarised in Table 29. There were 664 events occurring in 35.7% of participants in the
restrictive group and 648 events in 34.2% participants in the liberal group. There were slightly more
participants with pulmonary complications (12.9% vs. 10.6%) and arrhythmias (15.3% vs. 12.8%) in the
restrictive group than the liberal group, and slightly fewer participants with gastrointestinal (GI) complications
(3.8% vs. 5.1%). The most common events were arrhythmias (14.0%), pulmonary complications (11.8%)
and other (i.e. unexpected) events (9.0%).
A summary measure was created (as a post-hoc analysis) combining the events in Table 29 with the
primary outcome and mortality. This measure could be relevant if the mechanisms hypothesised to justify
the superiority hypothesis and to classify SAEs as expected or unexpected were subsequently considered to
be unsound. In the restrictive group 523 out of 961 (54.4%) participants experienced this composite,
compared with 492 out of 971 (50.7%) in the liberal group.
Detailed examination of the events is undertaken in the following sections.
TABLE 28 Sensitivity analyses for all-cause mortality
Outcome
Randomised to
restrictive threshold
(N= 1000), n/N (%)
Randomised to
liberal threshold
(N= 1003), n/N (%) HR (95% CI) p-value
Excluding deaths occurring in the
first 24 hours after randomisation
41/999 (4.1) 24/1001 (2.4) HR 1.73 (1.05 to 2.87) 0.029
Excluding participants transfused
red blood cells pre-randomisation
23/750 (3.1) 11/739 (1.5) HR 2.15 (1.04 to 4.40) 0.032
TABLE 29 Summary of all SAEs
Event type
Randomised to restrictive threshold Randomised to liberal threshold
Events (n)
Participants
(N= 1000),
(n/N) % Events (n)
Participants
(N= 1003),
(n/N) %
Any event 664 354/991 35.7 648 339/991 34.2
Transient ischaemic attack 6 6/987 0.6 3 3/981 0.3
GI complications 40 37/986 3.8 55 50/983 5.1
Post-operation haemorrhage 12 12/987 1.2 18 17/982 1.7
Cardiac tamponade 2 2/987 0.2 2 2/981 0.2
Pulmonary complications 200 127/986 12.9 170 105/988 10.6
Arrhythmias 186 151/989 15.3 152 126/984 12.8
Reoperation 70 63/988 6.4 80 73/983 7.4
Thromboembolic complications 9 9/985 0.9 15 12/981 1.2
Low cardiac output 17 16/988 1.6 20 16/983 1.6
Wound dehiscence 19 16/987 1.6 20 18/981 1.8
Other (unexpected event)a 103 88/1000 8.8 113 93/1003 9.3
GI, gastrointestinal.
a It has been assumed that if an unexpected SAE was not reported, then an event was not present.
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Expected adverse events
Prior to hospital discharge (Table 30) there were 988 expected AEs in the restrictive group occurring in
49.6% of participants, and 938 in 48.4% of participants in the liberal group. Of these, 418 events in the
restrictive group (23.2% of participants) and 405 events in the liberal group (21.5% of participants) were
classified as serious. The most frequent events were arrhythmias. The numbers of pulmonary complications
and arrhythmias were slightly larger in the restrictive group than the liberal group, which is consistent
with Table 29.
Expected SAEs occurred less frequently after hospital discharge (Table 31), when there were 143 SAEs in
11.4% of participants in the restrictive group and 130 SAEs in 10.5% of participants in the liberal group.
The most common events were pulmonary complications (5.0%). There were no clear differences between
the groups although, again, rates of pulmonary complications and arrhythmias were slightly higher in the
restrictive group than the liberal group (5.5% vs. 4.6% and 3.4% vs. 2.4%, respectively).
The classification of SAEs occurring at any time (either before or after discharge) suggests that the small
differences in the frequencies of GI complications, pulmonary complications and arrhythmias identified
between the groups were not due to any particular SAEs within each category (Table 32). Instead, all
subcategories of SAEs appear to demonstrate differences between the groups in the same direction, which
aggregate to the overall slight differences observed in Table 29.
TABLE 30 Expected serious and non-serious AEs before hospital discharge
Event type
Randomised to restrictive threshold Randomised to liberal threshold
Events Participants (N= 1000) Events Participants (N= 1003)
AE SAE AE, n/N (%) SAE, n/N (%) AE SAE AE, n/N (%) SAE, n/N (%)
Any event 988 418 496/1000 (49.6) 232/998 (23.2) 938 405 485/1003
(48.4)
216/1003 (21.5)
Transient ischaemic
attack
4 2 4/1000 (0.4) 2/1000 (0.2) 2 1 2/1003 (0.2) 1/1003 (0.1)
GI complications 49 20 44/1000 (4.4) 17/999 (1.7) 46 30 40/1003
(4.0)
26/1003 (2.6)
Pancreatitis 2 0 2/1000 (0.2) 0/1000 (0.0) 0 0 0/1003 (0.0) 0/1003 (0.0)
Intestinal
obstruction/
perforation
1 0 1/1000 (0.1) 0/1000 (0.0) 5 4 5/1003 (0.5) 4/1003 (0.4)
Other GI
complications
46 20 41/999 (4.1) 17/999 (1.7) 41 26 38/1003
(3.8)
24/1003 (2.4)
Post-operation
haemorrhage
31 11 31/1000 (3.1) 11/1000 (1.1) 37 16 34/1003
(3.4)
15/1003 (1.5)
Cardiac tamponade 1 1 1/1000 (0.1) 1/1000 (0.1) 1 1 1/1003 (0.1) 1/1003 (0.1)
Pulmonary
complications
288 137 177/998 (17.7) 81/998 (8.1) 286 118 169/1003
(16.8)
66/1003 (6.6)
ARDS 5 4 5/999 (0.5) 4/999 (0.4) 3 0 3/1003 (0.3) 0/1003 (0.0)
Reintubation/
ventilation
54 35 50/1000 (5.0) 31/1000 (3.1) 61 31 53/1003
(5.3)
25/1003 (2.5)
Tracheostomy 31 20 30/999 (3.0) 19/999 (1.9) 33 18 32/1003
(3.2)
18/1003 (1.8)
Initiation of mask
CPAP
95 29 87/1000 (8.7) 28/1000 (2.8) 88 26 77/1003
(7.7)
23/1003 (2.3)
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TABLE 30 Expected serious and non-serious AEs before hospital discharge (continued )
Event type
Randomised to restrictive threshold Randomised to liberal threshold
Events Participants (N= 1000) Events Participants (N= 1003)
AE SAE AE, n/N (%) SAE, n/N (%) AE SAE AE, n/N (%) SAE, n/N (%)
Pneumothorax
requiring drainage
10 6 10/999 (1.0) 6/999 (0.6) 9 3 9/1003 (0.9) 3/1003 (0.3)
Pleural effusion
requiring drainage
56 25 54/999 (5.4) 24/999 (2.4) 56 24 49/1003
(4.9)
22/1003 (2.2)
Other pulmonary
complications
37 18 36/999 (3.6) 17/999 (1.7) 36 16 33/1003
(3.3)
14/1003 (1.4)
Arrhythmias 489 148 374/1000 (37.4) 121/999 (12.1) 436 127 354/1003
(35.3)
108/1003 (10.8)
Pacing 87 25 84/1000 (8.4) 24/1000 (2.4) 62 14 58/1003
(5.8)
14/1003 (1.4)
SVT/AF requiring
treatment
346 96 312/1000 (31.2) 90/1000 (9.0) 329 94 292/1003
(29.1)
83/1003 (8.3)
VF/VT requiring
treatment
17 8 13/1000 (1.3) 6/1000 (0.6) 6 2 6/1003 (0.6) 2/1003 (0.2)
Other arrhythmias 39 19 34/999 (3.4) 17/999 (1.7) 39 17 39/1003
(3.9)
17/1003 (1.7)
Reoperation 68 68 62/1000 (6.2) 62/1000 (6.2) 78 78 71/1003
(7.1)
71/1003 (7.1)
Thromboembolic
complications
6 5 6/998 (0.6) 5/998 (0.5) 2 1 2/1003 (0.2) 1/1003 (0.1)
Deep-vein
thrombosis
0 0 0/1000 (0.0) 0/1000 (0.0) 1 1 1/1003 (0.1) 1/1003 (0.1)
Pulmonary embolus 0 0 0/1000 (0.0) 0/1000 (0.0) 0 0 0/1003 (0.0) 0/1003 (0.0)
Other
thromboembolic
complications
6 5 6/998 (0.6) 5/998 (0.5) 1 0 1/1003 (0.1) 0/1003 (0.0)
Low cardiac output 32 14 31/1000 (3.1) 13/1000 (1.3) 26 18 22/1003
(2.2)
14/1003 (1.4)
Wound dehiscence 20 12 17/1000 (1.7) 9/1000 (0.9) 24 15 22/1003
(2.2)
13/1003 (1.3)
AF, atrial fibrillation; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia.
SAEs are a subset of AEs.
One participant could experience multiple AEs or SAEs.
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TABLE 31 Expected SAEs after hospital discharge
Event type
Randomised to restrictive threshold Randomised to liberal threshold
SAEs, n
Participants
(N= 1000), n/N (%) SAEs, n
Participants
(N= 1003), n/N (%)
Any event 143 113/987 (11.4) 130 103/981 (10.5)
Transient ischaemic attack 4 4/987 (0.4) 2 2/981 (0.2)
GI complications 20 20/987 (2.0) 25 24/981 (2.4)
Pancreatitis 0 0/987 (0.0) 2 2/981 (0.2)
Intestinal obstruction/perforation 0 0/987 (0.0) 0 0/981 (0.0)
Other GI complications 20 20/987 (2.0) 23 23/981 (2.3)
Post-operation haemorrhage 1 1/987 (0.1) 2 2/981 (0.2)
Cardiac tamponade 1 1/987 (0.1) 1 1/981 (0.1)
Pulmonary complications 63 54/987 (5.5) 52 45/981 (4.6)
ARDS 0 0/987 (0.0) 0 0/981 (0.0)
Reintubation/ventilation 0 0/987 (0.0) 0 0/981 (0.0)
Tracheostomy 0 0/987 (0.0) 0 0/981 (0.0)
Initiation of mask CPAP 1 1/987 (0.1) 0 0/981 (0.0)
Pneumothorax requiring drainage 0 0/987 (0.0) 1 1/981 (0.1)
Pleural effusion requiring drainage 34 31/987 (3.1) 32 30/981 (3.1)
Other pulmonary complication 28 26/987 (2.6) 19 17/981 (1.7)
Arrhythmias 38 34/987 (3.4) 25 24/981 (2.4)
Pacing 0 0/987 (0.0) 0 0/981 (0.0)
SVT/AF requiring treatment 27 24/987 (2.4) 22 21/981 (2.1)
VF/VT requiring treatment 0 0/987 (0.0) 0 0/981 (0.0)
Other arrhythmias 11 10/987 (1.0) 3 3/981 (0.3)
Re-operation 2 2/987 (0.2) 2 2/981 (0.2)
Thromboembolic complications 4 4/987 (0.4) 14 11/981 (1.1)
Deep-vein thrombosis 2 2/987 (0.2) 5 4/981 (0.4)
Pulmonary embolus 1 1/987 (0.1) 7 6/981 (0.6)
Other thromboembolic complications 1 1/987 (0.1) 2 2/981 (0.2)
Low cardiac output 3 3/987 (0.3) 2 2/981 (0.2)
Wound dehiscence 7 7/987 (0.7) 5 5/981 (0.5)
AF, atrial fibrillation; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia.
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TABLE 32 Expected SAEs at any time
Event type
Randomised to restrictive threshold Randomised to liberal threshold
SAEs, n
Participants
(N= 1000), n/N (%) SAEs, n
Participants
(N= 1003), n/N (%)
Any event 561 311/990 (31.4) 535 293/991 (29.6)
Transient ischaemic attack 6 6/987 (0.6) 3 3/981 (0.3)
GI complications 40 37/986 (3.8) 55 50/983 (5.1)
Pancreatitis 0 0/987 (0.0) 2 2/981 (0.2)
Intestinal obstruction/perforation 0 0/987 (0.0) 4 4/981 (0.4)
Other GI complications 40 37/986 (3.8) 49 47/983 (4.8)
Post-operation haemorrhage 12 12/987 (1.2) 18 17/982 (1.7)
Cardiac tamponade 2 2/987 (0.2) 2 2/981 (0.2)
Pulmonary complications 200 127/986 (12.9) 170 105/988 (10.6)
ARDS 4 4/986 (0.4) 0 0/981 (0.0)
Reintubation/ventilation 35 31/988 (3.1) 31 25/983 (2.5)
Tracheostomy 20 19/987 (1.9) 18 18/985 (1.8)
Initiation of mask CPAP 30 29/987 (2.9) 26 23/982 (2.3)
Pneumothorax requiring drainage 6 6/986 (0.6) 4 4/981 (0.4)
Pleural effusion requiring drainage 59 52/987 (5.3) 56 52/981 (5.3)
Other pulmonary complication 46 42/986 (4.3) 35 31/983 (3.2)
Arrhythmias 186 151/989 (15.3) 152 126/984 (12.8)
Pacing 25 24/987 (2.4) 14 14/981 (1.4)
SVT/AF requiring treatment 123 110/990 (11.1) 116 102/982 (10.4)
VF/VT requiring treatment 8 6/987 (0.6) 2 2/981 (0.2)
Other arrhythmias 30 27/987 (2.7) 20 20/983 (2.0)
Re-operation 70 63/988 (6.4) 80 73/983 (7.4)
Thromboembolic complications 9 9/985 (0.9) 15 12/981 (1.2)
Deep-vein thrombosis 2 2/987 (0.2) 6 5/981 (0.5)
Pulmonary embolus 1 1/987 (0.1) 7 6/981 (0.6)
Other thromboembolic complications 6 6/985 (0.6) 2 2/981 (0.2)
Low cardiac output 17 16/988 (1.6) 20 16/983 (1.6)
Wound dehiscence 19 16/987 (1.6) 20 18/981 (1.8)
AF, atrial fibrillation; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia.
One participant could experience multiple AEs or SAEs.
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Unexpected serious adverse events
There were 103 unexpected SAEs occurring in 8.8% of participants in the restrictive group and 113 events
in 9.3% participants in the liberal group (Table 33). Classifying events according to the MedDRA dictionary
suggests that cardiac disorders were the most frequent unexpected SAEs (3.0% of participants), in
particular cardiac failure (30 events) and pericardial effusion (20 events). Other types of event were rare.
There were more cases of anaemia in the restrictive group (six cases vs. one case) and more cases of
cardiac failure in the liberal group (19 cases vs. 11 cases), although the numbers of both events were low.
There were no other trends between the groups.
The characteristics of the SAEs suggest slightly higher proportions in the restrictive group resulted in death
or were life-threatening (17% vs. 13% and 36% vs. 29%, respectively, Table 34). Similarly, slightly higher
proportions were classified as of severe intensity in the restrictive group (55% vs. 50%). In total,
41 SAEs were classified as possibly, probably or definitely related to the intervention: 20 (19%) in the
restrictive group and 21 (19%) in the liberal group. Of these, 34 were attributed to a red blood cell
transfusion being given (14 in the restrictive group and 20 in the liberal group), and seven to a transfusion
being withheld (six in the restrictive group and one in the liberal group). Finally, more participants
experiencing a SAE had their treatment according to protocol discontinued (14 participants vs.
four participants).
TABLE 33 Unexpected SAEs
Event type
Randomised to restrictive
threshold (N= 1000)
Randomised to liberal
threshold (N= 1003)
Events
(n)
Participants,
n (%)
Events
(n)
Participants,
n (%)
Any event 103 88 (8.8) 113 93 (9.3)
Description of events (MedDRA terms)
Blood and lymphatic system disorders 6 5 (0.5) 2 2 (0.2)
Anaemia 4 4 1 1
Haemolytic anaemia 2 1 0 0
Coagulopathy 0 0 1 1
Cardiac disorders 29 26 (2.6) 41 35 (3.5)
Cardiac arrest 7 7 1 1
Cardiac failure 11 11 19 18
Cardiorespiratory arrest 0 0 2 1
Heart valve incompetence 0 0 1 1
Left ventricular failure 2 2 1 1
Left ventricular hypertrophy 0 0 1 1
MV incompetence 1 1 0 0
Palpitations 0 0 1 1
Pericardial effusion 8 6 12 11
Pericarditis 0 0 1 1
Pericarditis constrictive 0 0 1 1
TV incompetence 0 0 1 1
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TABLE 33 Unexpected SAEs (continued )
Event type
Randomised to restrictive
threshold (N= 1000)
Randomised to liberal
threshold (N= 1003)
Events
(n)
Participants,
n (%)
Events
(n)
Participants,
n (%)
Eye disorders 2 2 (0.2) 0 0 (0.0)
Diplopia 1 1 0 0
Visual impairment 1 1 0 0
General disorders and administration site conditions 12 12 (1.2) 10 10 (1.0)
Adverse drug reaction 0 0 1 1
Chest pain 2 2 2 2
Local swelling 0 0 1 1
Malaise 0 0 1 1
Multiorgan failure 6 6 3 3
Non-cardiac chest pain 1 1 2 2
Oedema peripheral 1 1 0 0
Pain 1 1 0 0
Swelling 1 1 0 0
Hepatobiliary disorders 1 1 (0.1) 2 2 (0.2)
Alcoholic liver disease 0 0 1 1
Hepatic cyst 0 0 1 1
Hepatic necrosis 1 1 0 0
Immune system disorders 1 1 (0.1) 0 0 (0.0)
Anaphylactic reaction 1 1 0 0
Infections and infestations 4 4 (0.4) 7 7 (0.7)
Cellulitis 0 0 1 1
Diverticulitis 1 1 1 1
Empyema 0 0 1 1
Endocarditis 2 2 2 2
Gangrene 0 0 1 1
H1N1 influenza 1 1 0 0
Oral candidiasis 0 0 1 1
Injury, poisoning and procedural complications 6 5 (0.5) 10 9 (0.9)
Arteriovenous fistula site haemorrhage 0 0 1 1
Fall 1 1 3 3
Femoral neck fracture 0 0 2 2
Nerve injury 0 0 1 1
Overdose 0 0 1 1
Rib fracture 1 1 0 0
continued
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TABLE 33 Unexpected SAEs (continued )
Event type
Randomised to restrictive
threshold (N= 1000)
Randomised to liberal
threshold (N= 1003)
Events
(n)
Participants,
n (%)
Events
(n)
Participants,
n (%)
Seroma 1 1 0 0
Toxicity to various agents 2 2 0 0
Transfusion reaction 0 0 1 1
Upper limb fracture 1 1 0 0
Wound 0 0 1 1
Investigations 2 2 (0.2) 3 3 (0.3)
Blood pressure decreased 0 0 1 1
International normalised ratio 2 2 1 1
International normalised ratio increased 0 0 1 1
Metabolism and nutrition disorders 4 4 (0.4) 1 1 (0.1)
Hypernatraemia 1 1 0 0
Hypoglycaemia 1 1 1 1
Hyponatraemia 2 2 0 0
Musculoskeletal and connective tissue disorders 7 7 (0.7) 4 4 (0.4)
Back pain 1 1 1 1
Compartment syndrome 2 2 0 0
Muscular weakness 1 1 0 0
Musculoskeletal chest pain 2 2 3 3
Pain in extremity 1 1 0 0
Neoplasms benign, malignant and unspecified (including
cysts and polyps)
2 2 (0.2) 1 1 (0.1)
Bladder cancer 0 0 1 1
Brain cancer metastatic 1 1 0 0
Breast cancer 1 1 0 0
Nervous system disorders 9 9 (0.9) 11 10 (1.0)
Amnesia 1 1 0 0
Brain injury 0 0 2 1
Convulsion 3 3 1 1
Dizziness 0 0 1 1
Grand mal convulsion 2 2 1 1
Headache 1 1 1 1
Loss of consciousness 0 0 1 1
Neuralgia 0 0 1 1
Partial seizures 0 0 1 1
Syncope 2 2 2 2
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TABLE 33 Unexpected SAEs (continued )
Event type
Randomised to restrictive
threshold (N= 1000)
Randomised to liberal
threshold (N= 1003)
Events
(n)
Participants,
n (%)
Events
(n)
Participants,
n (%)
Psychiatric disorders 2 2 (0.2) 2 2 (0.2)
Alcohol withdrawal syndrome 1 1 1 1
Confusional state 0 0 1 1
Depression 1 1 0 0
Renal and urinary disorders 4 4 (0.4) 7 7 (0.7)
Haematuria 1 1 1 1
Renal colic 1 1 0 0
Renal vasculitis 0 0 1 1
Urinary retention 2 2 5 5
Respiratory, thoracic and mediastinal disorders 1 1 (0.1) 3 3 (0.3)
Dysphonia 0 0 1 1
Epistaxis 0 0 1 1
Hypoxia 1 1 1 1
Surgical and medical procedures 3 3 (0.3) 6 6 (0.6)
Aortic aneurysm repair 1 1 0 0
Cardiac pacemaker revision 0 0 1 1
Coronary arterial stent insertion 0 0 1 1
Debridement 0 0 1 1
Eye excision 1 1 0 0
Haematoma evacuation 0 0 1 1
Leg amputation 1 1 1 1
Ventriculocardiac shunt 0 0 1 1
Vascular disorders 8 8 (0.8) 3 3 (0.3)
Aortic aneurysm rupture 1 1 1 1
Haematoma 1 1 0 0
Hypotension 2 2 0 0
Orthostatic hypotension 2 2 1 1
Peripheral ischaemia 1 1 0 0
Peripheral vascular disorder 1 1 0 0
Vasculitis 0 0 1 1
MV, mitral valve; TV, tricuspid valve.
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Meta-analysis
A meta-analysis of mortality for TITRe2 and the five earlier RCTs24–26,37,38 is shown in Figure 15. The
combined estimate suggests an increased risk of death in the restrictive group, of borderline statistical
significance, RR 1.41 (95% CI 0.98 to 2.04). It should be noted that the restrictive and liberal thresholds
varied across these trials (Table 35). The trials also varied with respect to whether or not the intervention
was applied during the operation. In addition, with the exception of TITRe2, all of the studies randomised
all participants prior to their operation; hence, they included in their analyses participants who did not
TABLE 34 Characteristics of unexpected SAEs
Event type
Restrictive group SAEs
(N= 103)
Liberal group SAEs
(N= 113)
Events, % Participants, %
Timing of event
Pre-discharge 35 34 46 41
Post discharge 68 66 67 59
Reason event classified as SAEa
Resulted in death 18 17 15 13
Was life-threatening 37 36 33 29
Resulted in persistent or significant disability/incapacity 23 22 31 27
Required hospitalisation 62 60 72 64
Prolonged ongoing hospitalisation 26 25 36 32
Other 5 5 4 4
Maximum intensity
Mild 12 12 18 16
Moderate 34 33 39 35
Severe 57 55 56 50
Final outcome
Resolved no sequelae 52 50 61 54
Resolved with sequelae 33 32 34 30
Died 18 17 18 16
Relatedness
Not related 61 59 70 62
Unlikely to be related 22 21 22 19
Possibly related 14 14 18 16
Probably related 3 3 2 2
Definitely related 3 3 1 1
Related to
Red blood cell transfusion being given 14 14 20 18
Red blood cell transfusion being withheld 6 6 1 1
Treatment according to protocol permanently discontinued 4 4 14 12
a Some events were classified as SAEs for multiple reasons so the reasons sum to more than 100%.
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breach the liberal threshold and who were almost certainly not transfused. By virtue of randomisation,
there should have been similar numbers of participants in each group who did not breach the liberal
threshold. Including these participants would be expected to dilute any treatment effect.
Summary
The frequency of the primary outcome was slightly higher in the restrictive group than the liberal group
(35.1% vs. 33.0%), mainly owing to ischaemic events and, in particular, AKI. Sensitivity analyses either
restricted to participants who were not transfused pre-randomisation or including additional less-severe
AKI events augmented this difference. However, restricting the analysis to only the most severe primary
outcome events reduced the event frequencies to 14.7% and 14.9% in the restrictive and liberal groups,
respectively, and the treatment effect (OR) was reduced to unity. This event frequency was very
similar to that assumed at the outset for the sample size justification. There was no evidence of any
subgroup effects.
There were significantly more deaths in the restrictive group (4.2%) than the liberal group (2.6%);
HR 1.64 (95% CI 1.00 to 2.67). This difference persisted in two post-hoc sensitivity analyses of the
mortality outcome. A meta-analysis combining mortality data from five previous RCTs gave a pooled RR
1.41 (95% CI 0.98 to 2.04). There were no statistically significant differences between the groups for any
of the other secondary outcomes; however, all estimated treatment differences either favoured the liberal
group or were null apart from the EQ-5D-3L utility score. In terms of SAEs, the overall frequency was
slightly higher in the restrictive group than the liberal group (35.7% vs. 34.2%).
TABLE 35 Transfusion thresholds used in each study
Study Restrictive group threshold Liberal group threshold Intervention period
Johnson 199224 8.3 g/dl 10.7 g/dl Postoperative only
Bracey 199925 8.0 g/dl 9.0 g/dl Postoperative only
Murphy 200726 7.0 g/dl 8.0 g/dl Postoperative only
Hajjar 201037 8.0 g/dl 10.0 g/dl Intraoperative and
postoperative
Shehata 201238 7.0 g/dl intraoperatively during
CPB; 7.5 g/dl postoperatively
9.5 g/dl intraoperatively during
CPB; 10.0 g/dl postoperatively
Intraoperative and
postoperative
Murphy 201555 7.5 g/dl 9.0 g/dl Postoperative only
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Chapter 6 Results of the economic evaluation
Quality-adjusted life-years
A summary of the mean EQ-5D-3L scores at each of the time points and the QALYs gained in each group
are shown in Figure 16 and in Table 36 (compare with medians reported in Table 27). These figures differ
slightly to those presented earlier because we use means rather than medians, in contrast with the
description of effectiveness, and include participants who have died with scores of zero from the date of
death. The means are supported by SEs. On average, participants’ EQ-5D-3L scores did not fully return to
their pre-operative level by 3 months in either treatment group.
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FIGURE 16 Mean EQ-5D-3L utility scores (and 95% CI) at each time point for each treatment group.
TABLE 36 Results for EQ-5D-3L scores and QALYs
Time point
Randomised to
restrictive threshold
(n= 1000), mean (SE)
Randomised to
liberal threshold
(n= 1003), mean (SE)
Restrictive vs. liberal
threshold, mean
difference (SE)
EQ-5D-3L time pointa
Baseline 0.765 (0.008) 0.767 (0.007) –0.001 (0.011)
6 weeks 0.692 (0.008) 0.686 (0.008) 0.006 (0.011)
3 months 0.748 (0.009) 0.750 (0.008) –0.002 (0.012)
QALYs to 3 months (adjusted
for baseline EQ-5D-3L)
0.1802 (0.0015) 0.1798 (0.0016) 0.0004 (0.0021)
a Deaths included as zero.
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As Table 36 shows, there is very little difference between the groups for EQ-5D-3L scores at any of the
three time points and a tiny (non-significant) difference in QALYs between the groups. Indeed, the QALYs
to 3 months are 0.18 for both the restrictive and liberal groups, with a mean difference of only 0.0004
(SE 0.0021). This difference of 0.0004 QALYs is approximately 3.5 quality-adjusted hours. Given the
significant difference in deaths between the groups (more deaths in the restrictive group), we explored
potential reasons why the difference in deaths did not appear to translate into a difference in QALYs. We
would have assumed that the participants who died were more ill, which theoretically could have resulted
in them reporting lower EQ-5D-3L scores prior to death. We therefore plotted the QALY data for each
group: for all participants, for participants excluding deaths and only for deaths. This investigation revealed
that it was not merely the participants who died who had low QALYs, but also many other participants.
These low EQ-5D-3L scores for surviving participants had the effect of ‘diluting’ the impact on the means
of imputed zero EQ-5D-3L scores for participants who died. Most of the participants who died had total
QALYs of 0–0.05. When these participants were excluded, there were a few more participants in the
liberal group with QALYs < 0.05 than in the restrictive group and, overall, these low scores in the liberal
group appear to have partly balanced out the greater number of deaths in the restrictive group. In
addition, there were more participants in the restrictive group in the highest band for QALYs, which could
also be balancing out the greater number of deaths in the restrictive group. Therefore, we came to the
conclusion that the figures in Table 36 could be showing that there was genuinely no real difference in
QALYs between the restrictive and liberal groups, despite the difference in deaths.
Resource use and costs
Table 37 reports information on the main resource use items for the trial groups to 3 months. The table
includes information on surgery, blood products, LOS, complications and health-care contacts post
discharge. Frequencies are given for binary responses (yes/no) and means and SEs are presented for the
number of events or LOS per participant. Red blood cells are the only resource item for which there is a
clear difference between the groups, an expected finding given that the liberal group had more red blood
cells transfused. The average units of red blood cells transfused (compared with medians in Table 14) in the
restrictive group was 2.08 units (SE 0.09 units) per participant, compared with 3.07 units (SE 0.11 units)
units per participant in the liberal group, leading to an average difference of 1.00 unit (SE 0.14 units) per
participant. For most of the other categories of resource use, the differences between the groups are very
small. The differences are slightly larger for inpatient ward LOS, time in other hospitals and readmissions
than for some other resource use items, but these are nevertheless small differences.
In terms of unit costs which were attached to the main resource use items, Table 38 provides some
information on the main resource unit costs used and the source for the information, presented in
2012–13 prices. More detailed information on unit costs can be found in Appendix 3, Unit costs and
resource use assumed for complications.
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TABLE 37 Resource use per participant to 3 months from surgery
Resource use component
Randomised to
restrictive threshold
(n= 1000), frequency
(%) or mean (SE)
Randomised to
liberal threshold
(n= 1003), frequency
(%) or mean (SE)
Restrictive versus
liberal threshold,
% or mean (SE)
difference
Red blood cells, number of
units/participant 2.08 (0.09) 3.07 (0.11) –1.00 (0.14)
Cardiac procedure, n (%)
CABG 408 (41) 408 (41) 0
Valve 307 (31) 304 (30) 1
CABG and valve 195 (20) 203 (20) 0
Other 90 (9) 88 (9) 0
Blood products, number of units/participant
FFP 1.00 (0.06) 0.95 (0.06) 0.05 (0.08)
Platelets 0.65 (0.03) 0.64 (0.03) 0.01 (0.05)
Cryoprecipitate 0.23 (0.03) 0.21 (0.02) 0.02 (0.04)
Inpatient complications, n (%)
Primary outcome
Antibiotics for infectious complication 341 (34) 344 (34) 0
Stroke 14 (1) 16 (2) –1
Suspected MI 3 (0) 7 (1) –1
Gut infarction 5 (1) 1 (0) 1
AKI: stage 3 60 (6) 51 (5) 1
Other complications, n events/participant (%)
Reoperation 0.09 (0.01) 0.10 (0.01) –0.01 (0.02)
Reintubation 0.07 (0.01) 0.07 (0.01) 0.00 (0.01)
Tracheostomy 0.03 (0.01) 0.03 (0.01) 0.00 (0.01)
Mask CPAP 0.13 (0.01) 0.12 (0.01) 0.01 (0.02)
Pneumothorax requiring chest drainage 0.01 (0.00) 0.01 (0.00) 0.00 (0.01)
Pleural effusion requiring drainage 0.06 (0.01) 0.06 (0.01) 0.00 (0.01)
Pacing 0.31 (0.02) 0.31 (0.02) 0.00 (0.02)
SVT/AF requiring treatment 0.41 (0.02) 0.39 (0.02) 0.02 (0.03)
VF/VT requiring intervention 0.02 (0.01) 0.01 (0.00) 0.01 (0.01)
Low cardiac output 0.11 (0.01) 0.11 (0.01) 0.00 (0.01)
Inpatient LOS, days/participant
CICU 1.14 (0.12) 1.12 (0.13) 0.02 (0.18)
HDU 3.09 (0.12) 3.05 (0.12) 0.04 (0.17)
Ward 5.67 (0.15) 5.83 (0.17) –0.17 (0.23)
Another unit/hospital 1.27 (0.20) 1.36 (0.19) –0.09 (0.27)
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TABLE 37 Resource use per participant to 3 months from surgery (continued )
Resource use component
Randomised to
restrictive threshold
(n= 1000), frequency
(%) or mean (SE)
Randomised to
liberal threshold
(n= 1003), frequency
(%) or mean (SE)
Restrictive versus
liberal threshold,
% or mean (SE)
difference
Blood saving techniques, n (%)
Tranexamic acid 807 (81) 810 (81) 0
Trasylol 41 (4) 35 (3) 1
Intraoperative cell salvage 482 (48) 503 (50) –2
Post-operative cell salvage 56 (6) 46 (5) 1
Fluids in theatre/CICU/HDU, n (%)
Inotropes 624 (62) 614 (61) 1
Gelofusine® (B. Braun, Melsungen, Germany) 843 (84) 836 (83) 1
HES 231 (23) 233 (23) 0
Readmissions to hospital
LOS, days/participant 1.38 (0.15) 1.46 (0.16) –0.08 (0.22)
ED attendances
Total ED visits, number/participant 0.09 (0.01) 0.08 (0.01) 0.01 (0.01)
Outpatient appointments, n/participant (%)
Cardiac surgery outpatient visits 0.44 (0.02) 0.51 (0.02) –0.07 (0.03)
Cardiology outpatient visits 0.28 (0.02) 0.26 (0.02) 0.03 (0.03)
Other outpatient visits 0.17 (0.02) 0.17 (0.02) 0.00 (0.03)
Other health-care contacts, n/participant (%)
GP at surgery 1.99 (0.06) 2.07 (0.07) –0.09 (0.10)
GP at home 0.43 (0.04) 0.37 (0.03) 0.06 (0.06)
Practice nurse 1.56 (0.13) 1.57 (0.14) –0.01 (0.19)
District nurse 2.47 (0.20) 2.21 (0.23) 0.26 (0.30)
AF, atrial fibrillation; HES, hydroxyethyl starch; SVT, supraventricular tachycardia; VF, ventricular fibrillation;
VT, ventricular tachycardia.
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TABLE 38 Unit costs for key resources
Resource use Unit cost (£) Source
Red blood cells (per unit of blood) 123.31 NHSBT Price List 2012/1345
Cardiac procedure
CABG 6714 See Appendix 3, Table 61
Valve 7336 See Appendix 3, Table 61
CABG and valve 8054 See Appendix 3, Table 61
Other 8298 See Appendix 3, Table 61
Blood products (per unit)
FFP 27.46 NHSBT Price List 2012/1345
Platelets 209.30 NHSBT Price List 2012/1345
Cryoprecipitate 189.19 NHSBT Price List 2012/1345
Inpatient complications
Primary outcome
Antibiotics for infectious complication See Appendix 3,
Table 63
eMIT, 2014;46 BNF 66, 201347
Stroke 139 NHS Reference Costs 2012/1344
Confirmed by CT scan 62 NHS Reference Costs 2012/1344
Confirmed by MRI scan 248 NHS Reference Costs 2012/1344
Suspected MI 1868 NHS Reference Costs 2012/1344
Gut infarction 62 NHS Reference Costs 2012/1344
Confirmed by laparotomy 2693 NHS Reference Costs 2012/1344
AKI – stage 3 1438 NHS Reference Costs 2012/1344
Other complications
Reoperation (duration < 3 hours) 6608 NHS Reference Costs 2012/1344
Reoperation (duration ≥ 3 hours) 8298 NHS Reference Costs 2012/1344
Reintubation 395 NHS Reference Costs 2012/1344
Tracheostomy 5354 NHS Reference Costs 2012/1344
Mask CPAP 539 NHS Reference Costs 2012/1344
Pneumothorax requiring drainage 4218 NHS Reference Costs 2012/1344
Pleural effusion requiring drainage 4218 NHS Reference Costs 2012/1344
Pacing 3073 NHS Reference Costs 2012/1344
SVT/AF requiring treatment 4.79 eMIT, 201446
VF/VT requiring treatment 2007 NHS Reference Costs 2012/1344
Low cardiac output 313 NHS Reference Costs 2012/1344
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TABLE 38 Unit costs for key resources (continued )
Resource use Unit cost (£) Source
Inpatient LOS
CICU day 1190 NHS Reference Costs 2012/1345
HDU day 619 NHS Reference Costs 2012/1345
Ward day 392 NHS Reference Costs 2012/1345
Another unit/hospital ICU day 1168 NHS Reference Costs 2012/1345
Another unit/hospital ward day 265 NHS Reference Costs 2012/1345
Blood saving techniques
Tranexamic acid 15.50 BNF 66, 201348
Trasylol 316.83 Davies et al.56
Intra- and post-operative cell salvage 176 Davies et al.56
Fluids in theatre/CICU/HDU
Inotropes 57.30 eMIT, 201447
Gelofusine 7.92 Finance Department South Central, 2013,
personal communication
HES 40.60 BNF 58, 200957
Readmissions to hospital
Ward day 265 NHS Reference Costs 2012/1345
ICU day 1168 NHS Reference Costs 2012/1345
ED attendances
ED visit (not leading to admission) 101 NHS Reference Costs 2012/1345
Outpatient appointments
Cardiac surgery outpatient visit 299 NHS Reference Costs 2012/1345
Cardiology outpatient visit 131 NHS Reference Costs 2012/1345
Other outpatient visits See Appendix 3,
Tables 70 and 71
NHS Reference Costs 2012/1345
Other health-care contacts
GP at surgery 34 Unit Costs of Health and Social Care 201349
GP at home 85 Unit Costs of Health and Social Care 201349
Practice nurse 11.37 Unit Costs of Health and Social Care 201349
District nurse 39 Unit Costs of Health and Social Care 201349
AF, atrial fibrillation; HES, hydroxyethyl starch; SVT, supraventricular tachycardia; VF, ventricular fibrillation;
VT, ventricular tachycardia.
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The combined resource use and unit cost information are presented in Figure 17 in terms of a breakdown
of total costs for each treatment group. This clearly shows that there is very little difference in costs
between the groups apart from a difference in the average cost of red blood cells, which is to be
expected. Key drivers of total costs were surgery, complications and LOS. A breakdown of total costs is
given in Table 39. This table is broken down into three cost categories: red blood cells, inpatient episode
and post-hospital discharge. A more detailed breakdown of total costs is given in Table 74 in Appendix 3.
A separate analysis, which shows that the costs of regular medications were reduced after surgery, is
described in Appendix 3, Changes in the use of regular medications between admission to and discharge
from the cardiac surgery unit.
The total cost of care from surgery up to 3 months is £17,945 in the restrictive group and £18,127 in the
liberal group, creating a mean difference between the groups of £182 (SE £488). Most of this difference in
cost is associated with the higher cost of red blood cells in the liberal group (cost difference of £140). The
next main cost difference is in LOS costs, the complications and SAEs, with the liberal group being more
expensive than the restrictive group, but only slightly more. In terms of post-discharge costs, the restrictive
group costs slightly more than the liberal group for hospital readmissions, with a cost difference of £17
(SE £116) and ‘other’ medical/social care costs, with a difference of £12 (SE £21). The liberal group costs
more than the restrictive group for outpatient appointments with a cost difference of £14 (SE £9).
The differences in costs between the groups are small, although there is substantial uncertainty around the
differences in costs as shown in the SEs in the final column in Table 39. In terms of the distribution of
costs across the trial groups, the histograms presented in Figures 18 and 19 show that the cost data were
skewed for both groups, which is a common finding in health economic evaluations. This skewness was
enhanced by the existence of a few very high-cost outliers, especially in the liberal group. There were four
participants with costs over £100,000, who were all in the liberal group.
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FIGURE 18 Mean total costs (£) per participant in the restrictive group. The inset graph shows that there were
outliers in the liberal group but not in the restrictive group.
TABLE 39 Breakdown of total average cost per participant for both trial groups
Cost component
Randomised to restrictive
threshold (n= 1000),
mean cost (£) (SE)
Randomised to liberal
threshold (n= 1003),
mean cost (£) (SE)
Restrictive vs. liberal
threshold, mean cost
(£) difference (SE)
Red blood cells 287 (13) 427 (15) –140 (19)
Inpatient episode
Initial cardiac surgery 7309 (18) 7313 (18) –4 (26)
Other blood products 206 (12) 199 (11) 7 (16)
Complications and SAEs 2684 (137) 2714 (146) –30 (200)
LOSa 5854 (201) 5892 (221) –38 (299)
Blood saving techniques 159 (9) 152 (8) 7 (12)
Regular medications 26 (2) 29 (2) –3 (3)
Fluids 55 (1) 55 (1) 0 (2)
Total 16,293 (309) 16,353 (339) –60 (459)
Post-hospital discharge
Readmissions 770 (85) 753 (78) 17 (116)
ED visits 16 (2) 12 (2) 4 (3)
Outpatient appointments 202 (6) 216 (7) –14 (9)
Other medical/social care 378 (14) 366 (16) 12 (21)
Total 1365 (90) 1347 (82) 18 (122)
Total costs 17,945 (332) 18,127 (357) –182 (488)
a Includes days in another unit/hospital once transferred out of the cardiac unit.
Costs do not always sum to totals owing to rounding.
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Base-case cost-effectiveness results
The ICER for the restrictive threshold compared with the liberal threshold is shown in Table 40. The
differences in costs and QALYs between the groups are small and neither difference is statistically
significant. The difference between the groups for QALYs is particularly small, that is the denominator for
the ICER (the difference in QALYs) is therefore very small. Dividing the difference in costs by a tiny number
close to zero, results in a very large ICER (–£428,064). Based on the point estimate, the restrictive
threshold is considered cost-effective and the restrictive threshold is dominant over the liberal threshold as
it is both more effective and less costly. However, there is great uncertainty around this result, as shown
on the cost-effectiveness plane in Figure 20. The black dot is the point estimate of the cost and QALY
difference and is close to the origin. The bootstrap replicates of the cost and QALY differences cover all
four quadrants of the cost-effectiveness plane, which illustrates that there is actually very little difference
between the two groups and much uncertainty. There is a 43% probability that the restrictive threshold
dominates the liberal threshold, but also a 20% probability of the reverse scenario, that the liberal
threshold dominates the restrictive threshold.
The CEAC in Figure 21 shows the probability that the restrictive threshold is cost-effective for a range of
willingness-to-pay thresholds. If a decision-maker is willing to pay £20,000 for an additional QALY, then
the probability of restrictive being cost-effective is 65%. The probability that a restrictive threshold is
cost-effective changes little across a broad range of willingness-to-pay thresholds, indicating that this
probability is invariant to the willingness-to-pay threshold. Across ceiling ratios from £0 to £100,000, a
restrictive threshold has a probability of being cost-effective of 0.65–0.66 and the liberal threshold has
a probability of being cost-effective of 0.34–0.35. Clearly the restrictive threshold is more likely to be
cost-effective, but there is much uncertainty around this. The dashed lines at 0.1 and 0.9 indicate the 80%
confidence limits for the probability that a restrictive threshold is cost-effective. As these horizontal lines
do not cut the curve at any point, the 80% confidence limits on cost-effectiveness do not exist. Indeed it
is not possible to define even 50% confidence limits on cost-effectiveness across willingness-to-pay
thresholds from £0 to £100,000.
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FIGURE 19 Mean total costs (£) per participant in the liberal group. The inset graph shows that there were outliers
in the liberal group but not in the restrictive group.
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Sensitivity analyses
Sensitivity analyses for costing were conducted to investigate varying a number of unit costs, moving
the time origin from surgery to the time of randomisation and the impact of any high-cost participants.
We planned to consider a wider, societal perspective (instead of the NHS and Personal Social Services
perceptive taken in the base-case analysis) if non-NHS costs were found to differ between the trial groups.
This was not found to be the case (see Appendix 3, Non-NHS costs: did these differ between trial groups?)
and, therefore, this sensitivity analysis was not conducted. In terms of outcomes, alternative assumptions
for calculating QALYs were implemented in sensitivity analyses. Finally, we examined life-years gained as a
secondary outcome measure. Each of these sensitivity analyses is considered in turn.
Sensitivity analyses around unit costs
The results of the sensitivity analyses around the costs of bed-days, antibiotics, complications and
outpatient visits are shown in Table 79 in Appendix 3. Varying the costs of bed-days during the index
admission by ± 50% had the greatest impact on total costs in each group (increasing and decreasing total
costs to approximately £21,000 and £15,000 respectively). However, none of the sensitivity analyses had a
great impact on the cost difference between the groups. The cost differences across the sensitivity analyses
ranged from –£208 to –£161, bracketing and all very similar to the base-case cost difference of –£182.
These findings reinforce how similar resource use is between the groups.
Costing from the point of randomisation
Events that occurred before randomisation were excluded and costs from randomisation to 3 months
calculated. Participants were on average randomised 0.8 days after surgery. There is little difference in total
costs of care from randomisation to 3 months between the two treatment groups. The total costs from
randomisation are £8825 (SE £310) in the restrictive group and £8959 (SE £340) in the liberal group, with
a mean difference between the groups of –£134 (SE £460). The costs associated with red blood cells
are lower in the restrictive group than the liberal group, as expected. The costs of other inpatient and
post-discharge resource use are very similar. Further details on the methods for this analysis and a
breakdown of resource use and total costs are provided in Appendix 3, Costs from randomisation.
Total costs from randomisation are considerably less than total costs from surgery. Costs are lower because
the costs of surgery and complications occurring before randomisation have been excluded and LOS costs
are reduced. The LOS occurring pre-randomisation is at least, in part, time spent in CICU/HDU, as all
participants go to CICU/HDU after surgery. Red blood cell costs are also reduced because red blood cells
are sometimes transfused during surgery.
Sensitivity analyses around cost outliers
The distribution of total costs per participant is positively skewed in both transfusion groups, as seen in
Figures 18 and 19. It is possible that a few high-cost outliers are exerting influence over the mean costs in
each group and the overall findings; therefore, we investigated the existence of outliers and their effects.
There were 12 participants with costs over £80,000, of whom seven were in the liberal group and five
were in the restrictive group. Participants with the five highest costs were all in the liberal group. Four
participants had costs over £100,000 (£101,173; £107,163; £108,865; and one extreme outlier of
£144,985). These participants did not have unexpected events; rather, they had large numbers of expected
complications and stayed in hospital with a high level of care for some time. Therefore, there were no
grounds for excluding these participants from the analyses. Nevertheless, it is instructive to investigate the
impact they are having on cost and cost-effectiveness results, as the imbalance across groups of these
outliers could easily have arisen by chance.
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Table 41 shows the effects on costs and cost-effectiveness results of excluding the highest cost outlier and
of excluding the four highest cost outliers with total costs over £100,000. All of these participants were in
the liberal group and, therefore, results for the restrictive group are unchanged. If the participant with the
highest cost is excluded from the analyses, the difference in costs between the groups reduces from –£182
to –£55. If participants with the four highest costs are excluded, the liberal group becomes less expensive
than the restrictive group and the difference in costs between the groups changes from –£182 to +£208.
The liberal group also becomes marginally more effective than the restrictive group and the conclusions are
reversed, that is, the liberal group dominates the restrictive group as it is both less costly and more
effective. While there is much uncertainty around these findings, these four participants are clearly exerting
a significant impact on the cost and cost-effectiveness results.
Sensitivity analyses around quality-adjusted life-year calculations
We explored various assumptions for calculating QALYs, including the use of last observation carried
forward until death (rather than assuming that utility changes linearly until death) and using the date
of the 6-week EQ-5D-3L completion (rather than assuming it was completed exactly at 6 weeks). Details of
the alternative strategies explored are given in Table 42 and the results are provided in Table 43. In all
of these sensitivity analyses the difference in QALYs between the groups remained very small. When last
observation carried forward until death was used, QALYs increased slightly in both groups, more so in the
restrictive group as there were more deaths in this group and a greater number of participants whose
QALYs were increased by this sensitivity analysis (unless their EQ-5D-3L score was less than zero at
the previous observation). When the exact timing of the 6-week EQ-5D-3L questionnaire was used in the
QALY calculations, the mean QALYs gained up to 3 months were slightly higher in the liberal group than
in the restrictive group, a reversal of the base-case findings. Participants on average completed the 6-week
questionnaire later than planned, at 51 days rather than 42 days.
Life-years
Life-years gained from surgery up to 3 months are shown in Table 44. Given the greater number of deaths
in the restrictive group, slightly fewer life-years were gained in the restrictive group than in the liberal
group. The cost-effectiveness results using life-years as the outcome measure are also shown in Table 44.
This analysis generated the typical trade-off between the treatment effect and the difference in cost. This
trade-off is usually the result of a better effect at a higher cost; here, the reverse was the case with the
restrictive threshold gaining fewer life-years but at lower cost than the liberal threshold. The ICER of
£66,800 is the incremental saving associated with the loss of 1 life-year by adopting a restrictive rather
than a liberal threshold. If a decision-maker’s willingness to accept compensation for the loss of 1 life-year
was £20,000, then a restrictive threshold would be considered cost-effective.
The cost-effectiveness plane for life-years (Figure 22) and the CEAC for life-years (Figure 23) show quite
interesting differences compared with those for the QALY analysis. In particular, Figure 22 shows that with
life-years, many of the points are located in the bottom left quadrant of the plane (south-west quadrant),
indicating that a restrictive threshold is most likely to be less effective and less costly than a liberal
threshold. With the QALYs analysis, the plane had most of its points scattered around the origin showing
very little difference. Compared with the cost-effectiveness plane for QALYs, the points on the cost-
effectiveness plane for life-years have been pulled across to the left as there is a clearer difference in
effects, namely a reduction in the number of life-years gained in the restrictive group. The uncertainty
around the difference in costs remains. In this analysis, the probability that restrictive is more effective than
liberal is just 3% (not statistically significant). There is only a 2% probability that the restrictive threshold
dominates the liberal threshold (i.e. is more effective and less costly), but a 34% probability of the reverse
scenario – that the liberal threshold dominates the restrictive threshold.
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The CEAC in Figure 23 shows that if a decision-maker is willing to accept compensation of £20,000 for a
life-year, then the probability that restrictive is cost-effective is 61%. As was the case for the CEAC for
QALYs, there is much uncertainty around this finding. It is not possible to define 80%, or even 50%,
confidence limits on cost-effectiveness across ceiling ratios from £0 to £100,000.
Subgroup analyses
The results of the seven subgroup analyses conducted to investigate whether or not cost-effectiveness
results varied between participant subgroups are presented in Appendix 3, Table 82. Comparing costs
between subgroups as a whole, the findings are generally as expected. Participants in each low-risk
stratum before surgery cost less than those in each high-risk stratum, with the exception of sex for which
the high-risk stratum (females) cost less than the low-risk stratum (males), and the possible exception of
pulmonary disease/asthma, but the numbers at high risk for pulmonary comorbidity were small.
The cost and QALY differences between the treatment groups within the subgroups are all small relative to
their SEs. When the impact of subgroups was evaluated using ordinary least squares regression separately for
total costs and for QALYs, and considering interaction terms between treatment group and subgroup, only
the interaction term for the subgroup for lung disease for QALYs was found to be significant (p= 0.003).
Participants in the restrictive group with chronic pulmonary disease or asthma gained a reduced number of
QALYs compared with other participants. This effect is consistent with the corresponding subgroup analysis
of the primary outcome (see Chapter 5, Subgroup analyses).
For subgroup analyses 1–4 and 6 (further details in Appendix 3, Table 82), the direction of differences
between treatment groups does differ between the subgroups. In the ‘low-risk’ stratum of each subgroup
analysis (participants believed to be at lower risk of the primary outcome), the restrictive threshold is both
less costly and more effective than the liberal threshold and, therefore, a restrictive threshold is favoured.
In the ‘high-risk’ stratum of each subgroup (participants believed to be at higher risk of the primary
outcome), the restrictive threshold is both more costly and less effective than the liberal threshold, so the
liberal threshold is favoured. Note that negative ICERs need to be interpreted with caution (an ICER is a
ratio of two numbers and, if either of the two is negative, the ICER will be negative). Either the new
intervention is less costly and more effective, a desirable finding, or the new intervention is more costly
and less effective, an undesirable finding. Both scenarios result in negative ICERs, but have very different
meanings. These subgroup analyses should be considered as exploratory and further work would be
required to confirm these findings.
Summary
There was very little difference between the groups in either costs or effects, and great uncertainty around
the cost-effectiveness results. Mean QALYs to 3 months were 0.18 in both groups and there was a tiny
difference between the restrictive and liberal groups (mean difference 0.0004, 95% CI –0.0037 to
0.0045). The total cost of care from surgery up to 3 months was £17,945 in the restrictive group and
£18,127 in the liberal group, creating a small mean difference of –£182, 95% CI –£1108 to £744. There
were several outliers in the liberal group that exerted a substantial influence on the average costs of
participants in that group, altering the results when they were excluded.
The point estimate of cost-effectiveness suggested that the restrictive group was more effective and less
costly than the liberal group (i.e. dominant) and, therefore, cost-effective. However given the small
differences in costs and effects, there was much uncertainty around this result.
There was evidence of one subgroup effect: participants in the restrictive group with chronic pulmonary
disease or asthma gained a reduced number of QALYs compared with other participants (p= 0.003).
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Chapter 7 Observational analyses
As described in Chapter 2, Observational analyses, all red blood cells administered and haemoglobinlevels recorded after the time of the first event that qualified for the primary outcome or after
censoring have been excluded. The classification of all red blood cell transfusions as happening before
randomisation, after randomisation but before the primary outcome or censoring and after the
primary outcome or censoring is given in Table 45. Therefore, for analyses described in this chapter,
1381 participants are classified as having had at least one unit of red blood cells transfused after
randomisation and before experiencing the primary outcome or being censored, 484 in the restrictive
transfusion threshold stratum (total of 1074 units) and 897 in the liberal transfusion threshold stratum
(total of 2030 units).
For the same period (after randomisation and before the time of the primary outcome or censoring), all
participants were also classified as having experienced a minimum haemoglobin < 7.5 g/dl versus ≥ 7.5 g/dl.
No haemoglobin levels were recorded for two participants between randomisation and the first incidence of
the primary outcome or censoring. A total of 595 participants had a minimum haemoglobin level below
7.5 g/dl and 1406 participants had a haemoglobin level ≥ 7.5 g/dl throughout the period.
The analysis population is, therefore, identical to that for the analyses by transfusion threshold stratum
reported in Chapter 5. However, the two participants with no haemoglobin measurements after
randomisation and before experiencing the primary outcome or censoring are excluded from all models
that fitted haemoglobin level.
TABLE 45 Timing of red blood cell transfusions by randomisation and occurrence (or censoring) of the
primary outcome
Transfusion
Restrictive group Liberal group
Number of
transfusions of
red blood cells
(units)
Number of participants
receiving any
transfusions (%)
(n= 1000)
Number of
transfusions of
red blood cells
(units)
Number of participants
receiving any
transfusions (%)
(n= 1003)
Pre-randomisation
red blood cell
transfusions
587 250 (25.0) 589 264 (26.3)
Post-randomisation
red blood cell
transfusions
1494 534 (53.4) 2494 925 (92.2)
Before the
primary
outcome or
censoringa,b
1074 484 (48.4) 2030 897 (89.4)
After the
primary
outcome or
censoringa
420 121 (12.1) 464 147 (14.7)
a Participants are classified according to whether (1) one or more red blood cell transfusions occurred before the primary
outcome or censoring, or (2) all red blood cell transfusions occurred after the primary outcome or censoring.
b These transfusions comprise those considered in the remainder of this chapter.
DOI: 10.3310/hta20600 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 60
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
Red blood cells and haemoglobin levels
Trial characteristics and outcomes
Pre-operative and intraoperative characteristics and trial outcomes are described by red blood cell
transfusion status (after randomisation and before experiencing the primary outcome or censoring) in
Tables 46 and 47, and by minimum haemoglobin in Tables 48 and 49.
Compared with non-transfused participants, transfused participants were on average older [median
70.8 years (IQR 64.2–76.8 years) vs. 69.5 years (IQR 62.6–75.5 years)], had similar additive EuroSCOREs
[medians 5 (IQR 3–7)], higher logistic EuroSCOREs [median 4.2 (IQR 2.4–7.5) vs. 3.7 (IQR 2.0–6.6)]
and were less likely to be male (67.6% vs. 70.7%). Transfused participants had, on average, lower
pre-operative haemoglobin levels [mean 13.2 g/dl (SD 1.5 g/dl) vs. 13.5 g/dl (SD 1.4 g/dl)] and eGFR levels
[median 71.7ml/minute/1.73m2 (IQR 54.7–91.5ml/minute/1.73m2) vs. 77.4 ml/minute/1.73m2 (IQR
61.3–96.9ml/minute/1.73m2)]. Their surgery time was slightly longer [median 4.0 hours (IQR 3.3–5.0
hours) vs. 3.9 hours (IQR 3.3–4.9 hours)] and they were less likely to have had CABG surgery (39.2%
vs. 44.1%).
Pre-randomisation red blood cell transfusion frequencies were similar in the two groups (25.6% for
transfused and 25.7% for non-transfused). However, the transfusion of other blood products was higher
in the participants who also had red blood cells transfused; FFP was transfused in 32.5% of participants
who had a red blood cell transfusion vs. 21.2% of participants who did not, platelets in 40.7% and
28.3% of participants and cryoprecipitate in 11.4% and 6.9% of participants, respectively. The minimum
haemoglobin reached was lower in the transfused participants [median 7.8 g/dl (IQR 7.2–8.4 g/dl) vs.
8.3 g/dl (IQR 7.8–8.6 g/dl)], but the percentage decline in haemoglobin from the pre-operative level was
only very slightly more in the transfused participants [median 41.3% (IQR 35.1–46.7%) vs. 39.3%
(IQR 34.7–43.3%)]. In terms of trial outcomes, the primary outcome occurred in 35.3% of transfused
participants and 30.9% of non-transfused participants, both mortality (3.7% vs. 2.7%) and significant
pulmonary morbidity (14.0% vs. 8.3%) rates were higher for transfused participants, and the duration of
ICU/HDU stay was longer [median 59.6 hours (IQR 24.4–109 hours) vs. 32.6 hours (IQR 11.3–76.1 hours)].
TABLE 46 Characteristics of participants by red blood cell transfusion status
Characteristic Transfused (N= 1381) Not transfused (N= 622)
Cardiac history
Additive EuroSCORE,a median (IQR) 5.0 (3.0–7.0) 5.0 (3.0–7.0)
Logistic EuroSCORE,a median (IQR) 4.2 (2.4–7.5) 3.7 (2.0–6.6)
NYHA class, n/N (%)
I 342/1348 (25.4) 151/603 (25.0)
II 594/1348 (44.1) 291/603 (48.3)
III 382/1348 (28.3) 143/603 (23.7)
IV 30/1348 (2.2) 18/603 (3.0)
CCS class, n/N (%)
No angina 477/1354 (35.2) 241/608 (39.6)
I 259/1354 (19.1) 103/608 (16.9)
II 350/1354 (25.8) 176/608 (28.9)
III 208/1354 (15.4) 73/608 (12.0)
IV 60/1354 (4.4) 15/608 (2.5)
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TABLE 46 Characteristics of participants by red blood cell transfusion status (continued )
Characteristic Transfused (N= 1381) Not transfused (N= 622)
Coronary disease, n/N (%)
None 426/1375 (31.0) 194/616 (31.5)
Single vessel 168/1375 (12.2) 57/616 (9.3)
Double vessel 184/1375 (13.4) 98/616 (15.9)
Triple vessel 562/1375 (40.9) 243/616 (39.4)
Not investigated 35/1375 (2.5) 24/616 (3.9)
Disease in left main stem (> 50% stenosis) 204/1364 (15.0) 100/613 (16.3)
Non-cardiac history
Age (years), median (IQR) 70.8 (64.2–76.8) 69.5 (62.6–75.5)
Males, n/N (%) 933/1381 (67.6) 440/622 (70.7)
BMI (kg/m2),b mean (SD) 27.9 (4.8) 28.7 (5.1)
Urgent operative priority, n/N (%) 181/1381 (13.1) 64/622 (10.3)
Diabetic, n/N (%) 279/1381 (20.2) 120/622 (19.3)
Haemofiltration/dialysis, n/N (%) 16/1379 (1.2) 3/622 (0.5)
CVA/TIA, n/N (%) 112/1381 (8.1) 51/622 (8.2)
Pre-operative tests
Haemoglobin (g/dl), mean (SD) 13.2 (1.5) 13.5 (1.4)
eGFR (ml/minute/1.73m2),c median (IQR) 71.7 (54.7–91.5) 77.4 (61.3–96.9)
Intraoperative characteristics
Duration of operation (hours),d median (IQR) 4.0 (3.3–5.0) 3.9 (3.3–4.9)
CPB used, n/N (%) 1323/1381 (95.8) 580/621 (93.4)
Cardiac procedure, n/N (%)
CABG only 542/1381 (39.2) 274/622 (44.1)
Valve only 428/1381 (31.0) 183/622 (29.4)
CABG+ valve 301/1381 (21.8) 97/622 (15.6)
Other 110/1381 (8.0) 68/622 (10.9)
Tranexamic acid, n/N (%) 1112/1380 (80.6) 503/621 (81.0)
Trasylol, n/N (%) 48/1315 (3.7) 23/579 (4.0)
Cell saver, n/N (%) 689/1381 (49.9) 295/621 (47.5)
Blood loss at 4 hours (ml),e median (IQR) 275 (170–460) 210 (125–328)
Blood loss at 12 hours (ml),e median (IQR) 525 (340–840) 400 (290–600)
BMI, body mass index; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident; NYHA, New York Health
Association; TIA, transient ischaemic attack.
a Missing for 24 transfused participants and 14 non-transfused participants.
b Missing for one transfused participant.
c Missing for two transfused participants.
d Missing for one non-transfused participant.
e Missing for one transfused participant and two non-transfused participants.
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TABLE 47 Outcomes of participants by red blood cell transfusion status
Outcome
Transfused (N= 1381) Not transfused (N= 622)Intra- and post-operative use of other blood products
Pre-randomisation red blood cell transfusion, n/N (%) 354/1381 (25.6) 160/622 (25.7)
FFP transfusions, n/N (%) 449/1381 (32.5) 132/622 (21.2)
Platelet transfusions, n/N (%) 562/1381 (40.7) 176/622 (28.3)
Cryoprecipitate transfusions, n/N (%) 158/1381 (11.4) 43/622 (6.9)
Activated factor VII used, n/N (%) 7/1381 (0.5) 5/622 (0.8)
Beriplex used, n/N (%) 65/1381 (4.7) 35/622 (5.6)
Minimum haemoglobin (g/dl),a median (IQR) 7.8 (7.2–8.4) 8.3 (7.8–8.6)
Percentage decline in haemoglobin,a median (IQR) 41.3 (35.1–46.7) 39.3 (34.7–43.3)
Primary outcome, n/N (%)
Overall primary outcome 474/1342 (35.3) 174/564 (30.9)
Infectious event 351/1327 (26.5) 127/563 (22.6)
Sepsis 311/1360 (22.9) 113/605 (18.7)
Wound infection 72/1297 (5.6) 29/560 (5.2)
Ischaemic event 213/1371 (15.5) 82/611 (13.4)
Permanent stroke 25/1363 (1.8) 7/611 (1.1)
Suspected MI 6/1357 (0.4) 1/611 (0.2)
Gut infarction 4/1358 (0.3) 3/611 (0.5)
AKI 188/1367 (13.8) 74/611 (12.1)
Other trial outcomes
All-cause mortality, n/N (%) 51/1381 (3.7) 17/622 (2.7)
Significant pulmonary morbidity, n/N (%) 192/1367 (14.0) 51/614 (8.3)
Duration of ICU/HDU stay (hours), median (IQR) 59.6 (24.4–109) 32.6 (11.3–76.1)
Duration of post-randomisation hospital stay (days), median (IQR) 7.0 (5.0–11.0) 6.0 (4.0–9.0)
a Missing for two non-transfused participants.
OBSERVATIONAL ANALYSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
TABLE 48 Characteristics of participants by minimum haemoglobin level
Characteristic
Minimum haemoglobin
< 7.5 g/dl (N= 595)
Minimum haemoglobin
≥ 7.5 g/dl (N= 1406)
Cardiac history
Additive EuroSCORE,a median (IQR) 5.0 (4.0–7.0) 5.0 (3.0–7.0)
Logistic EuroSCORE,a median (IQR) 4.2 (2.4–7.2) 4.0 (2.2–7.2)
NYHA class, n/N (%)
I 133/580 (22.9) 360/1370 (26.3)
II 259/580 (44.7) 625/1370 (45.6)
III 170/580 (29.3) 355/1370 (25.9)
IV 18/580 (3.1) 30/1370 (2.2)
CCS class, n/N (%)
No angina 185/583 (31.7) 533/1378 (38.7)
I 102/583 (17.5) 260/1378 (18.9)
II 168/583 (28.8) 358/1378 (26.0)
III 98/583 (16.8) 182/1378 (13.2)
IV 30/583 (5.1) 45/1378 (3.3)
Coronary disease, n/N (%)
None 178/593 (30.0) 442/1396 (31.7)
Single vessel 64/593 (10.8) 161/1396 (11.5)
Double vessel 86/593 (14.5) 196/1396 (14.0)
Triple vessel 256/593 (43.2) 547/1396 (39.2)
Not investigated 9/593 (1.5) 50/1396 (3.6)
Disease in left main stem (> 50% stenosis), n/N (%) 97/590 (16.4) 206/1385 (14.9)
Non-cardiac history
Age (years), median (IQR) 70.8 (64.2–76.7) 70.0 (63.3–76.2)
Males, n/N (%) 391/595 (65.7) 980/1406 (69.7)
BMI (kg/m2),b mean (SD) 27.6 (4.9) 28.4 (4.9)
Urgent operative priority, n/N (%) 86/595 (14.5) 158/1406 (11.2)
Diabetic, n/N (%) 126/595 (21.2) 273/1406 (19.4)
Haemofiltration/dialysis, n/N (%) 7/595 (1.2) 12/1404 (0.9)
CVA/TIA, n/N (%) 44/595 (7.4) 119/1406 (8.5)
continued
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TABLE 48 Characteristics of participants by minimum haemoglobin level (continued )
Characteristic
Minimum haemoglobin
< 7.5 g/dl (N= 595)
Minimum haemoglobin
≥ 7.5 g/dl (N= 1406)
Pre-operative tests
Haemoglobin (g/dl), mean (SD) 13.0 (1.5) 13.4 (1.4)
eGFR (ml/minute/1.73m2),c median (IQR) 69.3 (52.5–86.7) 75.8 (58.5–95.4)
Intraoperative characteristics
Duration of operation (hours),b median (IQR) 4.2 (3.4–5.2) 4.0 (3.3–5.0)
CPB used, n/N (%) 567/595 (95.3) 1334/1405 (94.9)
Cardiac procedure, n/N (%)
CABG only 239/595 (40.2) 575/1406 (40.9)
Valve only 171/595 (28.7) 440/1406 (31.3)
CABG+ valve 132/595 (22.2) 266/1406 (18.9)
Other 53/595 (8.9) 125/1406 (8.9)
Tranexamic acid, n/N (%) 474/595 (79.7) 1139/1404 (81.1)
Aprotinin (Trasylol, The Nordic group), n/N (%) 24/561 (4.3) 47/1331 (3.5)
Cell saver, n/N (%) 292/595 (49.1) 691/1405 (49.2)
Blood loss at 4 hours (ml),d median (IQR) 328 (200–525) 225 (140–350)
Blood loss at 12 hours (ml),d median (IQR) 630 (380–1000) 450 (300–700)
BMI, body mass index; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident; NYHA, New York Health
Association; TIA, transient ischaemic attack.
a Missing for 32 participants in the minimum haemoglobin < 7.5g/dl group and six in minimum haemoglobin
≥ 7.5g/dl group.
b Missing for one participant, in the minimum haemoglobin < 7.5g/dl group.
c Missing for two participants, in the minimum haemoglobin < 7.5g/dl group.
d Missing for two participants, in the minimum haemoglobin < 7.5g/dl group.
Two participants with no haemoglobin levels recorded before first occurrence of the primary outcome are excluded from
this table.
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TABLE 49 Outcomes of participants by minimum haemoglobin level
Outcome
Minimum haemoglobin
< 7.5 g/dl (N= 595)
Minimum haemoglobin
≥ 7.5 g/dl (N= 1406)
Intra- and post-operative use of blood products
Pre-randomisation red blood cell transfusion, n/N (%) 181/595 (30.4) 333/1406 (23.7)
Post-randomisation (pre-primary outcome) red blood cell
transfusions, n/N (%)
555/595 (93.3) 826/1406 (58.7)
FFP transfusions, n/N (%) 243/595 (40.8) 337/1406 (24.0)
Platelet transfusions, n/N (%) 288/595 (48.4) 449/1406 (31.9)
Cryoprecipitate transfusions, n/N (%) 82/595 (13.8) 119/1406 (8.5)
Activated factor VII used, n/N (%) 1/595 (0.2) 11/1406 (0.8)
Beriplex used, n/N (%) 20/595 (3.4) 80/1406 (5.7)
Percentage decline in haemoglobin, median (IQR) 46.7 (42.4–50.7) 38.4 (33.3–42.8)
Primary outcome, n/N (%)
Overall primary outcome 237/574 (41.3) 411/1330 (30.9)
Infectious event 161/566 (28.4) 317/1322 (24.0)
Sepsis 141/583 (24.2) 283/1380 (20.5)
Wound infection 39/560 (7.0) 62/1295 (4.8)
Ischaemic event 128/593 (21.6) 167/1387 (12.0)
Permanent stroke 14/591 (2.4) 18/1381 (1.3)
Suspected MI 1/588 (0.2) 6/1378 (0.4)
Gut infarction 3/588 (0.5) 4/1379 (0.3)
AKI 114/590 (19.3) 148/1386 (10.7)
Other trial outcomes
All-cause mortality, n/N (%) 38/595 (6.4) 30/1406 (2.1)
Significant pulmonary morbidity, n/N (%) 111/590 (18.8) 132/1389 (9.5)
Duration of ICU/HDU stay (hours), median (IQR) 71.7 (42.3–131) 42.1 (17.4–87.6)
Duration of post-randomisation hospital stay (days), median (IQR) 8.0 (6.0–13.0) 6.0 (5.0–9.0)
Two patients with no haemoglobin levels recorded before first occurrence of the primary outcome are excluded from
this table.
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Compared with participants with a haemoglobin ≥ 7.5 g/dl, participants with a haemoglobin < 7.5 g/dl
were of a similar age and had a similar median additive EuroSCOREs but slightly higher median
logistic EuroSCOREs [median 4.2 (IQR 2.4–7.2) vs. 4.0 (IQR 2.2–7.2)] and were less likely to be male
(65.7% vs. 69.7%). Participants with a post-randomisation haemoglobin < 7.5 g/dl had slightly lower
pre-operative haemoglobin levels [mean 13.0 g/dl (SD 1.5 g/dl) vs. 13.4 g/dl (SD 1.4 g/dl)] and eGFR levels
[median 69.3ml/minute/1.73m2 (IQR 52.5–86.7ml/minute/1.73 m2) vs. 75.8 ml/minute/1.73 m2
(IQR 58.5–95.4ml/minute/1.73m2)].
Participants with a haemoglobin < 7.5 g/dl were more likely to have had a pre-randomisation red blood
cell transfusion (30.4% vs. 23.7%), post-randomisation red blood cell transfusion (93.3% vs. 58.7%), FFP
transfusion (40.8% vs. 24.0%), platelet transfusion (48.4% vs. 31.9%) and cryoprecipitate transfusion
(13.8% vs. 8.5%). In terms of trial outcomes, the primary outcome occurred in 41.3% of participants with
a haemoglobin < 7.5 g/dl and 30.9% of participants whose post-randomisation haemoglobin remained
≥ 7.5 g/dl. Both mortality (6.4% vs. 2.1%) and significant pulmonary morbidity (18.8% vs. 9.5%) were
more frequent in participants with a haemoglobin < 7.5 g/dl and the duration of ICU/HDU stay was longer
[median 71.7 hours (IQR 42.3–131 hours) vs. 42.1 hours (IQR 17.4–87.6 hours)].
Unadjusted relationship between red blood cells, haemoglobin and outcome
The outcome used for these analyses was the primary outcome and/or death, which occurred in 671 out
of 1908 (35.2%) participants. In the population as a whole, the risk of this outcome increased with
increasing number of transfused units (Table 50). For haemoglobin, the risk of outcome decreases as
haemoglobin increases.
Haemoglobin levels, transfusion status and outcome are described in Table 51 and Figure 24, both for all
participants and stratified by transfusion threshold stratum.
TABLE 50 Univariate relationships between red blood cell transfusion status and minimum haemoglobin level, and
primary outcome/death
Transfusions/haemoglobin levels
Number of
participants
Primary outcome/death,
n (%)
Unadjusted OR
(95% CI) p-value
Post-randomisation (pre-primary outcome) red blood cell transfusions
None 565 176 (31.2) Reference group 0.0200
One 577 198 (34.3) 1.15 (0.90 to 1.48)
Two 396 150 (37.9) 1.35 (1.03 to 1.77)
Three to four 260 96 (36.9) 1.29 (0.95 to 1.76)
Five or more 110 51 (46.4) 1.91 (1.26 to 2.89)
Post-randomisation (pre-primary outcome) minimum haemoglobin
Hb< 7 g/dl 216 99 (45.8) 1.91 (1.38 to 2.65) < 0.0001
7 g/dl<Hb≤ 7.5 g/dl 358 154 (43.0) 1.71 (1.29 to 2.26)
7.5 g/dl<Hb≤ 8 g/dl 363 119 (32.8) 1.10 (0.83 to 1.47)
8 g/dl<Hb≤ 8.5 g/dl 447 139 (31.1) 1.02 (0.78 to 1.34)
Hb≥ 8.5 g/dl 522 160 (30.7) Reference group
Hb, haemoglobin.
OBSERVATIONAL ANALYSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
TABLE 51 Relationship between red blood cell transfusion status, minimum haemoglobin level and primary
outcome/death
Haemoglobin levels
Transfused participants Non-transfused participants All participants
Primary outcome/death Primary outcome/death Primary outcome/death
N n (%) N n (%) N n (%)
All participants
Hb< 7 g/dl 205 89 (43.4) 11 10 (90.9) 216 99 (45.8)
7 g/dl<Hb≤ 7.5 g/dl 335 140 (41.8) 23 14 (60.9) 358 154 (43.0)
7.5 g/dl<Hb≤ 8 g/dl 213 76 (35.7) 150 43 (28.7) 363 119 (32.8)
8 g/dl<Hb≤ 8.5 g/dl 273 82 (30.0) 174 57 (32.8) 447 139 (31.1)
Hb≥ 8.5 g/dl 317 108 (34.1) 205 52 (25.4) 522 160 (30.7)
Total 1343 495 (36.9) 563 176 (31.3) 1906 671 (35.2)
Liberal group
Hb< 7 g/dl 62 29 (46.8) 6 5 (83.3) 68 34 (50.0)
7 g/dl<Hb≤ 7.5 g/dl 100 43 (43.0) 2 0 (0.0) 102 43 (42.2)
7.5 g/dl<Hb≤ 8 g/dl 149 48 (32.2) 2 1 (50.0) 151 49 (32.5)
8 g/dl<Hb≤ 8.5 g/dl 252 74 (29.4) 24 7 (29.2) 276 81 (29.3)
Hb≥ 8.5 g/dl 314 106 (33.8) 51 11 (21.6) 365 117 (32.1)
Total 877 300 (34.2) 85 24 (28.2) 962 324 (33.7)
Restrictive group
Hb< 7 g/dl 143 60 (42.0) 5 5 (100.0) 148 65 (43.9)
7 g/dl<Hb≤ 7.5 g/dl 235 97 (41.3) 21 14 (66.7) 256 111 (43.4)
7.5 g/dl<Hb≤ 8 g/dl 64 28 (43.8) 148 42 (28.4) 212 70 (33.0)
8 g/dl<Hb≤ 8.5 g/dl 21 8 (38.1) 150 50 (33.3) 171 58 (33.9)
Hb≥ 8.5 g/dl 3 2 (66.7) 154 41 (26.6) 157 43 (27.4)
Total 466 195 (41.9) 478 152 (31.8) 944 347 (36.8)
Hb, haemoglobin.
Percentages are row percentages, e.g. 89/205= 43.4%.
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A number of observations can be made from Table 51 and Figure 24.
l At haemoglobin levels below 7.5 g/dl it is difficult to assess the role of transfusion because almost all
such participants (540/574; 94.1%) were transfused; however, there is some evidence of a reduced risk
of outcome with transfusion. The overall risk at haemoglobin ≤ 7.5 g/dl was 229/540, 42.4% (95% CI
38.2% to 46.7%) for transfused participants and 24/34, 70.6% (95% CI 52.5% to 84.9%) for
non-transfused participants. At haemoglobin levels > 7.5 g/dl there was generally a slightly increased
risk of outcome associated with transfusion (with the exception of the 8.0 –8.5 g/dl group), although
CIs overlap (see Figure 24).
l The reduced risk of outcome with increasing haemoglobin for the entire population is observed
separately within transfused and non-transfused participants.
l Examining the difference in risk of the outcome in transfused and non-transfused groups in the
liberal threshold stratum only is not very informative because most participants in this stratum were
transfused. Within the group of transfused participants there is a general trend for the risk of outcome
to decrease with increasing haemoglobin. The overall proportion of non-transfused participants
experiencing the outcome in the liberal threshold stratum (28.2%) is slightly lower than the overall
proportion across both transfusion threshold strata (31.3%), although this is likely to be at least
partially attributable to the fact that non-transfused participants in the liberal stratum (arising mainly
owing to non-adherence with the study protocol) are likely to have been healthier participants.
l For participants in the restrictive threshold stratum, there is again a general trend within both
transfused and non-transfused participants for the risk of the outcome to decrease with increasing
haemoglobin. Similarly, the risk of the outcome appears to reduce among participants transfused
at haemoglobin ≤ 7.5 g/dl (although numbers of non-transfused participants are small) and to
increase among participants transfused at haemoglobin > 7.5 g/dl (again, arising mainly owing to
non-adherence with the study protocol). Outcome event rates for non-transfused participants in the
restrictive threshold stratum are similar to the rates for both strata combined, but somewhat higher for
transfused participants (except at low haemoglobin levels).
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FIGURE 24 Relationship between red blood cell transfusion status, minimum haemoglobin concentration and
primary outcome/death.
Hb, haemoglobin.
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Conventionally adjusted statistical models
As described in Chapter 2, Observational analyses, separate models have been fitted with (1) red blood
cell transfusion after randomisation and before the primary outcome or censoring and (2) haemoglobin
< 8 g/dl after randomisation and before the pre-primary outcome or censoring as explanatory variables,
adjusting for confounders. Models for post-randomisation red blood cells are described in Table 52.
Three models are fitted with red blood cells as a categorical variable, an ordinal variable (i.e. fitting the
five-level variable as a continuous variable) and a binary variable (i.e. any vs. no red blood cell transfusions).
From Table 52, the best fitting model in terms of deviance is the ordinal model and all models fit well
in terms of residual and leverage plots and goodness-of-fit tests. All three models suggest a clear
dose–response relationship of increased odds of outcome associated with increasing numbers of red blood
cell transfusions; for example, the ordinal model suggests increased odds of outcome of 12% (95% CI 3%
to 21%) associated with an increase of one level in the post-randomisation red blood cells variable. The
odds of outcome were also significantly increased by transfusion of pre-randomisation red blood cells
(OR 1.64, 95% CI 1.31 to 2.05).
The ordinal model from Table 52 was refitted separately within each transfusion threshold stratum
(Table 53). Associations are similar to those identified in Table 52, although there is some evidence of a
slightly stronger relationship between pre-randomisation red blood cells and outcome in the liberal threshold
stratum and, conversely, between cardiac procedure and outcome in the restrictive threshold stratum.
Models for post-randomisation haemoglobin levels are described in Table 54. Two models are fitted with
haemoglobin level as a continuous or binary variable (< 7.5 g/dl vs. ≥ 7.5 g/dl).
TABLE 52 Conventionally adjusted models of the effect of red blood cell transfusions on the primary
outcome/death
Explanatory
variables
Model 1: categorical red
blood cells
Model 2: ordinal red blood
cells
Model 3: binary red blood
cells
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Post-randomisation red blood cell units (before primary outcome)
0 Reference group 0.0900 1.12 (1.03 to 1.21) 0.0089 Reference group
1.28 (1.03 to 1.60)
0.0280
1 1.17 (0.90 to 1.51)
2 1.36 (1.02 to 1.81)
3–4 1.27 (0.92 to 1.76)
≥ 5 1.70 (1.09 to 2.63)
Pre-randomisation red
blood cells
1.64 (1.31 to 2.05) < 0.0001 1.64 (1.31 to 2.05) < 0.0001 1.67 (1.33 to 2.08) < 0.0001
Logistic EuroSCORE 1.27 (1.10 to 1.46) 0.0008 1.27 (1.10 to 1.46) 0.0008 1.28 (1.11 to 1.47) 0.0005
Cardiac procedure
CABG Reference group 0.0230 Reference group 0.0200 Reference group 0.0170
Valve 0.88 (0.67 to 1.14) 0.88 (0.67 to 1.14) 0.88 (0.67 to 1.14)
CABG+ valve 1.35 (1.01 to 1.79) 1.35 (1.02 to 1.80) 1.36 (1.02 to 1.82)
Other 1.00 (0.68 to 1.46) 1.00 (0.68 to 1.46) 1.01 (0.69 to 1.49)
The deviances of the models are: model 1 (categorical red blood cells): 2325.4; model 2 (ordinal red blood cells): 2326.6,
change in deviance from model 1= 1.15 (3 degrees of freedom), p-value 0.76; model 3 (binary red blood cells): 2328.6,
change in deviance from model 1= 3.21 (3 degrees of freedom), p-value 0.36.
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TABLE 53 Conventionally adjusted models of the effect of red blood cell transfusions on the primary
outcome/death, by transfusion threshold stratum
Explanatory variables
Restrictive threshold stratum Liberal threshold stratum
OR (95% CI) p-value OR (95% CI) p-value
Post-randomisation (pre-primary outcome)
red blood cells – ordinal variable
1.19 (1.06 to 1.35) 0.0042 1.13 (0.99 to 1.28) 0.072
Any pre-randomisation red blood cells 1.39 (1.01 to 1.93) 0.046 1.89 (1.38 to 2.59) 0.0001
Logistic EuroSCORE 1.24 (1.02 to 1.52) 0.035 1.32 (1.09 to 1.60) 0.0047
Cardiac procedure
CABG Reference group 0.047 Reference group 0.380
Valve 0.92 (0.64 to 1.33) 0.84 (0.57 to 1.22)
CABG+ valve 1.59 (1.06 to 2.41) 1.18 (0.79 to 1.77)
Other 1.05 (0.62 to 1.79) 0.98 (0.56 to 1.70)
TABLE 54a Conventionally adjusted models of the effect of minimum haemoglobin level on the primary
outcome/death: continuous minimum haemoglobin level
Explanatory variables OR (95% CI) p-value
Post-randomisation (pre-primary outcome) haemoglobina
CABG participants 0.92 (0.75 to 1.14) < 0.0001b
Valve participants 0.62 (0.48 to 0.79)
CABG+ valve participants 0.51 (0.38 to 0.68)
Other participants 0.68 (0.44 to 1.04)
Pre-operative haemoglobin 0.91 (0.85 to 0.98) 0.0094
Logistic EuroSCORE 1.34 (1.16 to 1.54) < 0.0001
Females 0.77 (0.61 to 0.97) 0.0250
CABG, at haemoglobin= 8 g/dl Reference group 0.0600c
Valve, at haemoglobin= 8 g/dl 0.84 (0.64 to 1.10)
CABG+ valve, at haemoglobin= 8 g/dl 1.26 (0.93 to 1.69)
Other, at haemoglobin= 8 g/dl 1.04 (0.70 to 1.55)
One outlier has been excluded from all models.
The deviances of the models are: model a (continuous haemoglobin): 2298.1; model b (binary haemoglobin): 2303.8.
a This relationship is described graphically in Figure 25.
b p-value from a test of haemoglobin+ haemoglobin by operation type.
c p-value from a test of operation type (with haemoglobin centred at 8 g/dl).
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All models fit well in terms of residual and leverage plots and goodness-of-fit tests. For both models, an
interaction between post-randomisation haemoglobin and cardiac procedure was statistically significant
and, therefore, interpretation of the relationship between haemoglobin and outcome is complex. The effect
of haemoglobin for each cardiac procedure is given in Table 54, along with the effect of the different cardiac
procedures (compared with CABG surgery) at an approximately median haemoglobin value of 8 g/dl
(see Table 54a). To visualise this relationship, marginal plots of the haemoglobin effect for different cardiac
procedures (from the continuous model) averaged across the other covariates are given in Figure 25.
There is evidence of a haemoglobin effect for the non-CABG surgery participants – an increase in
haemoglobin of 1 g/dl reduces the odds of outcome (valve surgery: OR 0.62, 95% CI 0.48 to 0.79; CABG
and valve surgery: OR 0.51, 95% CI 0.38 to 0.68; other procedures: OR 0.68, 95% CI 0.44 to 1.04), see
Table 54 and Figure 25. For CABG participants, there is little evidence of any haemoglobin effect (OR 0.92,
95% CI 0.75 to 1.14). Similarly, the binary model suggests reduced odds of outcome associated with
haemoglobin ≥ 7.5 g/dl for non-CABG participants (valve surgery: OR 0.51, 95% CI 0.35 to 0.75; CABG
and valve surgery: OR 0.37, 95% CI 0.23 to 0.58; other procedures: OR 0.47, 95% CI 0.23 to 0.93) but
little evidence of any effect for CABG participants (OR 0.89, 95% CI 0.63 to 1.26).
TABLE 54b Conventionally adjusted models of the effect of minimum haemoglobin level on the primary
outcome/death: binary minimum haemoglobin level
Explanatory variables OR (95% CI) p-value
Post-randomisation haemoglobin ≥ 7.5g/dl (vs. < 7.5g/dl)
CABG participants 0.89 (0.63 to 1.26) < 0.0001a
Valve participants 0.51 (0.35 to 0.75)
CABG+ valve participants 0.37 (0.23 to 0.58)
Other participants 0.47 (0.23 to 0.93)
Pre-operative haemoglobin (continuous) 0.90 (0.84 to 0.97) 0.0044
Logistic EuroSCORE 1.33 (1.16 to 1.54) 0.0001
Females 0.78 (0.62 to 0.99) 0.0380
CABG, at haemoglobin ≥ 7.5 g/dl Reference group 0.2200b
Valve, at haemoglobin ≥ 7.5 g/dl 0.76 (0.55 to 1.04)
CABG+ valve, at haemoglobin ≥ 7.5 g/dl 1.04 (0.73 to 1.47)
Other, at haemoglobin ≥ 7.5 g/dl 0.89 (0.56 to 1.42)
CABG, at haemoglobin ≥ 7.5 g/dl Reference group 0.0018c
Valve, at haemoglobin ≥ 7.5 g/dl 1.33 (0.86 to 2.05)
CABG+ valve, at haemoglobin ≥ 7.5 g/dl 2.52 (1.57 to 4.06)
Other, at haemoglobin ≥ 7.5 g/dl 1.70 (0.89 to 3.25)
One outlier has been excluded from all models.
The deviances of the models are: model a (continuous haemoglobin): 2298.1; model b (binary haemoglobin): 2303.8.
a p-value from a test of haemoglobin ≥ 7.5+ haemoglobin ≥ 7.5 by operation type.
b p-value from a test of operation type+ haemoglobin ≥ 7.5 by operation type.
c p-value from a test of operation type.
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FIGURE 25 Marginal plots of the effect of minimum haemoglobin on primary outcome/death for each cardiac
procedure type.
(a) Without CIs, p-values represent the operation type effect at three different haemoglobin levels.
(b) With CIs.
Hb, haemoglobin.
OBSERVATIONAL ANALYSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
The effect of cardiac procedure is estimated at various haemoglobin levels in both models. In the
continuous model, cardiac procedure was found to have greater effect at lower haemoglobin levels
(see Figure 25). Similarly, in the binary model the effect of cardiac procedure is greater for haemoglobin
< 7.5 g/dl participants than haemoglobin ≥ 7.5 g/dl participants. In both the continuous and binary models,
a reduced odds of outcome was found with increased pre-operative haemoglobin (continuous model OR
0.91, 95% CI 0.85 to 0.98), and increased odds of outcome associated with both increased logistic
EuroSCORE (continuous model OR 1.34, 95% CI 1.16 to 1.54) and sex (continuous model OR 0.77,
95% CI 0.61 to 0.97).
The continuous model from Table 54 was refitted separately within each transfusion threshold stratum
(Table 55).
The effect of post-randomisation haemoglobin was remarkably similar in the two transfusion threshold
strata; the equivalent marginal plots are given in Figure 26. Pre-operative haemoglobin had a greater effect
on the odds of outcome in the restrictive threshold stratum and EuroSCORE had a greater effect in the
liberal threshold stratum.
TABLE 55 Conventionally adjusted models of the effect of minimum haemoglobin level on the primary
outcome/death, by transfusion threshold stratum
Explanatory variables
Restrictive group Liberal group
OR (95% CI) p-value OR (95% CI) p-value
Post-randomisation haemoglobin
CABG participants 0.91 (0.67 to 1.23) 0.0029 0.94 (0.68 to 1.29) 0.0024
Valve participants 0.63 (0.43 to 0.93) 0.59 (0.41 to 0.85)
CABG+ valve participants 0.52 (0.34 to 0.79) 0.54 (0.35 to 0.84)
Other participants 0.67 (0.37 to 1.22) 0.69 (0.36 to 1.32)
Pre-operative haemoglobin 0.84 (0.76 to 0.94) 0.0013 0.98 (0.89 to 1.09) 0.72
Logistic EuroSCORE 1.23 (1.00 to 1.51) 0.049 1.47 (1.21 to 1.80) 0.0001
Females 0.82 (0.59 to 1.13) 0.22 0.72 (0.52 to 1.01) 0.054
CABG, at haemoglobin= 8 g/dl Reference group 0.16 Reference group 0.59
Valve, at haemoglobin= 8 g/dl 0.83 (0.55 to 1.26) 0.87 (0.59 to 1.28)
CABG+ valve, at haemoglobin= 8 g/dl 1.44 (0.90 to 2.30) 1.16 (0.77 to 1.74)
Other, at haemoglobin= 8 g/dl 1.09 (0.61 to 1.97) 1.02 (0.58 to 1.79)
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FIGURE 26 Marginal plots of the effect of minimum haemoglobin on primary outcome/death for each cardiac
procedure type, by transfusion threshold stratum. p-values represent tests of the operation type effect at a
haemoglobin level of 8.0 g/dl in each transfusion threshold stratum.
(a) Restrictive group.
(b) Liberal group.
Hb, haemoglobin.
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Instrumental variable analysis
The assumptions of IV analysis59 and why we believe that the assumptions are met in our analyses are
described below.
l The instrument (randomised allocation) is associated with the exposure (post-randomisation red blood
cell units or post-randomisation haemoglobin); if a regression of the instrument on the exposure is
performed, a F-statistic of > 10 is typically used as a cut-off criterion, with values ≤ 10 indicating a
weak instrument. There is evidence of a strong relationship between each of the exposure variables
and randomised allocation (Table 56). Furthermore, F-statistics from the relevant univariate regression
models are as follows: (1) a log-linear model regressing randomised allocation on the ordinal
transfusion variable gave a RR of 0.53, 95% CI 0.49 to 0.58; F-statistic 238.8; and (2) a linear
regression of randomised allocation on post-randomisation haemoglobin gave a mean difference
between groups of –0.44, 95% CI –0.50 to –0.38; F-statistic 181.5.
l The instrument is independent of confounders between exposure and outcome. We consider this
assumption to be met by virtue of the instrument being randomised allocation; there is no evidence of
an association between randomised allocation and any variables (other than haemoglobin and red
blood cell transfusions).
l The instrument is independent of the outcome, given the exposure and confounders between the
exposure and the outcome. Again we consider this assumption to be met as the instrument is
randomised allocation.
Results from IV models are given in Table 57. In terms of post-randomisation red blood cells, both models
show no statistically significant effect of transfusion. If anything, effect estimates indicate reductions in risk
of outcome with transfusion (RR 0.89, 95% CI 0.75 to 1.06, for the ordinal red blood cell transfusion model
and RR 0.78, 95% CI 0.53 to 1.14, for the binary predictor, i.e. any vs. no red blood cell transfusion). It is
interesting to compare these estimates with the main trial ITT estimate between the randomised groups
TABLE 56 Univariate relationships between (1) red blood cell transfusions and (2) minimum haemoglobin level,
and transfusion threshold stratum
Transfusions/haemoglobin levels Restrictive group (n= 1000) Liberal group (n= 1003)
Post-randomisation (pre-primary outcome) red blood cell transfusions, n (%)
None 516 (51.6) 106 (10.6)
One 211 (21.1) 379 (37.8)
Two 142 (14.2) 268 (26.7)
Three to four 94 (9.4) 176 (17.6)
Five or more 37 (3.7) 74 (7.4)
Post-randomisation (pre-primary outcome) minimum haemoglobin, n (%)
Hb < 7 g/dl 153 (15.3) 71 (7.1)
7<Hb ≤ 7.5 g/dl 267 (26.8) 104 (10.4)
7.5<Hb ≤ 8 g/dl 226 (22.7) 157 (15.7)
8<Hb ≤ 8.5 g/dl 186 (18.6) 289 (28.8)
Hb≥ 8.5 g/dl 166 (16.6) 382 (38.1)
Hb, haemoglobin.
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(inverted, i.e. comparing liberal ‘transfused’ to restrictive ‘not transfused’ participants), OR 0.90 (95% CI
0.74 to 1.10; p= 0.30). The estimates are remarkably similar despite the fact that they are estimating
different effects (ITT estimate of effect of transfusion threshold on primary outcome only in the context of
non-adherence in the trial compared with the effect of red blood cell transfusion on primary outcome or
death on participants who were actually transfused, adjusted for confounding, in the IV analysis).
For post-randomisation haemoglobin, both models show no statistically significant effect with effect
estimates indicating reductions in risk of outcome with increasing haemoglobin (RR 0.83, 95% CI 0.64 to
1.08, for the model with haemoglobin fitted as a continuous variable, and RR 0.71, 95% CI 0.43 to 1.19,
for the model with haemoglobin fitted as a binary variable comparing haemoglobin levels ≥ 7.5g/dl with
< 7.5g/dl). As anticipated, the CIs around effect estimates are relatively wide in all of the IV models.
Next steps
The main limitation of the analyses covered in this section is their restriction to investigating either
the effect of red blood cell transfusion or the effect of haemoglobin level. They do not address the
combined effects of these factors, preventing us from answering questions such as ‘at what haemoglobin
threshold does the receipt of transfusion become beneficial?’. This question is not straightforward to
answer because red blood cell transfusion is inevitably associated with haemoglobin level and the lowest
haemoglobin level experienced by a patient does not necessarily precede transfusion.
An extension to these analyses that may address this issue is to perform analyses restricted to groups of
participants that breach a certain haemoglobin threshold (e.g. 7.5 g/dl or 8 g/dl) and then compare
outcomes for participants transfused and not transfused at a haemoglobin below that level. Such an
analysis could be performed at a small number of different haemoglobin thresholds to estimate the
effect of transfusion at different thresholds of haemoglobin.
TABLE 57 Estimates of the effect of red blood cell transfusion/minimum haemoglobin effect on primary
outcome/death from four IV models
Instrument used RR (95% CI) p-value
Model 1: post-randomisation red blood cells as an ordinal variable 0.89 (0.75 to 1.06) 0.19
Model 2: post-randomisation red blood cells as a binary variable
(any transfusion vs. none)
0.78 (0.53 to 1.14) 0.20
Model 3: post-randomisation haemoglobin as a continuous variable 0.83 (0.64 to 1.08) 0.17
Model 4: post-randomisation haemoglobin as a binary variable
(haemoglobin ≥ 7.5 g/dl vs. < 7.5 g/dl)
0.71 (0.43 to 1.19) 0.19
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Age of blood
Descriptive analyses
The age of each red blood cell unit transfused was unable to be retrieved for a relatively large proportion
of units. Of the 3104 units transfused post-randomisation but prior to the time of the primary outcome
occurring or censoring, the age was unobtainable for 945 units (30.4%). In terms of participants, of the
1381 participants transfused one or more unit, 581 (42.1%) had one or more unit with unknown age.
The volume of blood transfused was a strong predictor of missing age of blood for one or more of the
units transfused (Table 58).
For the purposes of initial descriptive analyses, participants have been grouped into four categories:
(a) Transfused one or more unit older than 21 days (n= 527).
(b) Transfused, but received no units older than 21 days (n= 402).
(c) Transfused, but unknown if any units were received older than 21 days (n= 452). [Note: this number is
lower than the number of participants quoted above as having one or more unit with unknown age
(n= 581) because any participants transfused multiple units with one or more unit older than 21 days
will be classified in group (a) above, regardless of any other units with unknown age.]
(d) Not transfused any red blood cells (n= 622).
Characteristics and outcomes of participants according to these categories are given in Tables 59 and 60.
The three groups of transfused participants (older blood, younger blood and unknown) were of similar
ages, but compared with those only transfused younger blood, participants transfused older blood were
less likely to be male (71.6% vs. 66.4%), had higher average logistic EuroSCORE [median 4.3 (IQR 2.4–8.0)
vs. 3.6 (IQR 2.2–6.6)] and were less likely to have had CABG surgery (37.4% vs. 44.5%). It should be
noted that some of these apparent associations are likely to have arisen from confounding; for example,
female participants may have been more likely to be given older blood because they were more likely to
have multiple red blood cell units transfused, increasing the risk of having an older unit transfused.
Rates of pre-randomisation red blood cell transfusion were lower in the group with unknown age of blood
(22.8%) than the other three groups (older blood 27.1%, younger blood 26.9% and no blood 25.7%).
The number of post-randomisation red blood cells transfused was, on average, higher in those transfused
older blood (66.2% transfused two or more units) and unknown age (61.7% transfused two or more
units) than those transfused only younger blood (40.5% transfused two or more units). In addition,
participants transfused older blood were more likely to have been given non-red blood cell blood products
TABLE 58 Missing age of blood according to number of red blood cell units transfused
Transfusions Number of participants
One or more units with
missing age, n (%)
Post-randomisation (pre-primary outcome)
red blood cell transfusions
None 621 0 (0.0)
One 591 174 (29.4)
Two 409 170 (41.6)
Three to four 271 151 (55.7)
Five or more 111 86 (77.5)
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TABLE 59 Characteristics of participants by age of red blood cells transfused
Characteristic
Transfused one or
more unit older
than 21 days
(N= 527)
Transfused, but
received no units
older than 21 days
(N= 402)
Transfused, but
unknown if any
units were received
older than 21 days
(N= 452)
Not transfused
any red blood cells
(N= 622)
Cardiac history
Additive EuroSCORE,a
median (IQR)
5.0 (4.0–7.0) 5.0 (3.0–7.0) 6.0 (4.0–7.0) 5.0 (3.0–7.0)
Logistic EuroSCORE,a
median (IQR)
4.3 (2.4–8.0) 3.6 (2.2–6.6) 4.5 (2.6–7.5) 3.7 (2.0–6.6)
NYHA class, n/N (%)
I 138/505 (27.3) 104/393 (26.5) 100/450 (22.2) 151/603 (25.0)
II 208/505 (41.2) 187/393 (47.6) 199/450 (44.2) 291/603 (48.3)
III 143/505 (28.3) 97/393 (24.7) 142/450 (31.6) 143/603 (23.7)
IV 16/505 (3.2) 5/393 (1.3) 9/450 (2.0) 18/603 (3.0)
CCS class, n/N (%) 191/510 (37.5) 139/395 (35.2) 147/449 (32.7) 241/608 (39.6)
No angina, n/N (%)
I 103/510 (20.2) 72/395 (18.2) 84/449 (18.7) 103/608 (16.9)
II 121/510 (23.7) 108/395 (27.3) 121/449 (26.9) 176/608 (28.9)
III 73/510 (14.3) 52/395 (13.2) 83/449 (18.5) 73/608 (12.0)
IV 22/510 (4.3) 24/395 (6.1) 14/449 (3.1) 15/608 (2.5)
Coronary disease, n/N (%)
None 172/525 (32.8) 110/400 (27.5) 144/450 (32.0) 194/616 (31.5)
Single vessel 66/525 (12.6) 46/400 (11.5) 56/450 (12.4) 57/616 (9.3)
Double vessel 66/525 (12.6) 55/400 (13.8) 63/450 (14.0) 98/616 (15.9)
Triple vessel 211/525 (40.2) 179/400 (44.8) 172/450 (38.2) 243/616 (39.4)
Not investigated 10/525 (1.9) 10/400 (2.5) 15/450 (3.3) 24/616 (3.9)
Disease in left main stem
(> 50% stenosis), n/N (%)
78/520 (15.0) 66/398 (16.6) 60/446 (13.5) 100/613 (16.3)
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TABLE 59 Characteristics of participants by age of red blood cells transfused (continued )
Characteristic
Transfused one or
more unit older
than 21 days
(N= 527)
Transfused, but
received no units
older than 21 days
(N= 402)
Transfused, but
unknown if any
units were received
older than 21 days
(N= 452)
Not transfused
any red blood cells
(N= 622)
Non-cardiac history
Age (years), median (IQR) 70.7 (64.3–76.6) 70.5 (64.0–77.0) 70.9 (63.8–76.7) 69.5 (62.6–75.5)
Males, n/N (%) 350/527 (66.4) 288/402 (71.6) 295/452 (65.3) 440/622 (70.7)
BMI (kg/m2),b mean (SD) 28.0 (5.0) 27.9 (4.8) 27.8 (4.7) 28.7 (5.1)
Urgent operative priority,
n/N (%)
81/527 (15.4) 53/402 (13.2) 47/452 (10.4) 64/622 (10.3)
Diabetic, n/N (%) 104/527 (19.7) 86/402 (21.4) 89/452 (19.7) 120/622 (19.3)
Haemofiltration/dialysis,
n/N (%)
8/526 (1.5) 4/402 (1.0) 4/451 (0.9) 3/622 (0.5)
CVA/TIA, n/N (%) 47/527 (8.9) 30/402 (7.5) 35/452 (7.7) 51/622 (8.2)
Pre-operative tests
Haemoglobin (g/dl), mean
(SD)
13.1 (1.5) 13.3 (1.5) 13.2 (1.5) 13.5 (1.4)
eGFR (ml/minute/1.73m2),c
median (IQR)
71.2 (54.4–91.9) 72.1 (55.7–90.4) 72.5 (54.7–91.6) 77.4 (61.3–96.9)
Intra-operative characteristics
Duration of operation
(hours),d median (IQR)
4.0 (3.2–5.2) 4.1 (3.4–5.0) 4.0 (3.5–5.0) 3.9 (3.3–4.9)
CPB used, n/N (%) 511/527 (97.0) 385/402 (95.8) 427/452 94.5) 580/621 (93.4)
Cardiac procedure,
n/N (%)
CABG only 197/527 (37.4) 179/402 (44.5) 166/452 (36.7) 274/622 (44.1)
Valve only 170/527 (32.3) 116/402 (28.9) 142/452 (31.4) 183/622 (29.4)
CABG+ valve 111/527 (21.1) 82/402 (20.4) 108/452 (23.9) 97/622 (15.6)
Other 49/527 (9.3) 25/402 (6.2) 36/452 (8.0) 68/622 (10.9)
Tranexamic acid, n/N (%) 448/527 (85.0) 334/401 (83.3) 330/452 (73.0) 503/621 (81.0)
Trasylol, n/N (%) 17/515 (3.3) 15/398 (3.8) 16/402 (4.0) 23/579 (4.0)
Cell saver, n/N (%) 272/527 (51.6) 210/402 (52.2) 207/452 (45.8) 295/621 (47.5)
Blood loss at 4 hours (ml),e
median (IQR)
274 (160–450) 260 (150–425) 290 (180–500) 210 (125–328)
Blood loss at 12 hours (ml),f
median (IQR)
525 (350–850) 500 (325–800) 550 (350–865) 400 (290–600)
BMI, body mass index; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident; NYHA, New York Health
Association; TIA, transient ischaemic attack.
a Missing for 38 participants [14, 2, 8, 14 in each of the four groups (left to right across the table)].
b Missing for one participant [0, 0, 1, 0 in each of the four groups (left to right across the table)].
c Missing for two participants [0, 1, 1, 0 in each of the four groups (left to right across the table)].
d Missing for one participant [0, 0, 0, 1 in each of the four groups (left to right across the table)].
e Missing for three participants [0, 0, 1, 2 in each of the four groups (left to right across the table)].
f Missing for three participants [1, 0, 0, 2 in each of the four groups (left to right across the table)].
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TABLE 60 Outcomes of participants by age of red blood cells transfused
Outcome
One+ red blood
cells > 21 days
(N= 527)
No red blood
cells > 21 days
(N= 402)
Unknown red
blood cells
> 21 days (N= 452)
No red blood
cell transfusions
(N= 622)
Intra- and post-operative use of blood products
Pre-randomisation red blood cell
transfusion, n/N (%)
143/527 (27.1) 108/402 (26.9) 103/452 (22.8) 160/622 (25.7)
Post-randomisation (pre-primary
outcome) red blood cell
transfusions, n/N (%)
No units 0/527 (0.0) 0/402 (0.0) 0/452 (0.0) 622/622 (100.0)
1 unit 178/527 (33.8) 239/402 (59.5) 173/452 (38.3) 0/622 (0.0)
2 units 172/527 (32.6) 107/402 (26.6) 130/452 (28.8) 0/622 (0.0)
3–4 units 124/527 (23.5) 48/402 (11.9) 99/452 (21.9) 0/622 (0.0)
> 4 units 53/527 (10.1) 8/402 (2.0) 50/452 (11.1) 0/622 (0.0)
FFP transfusions, n/N (%) 185/527 (35.1) 126/402 (31.3) 138/452 (30.5) 132/622 (21.2)
Platelet transfusions, n/N (%) 225/527 (42.7) 165/402 (41.0) 172/452 (38.1) 176/622 (28.3)
Cryoprecipitate transfusions,
n/N (%)
68/527 (12.9) 34/402 (8.5) 56/452 (12.4) 43/622 (6.9)
Activated factor VII used, n/N (%) 5/527 (0.9) 2/402 (0.5) 0/452 (0.0) 5/622 (0.8)
Beriplex used, n/N (%) 24/527 (4.6) 20/402 (5.0) 21/452 (4.6) 35/622 5.6)
Minimum haemoglobin (g/dl),a
median (IQR)
7.8 (7.1–8.4) 7.9 (7.3–8.5) 7.7 (7.1–8.3) 8.3 (7.8–8.6)
Primary outcome, n/N (%)
Overall primary outcome 188/511 (36.8) 139/390 (35.6) 147/441 (33.3) 174/564 (30.9)
Infectious event 138/501 (27.5) 106/387 (27.4) 107/439 (24.4) 127/563 (22.6)
Sepsis 125/515 (24.3) 92/396 (23.2) 94/449 (20.9) 113/605 (18.7)
Wound infection 21/486 (4.3) 27/375 (7.2) 24/436 (5.5) 29/560 (5.2)
Ischaemic event 89/522 (17.0) 62/399 (15.5) 62/450 (13.8) 82/611 (13.4)
Permanent stroke 11/517 (2.1) 7/398 (1.8) 7/448 (1.6) 7/611 (1.1)
Suspected MI 5/514 (1.0) 1/396 (0.3) 0/447 (0.0) 1/611 (0.2)
Gut infarction 1/514 (0.2) 0/396 (0.0) 3/448 (0.7) 3/611 (0.5)
AKI 75/519 (14.5) 55/398 (13.8) 58/450 (12.9) 74/611 (12.1)
Other trial outcomes
All-cause mortality, n/N (%) 24/527 (4.6) 10/402 (2.5) 17/452 (3.8) 17/622 (2.7)
Significant pulmonary morbidity,
n/N (%)
68/518 (13.1) 52/400 (13.0) 72/449 (16.0) 51/614 (8.3)
Duration of ICU/HDU stay (hours),
median (IQR)
66.5 (24.5–117) 48.1 (23.5–97.0) 60.3 (26.4–99.3) 32.6 (11.3–76.1)
Duration of post-randomisation
hospital stay (hours), median (IQR)
7.0 (6.0–11.0) 7.0 (5.0–10.0) 7.0 (6.0–11.0) 6.0 (4.0–9.0)
Composite outcome
Primary outcome or death, n/N (%) 196/511 (38.4) 142/390 (36.4) 157/441 (35.6) 176/564 (31.2)
a Missing for two participants [0, 0, 0, 2 in each of the four groups (left to right across the table)].
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than the other groups but there were no clear trends in average post-randomisation haemoglobin levels
between the three groups of transfused participants.
In terms of trial outcomes, the primary outcome occurred in 36.8% of participants transfused older blood,
35.6% of participants transfused only younger blood, 33.3% of those with unknown age of blood and
30.9% of those not transfused. More participants died in the groups transfused older blood (4.6%)
and with unknown age of blood (3.8%) than those transfused only younger blood (2.5%) and those not
transfused (2.7%). Finally, the composite outcome of primary outcome or death occurred in 38.4% of
participants transfused older blood, 36.4% of participants transfused younger blood only, 35.6% of those
with unknown age of blood and 31.2% of those not transfused.
Next steps
The results from Descriptive analyses suggest some evidence of a weak association between older blood
and poorer outcome, particularly in terms of mortality; however, a major limitation is that no adjustment
for confounding has been performed. Therefore, it is unclear from these descriptive analyses whether or
not any differences observed are actually due to other factors, for example, the fact that participants
transfused older blood received, on average, more red blood cells than those transfused only
younger blood.
A further limitation of this work is that blood group was unfortunately not collected in the study and
is not considered retrievable. It has been suggested that this could be an important confounding factor,
especially if age of blood is defined in terms of giving older vs. younger blood. The rationale for this view is
that the turnover of blood stores varies according to the blood group of the donated blood; for example,
participants with rare blood groups may be more likely to have older blood.60
Therefore, an obvious next step would be to fit multivariate models addressing the confounding. This has
not been done owing to the number of missing data on age of blood, which is of a sufficiently high level
that any analyses ignoring missing data (‘complete-case analyses’) will be inefficient and possibly biased.
Addressing this missing data problem is not straightforward. Multiple imputation techniques are most
commonly used as they are considered most appropriate and flexible.61 Imputation (and, therefore,
subsequent modelling) could be implemented at the red blood cell unit level (i.e. by imputing the age
of each unit of red blood cells) or at level of a participant (e.g. imputing whether a participant received
any old blood or not). Further work is required to address the issue of whether imputation should be
implemented at the red blood cell unit level or at the participant level.
Another consideration is alternative ways of defining age of blood at the participant level (as described in
the methods), including the age of the oldest red blood cell transfused, the mean age of all red blood
cells, the use of any blood older than 14 days, and the number or percentage of red blood cells given that
are older than 14 or 21 days. These approaches will be affected to different extents by missing data;
therefore, we do not intend to proceed with this until we have addressed the missing data problem
described above.
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Chapter 8 Discussion
Main findings: study conduct
Recruitment
Recruitment was slower than expected and the duration of recruitment had to be extended in order to
reach the target sample size. Issues affecting recruitment have been described in Chapter 3, Recruitment.
Throughout the trial the rate of recruitment remained frustratingly resistant to any actions the
co-ordinating team took to increase it. It did not appear to increase as additional centres were recruited,
nor when mid-term site visits were carried out to encourage centre staff to share good practice tips
gleaned from the best recruiting centres and to discuss local circumstances that were perceived to be
limiting recruitment. However, the UK Comprehensive Research Network made TITRe2 a special focus for
their efforts and this is likely to explain the increase in recruitment in the second half of 2011.
Non-adherence to the allocated threshold
We identified non-adherence as a key issue at the outset and were able to put in place appropriate data
collection (although time-consuming) to differentiate non-adherence into mild, moderate and severe. The
importance of non-adherence was reinforced by the DMEC, both in terms of the threat to the overall
power of the trial and also the possibility of differential non-adherence by group. The central trial team
reported adherence to the DMEC regularly.
Even with our extreme awareness of the problem and a large investment in data collection, non-adherence
was still prevalent in the trial. Fortunately, severe non-adherence occurred for only a small number of
participants (9.7% in the restrictive group and 6.2% in the liberal group) and, therefore, good separation was
maintained between groups with respect to red blood cells transfused and haemoglobin levels. In calculating
the initial target sample size we assumed that no more than 35% of participants in the restrictive group and
no less than 74% of participants in the liberal group would be transfused. Although the absolute rates
differed, the transfusion rates (53% and 92%, respectively) achieved this separation in the rate of transfusion.
In a similar way to the rate of recruitment, non-adherence was resistant to our efforts to reduce its
incidence through a continuous education and awareness campaign and, latterly, detailed feedback to
centres about specific non-adherent instances. This resistance perhaps reflects the limited ability of these
initiatives to overcome staff shortages on the ground, which was the factor that we believed to be mainly
responsible. This leads to the question of whether or not we would advocate monitoring non-adherence
in this level of detail, to which our answer is unequivocally yes. Despite non-adherence not being
straightforward to predict, knowledge of non-adherence is vital. Even if non-adherence has been
considered when justifying the target sample size, there is still a need to monitor its incidence carefully and
ensure it is in line with the assumptions made.
The main drawback of trying to measure non-adherence is the demanding data collection required and, if
we were to design the study again, we would investigate more streamlined methods of capturing these
data, for example downloads of routine data from ICU software now commonly being used to manage
patient care. Many reasons for non-adherence were missing and, although these were queried, relevant
information was often difficult to retrieve. In addition, we believe the category ‘oversight’ was used as a
default reason when a clinician was not asked to justify non-adherence at the time it occurred.
It is difficult to compare non-adherence rates from TITRe2 to rates observed in previous trials that
randomised patients to different transfusion strategies. Two of the earliest studies defined non-adherence
either only in terms of withheld transfusions62 or extra transfusions.37 The former study (838 participants)
reported non-adherence for six participants (1.4%) in the restrictive group and 18 participants (4.3%) in
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the liberal group, and the latter (the largest study in cardiac surgery patients to date37) reported four cases
(all in the restrictive group) of non-adherence from 502 participants. Both studies reported markedly lower
non-adherence rates than TITRe2, although comparisons are not sensible owing to the different definitions
used, differences in the populations randomised (both trials included participants who did not breach the
liberal threshold) and the limited information about non-adherence that was reported in both studies.
Two more recent studies considered non-adherence both in terms of extra and withheld transfusions.
The FOCUS trial13 investigated transfusion strategies following hip surgery; severe protocol deviations that
were comparable with our definitions were reported in 9.0% of participants in the liberal strategy group
and 5.6% in the restrictive strategy group. These rates are similar to our rates of severe non-adherence,
although the differences between the randomised groups are in the opposite direction to TITRe2. This
could be due to the different hypotheses being addressed as FOCUS hypothesised that giving transfusion
would benefit patients. The second study was a pilot RCT of adherence to transfusion thresholds in
cardiac surgery;38 it used non-adherence definitions most comparable to TITRe2 and comprised a similar
population. Among the 50 participants recruited, post-operative non-adherence was reported as 18%
in the ICU and 0% on the ward in the restrictive group, and 31% in ICU and 86% on the ward in
the liberal group. As in TITRe2 for any non-adherence, rates were higher in the liberal group than the
restrictive group. The rate in the liberal group was substantially higher than TITRe2.
We believe that we are the first researchers to identify and classify, in detail, non-adherence to a transfusion
strategy in a complicated trial setting, in which both the timing of randomisation and intervention were not
at a fixed point in time. Adherence remains a key issue in trials comparing restrictive and liberal transfusion
strategies and this study has led to better understanding of potential motivations and mechanisms for
different types of non-adherence. Some of this understanding can be generalised to other trials with
complex interventions. In particular, vigilance and reminders appeared to be the most successful ways to
avoid non-adherence. We noted that non-adherence was less common in centres with successful research
infrastructures (e.g. a well organised NHS research department, recruiting to multiple NIHR portfolio studies,
well-integrated team of research nurses with expertise in managing cardiac surgery patients) and a high
throughput of patients. It is clear that having fewer, high-recruiting, sites as opposed to lots of low-recruiting
sites is preferable, as the constant presence of trial participants on the ICU or the ward is one of the best
reminders to staff. Even if increased vigilance results from higher staffing levels, it is unclear whether or not
this is cost-effective. Trials can suffer a large amount of non-adherence and still deliver meaningful results,
as we believe has been the case in TITRe2.
Higher-than-expected frequency of the primary outcome
The higher-than-expected frequency of the composite primary outcome and the dominance of less serious
events such as sepsis and milder AKI were the most substantive issues experienced. On the one hand, the
higher overall frequency meant that the trial had more statistical power than anticipated; however, on
the other hand, the dominance by less serious events had the potential to undermine the interpretation
of the primary outcome. The question of whether or not to revise the primary outcome was debated by
the DMEC before an application was made to extend the scheduled period of recruitment. The DMEC
recommended that neither the primary outcome nor the target sample size should be changed (see
Strengths and limitations).
Main findings: study results
Summary of findings of the trial
The TITRe2 trial tested the hypothesis that a restrictive red blood cell transfusion threshold is superior to a
liberal threshold after adult cardiac surgery, in terms of post-operative morbidity and health service costs.
We refuted this hypothesis because we observed no difference in the primary composite outcome between
the liberal and restrictive groups. Pre-planned subgroup analyses showed no differences, contrary to beliefs
that ‘at-risk’ groups should be transfused at different haemoglobin thresholds.
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We carried out a number of planned sensitivity analyses of the primary outcome in order to test the
robustness of the primary analysis. When we designed the trial we decided to include participants transfused
before randomisation, for example in the operating theatre, as the question the trial sought to answer applied
as much to these patients as others. Nevertheless, we recognised that by doing so we might dilute any effect
of randomisation as transfusion was the ‘exposure’ of interest and transfusion before randomisation would be
distributed similarly. As hypothesised, when we excluded this subgroup in a sensitivity analysis, the effect
estimate for the primary outcome moved away from the null, favouring the liberal threshold.
A second sensitivity analysis was planned because of the observation (in the pre-specified interim analysis)
that the majority of the primary outcome events were either sepsis or AKI. We considered that a treatment
effect for more ‘serious’ events would better reflect our original intention in formulating the composite
outcome but did not hypothesise that the effect estimate would move. Therefore, we were surprised to
find that effect estimate moved to towards the null.
Two other sensitivity analyses were designed to address uncertainty about the ascertainment of AKI events
(see Chapter 2, Sensitivity analyses). We did not hypothesise a change in the magnitude of the treatment
effect for either analysis. Excluding AKI events that may have been reported erroneously did not move the
effect estimate; however, including additional AKI events that we suspected had been missed did move
the effect estimate away from the null, again favouring the liberal threshold. Although we had not
hypothesised such a shift, this finding was consistent with the imbalance of qualifying AKI events (both
among AKI events that had been reported and AKI events that we suspected had been missed) across
the two groups. The small difference in the overall primary outcome event rate (2%) arose because
participants in the restrictive group had a 2% higher frequency of AKI events (14% vs. 12%). Including
the additional AKI events approximately doubled their frequency in both groups (approximately 28% vs.
24%), increasing the overall difference in the primary outcome from 2% to 4%.
All-cause mortality was the only secondary outcome for which the treatment effect suggested a difference
between groups, with more participants dying in the restrictive group. There were no differences in other
secondary outcomes, including unexpected SAEs and SAEs that did not qualify for the primary outcome.
In the course of peer review of a manuscript reporting the main outcome results, it was suggested that we
should carry out (the same) sensitivity analyses for all-cause-mortality. This suggestion was made owing
to the potential importance of a difference in mortality and the difficulty in quantifying uncertainty around
the observed difference, given that it was one among several secondary outcomes. However, only two
of the sensitivity analyses were applicable: first, excluding deaths occurring in the first 24 hours after
randomisation and, second, excluding participants who had red blood cells transfused before
randomisation. In both analyses, the magnitude of the treatment effect favouring a liberal threshold
increased as hypothesised (and its nominal statistical significance was maintained despite both analyses
having less power).
Interpreting secondary analyses is challenging when several statistical tests are carried out.40 Nevertheless,
the higher frequency of deaths in the restrictive group is a cause for serious concern. It is not clear how
anaemia attributable to the restrictive threshold may have resulted in an increased number of deaths. The
difference in haemoglobin between groups was modest (1 g/dl) and assessment of causes of death or SAEs
that preceded death did not demonstrate cause and effect, although expecting to deduce a causal
mechanism in this way may be unrealistic based on a small number of deaths in a setting in which death
typically occurs after a series of AEs.
The TITRe2 trial compared two active interventions, both of which probably reflected usual care although
in different centres. Safety is considered here in terms of a restrictive threshold compared with a liberal
one. There was a similarly small non-significant difference, again favouring the liberal threshold, in the
frequency of all SAEs not included in the primary outcome (35.7% and 34.2% of participants in the
restrictive and liberal groups, respectively). The trial did not have adequate power to distinguish any
difference in the types of SAEs between groups. The IV analysis estimating the effect of red blood cell
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transfusion (after randomisation and before the occurrence of the primary outcome or censoring) also
provided the most direct test of the safety of transfusion among participants who were transfused, finding
no evidence at all that transfusion increased the risk of the primary outcome or death.
Three observational analyses were planned investigating the effects of exposure to red blood cell
transfusion, post-operative anaemia and ‘old’ red blood cells (that had been stored for longer than
average). The main reasons for doing these analyses were:
(a) to try to replicate our observational finding2 and the findings of other observational studies,63 about the
risks of transfusion in the trial cohort
(b) to try to estimate the effect of transfusion at different levels of anaemia
(c) to try to replicate previous reports (e.g. Dzik60 and Koch et al.64) regarding the risk of poor clinical
outcome being attributable to red blood cells stored for longer than average
(d) to contrast effect estimates from analyses using conventional and IV methods to adjust for confounding
(added when drafting the SAP when recognised the opportunity that the trial afforded to do IV analyses).
The rationale (a) above for analysis may appear odd given that the main finding of the trial did not support
our original trial hypothesis about the superiority of a restrictive threshold. Nevertheless, it is interesting to
contrast the findings from this conventionally adjusted analysis with our previous observational estimate
and the main trial finding (remembering that Murphy et al.2 compared any versus no transfusion rather
than different transfusion thresholds). The conventionally adjusted analysis showed a dose–response
relationship between the odds of the composite poor outcome and increasing red blood cell transfusion,
as did the previous observational analysis for ischaemic and infectious events, although the gradient of
the relationship was shallower in TITRe2. However, it is very difficult to reconcile the dose–response
relationship with the main trial finding, which found no difference in the frequency of the composite
primary outcome between groups which received substantially different average volumes of red blood
cells, forcing us to conclude that this conventionally adjusted result is subject to residual confounding.
We successfully estimated the effect of anaemia in conventionally adjusted models in analysis (b) and
the effect estimates were consistent with our expectation – that is, as the nadir haemoglobin increased,
the odds of a poor outcome decreased. However, we were unable to investigate how nadir haemoglobin
modified the effect of red blood cell transfusion because of the intrinsic link between red blood
cell transfusion and haemoglobin level, and the unpredictability of the temporal relationship between
transfusion and the lowest haemoglobin level experienced by a patient.
We were unable to investigate the effect of duration of storage of red blood cells [analysis (c)] because
(1) the duration of storage was often missing and (2) we did not have access to information about the blood
groups of red blood cell donors and recipients, a likely important confounder. Missing duration of storage of
red blood cell units transfused was especially critical because the occurrence of such missing data for a
participant was associated with the number of red blood cell units transfused. Any simple attempt to deal
with these missing data, for example excluding participants who received any red blood cell unit with
missing duration of storage, would almost certainly introduce bias. The implications of imputing duration
of storage based on participants’ characteristics are uncertain and subject to ongoing analyses.
The IV analysis of the effect of red blood cell transfusion (d) also generated a striking three-way contrast
with the results of the conventionally adjusted analyses (a) and the main trial finding. The estimate from
the IV analysis was consistent with the main trial finding but different from the conventionally adjusted
estimate, implying again that the conventionally adjusted estimate was subject to residual confounding.
The conventionally adjusted estimates of the effect of lowest post-operative haemoglobin experienced
were complex to interpret, suggesting that the effect varied according to the operation that a participant
was undergoing and that the anticipated increased risk from anaemia was mainly apparent for non-CABG
operations. The IV analysis could not consider this interaction; it did not find a statistically significant
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increase in the odds of a poor outcome from anaemia but the point estimates increased with
increasing anaemia.
Instrumental variable analyses of trials in which the random allocation is not congruent with exposure to a
particular intervention (typically owing to non-adherence) are often reported as estimating ‘the effect of
treatment among the treated’. To this extent, the IV analysis provides the most direct estimate possible
of the effect of red blood cell transfusion. Although the CIs are wide (and are unadjusted for nadir
haemoglobin), the estimates of the IV analyses strongly suggest that transfusion after cardiac surgery
setting is safe.
Balance of benefits against harms
Safety has been discussed above (see Summary of findings of the trial) and there was a small non-significant
difference, favouring the liberal threshold, in the frequency of all SAEs not included in the primary outcome.
The primary outcome was also a composite of SAEs; therefore, consideration of the balance between
benefits and harms requires the primary outcome to be combined with deaths and all other SAEs.
Combining all of these events increased the risk difference between groups (54.4% and 50.7% of
participants in the restrictive and liberal groups, respectively); thus, although none of these differences was
statistically significant, the liberal threshold appears to offer the better balance of benefits and harms.
Economic evaluation
The main findings from the economic evaluation are that there is very little difference between the groups
in either costs or effects and great uncertainty around the cost-effectiveness results. There was very little
difference in total costs per participant between the two groups. Participants in the restrictive group cost were,
on average, £182 less than those in the liberal group. When a breakdown of total costs was considered,
there was a clear difference in the costs associated with red blood cells between the two groups, as expected,
but otherwise, cost components were very similar. (The differences in cost between groups were about the
same when considering only the red blood cell costs; however, the difference in costs attributable to red blood
cells was estimated more precisely than the overall difference in costs.) Total costs were lower when the
time origin was moved from surgery to the point of randomisation, but the mean cost difference between
groups did not change substantively. Varying unit costs in a sensitivity analysis made very little difference to
the mean cost difference, reinforcing how similar resource use was between the groups. There were several
outliers in the liberal group, which exerted a substantial influence on the average costs of participants in
that treatment group and reversing the direction of the results described above when they were excluded.
A difference of approximately £200 between the groups is a modest cost difference (approximately 1% of
total costs). However, as 34,174 cardiac surgery procedures were undertaken in the UK in 2012/13,65 a
difference of £200 in each procedure would have resulted in savings or additional costs of £6.8M. The
effect of this cost difference, and whether it is a cost saving or additional cost, is clearly important for
the NHS.
The difference between the groups for QALYs is particularly small, creating a very small denominator for
the ICER. Dividing the difference in costs by a tiny number close to zero resulted in a very large ICER
(–£428,064). The point estimate in our base-case analysis suggests that the restrictive threshold is
dominant over the liberal threshold as it is both more effective (very slightly greater QALY gain) and less
costly and, therefore, it is cost-effective. However, there is a great deal of uncertainty around this result.
This point estimate is close to the origin and the bootstrap replicates of the cost and QALY differences
covered all four quadrants of the cost-effectiveness plane. Given the higher mortality rate in the restrictive
group, there was a clearer difference between the groups favouring the liberal threshold when life-years
were considered as an alternative outcome measure. However, the liberal group was no longer favoured
when costs were considered alongside life-years and the cost-effectiveness point estimate suggested that
the restrictive threshold was still cost-effective compared with the liberal threshold when life-years were
used as the outcome measure in a sensitivity analysis.
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There was a single subgroup interaction for QALYs gained, which suggested that patients with chronic
obstructive pulmonary disease or asthma may be a particularly vulnerable group with respect to transfusion
at a restrictive threshold. This finding was consistent with the subgroup analyses of the primary outcome,
in so much as the largest difference between thresholds arose for this subgroup (see Figure 13). It is also
intuitive from a clinical perspective, in that patients with chronic respiratory diseases commonly develop a
reactive polycythaemia to chronic hypoxia and that these patients would experience a smaller QALY gain
when exposed to a more extreme degree of anaemia.
Comparison with results from similar studies
Here, we consider the findings of TITRe2 in the context of the results of other trials both in cardiac surgery
populations and other populations. (We do not consider observational studies given that their findings are
very likely to be affected by confounding; see Chapter 7.) A Cochrane systematic review including all RCTs
comparing restrictive and liberal transfusion thresholds in surgical patients and the critically ill was
published in 2012.12 The authors concluded:
In patients who do not have acute coronary artery disease, blood transfusion can probably be withheld
in the presence of haemoglobin levels as low as 7.0 g/dl to 8.0 g/dl as long as there is no notable
bleeding. The benefits of minimising allogeneic red cell transfusion are likely to be greatest where
there is doubt about the safety of the blood supply.
Reproduced with permission from Carson JL, Carless PA, Hebert PC. Transfusion thresholds
and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database
Syst Rev 2012;4:CD002042,12 John Wiley & Sons. Copyright © 2010 The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.
but expressed caution about applying this conclusion to patients with coronary disease:
For the present we recommend the use of a restrictive transfusion trigger, but suggest using caution in
patients from high-risk groups such as acute coronary syndrome as there is currently no evidence from
randomised controlled trials to guide treatment.
Our result is consistent with the findings of the review and also resonates with the caution expressed by
the authors. Four additional trials have been published since the last literature search for the Cochrane
review.13,14,38,66 Given this caution, three of these trials are relevant to this discussion.13,14,38 (Patients with
acute coronary syndrome were excluded from the Transfusion Strategies for Acute Upper Gastrointestinal
Bleeding trial,66 the only contemporary trial to have demonstrated a benefit for restrictive transfusion.) The
first of these RCTs was a single-centre pilot trial in high-risk cardiac surgery patients to assess adherence to
the proposed transfusion thresholds (discussed in the context of adherence above).38 The trial was very
small, recruiting just 50 participants, but reported more AEs in the restrictive group. In the second of these
RCTs, which recruited patients with hip fracture,13 63% had cardiovascular disease and the trial found no
benefit of restrictive transfusion. The third of these RCTs was a feasibility trial of transfusion thresholds in
patients with unstable coronary disease (MI). It also only recruited a small sample (n= 110) but reported a
reduced risk of major cardiac morbidity or death of borderline statistical significance with more
liberal transfusion.14
As part of our effort to put our trial results in context, we formally combined the results of five RCTs
comparing restrictive versus liberal transfusion thresholds in cardiac surgery patients (see Chapter 5,
Meta-analysis).24–26,37,38 Three of these RCTs were included in the Carson review,24,25,37 the other two were
the pilot trial for TITRe226 and another pilot trial.38 Mortality was the only outcome for which we could
synthesise data across all trials, with the pooled estimate indicating an increase in mortality of borderline
statistical significance for a restrictive threshold. It should be noted that TITRe2 randomised approximately
50% more participants than the total number randomised in all previous trials and contributed more than
50% of the weight of information in the meta-analysis. We have already described other limitations of this
meta-analysis arising from differences in the design of the included trials (see Chapter 5, Meta-analysis),
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including the possibility that previous trials underestimated their treatment effects by randomising
participants who did not breach the liberal threshold. A further limitation is that mortality does not capture
the full consequences of different transfusion thresholds.
In summary, although the result of our primary analysis implies non-inferiority of a restrictive threshold
compared with a liberal one, we consider that the totality of evidence available at present (including the
results of secondary analyses in TITRe2 and the evidence from other trials discussed above) supports
the caution expressed in the Cochrane review. Therefore, we are very uncertain about recommending
restrictive transfusion after cardiac surgery. The evidence does not lead us to recommend using a liberal
threshold after cardiac surgery; however, we believe that it should lead to a new hypothesis that more
liberal transfusion may be beneficial.
This new hypothesis is clinically plausible. TITRe2 differed from previous large trials of transfusion
thresholds in that all participants had symptomatic cardiovascular disease;67,68 moreover, a significant
proportion will have developed oxygen supply dependency in the immediate post-operative period.69,70
Cardiac surgery patients are, therefore, often at the limits of their cardiovascular reserve and may benefit
from higher haemoglobin levels and enhanced oxygen delivery. Patients with symptomatic disease may
represent a specific high-risk group when more liberal transfusion thresholds are to be recommended.
Patient and public involvement
The main impacts of PPI in the trial were with respect to:
l Developing information for participants.
l Making significant changes in the way in which trial follow-up as conducted and hence promoting the
completeness of outcome data; specifically, PPI led to endorsement of the acceptability of postal
follow-up and optimisation of the wording of items included in the questionnaire and their format.
l Discussion of the emerging findings from the trial based on the incomplete information available at
the time.
l Disseminating information about the findings of the trial to participants (ongoing).
We found it difficult to involve patients in operational details of the trial. As previously described (see
Chapter 2, Patient and public involvement), the trial needed to recruit anxious patients in an acute care
setting. When patients were approached about the trial, they were, unsurprisingly, primarily concerned
about the possible benefits and risks of withholding or giving extra transfusions.
We are aware that dissemination of the findings of the trial is also challenging. There is a risk that, despite
the weight of the information contributed to the research question, the trial will be seen as inconclusive.
The statistical issues are complex and it is challenging to find a lay form of words that reflects the findings
while at the same time avoids tipping the reader to favour one or other transfusion threshold.
The challenges of carrying out meaningful PPI in the acute setting of cardiac surgery are ongoing because
the trials unit that co-ordinated TITRe2 also manages a portfolio of early phase trials and other studies for the
NIHR Bristol Cardiovascular Biomedical Research Unit. In particular, through the Biomedical Research Unit we
are investing in PPI to improve the ways in which we approach potential participants to make the experience
for research participants better, for example by minimising anxiety, to promote a fuller understanding about
our trials and with the aspiration that this will enhance recruitment to these difficult-to-do studies.
DOI: 10.3310/hta20600 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 60
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
141
Strengths and limitations
The TITRe2 trial has many strengths, most obviously its size compared with previous trials of transfusion
thresholds in cardiac surgery patients; it randomised four times more participants than the next largest trial
comparing liberal and restrictive transfusion thresholds after cardiac surgery.24–26,37,38 The sample size was
designed to take into account non-adherence, which was observed at a similar level to that expected. The
higher-than-expected frequency of the primary outcome meant that the primary finding had more power
than it was designed to have. By only randomising participants who breached the liberal threshold, we
avoided diluting the treatment effect with similar numbers of participants in each group who would
probably not have been transfused. This design contrasts with previous RCTs, which included such patients
in their analysis populations.24–26,37,38
The TITRe2 was also highly pragmatic. Approximately half of all of the specialist cardiac surgery centres in
the UK took part and the trial was conducted in a usual-care setting. We are confident that the findings
of the trial can be applied to all cardiac surgery centres in the UK. Importantly, and to the great credit of
participating units, the trial succeeded (with the help of very many staff in the NHS) in monitoring
haemoglobin levels and treating participants according to their allocated thresholds. The separation in both
the volumes of red blood cell transfusion and average haemoglobin levels between groups demonstrates
the success of the trial in implementing the transfusion thresholds. Local research teams and the
co-ordinating centre together achieved excellent completeness of follow-up, with just one of the planned
outcomes, infectious events, having more than 5% of missing data. Assessors who were blind to the
allocation verified or adjudicated all reported events that qualified for the primary outcome, although we
suspect that AKI may have been under-ascertained (see below).
With hindsight, designing TITRe2 to test the superiority of a restrictive threshold may have been a mistake.
Answering the question of whether or not a restrictive threshold is non-inferior to a liberal threshold might
be considered more pressing. This limitation was assuaged to some extent by the additional power (better
precision) of the primary analysis but we have not formally been able to address this question because we
did not pre-specify and justify a non-inferiority margin at the outset. The totality of the findings from the
trial, and other evidence, make a simple conclusion very difficult. Through no fault of the trial, it is likely
that different readers will view the findings as supportive of either restrictive or liberal transfusion practice.
The possible 40–60% increase in mortality with a restrictive threshold remains a major concern but a very
much larger trial would be needed to provide a definitive answer about this effect.
At the outset, the trial was also presented as a comparison of a new intervention, that is a restrictive
threshold, against a usual-care comparator of a liberal threshold. In fact, practice was shifting towards a
more restrictive threshold during the course of applying for funding and during the trial, and usual care
varied across participating centres (as previously and more recently documented).5,71 Some readers may
want to reverse this perspective to consider liberal compared with restrictive.
Although the trial had greater power than planned, the downside was dominance of the composite
primary outcome by less serious events, sepsis and AKI, which was the consequence of implementing
objectively verifiable criteria for these events. This limitation was addressed to some extent by a sensitivity
analysis of more serious events, which occurred with a frequency of 14.8%, similar to that assumed when
estimating the required sample size. Unexpectedly, in this sensitivity analysis the treatment effect for the
primary outcome shifted to the null. This result is difficult to reconcile with a difference in mortality and we
have no explanation for these divergent findings. Verification of data led us to suspect that AKI events had
been underascertained by prospective data collection, leading to the sensitivity analysis including extra AKI
events identified from routinely collected serial creatinine data. We believe that this limitation arose
because of differences between centres in the baseline creatinine value they used to define AKI.36 It was
interesting that including the extra events generated the expected pyramidal distribution by AKI severity
(most mild, least severe), which was not apparent in the distribution of AKI events in the primary analysis.
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The main limitation in the conduct of the trial was our inability to blind health-care staff. However,
the use of objective end points or adjudication by blinded personnel protected against detection bias.
Non-adherence was a challenge throughout the trial but did not prevent us achieving substantial
separation in red blood cell transfusion between the groups. Non-adherence that was classified as mild or
moderate, despite occurring with greater frequency, was considered unlikely to alter transfusion frequency
(as opposed to the average number of units transfused). The nature of protocol non-adherence differed by
group but only affected the overall transfusion rate in a small percentage of participants and was similar
by group. The question of how much impact the effect of non-adherence (severe or non-severe) has had
on the outcome of the trial is difficult to quantify, although we note the consistency between the IV
analysis and the main trial finding. A sensitivity analysis excluding non-adherent participants would have
been biased because non-adherence arose for different reasons in the two groups, that is participants with
non-adherent instances had different characteristics. The consequences of non-adherence are to dilute
the treatment effect and, therefore, to provide a more conservative estimate.
Lessons for the future
Choosing specific restrictive and liberal thresholds in RCTs such as TITRe2 is particularly challenging. From
the point of view of the feasibility of the trial, the thresholds need to be sufficiently different in order to
investigate a clinically important target difference in outcome (whether specified in terms of a superiority or
non-inferiority hypothesis) with a sample size that can be achieved in a reasonable duration of recruitment.
However, the greater the separation of the thresholds, the more challenging it is to maintain adherence.
Moreover, a comparison between any two thresholds (likely to be set in a way that encompasses most
of the range of thresholds implemented in usual care) cannot answer the question ‘What threshold is
best?’. A modified version of the usual design would be to allocate participants to multiple groups with
different thresholds, powered to detect a non-zero gradient in effect across thresholds. Although this
design might be logistically more challenging to conduct, it might paradoxically promote recruitment and
adherence as fewer participants would be exposed to the highest and lowest thresholds.
When applying for funding, we underestimated the number of data that would be necessary to collect.
We make no apology for collecting these data as they supported our assessments of fidelity of
implementing the intervention (haemoglobin levels and red blood cell transfusions) as well as
non-adherence, which were aspects of the conduct of the trial that had been substantially neglected in
the pilot. We undertook a careful appraisal of data collection early in the course of the trial and removed
a few items that were considered to be unnecessary. The success of this process, both the initial
specification of the data items and removal of some at a later stage, is demonstrated by our use of all of
the data collected in analysing the trial findings and writing this report. The important lesson from the
trial is that it was possible to collect the data required to monitor non-adherence.
We underestimated the number of data needed because the extent of data collection, particularly with
respect to monitoring non-adherence, only became apparent when we were setting up the trial. Collecting
information about all blood products transfused, nursing observations of temperature, heart rate and
oxygen saturation (used to define sepsis), the lowest haemoglobin recorded each day (used to monitor
non-adherence) and creatinine biochemistry each day (used to validate instances of AKI) was all
time-consuming. However, the additional time needed was not simply to do with extracting more data, for
example, research nurses often had to make repeated visits to participants to check information or liaise
with doctors or nurses, given that randomisation and the intervention were not fixed in time.
When seeking extra time to recruit participants for the trial, we also sought extra funding for centres to
cover the higher than expected research costs they were incurring. Once we had succeeded in persuading
the funder of the need for this funding, implementation of the uplift of £80 per randomised participant
(about 4 hours of research nurse time) was relatively straightforward through a variation to the site
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contract. (The additional funding was paid for participants already randomised as well as participants
randomised after the variation to the contract was implemented.)
Had we adopted a payment model in which each participating centre was given a set amount of funding,
we would have faced a much more serious challenge in distributing the local research costs. Centres may
have resisted an attempt to reduce the amount owing to lower than expected recruitment, on the grounds
that we had underestimated the volume of work involved. Moreover, we originally intended to recruit four
to eight centres but had recruited 17 by the end of the trial; we think that increasing the number of
centres in this way (each participating for different lengths of time) would have been problematic.
The total funding award in the extension for the uplift in research costs (£120,000) would also have
represented substantially less per centre than we estimated a centre would (on average) generate per year
(about £13,000 for the remainder of the trial for an extra centre compared with approximately £15,000
per year for the first group of centres).
We found it difficult to estimate the local research costs that a participating centre was likely to incur.
Researchers have to do this task when writing the full application for a project and preparing a budget and
may be tempted to reduce this cost, which is inevitably uncertain, rather than the cost of resources that
they will use centrally to manage the trial (which they may believe they can estimate more confidently).
The importance of the local research income to a centre for a study is likely to become more important
in the future as NHS organisations increasingly compete for NIHR portfolio income in a region. If it is clear
that ‘boots on the ground’ at participating centres are a rate-limiting step in delivering a trial, increasing
the local research costs may be a relatively easy way to enhance recruitment. However, when multiple
trials are competing for the same group of patients, there is also a risk that NHS organisations may
cherry-pick the trials that generate the most income.
In TITRe2, although we believe that the primary factor determining the recruitment rate and quality of data
for a centre was the commitment and research awareness of the local research team (evidenced by the
impact of the absence of specific research nurses), the amount of local researcher time available to be
spent on the project was also very important. Having a team of research nurses was helpful in maintaining
recruitment and data collection over usual periods of annual leave. When this was not the case, such
periods doubled the period over which recruitment slowed or stopped, as there was no point in recruiting
participants in advance if no one was going to be available to collect the data. Similarly, there was no one
available to recruit participants during the period of absence for the usual research nurse, so no recruited
participants, for whom data collection was required, having surgery when he/she returned from leave
(e.g. 1 week’s annual leave typically affected recruitment for 3 weeks).
There is still debate about the best way to remunerate participating centres for local research costs and
whether one or other method enhances recruitment. We believe that a ‘fee’ per participant randomised,
as adopted in TITRe2, provides an incentive to recruit and most fairly rewards differential recruitment by
centres. In most circumstances, we consider it preferable to providing, for example, funding to each centre
for a fixed amount of time of a research nurse. As described in Chapter 2, Contractual and financial
arrangements, we successfully implemented a system of activity reports using data submitted from centres,
which were used by centres as the basis for invoices to the University of Bristol (the ‘contractor’). However,
with payment being made in arrears, this system can cause difficulties and delays in setting up centres that
may be sceptical about recruitment rates and unable to deploy staff to work on a trial without advance
funding. In current trials, we are using a mixed-economy method, awarding centres a fixed amount to put
in place staff to start recruiting participants, then applying the fee-per-participant system. The mixed
system will inevitably be somewhat less efficient if some centres are not successful in recruiting participants
but this inefficiency may be worthwhile to reduce the average delay in centres starting to recruit. Another
way to implement this principle would be initially to offer each centre a fixed amount of research nurse
time and subsequently to adjust the funding depending on actual recruitment.
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We believe that TITRe2 benefited substantially from efforts made by the cardiovascular specialty group of the
UK Comprehensive Research Network. We are unable to describe what measures the Network instituted as
they were applied discretely (which may explain their success) and were not disclosed to the trial team.
Other trials competing for the same target population was a final factor affecting recruitment and it was
frustrating that the NIHR (across its varied programmes) funded new trials that competed for cardiac surgery
patients during the course of TITRe2. Not surprisingly, centres employing chief investigators for these trials
tended to prioritise recruitment to their home-grown trials over TITRe2, with a dramatic effect on recruitment
at one or two sites. At any one time, specialty networks in the Comprehensive Research Network have an
overview of NIHR-funded trials currently recruiting patients with particular conditions but this is after the trials
have been funded. We are not aware that these networks feed information back to the NIHR about target
populations that are currently ‘over-researched’ and when a new trial may struggle to recruit.
Future research
The most pressing question to answer is whether or not a liberal threshold is superior to a restrictive
threshold in cardiac surgery patients who are likely to be at the limits of their cardiovascular reserve.
A RCT has recently started to recruit in the Canada and the USA which will help to answer this question.72
As with TITRe2, the TRICS-III trial is again comparing restrictive and liberal thresholds in patients having
cardiac surgery with CPB and the researchers aim to randomise 3592 participants. Key differences between
the trials are as follows:
l TRICS-III hypothesises a restrictive threshold to be non-inferior to a liberal threshold.
l TRICS-III is recruiting high-risk patients only (EuroSCORE of > 6).
l TRICS-III thresholds are slightly different and the thresholds are applied both during the operation and
subsequently (restrictive < 7.5 g/dl intraoperatively or postoperatively; liberal < 9.5 g/dl intraoperatively
or in the ICU and < 8.5 g/dl postoperatively on the ward).
l TRICS-III has a primary composite outcome consisting only of events that we considered to be serious in
our sensitivity analysis (i.e. death, MI, kidney failure requiring dialysis or stroke; expected frequency and
non-inferiority margin are not stated in the registration details).
Although not explicitly testing the hypothesis that a liberal transfusion threshold is superior, TRICS-III is
recruiting patients who are most likely to be at the limit of their cardiovascular reserve. The weight of
information contributed by this trial to a future meta-analysis will be substantial, although it is unclear
whether the researchers are randomising preoperatively or only when a participant breaches the liberal
threshold. Until this trial concludes, we do not see any particular merit in pursuing an individual participant
data meta-analysis of the existing trials. In our opinion, the only benefit of such an analysis would be
investigation of relevant subgroups but, even if achievable, these analyses would have low power. A more
fruitful approach would be to persuade previous triallists to reanalyse their trial datasets after excluding
from both restrictive and liberal groups all participants who did not breach the liberal threshold. These
analyses would make these trials more similar to TITRe2 and test the hypothesis that the results of
these trials currently underestimate the treatment effects. The revised treatment effects should be combined
in a further (aggregate) meta-analysis of mortality. An initiative of this kind might also allow meta-analyses
of other outcomes with higher frequencies, which would provide estimates with greater precision.
With respect to the investment already made in TITRe2, we believe that further analyses of the data may
be able to estimate the effects of transfusion at different haemoglobin levels and to estimate the effect of
longer versus shorter duration of storage of red blood cells (although we are aware that a RCT is currently
testing this73,74). Chapter 7, Red blood cells and haemoglobin levels, Next steps and Chapter 7, Age of
blood, Next steps have already described the analyses that we propose to pursue.
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There are two key areas of further health economic research that would be worthwhile. In this report,
we have described a within-trial analysis up to 3 months, consistent with the main analysis of clinical
outcomes. It would be useful to extrapolate the information about costs and effects obtained for the trial
and to explore different time horizons including a life-time time horizon. With respect to quality of life,
the EQ-5D-3L questionnaire was used in the trial because the 5-level version had not been validated at the
time. The 5-level version has been designed to be able to discriminate changes in health-related quality of
life better than the 3-level questionnaire. Given such small differences between the restrictive and liberal
groups, it would be interesting to investigate whether or not the use of the 5-level questionnaire in current
cardiac and blood transfusion studies could detect larger differences between trial groups.
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Chapter 9 Conclusion
We conclude that both TITRe2 and totality of evidence available at present indicate that a restrictivetransfusion threshold is definitely not superior, and probably not inferior, to a liberal threshold. In
terms of the economic component of the trial, we also conclude that there is no difference between the
two thresholds. However, the same evidence makes it difficult to recommend restrictive transfusion after
cardiac surgery, despite the reduction in costs that this might achieve by lowering the consumption of
allogeneic red blood cells. A new hypothesis, that more liberal transfusion may be beneficial after cardiac
surgery, needs to be investigated.
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Appendix 1 Transfusion Indication Threshold
Reduction study investigators
Trial sites
Blackpool Victoria Hospital and Lancaster University
Investigators: Mr Augustine Tang and Dr Palaniappan Saravanan. Research team: Charlotte Waterhouse.
Royal Sussex County Hospital, Brighton
Investigator: Dr Robert Kong. Research team: Nicola Skipper.
University Hospitals NHS Foundation Trust, Bristol
Investigator: Professor Gavin Murphy (until August 2012)/Professor Gianni Angelini (from August 2012).
Research team: Emma Hopkins and Penny Lambert.
University Hospital Coventry and Warwickshire NHS Trust, Coventry
Investigator: Mr Sunil K Bhudia. Research team: Denise Gocher.
Castle Hill Hospital, Hull
Investigator: Dr Sean Bennett. Research team: Neil Smith and Adam Walker.
Derriford Hospital, Plymouth
Investigators: Dr Mark Bennett and Mr Malcolm Dalrymple-Hay. Research team: Maxine Pearse.
Essex Cardiothoracic Centre, Basildon
Investigator: Professor Andrew J Ritchie. Research team: Emily Redman and Amanda Solesbury.
Royal Infirmary of Edinburgh, Edinburgh
Investigator: Mr Vipin Zamvar.
Hammersmith Hospital, London
Investigator: Dr Geoffrey Lockwood. Research team: Dr Francesca Fiorentino, Alima Rahman.
King’s College Hospital NHS Foundation Trust
Investigator: Dr Gudrun Kunst. Research team: Georgina Parsons and Fiona Wade-Smith.
The Leeds Teaching Hospitals NHS Trust
Investigator: Dr Michael H Cross. Research team: Stuart Elliot and Zoe Beardow.
Glenfield Hospital, Leicester
Investigator: Professor Tom Sypt. Research team: Martina Williams.
Liverpool Heart and Chest Hospital Foundation Trust
Investigator: Mr Brian Fabri (until December 2012)/Mr Mark Field (from January 2013). Research team:
Ian Kemp and Andrea Young.
The James Cook University Hospital, Middlesbrough
Investigator: Dr Nick Stratford. Research team: Heather Robinson.
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Freeman Hospital, Newcastle
Investigator: Mr Stephen Clark. Research team: Sarah Rowling and Hazel Forsyth.
University Hospital Southampton Foundation Trust
Investigator: Dr Ravi Gill. Research team: Beverley Wadhams and Kim de Courcy-Golder.
New Cross Hospital, Wolverhampton
Investigators: Dr Ian Morgan. Research team: Emma Greatbach and Alex Ng.
Resource centres
Trial management centre, Clinical Trials and Evaluation Unit, University
of Bristol
Professor Barnaby C Reeves, Dr Chris A Rogers, Dr Rachel CM Brierley, Dr Alice Miles, Wendy Underwood,
Dr Lucy A Culliford, Jonathan Evans, Katie Pike, Rachel Nash, David Hutton, Emma Hopkins,
Penny Lambert, Kate Rajakaruna, Kim Wright, Jenny Wilcox and Rachel Wyatt.
Health Economics Research Centre, University of Oxford
Dr Sarah Wordsworth, Elizabeth A Stokes and Danielle Bargo.
Adjudication Committee
Dr Tom W Johnson, Dr Sally Tomkins and Mr Jon Anderson.
NHS Blood and Transplant
Dr Edwin Massey and Ian Millar.
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Appendix 2 Transfusion Indication Threshold
Reduction committees
Data Monitoring and Safety Committee
Professor Gordon Murray (chairperson), Professor Tim Walsh and Professor Domenico Pagano.
Trial Steering Committee
Mr Patrick Magee (chairperson, until his death in May 2011), Professor John Pepper (chairperson, from
June 2011), Dr Duncan Young, Dr Edwin Massey, Dr Gordon Taylor and Karin Smyth.
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Appendix 3 Additional health economic
evaluation information
Unit costs and resource use assumed for complications
Note that unit costs not in 2012/13 prices have been inflated to 2012/13 prices using the HCHS
inflation index.48
TABLE 61 Unit costs for surgery, inpatient stays and blood products
Resource Unit cost (£) Reference
Cardiac surgery and reoperations
CABG 6714 NHS Reference Costs 2012/13.45 Elective inpatients. HRG code EA14 for
service codes 170 (cardiothoracic surgery) and 172 (cardiac surgery).
For each code, the costs associated with the average LOS reported were
subtracted at a cost of £392 per day (see Inpatient stay row, Cardiac
ward day, in this table), and £227 was subtracted for blood products
based on data from an audit of blood transfusion in cardiac surgery
(NHSBT, 20115). An average cost for the codes was then generated,
weighted by activity
Valve 7336 NHS Reference Costs 2012/13.45 Elective inpatients. HRG codes EA17
(single valve) and EA52 (more than one valve) for service codes 170 and
172. For each code, the costs associated with the average LOS reported
were subtracted at a cost of £392 per day, and £659 was subtracted for
blood products (NHSBT, 20115). An average cost for the codes was then
generated for single and more than one valve procedures, weighted by
activity. Finally these two figures were weighted to produce an average
that reflects the proportion of single-valve procedures in TITRe2
participants (90% single, 10% more than 1 valve)
CABG and valve 8054 NHS Reference Costs 2012/13.45 Elective inpatients. HRG code EA51 for
service codes 170 and 172. For each code, the costs associated with the
average LOS reported were subtracted at a cost of £392 per day, and
£1421 was subtracted for blood products (NHSBT, 20115). An average
cost for the codes was then generated, weighted by activity
Other 8298 NHS Reference Costs 2012/13.45 Elective inpatients. HRG code EA20 for
service codes 170 and 172. For each code, the costs associated with the
average LOS reported were subtracted at a cost of £392 per day, and
£1421 was subtracted for blood products (NHSBT, 20115). An average
cost for the codes was then generated, weighted by activity
Reoperations < 3 hours,
excluding blood and LOS
6608 As ‘other’ cardiac procedure above, but the lower quartile unit cost was
used rather than the mean cost
Reoperations < 3 hours,
including blood, excluding LOS
8029 As ‘reoperations < 3 hours, excluding blood and LOS’, with £1421 for
blood products added back in
Reoperations ≥ 3 hours,
excluding blood and LOS
8298 As ‘other’ cardiac procedure above
Reoperations ≥ 3 hours,
including blood, excluding LOS
9719 As ‘other’ cardiac procedure above, with £1421 for blood products
added back in
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TABLE 61 Unit costs for surgery, inpatient stays and blood products (continued )
Resource Unit cost (£) Reference
Inpatient stay
Cardiac ward day 392 NHS Reference Costs 2012/13.45 Weighted average of elective inpatient
excess bed-day costs for relevant HRGs (EA14, EA16, EA17, EA19, EA20,
EA22, EA51, EA52, excluding any service codes for paediatrics)
HDU day 619 NHS Reference Costs 2012/13.45 Critical Care Services – Adult: Critical
Care Unit (XC07Z, 0 organs supported)
CICU day 1190 NHS Reference Costs 2012/13.45 Critical Care Services – Adult: Critical
Care Unit (weighted average of XC01Z – XC06Z, 1–6 organs supported)
General ICU day 1608 NHS Reference Costs 2012/13.45 Critical Care Services – Adult: Critical
Care Unit (weighted average of XC01Z – XC03Z, 4–6 organs supported)
Ward day for another unit in
the hospital, or at another
hospital
265 NHS Reference Costs 2012/13.45 Non-elective inpatient excess bed-day
cost across all activities
Blood products
Red blood cells 123.31 NHSBT Price List 2012/1346
Red blood cell administration
cost, first unit
22 Primary data collection of the nursing time and consumables associated
with requesting blood and administering transfusions undertaken with
collaborators on the TOPPS trial, funded by NHSBT. Preliminary analyses
show it takes 49 minutes of nursing time and £6 of consumables to
request and administer the first unit of red blood cells
Red blood cell administration
cost, subsequent units
5 As above (see Resource row, Red blood cell administration cost, first unit,
in this table); analyses found it took 15 minutes of nursing time to
administer subsequent units (no additional consumables)
FFP 27.46 NHSBT Price List 2012/1346
Platelets 209.30 NHSBT Price List 2012/1346
Cryoprecipitate 189.19 NHSBT Price List 2012/1346
TOPPS, Trial of prophylactic vs. no prophylactic platelet transfusions.
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TABLE 62 Unit costs for blood saving techniques, fluids and medications in theatre/CICU/HDU
Resource Assumed quantity Unit cost (£) Reference
Tranexamic acid 5 g intravenously 15.50 BNF 66, 201348
Trasylol 6 million Kallikrein
Inhibitor Units
intravenously
316.83 Davies et al.56 using data from BNF 47, 2004.75
Costs have been inflated using the HCHS inflation
index
Intraoperative/post-operative
cell salvage
176 Davies et al.56 Costs have been inflated using the
HCHS inflation index
Activated factor VII 5mg intravenously 2486.60 Transfusion Laboratory of the John Radcliffe
Hospital, Oxford University Hospitals NHS Foundation
Trust, Oxford, 2013, personal communication
Human prothrombin complex
(Beriplex, CSL Behring UK Ltd)
1500 IU intravenously 420 Transfusion Laboratory at a district general
hospital, South Central, 2014, personal
communication
HES 1500ml intravenously 40.60 BNF 58, 2009.57 Costs have been inflated using
the HCHS inflation index
Human albumin solution
(Zenalb, Bio Products
Laboratory Ltd)
500ml intravenously 36 Transfusion Laboratory at a district general
hospital, South Central, 2014, personal
communication
Gelofusine 1500ml intravenously 7.92 Finance Department, teaching hospital, South
Central, 2013, personal communication
Inotropes Noradrenaline
1mg/hour for 5 days
57.30 eMIT, 201447
Hartmann’s solution
(compound sodium lactate)
1500ml intravenously 2.67 Finance Departmen, teaching hospital, South
Central, 2013, personal communication
Gelatin (Isoplex, Beacon
Pharmaceuticals)
1500ml intravenously 22.07 BNF 66, 201348
HES, hydroxyethyl starch; IU, international units.
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TABLE 63 Unit costs for antibiotics
Drug name Route
Assumed dose/frequency
per day Daily cost (£) Source
Daily cost (£) from
BNF47 for sensitivity
analyses
Amikacin i.v. 500mg 3× day 18.42 eMIT47
Amoxicillin Oral 500mg 4× day 0.10 eMIT47 0.31
Amoxicillin i.v. 500mg 4× day 1.46 eMIT47 2.20
Aztreonam i.v. 1 g 3 × day 28.20 BNF48
Benzylpenicillin i.v. 1.2 g 4× day 7.56 BNF48
Caspofungin i.v. 70mg first day, 50mg
1× day subsequent days
416.78 day 1,
327.67 thereafter
BNF48
Cefalexin Oral 250mg 4× day 0.11 eMIT47
Cefotaxime i.v. 1 g 2 × day 1.22 eMIT47
Ceftazidime i.v. 1 g 3 × day 2.56 eMIT47
Ceftriaxone i.v. 1 g 1 × day 0.53 eMIT47
Cefuroxime i.v. 750mg 3× day 1.37 eMIT47
Cefuroxime 1.5 g i.v. 1.5 g 3× day 2.13 eMIT47
Cefuroxime 750mg i.v. 750mg 3× day 1.37 eMIT47
Chloramphenicol i.v. 1 g 4 × day 5.56 BNF48
Ciprofloxacin Oral 500mg 2× day 0.05 eMIT47 0.15
Ciprofloxacin i.v. 400mg 2× day 2.02 eMIT47 39.58
Clarithromycin Oral 250mg 2× day 0.13 eMIT47
Clarithromycin i.v. 500mg 2× day 5.24 eMIT47
Clindamycin Oral 150mg 4× day 0.24 eMIT47
Clindamycin i.v. 600mg 3× day 7.27 eMIT47
Co-amoxiclav Oral 375mg 3× day 0.21 eMIT47 0.32
Co-amoxiclav 625mg Oral 625mg 3× day 0.22 eMIT47
Co-amoxiclav i.v. 600mg 3× day 1.64 eMIT47 3.63
Co-amoxiclav 1.2 g i.v. 1.2 g 3× day 1.91 eMIT47
Colomycin nebs
(Colistimethate
sodium)
Oral 1 million units 2 × day 3.36 BNF48
Colistimethate sodium i.v. 1 million units 2 × day 3.36 BNF48
Co-trimoxazole Oral 960mg 2× day 0.49 eMIT47
Co-trimoxazole i.v. 960mg 2× day 7.12 BNF48
Daptomycin i.v. 350mg 1× day 62.00 BNF48
Demeclocycline Oral 150mg 4× day 11.64 BNF48
Doxycycline Oral 200mg first day, 100mg
1× day subsequent days
0.07 day 1, 0.03
thereafter
eMIT47 0.28 day 1, 0.14
thereafter
Ertapenem i.v. 1 g 1 × day 31.65 BNF48
Erythromycin Oral 250mg 4× day 0.11 eMIT47 0.24
Erythromycin i.v. Erythromycin lactobionate
1 g 4 × day
43.92 BNF48
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TABLE 63 Unit costs for antibiotics (continued )
Drug name Route
Assumed dose/frequency
per day Daily cost (£) Source
Daily cost (£) from
BNF47 for sensitivity
analyses
Flucloxacillin Oral 250mg 4× day 0.11 eMIT47
Flucloxacillin i.v. 0.25 g 4 × day 1.68 eMIT47 4.92
Fluconazole Oral 400mg first day, 200mg
1× day subsequently
0.19 day 1, 0.09
thereafter
eMIT47
Fluconazole i.v. 400mg first day, 200mg
1× day subsequently
1.80 day 1, 0.94
thereafter
eMIT47
Fusidic acid Oral 500mg 3× day 1.81 BNF48
Gentamicin i.v. 80mg 3× day 1.57 eMIT47 5.85
Imipenem i.v. 500mg 4× day 17.67 eMIT47
Levofloxacin Oral 500mg 1× day 0.23 eMIT47
Levofloxacin i.v. 500mg 1× day 1.87 eMIT47
Linezolid Oral 600mg 2× day 89.00 BNF48
Linezolid i.v. 600mg 2× day 89.00 BNF48
Meropenem i.v. 0.5 g 3× day 7.86 eMIT47 24.00
Metronidazole Oral 400mg 3× day 0.05 eMIT47 0.21
Metronidazole i.v. 500mg 3× day 1.20 eMIT47 9.30
Nitrofurantin Oral 50mg 4× day 5.23 BNF48
Piperacillin/tazobactam i.v. 4.5 g 3× day 5.68 eMIT47
Rifampicin Oral 300mg 3× day 0.42 eMIT47
Rifampicin i.v. 600mg 3× day 7.66 eMIT47
Oseltamivir
(Tamiflu®, Roche
pharmaceuticals)
Oral 75mg 2× day 3.08 BNF48
Teicoplanin i.v. 400mg 2× day for three
doses, subsequently 400mg
1× day
12.24 day 1, 6.12
thereafter
eMIT47 14.64 day 1, 7.32
thereafter
Temocillin i.v. 1 g 2 × day 50.90 BNF48
Timentin i.v. 3.2 g 3× day 15.99 BNF48
Trimethoprim Oral 200mg 2× day 0.03 eMIT47 0.14
Vancomycin i.v. 0.5 g 2× day 2.32 eMIT47 12.50
i.v., intravenous; nebs, nebulisers.
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TABLE 64 Unit costs for regular medications
Recorded on CRF Assumed drug
Assumed
route
Assumed dose/frequency
per day
Daily cost (£)
from BNF47
Digoxin Digoxin Oral 125 µg daily 0.04
Diuretics Furosemide Oral 40mg daily 0.03
Beta-blockers Atenolol Oral 25mg daily 0.03
Calcium antagonists Amlodipine Oral 5mg daily 0.03
Aspirin Aspirin Oral 75mg daily 0.03
Oral nitrates Isosorbide dinitrate Oral 80mg daily 0.98
Angiotensin 2 blockers Losartan Oral 25mg daily 0.04
ACE inhibitors Ramipril Oral 5mg daily 0.04
Warfarin Warfarin sodium Oral 3mg daily 0.03
Clopidogrel Clopidogrel Oral 75mg daily 0.06
Statins Simvastatin Oral 40mg daily 0.04
Antiarrhythmic Amiodarone Oral 200mg daily 0.06
Heparin/clexane Enoxaparin sodium S/C 20mg daily 2.27
Intravenous glyceryl
trinitrate/nitrates
Glyceryl trinitrate i.v. 25mg daily 6.49
FeSO4 Ferrous Sulphate Oral 200mg (65mg iron) 3 × day 0.11
ACE, angiotensin-converting enzyme; i.v., intravenous; S/C, subcutaneous.
TABLE 65 Resource use assumed for complications and total costs
Complication Treatment/action Cost (£) Assumptions
Sepsis No additional treatment 0 Antibiotics recorded separately
and costed
Wound infection No additional treatment 0 Antibiotics recorded separately
and costed
Permanent stroke Rehabilitation (plus scan) 139
CT scan 62
MRI scan 248
Suspected MI Emergency angiography,
transthoracic echocardiography,
ECG
1868
Gut infarction CT scan 62
If confirmed by laparotomy 2693
AKI – stage 3 only Haemofiltration 1438 Assume treatment for 2 days
TIA CT scan 62
Pancreatitis CT scan, parenteral nutrition,
intravenous fluids
275.49 Reoperations already captured
Intestinal obstruction/perforation Laparotomy, parental nutrition 2893 Reoperations already captured
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TABLE 65 Resource use assumed for complications and total costs (continued )
Complication Treatment/action Cost (£) Assumptions
Post-operative haemorrhage Chest radiograph 41 Reoperations already captured.
Assume no additional costs for
participants who have a
reoperation on the same day/
following day as post-operative
haemorrhage
ARDS Transoesophageal
echocardiography, three chest
radiographs
395 Reintubation and intensive care
already captured
Reintubation/ventilation Transoesophageal
echocardiography, three chest
radiographs
395
Initiation of mask CPAP CPAP, chest radiograph 539
Tracheostomy Tracheostomy, chest radiograph 5354
Pneumothorax requiring chest
drainage
Chest radiograph, chest drain 4218
Pleural effusion requiring drainage Chest radiograph, chest drain 4218
Pacing Temporary pacemaker 3073
SVT/AF requiring treatment Amiodarone 4.79
Deep-vein thrombosis Duplex scan of leg veins,
intravenous heparin
202.43 Warfarin already captured
VF/VT requiring intervention Transoesophageal
echocardiography, emergency
coronary angiography, chest
radiograph
2007 Emergency reoperations and
reintubation captured elsewhere
Low cardiac output requiring
management (including IABP)
Transoesophageal
echocardiography, chest radiograph
313
Wound dehiscence requiring
rewiring/treatment
Minor treatment (£161), or VAC
therapy if stated (£3501)
161 or
3501
Assume reoperation covers this
complication if reoperation the
same day or next day
Cardiac tamponade Transoesophageal
echocardiography, chest radiograph
313 Reoperations and red blood cells
already captured
Other GI complications
Abdominal distention/small
bowel dilatation/abdominal pain
CT scan 62
Coffee ground vomitus Omeprazole 12.68
Colonic pseudo-obstruction CT scan 62
Constipation Laxatives, enemas 2.25
Diabetes inference/exacerbation Insulin 138.60
Diagnostic laparotomy Laparotomy 2693
Diarrhoea/diarrhoea and vomiting Isolation room, stool culture and i.v.
for dehydration
3592
Duodenal ulcer Endoscopy 676
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TABLE 65 Resource use assumed for complications and total costs (continued )
Complication Treatment/action Cost (£) Assumptions
Dysphagia/poor swallow/difficult
chewing with hoarse voice
Speech and language therapy
review, nasendoscopy,
oropharyngeal fluoroscopy and
maybe CT head
370
Gastric bubble Nasogastric tube insertion 252
Gastritis, gastro-oesophageal
reflux
Omeprazole 12.68
GI bleed Endoscopy 676
GI bleed – duodenal ulcer Endoscopy and in severe cases
laparotomy
2022
Haematemesis Omeprazole 12.68
Hepatic impairment CT scan 62
Ileus/gallstone ileus/paralytic ileus CT scan 62
Intestinal ischaemia Laparotomy, CT scan 2755
Ischaemic bowel and GI bleed Laparotomy, CT scan 2755
Laparoscopy Laparoscopy 2693
Melaena Endoscopy, omeprazole 688.68
Melaena and bleeding duodenal
ulcers
Endoscopy, omeprazole 688.68
Nausea and/or vomiting Anti-nausea medication 0.63
Nasogastric tube inserted Nasogastric tube inserted 252
Not absorbing owing to
abdominal aortic aneurysm
repair
CT scan 62
Rectal bleed Endoscopy 676
Upper GI bleed owing to
transoesophageal
echocardiography
Endoscopy 676
Other pulmonary complications – all assumed to have two chest radiographs, add £82 to all
Suspected chest infection No additional treatment 0 Antibiotics and reintubation
already captured
Aspiration pneumonia/
pneumonia
No additional treatment 0 Antibiotics and reintubation
already captured
BIPAP commenced BIPAP 498
Basal atelectasis Chest radiographs, physiotherapy 180 CPAP already captured
Basal respiratory wheeze Nebulised 0.9% saline (10ml) or
salbutamol (2.5mg) 4 times daily
1035
Bronchopneumonia No additional treatment 0 Antibiotics and reintubation
already captured
Fluid overload No additional treatment 0 Antibiotics and reintubation
already captured
Left and right haemothorax/
haemothorax requiring chest
drainage
Chest drain 4177
Heart failure Diuretics 0.15 Reintubation already captured
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TABLE 65 Resource use assumed for complications and total costs (continued )
Complication Treatment/action Cost (£) Assumptions
Increasing oxygen requirements,
chest examination
Physiotherapy 139 CPAP and reintubation already
captured
Infection No additional treatment 0 Antibiotics and reintubation
already captured
Left pneumothorax Chest radiograph 41
Lower respiratory tract infection No additional treatment 0 Antibiotics and reintubation
already captured
Overloaded Diuretics 0.15 Reintubation already captured
Pericardial effusion/pericardial
effusions with atelectasis
No treatment in mild cases 0 Reoperation and reintubation
already captured
Pleuritic pain Analgesia 6
Pneumonia and respiratory
failure
No additional treatment 0 Antibiotics and reintubation
already captured
Pulmonary oedema Diuretics 0.15 Reintubation already captured
Right lower lobe collapse and
atelectasis changes on chest
radiograph
Chest radiograph, physiotherapy 180 CPAP and reintubation already
captured
Reduced air entry to bases/
respiratory distress/respiratory
failure
Physiotherapy 139 CPAP and reintubation already
captured
Respiratory arrest No additional treatment 0 Reintubation already captured
Slight decrease in entry in both
bases
Physiotherapy 139 CPAP and reintubation already
captured
(Small) pleural effusion left side/
right side/bilateral
No treatment 0
Surgical emphysema Chest drain, chest radiograph 4218
Aspirated on nasogastric tube
insertion
Nasogastric tube insertion
(if not already included)
252
Disconnected chest drain Chest drain 4177
Increased pulmonary artery
pressure
No treatment 0
Left basal effusion and right
basal collapse
Physiotherapy 139 CPAP and reintubation already
captured
Other arrhythmia complications – all assumed to have two ECGs, add £106 to all
AV block/first degree heart
block/third degree AV block/
complete heart block
No additional treatment 0 Pacing already captured
First degree heart block with
atrial ectopics
No treatment 0
Complete heart block,
permanent pacemaker
Permanent pacemaker 14,564
Heart block-paced No additional treatment 0 Pacing already captured
Arrhythmia Amiodarone 4.79
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TABLE 65 Resource use assumed for complications and total costs (continued )
Complication Treatment/action Cost (£) Assumptions
Asystole/P wave asystole/cardiac
arrest/pulseless electrical activity
arrest
CPR 1491 Reintubation already captured
Asystole with permanent
pacemaker insertion
Permanent pacemaker 14,564
Atrial flutter Amiodarone 4.79
Bradycardia/intermittent
bradycardia/nodal bradycardia/
sinus bradycardia
No additional treatment 0 Pacing already captured
Bradycardic episode with left
bundle branch block, 24-hour
tape performed
24-hour Holter monitor 204
Cardioversion Cardioversion 808
Heart rate irregular, commenced
on amiodarone
Amiodarone 4.79
Ectopics/multiple ectopics/
ventricular ectopics
No treatment 0
Fast AF requiring amiodarone
and pacing switched off
Amiodarone 4.79
Junctional rhythm No additional treatment 0 Pacing already captured
Left bundle branch block/new
onset of left branch block/right
bundle branch block
No treatment 0
Loss of cardiac output CPR 1491 Reintubation already captured
New AF No additional treatment 0 Pacing already captured
Permanent pacemaker implanted Permanent pacemaker 14,564
SVT/flutter Amiodarone 4.79
Sinus tachycardia No treatment 0
Type B Wolff–Parkinson–White
pattern
No treatment 0
Sinus pauses No additional treatment 0 Pacing already captured
Vasovagal episode No treatment 0
Other thromboembolic complications
CT head confirmed occipital
infarction
CT scan 62
Cerebral infarct CT scan 62
Saphenous vein graft
thrombosed to right coronary
artery
Coronary angiography 1694
Thrombophlebitis Analgesia 6
AF, atrial fibrillation; AV, aortic valve; BIPAP, bilevel positive airway pressure; CPR, cardiopulmonary resuscitation;
IABP, intra-aortic balloon pump; i.v., intravenous; SVT, supraventricular tachycardia; TIA, transient ischaemic attack;
VAC, vacuum-assisted closure; VF, ventricular fibrillation; VT, ventricular tachycardia.
Resource use assumed for complications and total costs are shown here, unit costs and sources are shown in Table 66.
VAC therapy comprises a vacuum (negative pressure) device applied to wounds that are infected.
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TABLE 66 Unit costs for complications
Treatment/action Unit cost (£) Source for cost information
24-hour Holter monitor 204 NHS Reference Costs 2012/13.45 Day cases. EA47Z
electrocardiogram monitoring and stress testing. 320 cardiology.
Lower quartile cost
Antibiotics (piperacillin/tazobactam,
4.5g i.v. 3 × day for 5 days)
28.40 eMIT47
Amiodarone (1.2 g i.v., then oral
200mg 3× day for 1 week, 2 × day
for 1 week)
4.79 eMIT47
Analgesia (morphine sulphate, 10mg
i.v. every 4 hours for 5 days)
6 eMIT47
Antinausea medication (ondanestron,
4mg i.v. for 5 days)
0.63 eMIT47
BIPAP 498 As CPAP
Cardioversion 808 Lord et al.76 Costs have been inflated using the HCHS inflation index
Chest drain 4177 NHS Reference Costs 2012/1345
Chest radiograph 41 Finance Department, teaching hospital, South Central, 2012,
personal communication. Costs have been inflated using the HCHS
inflation index
Coronary angiography 1694 NHS Reference Costs 2012/1345
CPAP 498 Grey et al.77 Costs have been inflated using the HCHS inflation
index
CPR 1491 NHS Reference Costs 2012/1345
CT scan 62 NHS Reference Costs 2012/13.45 Diagnostic Imaging – Direct Access.
RA08A Computerised Tomography Scan, one area, no contrast,
19 years and over. 100 general surgery
Diuretics (furosemide 40mg orally
for 5 days)
0.15 BNF48
Drainage of pus under local
anaesthesia
426 NHS Reference Costs 2012/13.45 Elective inpatients. JC43A Minor
Skin Procedures, 13 years and over. 320 Cardiology
Drainage of pus under general
anaesthesia
1919 NHS Reference Costs 2012/13.45 Elective inpatients. JC43A Minor
Skin Procedures, 13 years and over. 172 Cardiac Surgery
Duplex scan of leg veins 155 NHS Reference Costs 2012/13.45 Diagnostic Imaging – Outpatients.
RA10Z Computerised Tomography Scan, one area, pre and post
contrast. 172 Cardiac Surgery
ECG 53 NHS Reference Costs 2012/13.45 Directly Accessed Diagnostic
Services. EA47Z Electrocardiogram Monitoring and stress testing
Echocardiography – transthoracic 121 NHS Reference Costs 2012/13.45 Diagnostic Imaging – Outpatients.
RA60A Simple Echocardiogram, 19 years and over. 172 Cardiac
Surgery
Echocardiography – transoesophageal 272 NHS Reference Costs 2012/13.45 Day Cases. EA45Z Complex
Echocardiogram, including Transoesophageal and Fetal
Echocardiography. 320 Cardiology. Lower quartile cost
Endoscopy 676 NHS Reference Costs 2012/1345
Fluoroscopy 115 NHS Reference Costs 2012/13.45 Diagnostic Imaging – Outpatients.
RA16Z Contrast Fluoroscopy Procedures, less than 20 minutes.
172 Cardiac Surgery
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TABLE 66 Unit costs for complications (continued )
Treatment/action Unit cost (£) Source for cost information
Haemofiltration (assume for 2 days) 1438 NHS Reference Costs 2012/13.45 Renal Dialysis at Base. LE01 A.
Haemodialysis for Acute Kidney Injury, 19 years and over
IABP – used in sensitivity analysis 2776 NICE Medical Technology Guidance 8, 2011.78 Costs have been
inflated using the HCHS inflation index
Intravenous fluids (gelofusine,
1500ml)
13.49 BNF48
Insulin (1000 units for 5 days) 138.60 BNF48
i.v. heparin (initial 5000 units, then
15,000 units every 12 hours for
5 days)
47.43 BNF48
Isolation room, stool culture and
i.v. for dehydration
3592 NHS Reference Costs 2012/1345
Omeprazole (i.v. omeprazole 40mg
for 3 days, then 40mg oral daily for
5 days)
12.68 BNF,48 eMIT47
Laparoscopy 2693 As laparotomy
Laparotomy 2693 NHS Reference Costs 2012/1345
Laxatives, enemas (bisacodyl, 5mg;
sodium citrate, assume for
5 days)
2.25 BNF,48 eMIT47
Minor treatment for wound
dehiscence
161 NHS Reference Costs 2012/13.45 Elective inpatients. JC43A Minor
Skin Procedures, 13 years and over. 320 Cardiology, with the costs
associated with the average LOS reported subtracted at a cost of
£265 per day
MRI scan 248 NHS Reference Costs 2012/13.45 Diagnostic Imaging – Direct Access.
RA07Z Magnetic Resonance Imaging Scan, requiring extensive
patient repositioning and/or more than one contrast agent.
320 Cardiology
Nasendoscopy 115 As fluoroscopy
Nasogastric tube insertion 252 NHS Reference Costs 2012/1345
Nebulised 0.9% saline (10ml) or
salbutamol (2.5mg) 4 times daily
1035 NHS Reference Costs 2012/1345
Parenteral nutrition (assume 5 days) 200 NICE, Nutrition Support in Adults: Oral Nutrition Support, Enteral
Tube Feeding and Parenteral Nutrition Costing Report, 2006.79 Costs
have been inflated using the HCHS inflation index
Permanent pacemaker 14,564 NHS Reference Costs 2012/1345
Physiotherapy/rehabilitation 139 NHS Reference Costs 2012/13.45 Elective inpatients. DZ30Z Chest
Physiotherapy. 340 Respiratory Medicine
Speech and language therapy review 109 NHS Reference Costs 2012/13.45 Non Consultant Led Outpatient
Attendances. WF01B Non-Admitted Face to Face Attendance, First.
652 Speech and Language Therapy
Stroke (alternative cost used in
sensitivity analysis)
705 NHS Reference Costs 2012/13.45 Non elective inpatients. AA35E
Stroke with CC Score 4–6, 300 General Medicine, with the costs
associated with the average LOS reported subtracted at a cost of
£265 per day
Temporary pacemaker 3073 NHS Reference Costs 2012/13.45 Elective inpatients. EA39B
Pacemaker Procedure without Generator Implant, including Re-siting
and Removal of Cardiac Pacemaker System, with CC Score 2–4,
320 Cardiology, with the costs associated with the average LOS
reported subtracted at a cost of £265 per day
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TABLE 66 Unit costs for complications (continued )
Treatment/action Unit cost (£) Source for cost information
Tracheostomy 5313 NHS Reference Costs 2012/1345
Ultrasound 67 NHS Reference Costs 2012/13.45 Diagnostic Imaging – Outpatients.
Weighted average of RA25Z Ultrasound Mobile Scan or
Intraoperative Procedures, less than 20 minutes; RA26Z Ultrasound
Mobile Scan or Intraoperative Procedures, 20 to 40 minutes, RA27Z
Ultrasound Mobile Scan or Intraoperative Procedures, more than
40 minutes. 100 General Surgery
Negative Pressure Wound Therapy 3501 NHS Reference Costs 2012/13.45 Elective inpatients. JC42A
Intermediate Skin Procedures, 13 years and over. 172 Cardiac
Surgery, with the costs associated with the average LOS reported
subtracted at a cost of £265 per day
BIPAP, bilevel positive airway pressure; CPR, cardiopulmonary resuscitation; IABP, intra-aortic balloon pump;
i.v., intravenous.
TABLE 67 Unit costs for reattending hospital
Resource Unit cost (£)
Reference: sheet from which costs were taken, specific HRG
code and/or specialty code from which costs were taken
Ward day for readmissions 265 NHS Reference Costs 2012/13.45 Non-elective inpatient excess
bed-day cost across all activities
ICU day for readmissions 1168 NHS Reference Costs 2012/13.45 Critical Care Services – Adult:
Critical Care Unit (weighted average of XC01Z–XC07Z, 0–6 organs
supported)
ED attendance, leading to admission 154 NHS Reference Costs 2012/13.45 ED services, excluding dental care.
Weighted average of all admitted codes
ED attendance, not leading to
admission
101 NHS Reference Costs 2012/13.45 ED services, excluding dental care.
Weighted average of all non-admitted codes
Ambulance to hospital 230 NHS Reference Costs 2012/13.45 Ambulance services, ASS02, see
and treat and convey
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TABLE 68 Resource use assumed for readmission complications and total costs
Complication Treatment/action Cost (£) Assumption
Antibiotics
Site= respiratory Antibiotics, chest radiograph 69.40
Site= surgical wound Antibiotics, chest radiograph,
CT scan
131.40
Site= blood Antibiotics 28.40
Site= other – endocarditis Antibiotics, chest radiograph,
CT scan
131.40
Site= other – infective endocarditis Antibiotics, chest radiograph,
CT scan, transthoracic
echocardiography
252.40
Site= other – respiratory tract infection Antibiotics, chest radiograph 69.40
Site= other – wound Antibiotics, chest radiograph,
CT scan
131.40
Site= other – all others including UTI Antibiotics 28.40
Deep-vein thrombosis Duplex scan of leg veins,
i.v. heparin, warfarin
203.78
Cardiac tamponade Transoesophageal
echocardiography, chest
radiograph, two red blood cells
559.62 Reoperations captured
elsewhere
Other GI complications
Barrett’s oesophagus Endoscopy 676
Dehydration, hypovolaemia secondary
to 3 days of diarrhoea
i.v. fluids 13.49
Gastroenteritis i.v. fluids 13.49
Oesophageal ulcer Endoscopy 676
Peritonitis Laparotomy, CT scan 2755
Vomiting related to amiodarone.
Medication changed
i.v. fluids 13.49
Other pulmonary complications: all assumed to have two chest radiographs and an ECG – add £135 to all
Suspected/possible pulmonary
embolism – diagnosed with pleuritic
chest pain
CT scan, transthoracic
echocardiography
183
Acute shortness of breath – treated
with diuretics
Diuretics, transthoracic
echocardiography
121.15
Breathing difficulties at routine
outpatients. Kept in overnight for
breathing assessment
Transthoracic echocardiography 121
Breathlessness and cough Transthoracic echocardiography 121
Chest pain and shortness of breath Transthoracic echocardiography 121
Chest pain on inspiration/coughing CT scan 62
Cough No treatment 0
Dyspnoea Transthoracic echocardiography 121
End stage heart failure Diuretics, transthoracic
echocardiography
121.15
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TABLE 68 Resource use assumed for readmission complications and total costs (continued )
Complication Treatment/action Cost (£) Assumption
Failed extubation No additional treatment 0 Covered in ICU cost
Left hydropneumothorax Chest ultrasonography, chest drain 4244
Musculoskeletal chest pain Analgesia 6
Pleural effusion and bilateral pedal
oedema
Chest ultrasonography, diuretic
therapy
67.15
Pleural effusion not requiring drainage Chest ultrasonography 67
Pleural effusion treated with increased
dose of furosemide
Furosemide (80mg) 0.30
Pleuritic left lung (not requiring
drainage)
Analgesia 6
Pulmonary fibrosis No treatment 0
Right sided pleural effusion and
empyema, ultrasonography-guided
drainage, 2 units blood transfused,
treated with i.v. antibiotics
Chest drain, 2 units red blood cells,
i.v. antibiotics
4452.02
Severe chest pain, possible pulmonary
embolism but ruled out following
investigations
Transthoracic echocardiography, CT
pulmonary angiogram (CT chest)
183
Shortness of breath Transthoracic echocardiography 121
Shortness of breath owing to fluid
overload, diuretics increased
Transthoracic echocardiography,
furosemide (80mg)
121.30
Sudden onset of shortness of breath,
small right pleural effusion
Transthoracic echocardiography 121
Other arrhythmia complications: all assumed to have two ECGs – add £106 to all
Accelerated junctional rhythm No additional treatment 0 Pacing already captured
Atrial fibrillation Amiodarone 4.79
Chest discomfort, palpitations No treatment 0
Fast atrial flutter Amiodarone 4.79
Paroxysmal AF Amiodarone 4.79
Re-entry tachycardia No additional treatment 0 Only cost permanent
pacemaker if clear indication
participant had this
treatment
Other thromboembolic complications
Pulmonary embolus Transthoracic echocardiography, CT
pulmonary angiogram (CT chest),
i.v. heparin for 5 days, warfarin
231.78
Apical thrombus Transthoracic echocardiography, i.v.
heparin for 5 days, warfarin
169.78
Possible bilateral renal infarcts CT scan, i.v. heparin, warfarin 110.78
Small leg thrombus Ultrasonography of leg, i.v. heparin,
warfarin
115.78
AF, atrial fibrillation; i.v. intravenous; UTI, urinary tract infection.
Resource use assumed for readmission complications and total costs are shown here, unit costs and sources are shown in
Table 69. Resource use and costs for readmission complications as inpatient complications if not reported here.
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TABLE 69 Unit costs for readmission complications (not previously presented)
Treatment/action Unit cost (£) Reference
Diuretics (furosemide 80mg orally for 5 days) 0.30 BNF48
Warfarin (3mg daily, assumed given for half of follow up time, 45 days) 1.35 BNF48
TABLE 70 Unit costs for outpatient appointments
Specialty Unit cost (£) Service code
Reference: sheet from which costs were taken, specific HRG
code and/or specialty code from which costs were taken
Anticoagulation service 25 324 These are all sourced from NHS Reference Costs 2012–13.45
They are all average costs for each specialty (costs taken from the
Total – Outpatient Attendances page of the NHS Reference
Costs 2012–13, Total activity section)
Cardiac rehabilitation 42 327
Cardiac surgery 299 172
Cardiology 131 320
Cardiothoracic surgery 275 170
Clinical haematology 151 303
Colorectal surgery 113 104
Dermatology 98 330
Diabetic medicine 136 307
Endocrinology 152 302
Gastroenterology 137 301
General medicine 153 300
General surgery 128 100
Geriatric medicine 204 430
Hepatology 213 306
Infectious diseases 142 350
Medical oncology 138 370
Nephrology 158 361
Neurology 176 400
Occupational therapy 63 651
Ophthalmology 86 130
Physiotherapy 42 650
Plastic surgery 88 160
Rehabilitation 90 314
Respiratory medicine 150 340
Stroke clinic 200 328
Thoracic surgery 253 173
Upper GI surgery 120 106
Urology 101 101
Vascular surgery 142 107
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TABLE 71 Unit costs for other outpatient attendances
Resource Unit cost (£)
Reference: sheet from which costs were taken, specific HRG
code and/or specialty code from which costs were taken
Renal/dialysis 157 NHS Reference Costs 2012/13.45 Renal Dialysis at Base. LD02A
Hospital Haemodialysis or Filtration, with Access via Arteriovenous
Fistula or Graft, 19 years and over
Outpatient endoscopy 676 As endoscopy, previously given (see Table 66)
ECG 53 As previously given (see Table 66)
Electrocardiogram monitoring and
stress testing
204 As 24-hour Holter monitor (see Table 66)
CT scan 62 As previously given (see Table 66)
Echocardiography scan –
transthoracic
121 As previously given (see Table 66)
MRI scan 248 As previously given (see Table 66)
Chest radiography 41 As previously given (see Table 66)
Chest radiography and
ultrasonography
108 As previously given (see Table 66)
Sigmoidoscopy 164 NHS Reference Costs 2012/13.45 Procedures in Outpatients. FZ57Z
Diagnostic or Therapeutic, Rigid Sigmoidoscopy, 19 years and over.
104 Colorectal Surgery
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TABLE 72 Costs for resource use associated with SAEs (not previously presented)
Treatment/action Unit cost (£)
Reference: sheet from which costs were taken, specific HRG
code and/or specialty code from which costs were taken
Bladder cystoscopy 129 NHS Reference Costs 2012/13.45 Procedures in Outpatients. LB15E
Minor Bladder Procedures, 19 years and over. 101 Urology
Colonoscopy 257 NHS Reference Costs 2012/13.45 Procedures in Outpatients. FZ51Z
Diagnostic Colonoscopy, 19 years and over. 100 General Surgery
Diverticulitis 686 NHS Reference Costs 2012/13.45 Elective inpatients. FZ83H Major
Oesophageal, Stomach or Duodenum Procedures, 19 years and
over with CC Score 4–6. 301 Gastroenterology, with the costs
associated with the average LOS reported subtracted at a cost of
£265 per day
ECG 477 NHS Reference Costs 2012/13.45 Day Cases. EA47Z
Electrocardiogram Monitoring and stress testing. 320 Cardiology
Fasciotomy 6182 NHS Reference Costs 2012/13.45 Non-elective inpatients. QZ02D
Lower Limb Arterial Surgery with CC Score 6–10. 107 Vascular
Surgery, with the costs associated with the average LOS reported
subtracted at a cost of £265 per day
Gastroscopy 676 As endoscopy (see Table 66)
Groin scan/procedure of lymphatic
system
3191 NHS Reference Costs 2012/1345
Oesophagogastroduodenoscopy 676 As endoscopy (see Table 66)
Leg amputation 13,353 NHS Reference Costs 2012/13.45 Non-elective inpatients. QZ11D
Amputations with CC Score 8–13. 107 Vascular Surgery
Recatheterisation 1534 NHS Reference Costs 2012/1345
Stoma bag system 63.38 NHS Electronic Drug Tariff.80 Part IXC – Stoma Appliances
(Colostomy Sets). Weighted average of all sets
Tesio catheter insertion under
fluoroscopy
325 NHS Reference Costs 2012/1345
Uroscopy 129 NHS Reference Costs 2012/13.45 Procedures in Outpatients. LB15E
Minor Bladder Procedures, 19 years and over. 101 Urology
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TABLE 73 Unit costs for post-discharge community health and social care contacts
Resource Unit cost (£)
Reference: sheet from which costs were taken, specific HRG code
and/or specialty code from which costs were taken
GP at surgery 34 Unit Costs of Health and Social Care 2013;49 10.8b, GP – unit costs.
Per-patient contact lasting 11.7 minutes. Excluding qualification costs and
direct care staff costs
GP at home 85 Unit Costs of Health and Social Care 2013;49 10.8b, GP – unit costs. Per
out-of-surgery visit lasting 23.4 minutes. Excluding qualification costs and
direct care staff costs
Out-of-hours GP 34 As GP at surgery
Walk-in centre 34 As GP at surgery
GP nurse 11.37 Unit Costs of Health and Social Care 2013;49 10.6, Nurse (GP practice).
£44 per hour of face-to-face contact, excluding qualification costs. Average
contact 15.5 minutes
District nurse 39 Unit Costs of Health and Social Care 2013;49 10.1, Community Nurse.
Using data from NHS Reference Costs 2011/12,45 the mean average cost
for a face-to-face contact in district nursing services for 2012/2013 was
£39, with an IQR of £33 to £46. Costs have been uprated using the HCHS
pay and prices inflator
Other NHS or social services
Cardiac rehabilitation/
exercise class
42 NHS Reference Costs 2012/13;45 Total – Outpatient Attendances.
327 – Cardiac Rehabilitation
Cardiac nurse 70 NHS Reference Costs 2012/13;45 Community Health Services – Nursing,
N11AF, Specialist Nursing – Cardiac Nursing/Liaison, Adult, Face to face
Diabetic nurse 70 NHS Reference Costs 2012/13;45 Community Health Services – Nursing,
N15AF, Specialist Nursing – Diabetic Nursing/Liaison, Adult, Face to face
Anticoagulation service 10 NHS Reference Costs 2012/13;45 Non Consultant Led Outpatient
Attendances; Non-Admitted Non-Face to Face Attendance, Follow-up,
324 – Anticoagulation Service
Community pharmacist 69.64 Unit Costs of Health and Social Care 2013;49 9.6, Community pharmacist.
£127 per hour of direct clinical activities. Contact assumed to be for
32.9 minutesa
Cardiac rehabilitation by
phone
50 NHS Reference Costs 2012/13;45 Non Consultant Led Outpatient
Attendances; Non-Admitted Non-Face to Face Attendance, Follow-up,
327 – Cardiac Rehabilitation
Dietitian 71 NHS Reference Costs 2012/13;45 Community Health Services – Allied Health
Professionals. A03 – Dietician
Health-care support worker 16 Unit Costs of Health and Social Care 2013;49 10.5, Clinical support worker
nursing (community). £30 per hour of home visiting. Contact assumed to
be for 32.9 minutesa
Occupational therapist 53 Unit Costs of Health and Social Care 2013;49 13.2, Hospital occupational
therapist. Using data from NHS Reference Costs 2011/12, the mean
average cost for a non-consultant led (non-admitted) follow-up
occupational therapy attendance was £53, with an IQR of £30 to £64.
Costs have been uprated using the HCHS pay and prices inflator
Physiotherapist 34 Unit Costs of Health and Social Care 2013;49 13.1, Hospital physiotherapist.
Using data from NHS Reference Costs 2011/12, the mean average cost for
a non-consultant-led (non-admitted) follow-up physiotherapy attendance
was £34, with an IQR of £28 to £38. Costs have been uprated using the
HCHS pay and prices inflator
Social worker 87.19 Unit Costs of Health and Social Care 2013;49 11.2, Social worker (adult
services). £159 per hour of face-to-face contact, excluding qualification
costs. Contact assumed to be for 32.9 minutesa
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TABLE 73 Unit costs for post-discharge community health and social care contacts (continued )
Resource Unit cost (£)
Reference: sheet from which costs were taken, specific HRG code
and/or specialty code from which costs were taken
Other NHS or social services at home
Cardiac rehabilitation/nurse 70 NHS Reference Costs 2012/13;45 Community Health Services – Nursing.
N11AF Specialist Nursing – Cardiac Nursing/Liaison, Adult, Face to face
Phone call to cardiology 49 NHS Reference Costs 2012/13;45 Outpatients. WF01C, Non-Admitted
Non-Face to Face Attendance, Follow-up. 320 – Cardiology
Carer 8.50 Unit Costs of Health and Social Care 2013;49 11.6, Home care worker. The
mean hourly cost of all home care including LA-funded and independent
provision was £17. Just over half of local authority funded visits lasted
30 minutes. Sixteen per cent of visits were 15 minutes and 19% of a home
care workers’ time was spent travelling. Assume 30-minute visit
Community matron 68 NHS Reference Costs 2012/13;45 Community Health Services – Nursing.
N06AF – Specialist Nursing – Active Case Management (Community
Matrons), Adult, Face to face
Community mental health
team carer
36 Unit Costs of Health and Social Care 2013;49 10.2 Nurse (mental health),
£65 per hour of face-to-face contact, excluding qualifications. Contact
assumed to be for 32.9 minutesa
Dietitian 71 NHS Reference Costs 2012/13;45 Community Health Services – Allied Health
Professionals. A03 – Dietician
Occupational therapist 73 Unit Costs of Health and Social Care 2013;49 9.2, NHS community
occupational therapist. Using data from NHS Reference Costs 2011/12,
the mean average cost for a one-to-one contact of occupational therapy
services was £73, with an IQR of £50 to £86. Costs have been updated
using the HCHS pay and prices inflator
Paramedic 174 NHS Reference Costs 2012/13;45 Ambulance Services. ASS01 – See and
treat or refer
Physiotherapist 47 Unit Costs of Health and Social Care 2013;49 9.1, Community
physiotherapist. Using data from NHS Reference Costs 2011/12, the mean
average cost for a one-to-one contact in physiotherapy services was £47,
with an IQR of £37 to £52. Costs have been uprated using the HCHS pay
and prices inflator
Social worker 87.19 Unit Costs of Health and Social Care 2013;49 11.2, Social worker (adult
services). £159 per hour of face-to-face contact, excluding qualification
costs. Contact assumed to be for 32.9 minutesa
Nurse specialist 60 NHS Reference Costs 2012/13;45 Community Health Services – Nursing,
N29AF, Other Specialist Nursing, Adult, Face to face
Respiratory nurse 75 NHS Reference Costs 2012/13;45 Community Health Services – Nursing,
N08AF, Specialist Nursing – Asthma and Respiratory Nursing/Liaison, Adult,
Face to face
NHS direct call 13 NHS Direct annual report 2012/1381
Indoor and outdoor grab
rails
91 Unit Costs of Health and Social Care 2013;49 7.3.1, social services access
improvements
Mobile shower chair 55 Unit Costs of Health and Social Care 2013;49 7.3.1, social services shower
AF, atrial fibrillation; LA, local authority.
a When no information was available on the duration of appointments, an average duration of 32.9 minutes has been
assumed. This is the average length of a hospital physiotherapy session (Unit Costs of Health and Social Care 2013;49
section 13.1).
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A detailed breakdown of total average costs per participant
TABLE 74 Detailed breakdown of total average costs per participant to 3 months from surgery for both
trial groups
Resource use
Randomised to
restrictive threshold
(n= 1000), mean cost
(£) (SE)
Randomised to liberal
threshold (n= 1003),
mean cost (£) (SE)
Restrictive vs. liberal
threshold, mean cost
(£) difference (SE)
Red blood cells
Red blood cells 257 (12) 379 (13) –122 (18)
Red blood cell administration 30 (1) 48 (1) –17 (2)
Total red blood cells 287 (13) 427 (15) –140 (19)
Cardiac procedure
Initial cardiac surgery 7309 (18) 7313 (18) –4 (26)
Blood products
FFP 27 (2) 26 (2) 1 (2)
Platelets 135 (7) 134 (7) 1 (10)
Cryoprecipitate 43 (5) 39 (4) 4 (7)
Total blood products 206 (12) 199 (11) 7 (16)
Inpatient complications
Primary outcome
Antibiotics for infectious complication 21 (5) 14 (2) 7 (5)
Stroke 3 (1) 3 (1) 0 (1)
Suspected MI 6 (3) 13 (5) –7 (6)
Gut infarction 11 (6) 3 (3) 8 (6)
AKI – stage 3 86 (11) 73 (10) 13 (15)
Other complications
Reoperation 636 (70) 704 (75) –67 (102)
Reintubation 28 (4) 29 (4) –1 (5)
Tracheostomy 182 (32) 176 (31) 6 (45)
Mask CPAP 68 (6) 65 (7) 3 (9)
Pneumothorax requiring chest drainage 59 (16) 55 (15) 4 (22)
Pleural effusion requiring drainage 245 (32) 248 (36) –3 (48)
Pacing 946 (48) 956 (47) –9 (67)
SVT/AF requiring treatment 2 (0) 2 (0) 0 (0)
VF/VT requiring intervention 44 (11) 16 (6) 28 (13)
Low cardiac output 33 (3) 35 (4) –1 (5)
SAEs 17 (7) 12 (5) 5 (9)
Other inpatient complications 296 (54) 311 (54) –15 (76)
Total complications and SAEs 2684 (137) 2714 (146) –30 (200)
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TABLE 74 Detailed breakdown of total average costs per participant to 3 months from surgery for both
trial groups (continued )
Resource use
Randomised to
restrictive threshold
(n= 1000), mean cost
(£) (SE)
Randomised to liberal
threshold (n= 1003),
mean cost (£) (SE)
Restrictive vs. liberal
threshold, mean cost
(£) difference (SE)
Inpatient LOS
CICU 1359 (138) 1330 (158) 29 (210)
HDU 1916 (72) 1890 (74) 25 (104)
Ward 2221 (59) 2287 (68) –66 (90)
ICU 8 (8) 17 (12) –9 (14)
Another unit/hospital 351 (51) 368 (51) –17 (72)
Total LOS 5854 (201) 5892 (221) –38 (299)
Blood saving techniques
Tranexamic acid 13 (0) 13 (0) 0 (0)
Trasylol 13 (2) 11 (2) 2 (3)
Intraoperative cell salvage 85 (3) 88 (3) –4 (4)
Post-operative cell salvage 10 (1) 8 (1) 2 (2)
Beriplex 22 (3) 20 (3) –2 (4)
Factor VIIa 17 (7) 12 (6) 5 (9)
Total blood saving techniques 159 (9) 152 (8) 7 (12)
Fluids in theatre/CICU/HDU
Inotropes 36 (1) 35 (1) 1 (1)
Gelofusine 7 (0) 7 (0) 0 (0)
HES 9 (1) 9 (1) 0 (1)
Other fluids 3 (0) 3 (0) 0 (0)
Total fluids 55 (1) 55 (1) 0 (2)
Readmissions to hospital
LOS (ward and ICU) 446 (58) 447 (50) –1 (76)
Complications and SAEs 271 (38) 259 (40) 12 (55)
Readmission via ED and/or ambulance 52 (4) 47 (4) 5 (6)
Total readmissions 770 (85) 753 (78) 17 (116)
ED attendances
Total ED visits 9 (1) 8 (1) 1 (1)
Ambulance to ED 7 (1) 4 (1) 3 (2)
Total ED 16 (2) 12 (2) 4 (3)
Outpatient appointments
Cardiac surgery outpatient visits 131 (5) 151 (6) –20 (8)
Cardiology outpatient visits 37 (2) 33 (2) 4 (3)
Other outpatient visits 32 (4) 30 (4) 2 (5)
Ambulance to appointment 1 (0) 2 (1) 0 (1)
Total outpatients 202 (6) 216 (7) –14 (9)
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Changes in the use of regular medications between admission
to and discharge from the cardiac surgery unit
Information on regular medications taken by participants was recorded on CRF Form D2 for two time
points (1) on admission to the cardiac surgery unit (baseline) and (2) at discharge from the cardiac surgery
unit. In the main costing analyses, we assumed that any medications participants were on at discharge,
they took for the 3-month follow-up and were costed for 3 months.
In this separate analysis, we summarised the number of participants on each medication at baseline and at
discharge, and the change in the use of medications. We then costed the medications participants were on
at baseline and at discharge for a period of 1 week to get an insight into the costs of their regular use.
Comparisons were then made between the costs of these medications taken at baseline and at discharge
from hospital, to determine whether or not there were significant changes before and after surgery. There
was very little missing data for the use of regular medications at baseline and at discharge. Complete
information was available for all drugs at both time points for 1990 of the 2003 participants and,
therefore, a complete case analysis was performed.
TABLE 74 Detailed breakdown of total average costs per participant to 3 months from surgery for both
trial groups (continued )
Resource use
Randomised to
restrictive threshold
(n= 1000), mean cost
(£) (SE)
Randomised to liberal
threshold (n= 1003),
mean cost (£) (SE)
Restrictive vs. liberal
threshold, mean cost
(£) difference (SE)
Other health and social care contacts
GP at surgery 68 (2) 71 (2) –3 (3)
GP at home 37 (3) 32 (2) 5 (4)
Practice nurse 18 (1) 18 (1) 0 (2)
District nurse 96 (8) 86 (7) 10 (11)
Other contacts 160 (9) 160 (12) 0 (15)
Total other contacts 378 (14) 366 (16) 12 (21)
Total costs 17,945 (332) 18,127 (357) –182 (488)
AF, atrial fibrillation; HES, hydroxyethyl starch; SVT, supraventricular tachycardia; VF, ventricular fibrillation;
VT, ventricular tachycardia.
Costs do not always sum to totals owing to rounding.
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Table 75 shows the number of participants on each medication at baseline and at discharge, and the
change between the time points for each transfusion group. There was quite a lot of change in the use of
medications before and after surgery. The use of diuretics, aspirin, warfarin and antiarrhythmics increased
considerably in both groups from baseline to discharge, whereas the use of calcium antagonists, oral
nitrates and angiotensin-converting enzyme (ACE) inhibitors reduced after surgery in both groups. The use
of FeSO4 increased after surgery, but to a much greater extent in the restrictive group than the
liberal group.
Table 76 shows the mean weekly costs per participant in each group for each of the medications at
baseline and at discharge. The daily unit cost for each of the drugs is also shown and most are very
inexpensive. Costs have reduced after surgery – mean total costs are similar in both groups, approximately
£4 at baseline and £2 at discharge. The reduction in costs after surgery is driven by the reduced costs of
oral nitrates and intravenous glyceryl trinitrate in both groups, and also by the reduced cost of heparin in
the liberal group.
TABLE 75 The number of participants on each regular medication at baseline and discharge, for each
transfusion group
Drug name
Restrictive threshold, n= 992 Liberal threshold, n= 998
Baseline,
frequency
(%)
Discharge,
frequency
(%)
Discharge vs.
baseline,
frequency (%)
difference
Baseline,
frequency
(%)
Discharge,
frequency
(%)
Discharge vs.
baseline,
frequency (%)
difference
Digoxin 44 (4) 38 (4) –6 (–1) 57 (6) 54 (5) –3 (–0)
Diuretics 336 (34) 634 (64) 298 (30) 360 (36) 652 (65) 292 (29)
Beta blockers 590 (59) 668 (67) 78 (8) 588 (59) 671 (67) 83 (8)
Calcium antagonists 228 (23) 101 (10) –127 (–13) 247 (25) 106 (11) –141 (–14)
Aspirin 597 (60) 754 (76) 157 (16) 606 (61) 777 (78) 171 (17)
Oral nitrates 222 (22) 27 (3) –195 (–20) 217 (22) 26 (3) –191 (–19)
Angiotensin 2
blockers
116 (12) 55 (6) –61 (6) 114 (11) 60 (6) –54 (–5)
ACE inhibitors 453 (46) 338 (34) –115 (–12) 425 (43) 328 (33) –97 (10)
Warfarin 108 (11) 263 (27) 155 (16) 119 (12) 251 (25) 132 (13)
Clopidogrel 187 (19) 141 (14) –46 (–5) 162 (16) 152 (15) –10 (–1)
Statins 713 (72) 726 (73) 13 (1) 720 (72) 757 (76) 37 (4)
Anti-arrhythmic 24 (2) 284 (29) 260 (26) 29 (3) 273 (27) 244 (24)
Heparin 33 (3) 33 (3) 0 (0) 54 (5) 33 (3) –21 (–2)
Intravenous glyceryl
trinitrate
23 (2) 2 (0) –21 (–2) 21 (2) 9 (1) –12 (–1)
FeSO4 29 (3) 154 (16) 125 (13) 37 (4) 63 (6) 26 (3)
ACE, angiotensin-converting enzyme.
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The costs of these medications are low but it is important to bear in mind that these are weekly costs,
whereas participants are likely to be on these medications for a long time. Furthermore, people
on long-term medication are likely to have additional health-care appointments, for example people on
warfarin have regular monitoring checks, so costs are incurred to the NHS beyond the drug costs.
Non-NHS costs: did these differ between trial groups?
The primary perspective of the evaluation was that of the UK NHS and Personal Social Services. However,
data were collected on some types of non-NHS costs and if resource use differed between the trial groups
for these non-NHS costs, we planned to include these costs in a wider perspective in a sensitivity analysis.
The main non-NHS resource collected was participants’ means of travel to hospital for readmissions or
visits after discharge. We investigated whether or not resource use for travel to hospital differed between
trial groups, to determine whether or not it was important to conduct a sensitivity analysis around this.
On the follow-up questionnaire, participants were asked to record how they travelled to hospital for each
readmission, ED visit and outpatient appointment. The means of transport was recorded for 315 of the
418 readmissions recorded on the CRFs that were included in the costings for 112 of the 144 ED visits
recorded and for 1387 of the outpatient appointments recorded. These responses are shown in Table 77.
TABLE 76 Weekly costs per participant for regular medications at baseline and at discharge
Restrictive threshold, n= 992 Liberal threshold, n= 998
Drug name
Daily
unit
cost
(£)
Baseline,
mean
cost (£)
Discharge,
mean cost
(£)
Discharge vs.
baseline,
mean cost (£)
difference
Baseline,
mean
cost (£)
Discharge,
mean cost
(£)
Discharge vs.
baseline,
mean cost (£)
difference
Digoxin 0.04 0.01 0.01 0.00 0.02 0.02 0.00
Diuretics 0.03 0.07 0.13 0.06 0.08 0.14 0.06
Beta-blockers 0.03 0.12 0.14 0.02 0.12 0.14 0.02
Calcium
antagonists
0.03 0.05 0.02 –0.03 0.05 0.02 –0.03
Aspirin 0.03 0.13 0.16 0.03 0.13 0.16 0.04
Oral nitrates 0.98 1.54 0.19 –1.35 1.49 0.18 –1.31
Angiotensin 2
blockers
0.04 0.03 0.02 –0.02 0.03 0.02 –0.02
ACE inhibitors 0.04 0.13 0.10 –0.03 0.12 0.09 –0.03
Warfarin 0.03 0.02 0.06 0.03 0.03 0.05 0.03
Clopidogrel 0.06 0.08 0.06 –0.02 0.07 0.06 0.00
Statins 0.04 0.20 0.20 0.00 0.20 0.21 0.01
Antiarrhythmic 0.06 0.01 0.12 0.11 0.01 0.11 0.10
Heparin 2.27 0.53 0.53 0.00 0.86 0.53 –0.33
Intravenous
glyceryl trinitrate
6.49 1.05 0.09 –0.96 0.96 0.41 –0.55
FeSO4 0.11 0.02 0.12 0.10 0.03 0.05 0.02
Total cost 4.00 1.95 –2.05 4.19 2.19 –1.99
Costs do not always sum to total cost due to rounding.
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TABLE 77 Means of transport for hospital attendances post discharge
Means of transport
Randomised to
restrictive threshold,
frequency (%)
Randomised to
liberal threshold,
frequency (%)
Restrictive vs.
liberal threshold,
% difference
Transport to readmission n = 153 n = 162
Ambulance 77 (50) 79 (49) 1
Hospital provided transport 5 (3) 8 (5) –2
Hospital transport 4 (3) 8 (5) –2
Taxi (hospital paid) 1 (1) 0 (0) 1
Transport at private expense 67 (44) 75 (46) –2
Friend/relative in car 62 (41) 68 (42) –1
Self-driven in car 2 (1) 1 (1) 0
Taxi (self-paid) 3 (2) 5 (3) –1
Public transport 0 (0) 1 (1) –1
Other 4 (3)a 0 (0) 3
Transport to ED n = 59 n = 53
Ambulance 24 (41) 11 (21) 20
Hospital provided transport 1 (2) 0 (0) 2
Hospital transport 1 (2) 0 (0) 2
Taxi (hospital paid) 0 (0) 0 (0) 0
Transport at private expense 34 (57) 42 (79) –22
Friend/relative in car 23 (39) 34 (64) –25
Self-driven in car 3 (5) 6 (11) –6
Taxi (self-paid) 3 (5) 1 (2) 3
Public transport 5 (8) 1 (2) 6
Transport to OP appointment n = 654 n = 733
Ambulance 4 (1) 6 (1) 0
Hospital provided transport 19 (3) 28 (4) –1
Hospital transport 14 (2) 22 (3) –1
Taxi (hospital paid) 5 (1) 6 (1) 0
Transport at private expense 624 (95) 691 (94) 1
Friend/relative in car 395 (60) 455 (62) –2
Self-driven in car 141 (22) 119 (16) 6
Taxi (self-paid) 24 (4) 40 (5) –1
Public transport 64 (10) 77 (11) –1
Other 7 (1)b 8 (1)c 0
OP, outpatient.
a One walked, two already at hospital, one charity.
b Three walked, three charity, one motorcycle.
c Five walked, two charity, one hospital car.
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For readmissions to hospital, approximately 50% of participants were taken by ambulance, the majority of
other participants travelled at their own expense, most frequently being taken by a friend or relative by
car. The proportion of participants travelling by each means is very similar between the trial groups.
Relatively few ED visits were recorded by participants, so while the proportion of participants travelling by
different means looks to vary between the groups, the numbers are small. For outpatient appointments,
95% of participants travelled at private expense, the majority being taken by a friend or relative by car or
driving himself or herself. The proportion of participants travelling by each means is very similar between
the trial groups.
Means of transport to hospital did not appear to differ between the trial groups; therefore, a sensitivity
analysis taking a wider perspective was not conducted.
Sensitivity analyses
Sensitivity analyses around unit costs
TABLE 78 Sensitivity analyses performed around unit costs
Sensitivity
analysis Resource/complication
Unit costs used in base-case
analysis
Alternative strategies for
sensitivity analysis
1 Ward stay in cardiac unit
(first admission)
£392 £265 (cost used for ward stay
beyond index cardiac admission)
2 Ward stay beyond index cardiac
admission (further stay in
another unit/hospital or
readmission)
£265 £392 (cost used for ward stay in
cardiac unit, first admission)
3 Bed-days in first admission £1608 general ICU
£1190 CICU
£619 HDU
£392 cardiac ward
£265 another unit/hospital ward
(£1168 if known to be ICU)
Alter bed-day costs in first
admission by ± 25% and 50%
4 Bed-days in readmissions £1168 ICU
£265 ward
Alter readmission ICU/ward costs
by ± 25% and 50%
5 Stroke £139 for physiotherapy and
diagnostics as recorded
(CT scan £62; MRI scan £248)
£705 (taken from Reference
Costs,45 see Table 66)
6 Wound dehiscence Covered by reoperation if the two
dates are the same; otherwise
£161 unless VAC therapy is stated
then £3501
Assume VAC therapy for those
without reoperations (£3501)
7 Low cardiac output £313; IABP not included Add cost of IABP £2776
8 Chest drain £4177 –50%: £2088.50
9 Pacing £3073 ± 25% and 50%
10 Tracheostomy £5354 (includes one radiograph) ± 25% and 50%
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TABLE 78 Sensitivity analyses performed around unit costs (continued )
Sensitivity
analysis Resource/complication
Unit costs used in base-case
analysis
Alternative strategies for
sensitivity analysis
11 Reoperations £6608 if operation takes < 3
hours and £8298 if ≥ 3 hours.
Reoperations in readmissions
costed at £6608+ £1421 for
blood products
Cost all reoperations at the
lower (£6608) and higher figures
(£8298). Include £1421 for
blood products for reoperations
in readmissions
12 Antibiotics eMIT47 when available, otherwise
BNF;48 see Table 63
Increase costs by 100%
13 Antibiotics eMIT47 when available, otherwise
BNF;48 see Table 63
Cost most common antibiotics
(those received by 20 or more
participants) using BNF;48 see
Table 62
14 Antibiotics eMIT47 when available, otherwise
BNF;48 see Table 63
For antibiotics participants
receive orally or intravenously,
cost all as oral
15 Antibiotics eMIT47 when available, otherwise
BNF;48 see Table 63
For antibiotics participants
receive orally or intravenously,
cost all as intravenous
16 Outpatient visits See Tables 70 and 71 ± 25% and 50%
IABP, intra-aortic balloon pump; VAC, vacuum-assisted closure.
TABLE 79 Results of sensitivity analyses around unit costs
Sensitivity analysis
Randomised to
restrictive threshold
(n= 1000), mean cost
(£) (SE)
Randomised to liberal
threshold (n= 1003),
mean cost (£) (SE)
Restrictive vs. liberal
threshold, mean cost
(£) difference (SE)
Base case 17,945 (332) 18,127 (357) –182 (488)
SA1 (ward stay, cardiac unit) 17,226 (327) 17,386 (352) –161 (480)
SA2 (ward stay, beyond index
cardiac admission)
18,267 (346) 18,476 (370) –208 (507)
SA3 (bed-days, first admission)
+ 25% 19,409 (377) 19,600 (408) –191 (556)
–25% 16,482 (289) 16,654 (308) –173 (422)
+ 50% 20,872 (423) 21,073 (460) –201 (625)
–50% 15,018 (248) 15,181 (261) –163 (360)
SA4 (bed-days, readmissions)
+ 25% 18,057 (336) 18,239 (360) –182 (493)
–25% 17,834 (329) 18,016 (355) –182 (484)
+ 50% 18,168 (341) 18,350 (363) –182 (498)
–50% 17,722 (326) 17,904 (353) –182 (481)
SA5 (stroke) 17,954 (333) 18,137 (358) –182 (489)
SA6 (wound dehiscence) 18,022 (337) 18,200 (361) –178 (494)
SA7 (low cardiac output) 18,248 (341) 18,439 (369) –192 (502)
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TABLE 79 Results of sensitivity analyses around unit costs (continued )
Sensitivity analysis
Randomised to
restrictive threshold
(n= 1000), mean cost
(£) (SE)
Randomised to liberal
threshold (n= 1003),
mean cost (£) (SE)
Restrictive vs. liberal
threshold, mean cost
(£) difference (SE)
SA8 (chest drain) 17,712 (324) 17,905 (348) –193 (475)
SA9 (pacing)
+25% 18,182 (336) 18,366 (361) –184 (493)
–25% 17,709 (329) 17,888 (355) –180 (484)
+50% 18,419 (340) 18,605 (364) –187 (498)
–50% 17,472 (326) 17,649 (352) –177 (480)
SA10 (tracheostomy)
+25% 17,991 (337) 18,171 (362) –180 (495)
–25% 17,900 (327) 18,083 (352) –183 (481)
+50% 18,036 (342) 18,215 (367) –179 (502)
–50% 17,854 (323) 18,039 (348) –185 (474)
SA11 (reoperations)
£6608 17,930 (331) 18,115 (356) –185 (486)
£8298 18,092 (339) 18,296 (366) –203 (499)
SA12 (antibiotics) 17,968 (334) 18,143 (358) –175 (490)
SA13 (antibiotics, BNF) 18,004 (335) 18,190 (361) –186 (492)
SA14 (antibiotics, oral) 17,943 (332) 18,126 (357) –182 (488)
SA15 (antibiotics, i.v.) 17,948 (332) 18,131 (358) –183 (488)
SA16 (outpatient visits)
+25% 17,995 (332) 18,181 (357) –185 (488)
–25% 17,895 (332) 18,074 (357) –178 (488)
+50% 18,045 (332) 18,234 (357) –189 (488)
–50% 17,845 (333) 18,020 (358) –175 (488)
i.v., intravenous; SA, sensitivity analysis.
Costs do not always sum to total cost due to rounding.
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Costs from randomisation
Costs for 3 months from randomisation rather than from surgery have been calculated for each
participant. Events that occurred before randomisation were excluded: the cardiac procedure and blood
saving techniques in theatre [tranexamic acid, aprotinin (Trasylol, The Nordic group) and cell salvage].
Costs associated with post-operative cell saver were included only if participants were randomised within
4 hours of surgery. The costs of red blood cells given pre-randomisation and complications occurring
pre-randomisation were excluded. For events which may have started before randomisation but extended
beyond randomisation, such as LOS and intubations, durations were calculated from the time
of randomisation.
Resource use for other blood products (FFP, platelets, cryoprecipitate) and activated factor VII and Beriplex
was captured for the hospital stay. It was not possible to determine if these resources were used pre or
post randomisation. The costs of these products have been included in this analysis. It was not possible to
determine if fluids given in theatre, CICU or HDU were given pre or post randomisation and the costs of
these products were excluded.
Any events occurring within 3 months of randomisation rather than of surgery were included in the
analysis. Given that randomisation occurs after surgery, slightly more post-discharge resource use was
included in this analysis than the costs to 3 months from surgery.
Tables 80 and 81 present the mean resource use and mean costs to 3 months from randomisation.
Participants in the restrictive group received on average one less unit of red blood cells than participants in
the liberal group; other resource use was similar between the groups. In terms of costs, the reduced use
of red blood cells in the restrictive group resulted in a cost difference of –£141 in red blood cells between
the groups, which is largely what drives the difference in total costs between the groups of –£134.
TABLE 80 Resource use per participant to 3 months from randomisation
Resource use component
Randomised to
restrictive threshold
(n= 1000), frequency
(%) or mean (SE)
Randomised to
liberal threshold
(n= 1003), frequency
(%) or mean (SE)
Restrictive vs. liberal
threshold, % or mean
(SE) difference
Red blood cells, number of
units/participant 1.49 (0.08) 2.49 (0.09) –1.00 (0.12)
Blood products, number of units/participant
FFP 1.00 (0.06) 0.95 (0.06) 0.05 (0.08)
Platelets 0.65 (0.03) 0.64 (0.03) 0.01 (0.05)
Cryoprecipitate 0.23 (0.03) 0.21 (0.02) 0.02 (0.04)
Inpatient complications
Primary outcome, number (%) of participants
Antibiotics for infectious complication 319 (32%) 322 (32%) 0%
Stroke 11 (1%) 14 (1%) 0%
Suspected MI 2 (0%) 4 (0%) 0%
Gut infarction 5 (1%) 1 (0%) 0%
AKI, stage 3 47 (5%) 45 (4%) 0%
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TABLE 80 Resource use per participant to 3 months from randomisation (continued )
Resource use component
Randomised to
restrictive threshold
(n= 1000), frequency
(%) or mean (SE)
Randomised to
liberal threshold
(n= 1003), frequency
(%) or mean (SE)
Restrictive vs. liberal
threshold, % or mean
(SE) difference
Other complications, number of events/participant
Reoperation 0.07 (0.01) 0.08 (0.01) –0.01 (0.01)
Reintubation 0.05 (0.01) 0.06 (0.01) –0.01 (0.01)
Tracheostomy 0.03 (0.01) 0.03 (0.01) 0.00 (0.01)
Mask CPAP 0.10 (0.01) 0.09 (0.01) 0.01 (0.02)
Pneumothorax requiring chest
drainage
0.01 (0.00) 0.01 (0.00) 0.00 (0.00)
Pleural effusion requiring drainage 0.06 (0.01) 0.06 (0.01) 0.00 (0.01)
Pacing 0.09 (0.01) 0.06 (0.01) 0.03 (0.01)
SVT/AF requiring treatment 0.35 (0.02) 0.33 (0.02) 0.02 (0.03)
VF/VT requiring intervention 0.02 (0.01) 0.01 (0.00) 0.01 (0.01)
Low cardiac output 0.03 (0.01) 0.03 (0.01) 0.01 (0.01)
Inpatient LOS, days/participant
CICU 0.89 (0.11) 0.86 (0.13) 0.03 (0.17)
HDU 2.75 (0.12) 2.71 (0.12) 0.04 (0.17)
Ward 5.49 (0.15) 5.68 (0.17) –0.19 (0.22)
Another unit/hospital 1.26 (0.18) 1.36 (0.21) –0.09 (0.28)
Blood saving techniques, number (%) of participants
Post-operative cell salvagea 24 (2%) 20 (2%) 0%
Readmissions to hospital
LOS, days/participant 1.39 (0.15) 1.48 (0.16) –0.09 (0.22)
ED attendances
Total ED visits, number/participant 0.08 (0.01) 0.07 (0.01) 0.01 (0.01)
Outpatient appointments, number/participant
Cardiac surgery outpatient visits 0.44 (0.02) 0.51 (0.02) –0.07 (0.03)
Cardiology outpatient visits 0.28 (0.02) 0.26 (0.02) 0.02 (0.03)
Other outpatient visits 0.17 (0.02) 0.17 (0.02) –0.01 (0.03)
Other health-care contacts, number/participant
GP at surgery 1.99 (0.07) 2.10 (0.08) –0.11 (0.10)
GP at home 0.43 (0.05) 0.38 (0.03) 0.05 (0.06)
Practice nurse 1.55 (0.15) 1.57 (0.13) –0.02 (0.18)
District nurse 2.40 (0.22) 2.18 (0.21) 0.22 (0.30)
AF, atrial fibrillation; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia.
a Included if participant randomised within 4 hours of surgery.
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Inpatient resource use for red blood cells, LOS and complications reduces when we consider resource use
from randomisation rather than from surgery (see Table 80 and Chapter 6, Table 37). The differences
between the groups are similar for both analyses, but units of red blood cells transfused reduce by 0.6 units
when we consider resource use from randomisation rather than from surgery, and CICU stay reduces by
0.25 days and HDU stay by 0.34 days. The number of complications experienced by participants also
reduces, particularly for pacing, supraventricular tachycardia/atrial fibrillation requiring treatment, and low
cardiac output.
TABLE 81 Breakdown of total average costs per participant from randomisation to 3 months for both trial groups
Cost component
Randomised to
restrictive threshold
(n= 1000), mean
cost (£) (SE)
Randomised to liberal
threshold (n= 1003),
mean cost (£) (SE)
Restrictive versus
liberal threshold,
mean cost (£)
difference (SE)
Red blood cells 208 (11) 349 (13) –141 (17)
Inpatient episode
Other blood products 206 (12) 199 (11) 7 (16)
Complications and SAEs 1694 (120) 1663 (128) 31 (175)
LOSa 5274 (198) 5318 (219) –45 (295)
Blood saving techniques 43 (8) 36 (7) 7 (10)
Regular medications 26 (2) 29 (2) –3 (3)
Total 7243 (286) 7245 (322) –2 (430)
Post discharge
Readmissions 780 (87) 765 (79) 15 (117)
ED visits 16 (2) 12 (2) 4 (3)
Outpatient appointments 202 (6) 219 (7) –17 (9)
Other medical/social care 376 (13) 369 (17) 7 (21)
Total 1374 (92) 1365 (83) 9 (124)
Total costs 8825 (310) 8959 (340) –134 (460)
a Includes days in another unit/hospital once transferred out of the cardiac unit.
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Appendix 4 Transfusion Indication Threshold
Reduction case report forms
Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
NOTE: IF ANY          ARE TICKED THEN PATIENT IS NOT ELIGIBLE FOR THE TRIAL 
CONFIRMATION OF TRIAL ELIGIBILITY 
- If patient is not eligible, please enter reason(s) for ineligibility to the screening log (destroy this page if completed or 
partially completed). 
- If patient is eligible and wishes to take part, obtain written consent before proceeding.  
 
 
Undergoing cardiac surgery? 
 
System of beliefs prevents them  
from having blood and blood products  
 
 
Congential or acquired platelet, red cell 
 or clotting disorder? 
 
Ongoing or recurrent sepsis? 
PATIENT ASSESSMENT FOR TRIAL ELIGIBILITY & CONSENT CHECKLIST 
A1 
Critical limb ischaemia? 
 
Undergoing emergency surgery? 
 
Currently participating in any other 
interventional clinical study? 
 
Patient able to give fully informed consent for 
the study (e.g. no learning or language 
difficulties)? 
Yes No Yes No 
 
__ __ __ __    __ __ __ 
Remind the patient about the 3-month follow-up questionnaire 
(include dialling code): 
Does the patient wish to be informed of the results of the study once it has ended? 
 
Does the patient wish to know their treatment allocation (if randomised) once the study has ended? 
 
 
Postcode 
Once consent is obtained, please ensure the following are carried out with patient present: 
AFTER PATIENT HAS CONSENTED: 
Yes No 
This section can be completed without patient present (tick box when task is complete): 
(for postal     
questionnaire) 
Study registration sticker & blue clip attached and 
 
 
Patient given baseline EQ5D booklet to complete prior 
to surgery? 
 
Copy  
 
Copy  
 
Copy 
notes  
 
 
Checklist of tasks for site to complete at registration: 
Patient given a copy of their signed consent  
form to keep? 
 
Patient given a copy of the PIS to keep? 
Original 
CRF folder 
 
Copy of the signed patient consent form filed in 
 
Fax the signed patient consent form to the  
co-ordinating centre in Bristol (0117 342 3288) 
Version 4.0, 22/03/2012 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
Date of Birth 
Operative priority: Urgent Elective 
EUROSCORE 
PATIENT AND GP DETAILS 
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
Haemoglobin (Hb)    . g / dL Creatinine     µmol / L   . %  Haematocrit (Hct) 
Baseline (pre-operative) blood tests: 
LV function: Good (> 50%)          Moderate (30 - 50%)  Poor (< 30%) 
Yes No 
 
Surgery on thoracic aorta  
 
Chronic pulmonary disease / asthma?  
 
Extracardiac arteriopathy? (claudication, carotid occlusion or > 50% stenosis , previous or planned surgery on 
 
 
Neurological dysfunction? (disease severely affecting ambulation or day-to-  
 
Previous cardiac surgery?  
 
Active endocarditis?  
 
Critical preoperative state? (VT, VF, aborted sudden death, pre-operative cardiac massage, IPPV, inotropes, 
 
 
Unstable angina?  
 
Recent MI? (< 90 days pre-  
 
Pulmonary hypertension?  
 
Postinfarct septal rupture?.................................................................................................. .................................. 
 
Sex: Male Female 
Height cm 
kg Weight 
GP Name 
GP Address 
GP Postcode 
NHS Number  
 
__ __ __ __    __ __ __ 
 
__ __ __ __ __ __ __ __ __ __ CHI Number (for Scottish centres)  
 
__ __ __ __ __ __ __ __ __ __ OR 
PATIENT DETAILS AT REGISTRATION all consented patient (con) 
A2 
 . 
Version 3.0, 31/01/2011 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
OTHER MEDICAL HISTORY 
Diabetes? Diet 
NYHA class: 
Angina class (CCS): 
 
 
 
 
I 
II 
III 
IV 
No symptoms and no limitations in ordinary physical activity. 
Mild symptoms and slight limitation during ordinary activity.  Comfortable at rest. 
Marked limitation in activity due to symptoms, even during less-than-ordinary activity.  
Comfortable only at rest. 
Severe limitations.  Experiences symptoms even while at rest. 
 
 
 
 
I 
II 
III 
IV 
 0 No angina.  Asymptomatic. 
Angina with strenuous / prolonged exertion.  Ordinary activity such as walking does not cause 
angina. 
Slight limitation of activity.  Events such as rapid walking or climbing stairs, emotional stress 
cause angina. 
Marked limitation of activity.  Walking or climbing stairs in normal conditions at normal pace 
cause angina. 
Inability to carry out any physical activity without discomfort, anginal symptoms may be 
present at rest. 
(Tick one only) 
(Tick one only) 
Heart rhythm? Heart block 
No 
Yes Smoker? 
Sinus 
Ex-smoker 
(>1 month) 
NB. Ex-smoker (<1 month) is 
considered as a smoker 
Yes Haemofiltration / dialysis? 
Yes 
Oral 
medication 
Atrial fibrillation / 
flutter 
No 
No 
No CVA / TIAs? 
Coronary disease? None Double  vessel 
Triple  
vessel 
Not  
investigated 
Yes No 
Single  
No Insulin 
Disease in left main stem 
(> 50% stenosis)? 
 
IV nitrates until theatre?................................................................................................. .  
 
Unfractionated heparin intravenously within 6 h of surgery  
 
Low molecular weight heparin (clexane, tinzaparin) at therapeutic dose within 12 h preoperatively?..... 
 
Inotropes until theatre?  
 
Aspirin within 5 days pre-operatively?  
 
Clopidogrel within 5 days pre-operatively?  
Pacemaker?  Temporary Permanent 
PATIENT DETAILS AT REGISTRATION  (con) 
A3 
Version 3.0, 27/07/2010 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
 
(Please randomise patient in either of the above cases) 
SECTION 1: TRIAL ELIGIBILITY AT RANDOMISATION 
Qualifying Hb value    . g / dL 
(24 hour clock) 
 
__ __ /__ __ /__ __ __ __ 
Date and time Hb < 9.0 g/dL 
OR Hct < 27 recorded: 
dd/mm/yyyy 
 . %  Qualifying Hct value 
 No  Yes 
 NOTE: If NO is ticked, then patient is  
NOT ELIGIBLE for randomisation.   
Operation type: CABG only 
Valve only 
CABG and Valve 
Other 
(this information is required for randomisation) and then complete randomisation at: 
http://www.sealedenvelope.com/titre2 
 
 __ __ : __ __  
OR 
Treatment allocation:  
(transfuse if Hb < 9.0 g / dL 
OR Hct < 27) 
 
Name of clinician consulted for decision (please print) 
Grade of clinician consulted for decision:  Consultant  Registrar  Other 
 No Is the clinician responsible for this patient at time of randomisation willing for the 
patient to be treated at this time in accordance with the allocated protocol group? *  Yes 
Name of person who randomised patient (please print): 
Please ensure the correct colour coded clip (indicating treatment allocation) is attached to  
 
- GREEN LABEL  - ORANGE LABEL  
Please tick ONE of the below when completed: 
OR 
  
(transfuse if Hb <7.5 g / dL 
OR Hct < 22) 
Note to person randomising: please file this completed Randomisation Form in the patient's notes for the 
attention of the research co-ordinator.   
*Note to research co-ordinator: If responsible clinician not in agreement with patient being treated  
according to protocol at this time , please ensure the relevant form in CRF Section E is completed to document 
this 
Randomisation number (generated by computer at randomisation):      
RANDOMISATION FORM 
A4 
SECTION 2: AFTER RANDOMISATION, COMPLETE THE SECTION BELOW:  
Date of Birth 
(dd/mm/yyyy) 
 
__ __ /__ __ /__ __ __ __ 
Hospital number 
Version 2.0, 24/07/2009 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
SUMMARY OF Hb, Hct AND RBC TRANSFUSION DATA FOR DURATION OF HOSPITAL STAY 
Complete this table daily for ALL CONSENTED PATIENTS for each day the patient was in hospital after their 
operation up to and including day 10.  
 Please complete both Hb and Hct if recorded 
(indicate with NR if not recorded on any day)
RBC transfusion received?  
Day Date (dd/mm/yyyy) Lowest Hb (g/dL) Lowest Hct (%) Yes No 
0 * ____ / ____ / ________     
1 ____ / ____ / ________     
2 ____ / ____ / ________     
3 ____ / ____ / ________     
4 ____ / ____ / ________     
5 ____ / ____ / ________     
6 ____ / ____ / ________     
7 ____ / ____ / ________     
8 ____ / ____ / ________     
9 ____ / ____ / ________     
10 ____ / ____ / ________     
For randomised participants use this form and B2 to monitor breaches of protocol allocation 
(giving or withholding RBC in contravention of allocated group).  
If there are any instances of this, complete relevant form (in Section E) 
POST-OPERATIVE INFORMATION & DAILY CHECKS FOR ALL PATIENTS - (con) 
  
  
  
  
  
  
  
  
  
  
  
TOTAL BLOOD PRODUCTS USED DURING HOSPITAL STAY  
RBC FFP Platelets Cryoprecipitate Activated Factor VII 
Total blood products given intra-operatively and post-operatively (units) (if none, enter 0) 
Status at end of operation (complete post-operatively) 
Alive  Dead  
 Yes No  
Please complete the following for ALL patients at discharge: 
Patient status at discharge from cardiac surgery unit 
 Alive Dead  
B1 
* Note: for day 0 (i.e. day of surgery), complete post-op details only 
Beriplex  Yes No  
Version 5.0, 01/09/2011 
CABG only Valve only Other CABG + valve If other, specify: 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
PLEASE COMPLETE THIS SECTION DAILY FOR EACH RBC UNIT TRANSFUSED (Post-op only one RBC unit should 
be transfused then recheck the Hb/Hct before transfusing another unit unless there are clear clinical reasons to do otherwise.) 
RBC TRANSFUSION FORM - randomised patients only (rand) 
Did the patient receive any RBC transfusions during their stay? Yes No 
If more than 10 RBC 
units are transfused, use 
extension form H2 for 
additional units. 
B2 
Version 6.0, 31/01/2011 
    
 
  
Date and time of 
transfusion 
 
Reason 
(use 
code 
from 
table 
below) 
Date and time of 
breach that 
triggered 
prescription 
 
Hb/Hct at 
 
RBC prescribed 
<24 hours since 
 
*How many 
breaches 
occurred since 
randomisation/
last transfusion, 
before blood was 
prescribed? Unit  Unit Batch No  
dd/mm/yyyy 
24 hour clock 
dd/mm/yyyy 
24 hour clock Hb Hct Yes No 
1 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
2 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
3 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
4 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
5 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
6 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
7 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
8 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
9 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
10 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
If Yes, complete one row per unit in table below for each unit transfused (include all RBC given intra-operatively, post-operatively 
and for any re-operations). 
Code Reason for transfusion given:  Code Reason for transfusion given:  
A Intra-operatively (no E1 or E2 needed) D Pre-randomisation (post-op) (complete Note To File) 
B Re-operation (no E1 or E2 needed) In breach of protocol (complete form E1 for each unit) E 
C Treatment according to protocol discontinued 
(check G1 completed, no E1 or E2 needed) 
Per protocol (*complete E2 for each breach recorded in the 
final column)  
F 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
Responsible consultant surgeon (initials) 
First Operator (initials)  
Date of operation 
(24 hour clock) 
Start of operation (time entered 
theatre)  
End of operation (time)  
Valve(s) replaced / repaired: 
Aortic 
Mitral 
Pulmonary 
Tricuspid 
   
   
  . %  Lowest Hct during surgery 
(dd/mm/yyyy) 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
(24 hour clock) 
 
 __ __ : __ __  
  Yes No 
  Yes No 
Yes No 
  Yes No 
No of distal coronary anastomoses:  
Myocardial protection used: Blood Other Crystalloid  
CPB used?  Yes  No 
Cumulative cross-clamp time 
Total bypass    min 
  min 
Cell Saver Blood saving techniques: Tranexamic acid 
Harvest site(s): 
If CPB used:  
  Yes No   Yes No 
 N/A 
 Right arm Yes No  
Right leg 
Left leg 
LIMA 
 Yes No  
 Yes No  
 Yes No  
 Yes No  
RIMA  Yes No  
Other  Yes No  
DETAILS OF PERI-OPERATIVE PERIOD - (rand) 
 Unrecorded 
  
Total chest tube drainage at 4 h 
Total chest tube drainage at 12 h 
ml     
ml     
C1 
Left arm 
Trasylol   Yes No 
Reason why chest was re-opened (tick all that apply): Bleeding Infection    
How many times was chest re-opened (at any time) during hospital stay? (if none, enter 0)  
Date of re-operation 
(dd/mm/yyyy) 
 
__ __ /__ __ /__ __ __ __ 
Other  Cardiovascular instability 
Was post-op cell salvage used?   Yes No 
Version 7.0, 01/09/2011 
Day 1:  Creatinine:    µmol / L
Day 2:  Creatinine    µmol / L 
Day 3:  Creatinine:    µmol / L 
Day 4:  Creatinine:    µmol / L 
Day 5:  Creatinine:    µmol / L 
Day 6:  Creatinine:    µmol / L 
Day 7:  Creatinine:    µmol / L 
Day 8:  Creatinine:    µmol / L 
Day 9:  Creatinine:    µmol / L 
Day 10: Creatinine: µmol / L 
N/A  
N/A 
N/A 
N/A  
N/A  
N/A 
N/A 
N/A  
 N/A 
 
    
 
 
OPERATION DETAILS 
POST-OPERATIVE DETAILS 
RE-OPERATION DETAILS (Enter details of 1st re-operation below, for more than 1 re-operation , complete H5) 
HIGHEST CREATININE ON EACH POST-OPERATIVE DAY OF HOSPITAL STAY (Day 1 is the 1st day after operation) 
Please collect for 10 days post-op. 
If >0, complete 
below ± H5 
 
__ __ : __ __
 
__ __ : __ __
Re-op start time  Re-op end time  
(24 hour clock) (24 hour clock) 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
ASEPSIS WOUND ASSESSMENT - Day 3 
If any of the above answers are YES, please complete wound scoring (below) for each affected wound.  
(If there are more than 2 affected wounds, please print out continuation sheet Form H3 for additional space) 
*Ask patient, or if unconscious, check with nursing staff 
Is the dressing or wound wet?* 
Does the wound feel hot?* 
No 
 
Yes 
Chest Right Arm Left Arm Right Leg Left Leg Other 
No
 
Yes NA 
 
No 
 
Yes NA No 
 
Yes NA 
 
No 
 
Yes NA No 
 
Yes NA 
(If unable to complete on day 3, please complete as close to day 3 as possible) 
 
__ __ /__ __ /__ __ __ __ 
dd/mm/yyyy 
Date performed 
ASEPSIS ASSESSMENT DAY 3 - (rand) 
1st Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for 
wound infection 
   
____/____/_______ 
Erythema 
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
2nd Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for  
wound infection 
   
____/____/_______ 
Erythema
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
C2 
Version 5.0, 31/01/2011 
* including vac therapy 
 Including debridement in theatre 
N/A - patient discharged/died by day 3 
N/A - patient not randomised by day 3 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
ASEPSIS WOUND ASSESSMENT - Day 5 
(If unable to complete on day 5, please complete as close to day 5 as 
ASEPSIS ASSESSMENT DAY 5 - (rand) 
C3 
Version 5.0, 31/01/2011 
If any of the above answers are YES, please complete wound scoring (below) for each affected wound.  
(If there are more than 2 affected wounds, please print out continuation sheet Form H3 for additional space) 
*Ask patient, or if unconscious, check with nursing staff 
Is the dressing or wound wet?* 
Does the wound feel hot?* 
No Yes 
Chest Right Arm Left Arm Right Leg Left Leg Other 
NoYes NA No Yes NA No Yes NA No Yes NA No Yes NA 
 
__ __ /__ __ /__ __ __ __ 
dd/mm/yyyy 
Date performed N/A - patient discharged/died by day 5 
1st Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for 
wound infection 
   
____/____/_______ 
Erythema 
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
2nd Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for  
wound infection 
   
____/____/_______ 
Erythema
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
* including vac therapy 
 Including debridement in theatre 
N/A - patient not randomised by day 5 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
ASEPSIS WOUND ASSESSMENT - Day 8 
(If unable to complete on day 8, please complete as close to day 
ASEPSIS ASSESSMENT DAY 8 - (rand) 
C4 
Version 5.0, 31/01/2011 
If any of the above answers are YES, please complete wound scoring (below) for each affected wound.  
(If there are more than 2 affected wounds, please print out continuation sheet Form H3 for additional space) 
*Ask patient, or if unconscious, check with nursing staff 
Is the dressing or wound wet?* 
Does the wound feel hot?* 
No Yes 
Chest Right Arm Left Arm Right Leg Left Leg Other 
NoYes NA No Yes NA No Yes NA No Yes NA No Yes NA 
 
__ __ /__ __ /__ __ __ __ 
dd/mm/yyyy 
Date performed 
1st Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for 
wound infection 
   
____/____/_______ 
Erythema 
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
2nd Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for  
wound infection 
   
____/____/_______ 
Erythema
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
* including vac therapy 
 Including debridement in theatre 
N/A - patient discharged/died by day 8 
N/A - patient not randomised by day 8 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
INFECTIOUS EVENTS SUMMARY 
(24 hour clock) dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
In the 24h preceding the start of antibiotics did the patient have any of the following symptoms? 
Date and time 
started antibiotic: 
Temperature > 38°C or < 36°C? Yes No 
Heart rate > 90 beats per minute? Yes No 
Respiratory rate > 20 breaths per minute? Yes No 
PaCO2 < 32 mmHg or < 4.3 kPa? Yes No 
WBC count > 12,000 / mm3 or < 4,000 / mm3? Yes No 
Was infection subsequently 
confirmed by positive culture? 
Yes No 
Yes No 
Please add details for all courses of antibiotics (excluding post-op prophylaxis) prescribed to the patient during their post-
op hospital stay.  Data collection is recommended on day 3, 5, 8 (if not previously discharged) and on discharge.  For all 
courses provide anonymised copies of the drug chart, with patient study ID and initials, to the TITRe 2 co-ordinating centre. 
Was the patient given antibiotics at any time during 
their post-operative stay (excluding prophylaxis)? 
If Yes, how many courses?                     
For each course of antibiotics given to the patient, please complete a section below: 
Unrecorded 
Name of  
antibiotic: 
Oral? IV? Were the antibiotics: 
Unrecorded 
Unrecorded 
Unrecorded 
Unrecorded 
days Duration of course: 
SUMMARY OF INFECTIOUS POST-OPERATIVE COMPLICATIONS - (rand) 
C5 
1 
Version 4.0, 27/07/2010 
Site of suspected infection (tick all that apply): Respiratory Blood Other Wound 
In the 24h preceding the start of antibiotics did the patient have any of the following symptoms? 
Temperature > 38°C or < 36°C? Yes No 
Heart rate > 90 beats per minute? Yes No 
Respiratory rate > 20 breaths per minute? Yes No 
Yes No 
Yes No 
Was infection subsequently 
confirmed by positive culture? 
Yes No 
Unrecorded 
Oral? IV? Were the antibiotics: 
Unrecorded 
Unrecorded 
Unrecorded 
Unrecorded 
days Duration of course: 
(24 hour clock) dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
Date and time 
started antibiotic: 
Name of  
antibiotic: 
2 
PaCO2 < 32 mmHg or < 4.3 kPa? 
WBC count > 12,000 / mm3 or < 4,000 / mm3? 
In the 24h preceding the start of antibiotics did the patient have any of the following symptoms? 
Temperature > 38°C or < 36°C? Yes No 
Heart rate > 90 beats per minute? Yes No 
Respiratory rate > 20 breaths per minute? Yes No 
Yes No 
Yes No 
Was infection subsequently 
confirmed by positive culture? 
Yes No 
Unrecorded 
Oral? IV? Were the antibiotics: 
Unrecorded 
Unrecorded 
Unrecorded 
Unrecorded 
days Duration of course: 
(24 hour clock) dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
Date and time 
started antibiotic: 
Name of  
antibiotic: 
3 
PaCO2 < 32 mmHg or < 4.3 kPa?
WBC count > 12,000 / mm3 or < 4,000 / mm3? 
Site of suspected infection (tick all that apply): Respiratory Blood Other Wound 
Site of suspected infection (tick all that apply): Respiratory Blood Other Wound 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
Permanent 
stroke 
 
If yes, please complete date and time when first 
documented in the notes: 
(24 hour clock) dd/mm/yyyy 
ISCHAEMIC EVENTS SUMMARY 
If time is not known, please indicate time of day: 
VERIFICATION* 
  
CT  
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
AM PM Overnight Not known 
Suspected 
myocardial 
infarction  
 
(24 hour clock) dd/mm/yyyy 
If time is not known, please indicate time of day: 
  
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
AM PM Overnight Not recorded 
COMPLICATION 
Acute kidney 
injury   
(24 hour clock) dd/mm/yyyy 
If time is not known, please indicate time of day: 
  
AKIN 
criteria 
Stage 1, 2 or 3 (see 
box below for 
definitions) 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
AM PM Overnight 
No Yes 
No Yes 
No Yes 
 
No Yes 
 
No Yes 
Please add details of all ischaemic events as they occur.  Data collection is recommended on day 3, 5, 8 (if not prev iously 
discharged) and on discharge.  Please also provide documentary evidence of verification as appropriate *. 
Stage 1: -fold to 2-fold from baseline  OR urine output  
< 0.5ml/kg/h for >6 h. 
Stage 2: Serum creatinine increase > 2-fold to 3-fold from baseline  OR urine output < 0.5 ml/kg/h for >12 h. 
Stage 3: Serum creatinine increase >3-fold from baseline  
increase of at least 0.5 mg/dl (44 µmol/l) OR need for renal replacement therapy (RRT) irrespective of stage at time of RRT 
OR urine output <0.3 ml/kg/h for 24 h or anuria for 12 h.   
                                                                                                  baseline refers to pre-operative serum creatinine measurement 
If Yes to Acute kidney injury, please specify most severe stage experienced (complete on discharge): 
MRI   
*NB. Documentary evidence should take the form of copies of the relevant report (i.e. CT / MRI / PM / biochemistry / operation) / obs chart / 
copy of page in notes signed off by doctor / copy of discharge letter containing the relevant information.  
-ordinating centre 
SUMMARY OF ISCHAEMIC POST-OPERATIVE COMPLICATIONS - (rand) 
C6 
Not known 
Gut infarction  
(24 hour clock) dd/mm/yyyy 
If time is not known, please indicate time of day: 
  
Laparotomy  
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __  
AM PM Overnight 
No Yes 
 
No Yes 
Post mortem  
Not known 
Version 4.0, 25/07/2011 
µg/L* . 
Please give highest level 
  
Which Troponin was 
measured? 
I T 
    
ng/L* 
*delete as applicable 
  
ng/ml* 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
C7 
Version 6.0, 31/01/2011 
SUMMARY OF OTHER COMPLICATIONS (For all re-occurrences of complications, complete H5) 
Please add details of all other events listed below if / when they occur.  Data collection is recommended on day 3, 5, 8 (if not previously 
discharged) and on discharge. 
SUMMARY OF OTHER POST-OPERATIVE COMPLICATIONS - (rand) 
Please use this box for any additional information/comments on Forms C5-C7: 
Tick SAE as Yes for any complications listed that met the definition of serious, i.e. are/were life-threatening, resulted in 
persistent or significant disability/incapacity, prolonged hospitalisation or resulted in death.  
If any complications listed above resulted in death, or another event not listed was serious (see box above), you MUST report 
it to the CTEU as an SAE using the forms in Section F within 24h of discovering the event. 
   Date and time first documented in notes 
If time is unknown please 
indicate time of day  SAE*  
Number 
of events 
Complication* (see TITRe 2 trial 
manual, section 10, for full definitions) Yes No 
Date  
(dd/mm/yyyy) 
Time  
(24 hour clock) 
AM PM Overnight Unknown Yes No (enter 0 if none) 
Transient ischaemic attack            
Pancreatitis             
Intestinal obstruction/perforation            
Post-operative haemorrhage  
(400ml/h for 1h or 200ml/h for 4h)            
ARDS            
Re-intubation/ventilation (if >1, use 
H5 to record multiple instances)            
Tracheostomy            
Initiation of mask CPAP            
Pneumothorax requiring chest 
drainage            
Pleural effusion requiring drainage           
Pacing            
SVT/AF requiring treatment            
VF/VT requiring intervention            
Deep vein thrombosis            
Pulmonary embolus            
Low cardiac output requiring 
management (including IABP)            
Wound dehiscence requiring 
rewiring/treatment            
Other GI (specify)            
Other pulmonary 
(specify)            
Other arrhythmia  
(specify)            
Other  
thromboembolic  
(specify) 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
PATIENT MOVEMENT BETWEEN WARDS  
Date and time first admitted to CICU/HDU 
post-operatively 
(Tick N/A if not 
applicable) 
Patient discharged from CICU/HDU to:  Ward Patient died  
Date and time first admitted to ward 
(if applicable) 
 Ward  
(24 hour clock) dd/mm/yyyy 
 Ward  
 
Have you reminded the patient about the postal questionnaires at 6 and 12 weeks? 
  
Yes No 
Ask:   Yes No 
  Group 1 (< 9g/   Group 2 (<7.5g/
  
Date of discharge from cardiac surgery unit or date 
of death (if patient died before discharge)*: 
DETAILS AT DISCHARGE  
If time admitted to ward not known, please indicate time of day:   AM PM Overnight 
*Note: please ensure that 
deaths are reported on the 
study SAE form (Section 
F) 
 General ICU 
Is the patient available to answer questions? 
PATIENT DETAILS AT DISCHARGE - (rand) 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __ 
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
  
Date and time patient 
1st readmitted to: 
How many times was the patient readmitted? (if none, enter 0) 
Date and time patient 
2nd readmitted to: 
 
Yes No   
 
 Home 
Other  
 
Other 
hospital 
dd/mm/yyyy
 
__ __ /__ __ /__ __ __ __ OR  Ongoing  
Give name 
Specify 
(e.g. died) 
D1 
If Yes, enter  
date answered 
& details below: 
Date and time first admitted to general 
ICU (if applicable) 
 General ICU CICU/HDU 
 General ICU CICU/HDU 
Where was the patient 
discharged from cardiac 
surgery unit to? 
Other unit in 
this hospital 
Give date of final 
discharge from 
hospital / death* 
 N/A 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __ 
 N/A 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
 N/A 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ __ 
Date and time of extubation 
(Use H5 if patient was re-extubated) 
Ask: 
  No 
 Group 1 (< 9g/   Group 2 (<7.5g/
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
Version 10.0, 22/03/2012 
Home  
READMISSIONS TO CICU/HDU / GENERAL ICU / WARD (If >2 readmissions, use H5) 
QUESTIONS FOR PATIENT AT DISCHARGE (if possible) 
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
If >0, please complete section below ± H5,  
if 0, go to status at discharge 
 Other 
 N/A* 
(*i.e. N/A if 
patient dies 
whilst intubated) 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
INFORMATION ABOUT MEDICATIONS- (rand) 
D2 
Please complete on discharge: details of medication patients were on at baseline, in theatre /CICU/CHDU and at 
discharge.  Do NOT include any analgesics or laxatives. 
Other please specify 
Digoxin  
Diuretics  
Beta blockers  
Calcium antagonists  
Heparin/clexane 
IV GTN/nitrates 
Oral Nitrates 
ACE inhibitors 
Statins 
Angiotensin 2 blockers 
Anti-arrhythmic 
Warfarin 
Clopidogrel 
Aspirin 
 
Yes No 
 
 
 
 
 
 
FeSO4 
Yes No 
REGULAR MEDICATIONS AT BASELINE (i.e. on admission to the cardiac surgery unit, include 
Other please specify 
Digoxin  
Diuretics  
Beta blockers  
Calcium antagonists  
Heparin/clexane 
IV GTN/nitrates Oral Nitrates 
ACE inhibitors 
Statins 
Insulin 
Oral anti-diabetics 
Angiotensin 2 blockers 
Anti-arrhythmic 
Warfarin 
Clopidogrel 
Aspirin
 
Yes No 
 
 
 
 
 
 
 
FeSO4  
Yes No 
MEDICATIONS ON DISCHARGE (i.e. at time of discharge from cardiac surgery unit) 
MEDICATIONS IN THEATRE / CICU / CHDU 
Yes No 
Hydroxyethyl starch (HES/HAES)  Gelofusin  
Inotropes Human albumin solution (HAS)  
Yes No 
Version 7.0, 31/01/2011 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
COMPLETE A SECTION BELOW EACH TIME A UNIT OF RBC IS TRANSFUSED, IN CONTRAVENTION OF THE 
ALLOCATED THRESHOLD (Use additional pages for E1 if required.)    
NB. On any given date, if >1 unit is transfused in contravention of allocated group, for the same reason and under direction of 
the same clinician, one section can be completed for multiple units.  Otherwise, complete a separate section for each unit.   
GIVING A RBC TRANSFUSION IN BREACH OF PROTOCOL - (rand) 
E1 
Version 3.0, 31/01/2011 
UNIT NUMBER(S) 
(Enter unit number(s) listed on B2 OR H2 
that this completed section applies to)    
Indicate why these RBC units were transfused in breach of the 
allocated threshold (see E (info) for definitions) 
Excessive blood loss  Physiological indicators of oxygen debt Sepsis  Oversight / Error   
Other   Specify: 
Name of the clinician making decision: 
Job title of the clinician making decision: 
 N/A 
 N/A 
   g / dL Hb recorded*  
 . %   OR  Hct recorded* 
. 
*Immediately prior to prescription: 
UNIT NUMBER(S) 
(Enter unit number(s) listed on B2 OR H2 
that this completed section applies to)    
Indicate why these RBC units were transfused in breach of the 
allocated threshold (see E (info) for definitions) 
Excessive blood loss  Physiological indicators of oxygen debt Sepsis  Oversight / Error   
Other   Specify: 
Name of the clinician making decision: 
Job title of the clinician making decision: 
 N/A 
 N/A 
   g / dL Hb recorded*  
 . %   OR  Hct recorded* 
. 
*Immediately prior to prescription: 
UNIT NUMBER(S) 
(Enter unit number(s) listed on B2 OR H2 
that this completed section applies to)    
Indicate why these RBC units were transfused in breach of the 
allocated threshold (see E (info) for definitions) 
Excessive blood loss Physiological indicators of oxygen debt Sepsis Oversight / Error  
Other   Specify: 
Name of the clinician making decision: 
Job title of the clinician making decision: 
 N/A 
 N/A 
   g / dL Hb recorded*  
 . %   OR  Hct recorded* 
. 
*Immediately prior to prescription: 
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TITRe2
 
REASONS FOR RED BLOOD CELL TRANSFUSION OUT OF PROTOCOL (FOR USE WITH FORM E1) 
Reason for Red Blood Cell Transfusion 
IN ACCORDANCE WITH ASSIGNED RED BLOOD CELL TRANSFUSION THRESHOLDS 
 
Hb < 9.0 g / dL / Hct < 27 if  in control group 
OR 
Hb < 7.5 g / dL / Hct < 22 if  in restrictive group 
Other indications for red blood cell transfusions (outside assigned thresholds) 
EXCESSIVE BLOOD LOSS 
 
Defined as ONE OF (a), (b) or (c): 
(a) > 4 ml kg-1 h-1 in any one hour  
(b) > 2 ml kg-1 h-1 for two consecutive hours  
(c) > 5 ml kg-1 h-1 in the first four hours post-op 
PLUS 
MABP < 60 mmHg OR  
MABP < 75 mmHg in hypertensive patients OR  
Tachycardia > 120 bpm 
PHYSIOLOGICAL INDICATORS OF OXYGEN DEBT 
 
Defined as one or more of the following: 
PvO2 < 32 mmHg 
O2ER > 50% 
SvO2 < 50% 
SEPSIS 
 
Defined as culture positive or suspected infection AND antibiotics AND at least two or more of the following 
conditions: 
Temperature > 38 °C or < 36 °C 
Heart rate > 90 beats / min 
Respiratory rate > 20 breaths / min or PaCO2 < 32 mmHg or < 4.3 kPa 
WBC count > 12,000 / mm3 or < 4000 / mm3 
 
Derived from Madjdpour and Spahn, British Journal of Anaesthesia 2005; 95:33-52 
RBC TRANSFUSION FORM - Information sheet 
E(Info) 
Version 3.0, 26/02/2010 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
PLEASE COMPLETE A SECTION BELOW EACH TIME A RBC TRANSFUSION IS NOT GIVEN, IN 
CONTRAVENTION OF THE ALLOCATED THRESHOLD (Use additional pages for E2 if required) 
WITHHOLDING A RBC TRANSFUSION IN BREACH OF PROTOCOL - (rand) 
E2 
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
(24 hour clock) 
 
 __ __ : __ __  .    g / dL 
Breach Hb 
recorded  Date and time Hb / Hct fell below allocated threshold 
Please give details of why the RBC transfusion was NOT given in accordance with the protocol: 
Oversight / Error  Clinician preference (specify below)  
Name of the clinician making decision: 
Job title of the clinician making decision: 
 N/A 
 N/A 
Other (specify below)  
Specify: 
 . %   
OR  
Breach Hct 
recorded 
Version 3.0, 31/01/2011 
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
(24 hour clock) 
 
 __ __ : __ __  .    g / dL 
Breach Hb 
recorded  Date and time Hb / Hct fell below allocated threshold 
Please give details of why the RBC transfusion was NOT given in accordance with the protocol: 
Oversight / Error  Clinician preference (specify below)  
Name of the clinician making decision: 
Job title of the clinician making decision: 
 N/A 
 N/A 
Other (specify below)  
Specify: 
 . %   
OR  
Breach Hct 
recorded 
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
(24 hour clock) 
 
 __ __ : __ __  .    g / dL 
Breach Hb 
recorded  Date and time Hb / Hct fell below allocated threshold 
Please give details of why the RBC transfusion was NOT given in accordance with the protocol: 
Oversight / Error  Clinician preference (specify below)  
Name of the clinician making decision: 
Job title of the clinician making decision: 
 N/A 
 N/A 
Other (specify below)  
Specify: 
 . %   
OR  
Breach Hct 
recorded
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Date data entered (dd/mm/yyyy) 
          
 
TITRe2
Patient Study ID 
Signature of person completing form Date completed (dd/mm/yyyy) 
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code 
          
F1 
Sex: 
Yes No 
 
 
Resulted in death * 
*Please provide copy of PM report or death certificate 
Yes No 
 
 
Is / was life-threatening 
Resulted in persistent or significant disability / 
incapacity 
Prolonged an ongoing hospitalisation 
Other (if Yes, please specify below) 
Required hospitalisation 
Sponsor Ref: CS/2007/2695 
REC Ref: 08/H0606/125  
SAE INITIAL REPORT FORM Complete ONE form per SAE (rand) 
Version 5.0, 04/03/2010 
Date and 
time of  
onset dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
24 hour clock 
 __ __ : __ __  
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
(24 hour clock) 
 __ __ : __ __  End date and time (if  
resolved) 
 
Full description of event, including body site, reported signs and symptoms and diagnosis where possible: 
Maximum intensity of event 
(up until time of initial report):   
Moderate: an event 
interfering with normal 
everyday activities.* 
 
Severe: an event 
that prevents normal 
everyday activities.* 
(* doing at that stage in their recovery) 
1. PARTICIPANT DETAILS 
Patient initials: 
2. BRIEF DESCRIPTION OF EVENT (max 70 characters) 
6. FURTHER DETAILS OF EVENT 
4. DETAILS OF ONSET AND DURATION 
Protocol allocated group:   
   . g / dL 
Has the patient received a RBC transfusion since randomisation and prior to onset of event?   Yes No  
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
(24 hour clock) 
 __ __ : __ __   Number of units given at that 
transfusion 
 
First Hb / HCT recorded after transfusion: 
Last Hb / HCT recorded prior to onset of event:    . % OR 
   . g / dL    . % OR 
OR 
Was treatment of patient according to allocated protocol group permanently discontinued? 
 
If Yes: Date and time of last 
RBC transfusion given 
before onset of event 
 Yes No  
7. DETAILS OF RESEARCH INTERVENTION 
3. REASON FOR REPORTING EVENT AS SAE (please tick as many as apply) 
Male Female 
Date of Birth: 
(dd/mm/yyyy) 
Ongoing * (please complete and return 
follow-up report form within 5 days) 
Died * (give cause and PM 
details or Death Certificate) 
Resolved,  
with sequelae * 
5. OUTCOME OF EVENT 
 *Give details: 
Mild: an event easily tolerated 
by patient, causing minimal 
discomfort, not interfering with 
Resolved,  
no sequelae 
Tick if not 
available 
 
 
__ __ /__ __ /__ __ __ __ 
 
(Hb < 9.0 g / dL OR HCT < 27 ) 
 
(Hb <7.5 g / dL OR HCT < 22) 
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Date data entered (dd/mm/yyyy) 
          
 
TITRe2
Patient Study ID 
Signature of person completing form Date completed (dd/mm/yyyy) 
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code 
          
SAE INITIAL REPORT FORM Complete ONE form per SAE (rand) 
Sponsor Ref: CS/2007/2695 
REC Ref: 08/H0606/125  F2 
Version 5.0, 31/01/2011 
Name: 
Box number Further information 
  
  
  
I confirm that the contents of this form (pages F1 and F2) are accurate and complete 
The completed SAE form must be signed off by the PI or other delegated doctor at the site, prior to faxing to the  
TITRe 2 study office. 
Job title / role 
in study: 
8. ACTION TAKEN AND FURTHER INFORMATION (further space available in box 11) 
10. DETAILS OF PRINCIPAL INVESTIGATOR, OR DELEGATED  DOCTOR, AT THIS SITE 
11. ADDITIONAL INFORMATION (refer to box number of this SAE form that additional information applies to) 
In the opinion of the PI or delegated doctor, was the event related either to having given or having withheld a RBC transfus ion? 
Probably 
related * 
Unlikely to 
be related 
Possibly 
related * 
Definitely 
related * 
Not related 
  OR RBC transfusion 
being given 
RBC transfusion 
being withheld  
* If one of these is selected, please indicate whether 
the doctor considered the event to be related to: 
9. RELATEDNESS (see trial manual for definitions) 
Please record any other information relevant to assessment of case (e.g. 
medical history, test results) below: 
Please describe action taken below: 
«s
Signature Date:  
(dd/mm/yyyy) 
 
__ __ /__ __ /__ __ __ __ 
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Date data entered (dd/mm/yyyy) 
          
 
TITRe2
Patient Study ID 
Signature of person completing form Date completed (dd/mm/yyyy) 
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code 
          
Sponsor Ref: CS/2007/2695 
REC Ref: 08/H0606/125  F3 
SAE FOLLOW-UP FORM Complete ONE form per SAE (rand) 
The follow-up SAE form should be completed for: 
-up reports should be provided every 5 days until SAE is resolved) 
2.  Any SAE for which additional relevant information has become available since the initial report (e.g. lab results, post mortem, 
pathology report, etc) 
Version 4.0, 04/03/2010 
Date of Birth Sex:      Male           Female (dd/mm/yyyy) 
 
__ __ /__ __ /__ __ __ __ Patient initials   
Date of onset of SAE:  
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ Date Initiaal SAE report sent to TITRe 2 Co-ordinating Centre:  
3. FURTHER DETAILS OF EVENT 
dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
*Give details: 
 Yes No  
Ongoing * (please complete and return 
follow-up report form within 5 days)  
Died * (give cause and 
PM details if available) 
Resolved,  
no sequelae 
dd/mm/yyyy 
Resolved,  
with sequelae* 
 
__ __ /__ __ /__ __ __ __ 
(24 hour clock) 
 __ __ : __ __  Resolution date and time (once resolved) 
4. OUTCOME OF EVENT 
2. SAE DETAILS 
1. PARTICIPANT DETAILS 
 
Full description of event, including body site, reported signs and symptoms and diagnosis where possible: 
Maximum intensity of event 
(up until time of follow-up 
report): 
 
Mild: an event easily tolerated by 
patient, causing minimal 
discomfort, not interfering with 
everyday activities.* 
 
Moderate: an event 
interfering with normal 
everyday activities.* 
 
Severe: an event 
that prevents normal 
everyday activities.* 
 in their recovery) 
Describe further action taken & record any other information relevant to assessment of case (e.g. medical history, test results): 
5. ADDITIONAL ACTION TAKEN AND FURTHER INFORMATION SINCE INITIAL REPORT 
Name: 
I confirm that the contents of this form are accurate and complete. 
Signature: Date:  (dd/mm/yyyy) 
 
__ __ /__ __ /__ __ __ __ 
The completed SAE follow-up form must be signed off by the PI or delegated doctor at the site, prior to faxing to the TI-
TRe 2 co-ordinating centre. 
Job title / role 
in study: 
6. DETAILS OF PRINCIPAL INVESTIGATOR, OR DELEGATED DOCTOR, AT THIS SITE 
Was treatment of patient according to allocated protocol group permanently discontinued? 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
Date of withdrawal 
from trial 
Time of withdrawal 
(24 hour clock) dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ 
Please give reason for withdrawal (if known): 
Did the patient withdraw from the trial: 
Before surgery? After surgery but before randomisation? After randomisation? 
Is the patient happy for data routinely collected about them by the NHS to still be collected and used in this study? 
Yes 
No, patient withdraws 
all consent 
No, consultant no longer 
wants patient included 
Time of 
discontinuation  
(24 hour clock) dd/mm/yyyy 
 
__ __ /__ __ /__ __ __ __ 
 
 __ __ : __ 
SECTION 1:  DISCONTINUATION OF TREATMENT ACCORDING TO ALLOCATED PROTOCOL GROUP 
Please give reason for discontinuation: 
Was treatment according to 
protocol permanently discontinued: 
Before 
surgery? 
After 
randomisation? 
Time not 
recorded 
Please complete this section for any patient for whom a decision has been made by the responsible consultant to 
permanently discontinue treatment according to the allocated protocol group, and return the form to the co-
ordinating centre in Bristol immediately. 
Has the patient withdrawn consent? If Yes, complete Section 2 
If Yes, complete Section 1 
NB.  Permanent discontinuation of protocol treatment due to clinician decision is NOT classed as a 
withdrawal from the trial.  Data should still be collected for these patients according to the protocol unless 
 
Date of discontinuation 
of protocol treatment 
DISCONTINUATION OF TREATMENT (rand) & WITHDRAWAL FORM - (con) 
G1 
Time not 
recorded 
Has the responsible clinician decided to permanently discontinue 
  Yes No  
 Yes No  
After surgery but before 
randomisation? 
Version 5.0, 27/07/2010 
Is the patient happy to participate in completion of follow-up questionnaires? 
Yes No, patient withdraws all consent 
out any further ASEPSIS wound inspections).   
If NO, stop all data collection and return forms to the co-ordinating centre in Bristol. 
 
SECTION 2:  WITHDRAWAL FROM TRIAL 
Name of clinician 
Please complete this section for any patient withdrawing from the trial after giving consent and return it to 
the co-ordinating centre in Bristol immediately. 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
LOWEST Hb, Hct AND RBC TRANSFUSION FOR EACH DAY POST-OPERATIVELY (extension from B1) 
Please complete the lowest Hb and Hct and whether or not the patient received a RBC transfusion for each 
day the patient was in hospital after their operation  
For randomised participants only please use this form to monitor breaches of protocol allocation (giving or not giving 
transfusion in contravention of allocated group).  If there are any instances of this, please complete relevant form (in Section E) 
  Please complete both Hb and Hct if recorded  
(indicate with NR if not recorded on any day) 
RBC transfusion received  
Day Date (dd/mm/yyyy) Lowest Hb (g/dL) Lowest Hct (%) Yes No 
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
___      
For all RANDOMISED patients, please give further details of ALL RBC transfusions in Section E 
 
  
  
  
  
  
 
 
  
 
 
 
 
 
 
 
 
EXTENSION FOR FORM B1 (OPTIONAL DAILY CHECKS FOR ALL PATIENTS) - (con) 
H1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Version 4.0, 22/03/2012 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
PLEASE COMPLETE THIS SECTION DAILY FOR EACH RBC UNIT TRANSFUSED (Post-op only one RBC unit should 
be transfused then recheck the Hb/Hct before transfusing another unit unless there are clear clinical reasons to do otherwise.) 
EXTENSION FORM FOR B2 (RBC TRANSFUSION FORM) - (rand) 
H2 
Version 4.0, 31/01/2011 
    
F) 
  
Date of transfusion 
(dd/mm/yyyy)  
Reason 
(use 
code 
from 
table 
below) 
Date and time of 
breach that 
triggered 
prescription 
Hb/Hct at 
 
RBC prescribed 
<24 hours since 
 
*How many 
breaches occurred 
since randomisation/
last transfusion, 
before blood was 
prescribed? Unit  Unit Batch No  
Time of transfusion 
(24 hour clock) 
dd/mm/yyyy 
24 hour clock Hb Hct Yes No 
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 ____ /____/_____ 
 
 __ __ : __ __ 
 ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 
 
____ /____/_____ 
 
 __ __ : __ __ 
  ____ /____/_____ 
 
 __ __ : __ __ 
     
__ 
 ____ /____/_____ 
 
 __ __ : __ __ 
 ____ /____/_____ 
 
 __ __ : __ __ 
     
Complete one row per unit in table below for each unit transfused (include all RBC given intra-operatively, post-operatively and for 
any re-operations). 
Code Reason for transfusion given:  Code Reason for transfusion given:  
A Intra-operatively (no E1 or E2 needed) D Pre-randomisation (post-op) (complete Note To File) 
B Re-operation (no E1 or E2 needed) In breach of protocol (complete form E1 for each unit) E 
C Treatment according to protocol discontinued 
(check G1 completed, no E1 or E2 needed) 
Per protocol (*complete E2 for each breach that occurred 
before most recent breach)  
F 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
ASEPSIS WOUND ASSESSMENT EXTENSION FORM FROM PAGE C2, C3 OR C4 
 
__ __ /__ __ /__ __ __ __ (dd/mm/yyyy) 
Date performed 
This is an extension sheet for form (tick one): C2 (Day 3) C3 (Day 5) C4 (Day 8) 
EXTENSION FOR FORMS C2, C3 OR C4 (ASEPSIS ASSESSMENT) - (rand) 
3rd Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for 
wound infection 
   
____/____/_______ 
Erythema 
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
4th Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for 
wound infection 
   
____/____/_______ 
Erythema 
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
5th Wound being scored: Chest Right Arm Left Arm Right Leg Left Leg Other 
Proportion of 
wound affected  
0% <20% 20-
39% 
40-
59% 
60-
79% 
>80%  Yes No If Yes, please give 
date (dd/mm/yyyy) 
Serous 
exudates 
      Antibiotics given for 
wound infection 
   
____/____/_______
Erythema 
 
      Isolation of bacteria    
____/____/_______ 
Purulent 
exudates 
      Drainage of pus under 
local anaesthesia* 
   
____/____/_______ 
Separation of 
deep tissue 
      Drainage of pus under 
general anaesthesia  
   
____/____/_______ 
H3 
Version 3.0, 26/02/2010 
* including vac therapy 
 Including debridement in theatre 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
HIGHEST CREATININE ON EACH POST-OPERATIVE DAY OF HOSPITAL STAY (Randomised patients only)  
EXTENSION FOR FORM C1 (OPTIONAL PATIENT DETAILS AT DISCHARGE) - (rand) 
H4 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
Creatinine: µmol / L 
N/A  
N/A  
N/A 
N/A 
 N/A 
 
     
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
Creatinine: µmol / L 
N/A  
N/A  
N/A 
N/A 
 N/A 
 
     
 Creatinine:    µmol / L 
 Creatinine:    µmol / L N/A  
 N/A 
Version 5.0, 22/03/2012 
«s
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
Creatinine: µmol / L 
N/A  
N/A  
N/A 
N/A 
 N/A 
 
     
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
 Creatinine:    µmol / L 
Creatinine: µmol / L 
N/A  
N/A  
N/A 
N/A 
 N/A 
 
     
 Creatinine:    µmol / L 
 Creatinine:    µmol / L N/A  
 N/A 
Day ___ 
Day ___ 
Day ___ 
Day ___ 
 Creatinine:    µmol / L 
Creatinine: µmol / L 
N/A 
N/A 
 
     
 Creatinine:    µmol / L 
 Creatinine:    µmol / L N/A  
 N/A 
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Date data entered  
        
Patient Study ID 
Signature of person completing form Date completed  
__ __ /__ __ /__ __ __ __ 
Name of person entering data* (capitals) 
* Names must appear on the site signature & delegation log 
Name of person completing form* (capitals)  
__ __ /__ __ /__ __ __ __ 
Centre Code Patient Name 
         
(dd/mm/yyyy) 
(dd/mm/yyyy) 
POST-OPERATIVE EXTENSION FORM - (rand)  
H5 
Version 2.0, 31/01/2011 
« «s « « «
Complete Section(s) 1, 2 3, and/or 4 as necessary. 
Multiple copies of this CRF can be completed if required  
(e.g. for multiple re-occurrences of complications, re-intubations and/or re-admissions). 
COMPLICATION CODES: 
 
A=TIA,  
B=pancreatitis,  
C=intestinal obstruction/perforation,  
D=other GI complication,  
E=post-op haemorrhage,  
F=ARDS,  
G=tracheostomy,  
H=initiation of CPAP,  
I=pneumothorax requiring chest  
 drainage,  
J=pleural effusion requiring  
 drainage,  
K=other pulmonary complication, 
L=SVT/AF requiring treatment,  
 
Code Date started (dd/mm/yyyy): 
SECTION 2: RE-INTUBATION & RE-EXTUBATION 
Re-extubation  
N/A* 
Date/time of re-extubation 
*Patient died (24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
Date/time of re-admission to CICU/HDU Date/time of re-admission to ward 
SECTION 3: READMISSIONS TO ANY WARDS (before hospital discharge) 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
SECTION 1: RE-OPERATION DETAILS (for >1 re-operation) 
Reason why chest was re-opened (tick all that apply): Bleeding Infection    
Date of re-operation 
(dd/mm/yyyy) 
Other  Cardiovascular 
instability 
SECTION 4: OTHER COMPLICATIONS RE-OCCURRENCE 
SAE* 
 
No Yes 
__ __ /__ __ /__ __ __ __ 
 __ __ /__ __ /__ __ __ __ 
 __ __ /__ __ /__ __ __ __ 
 __ __ /__ __ /__ __ __ __ 
Complete this section for re-occurrence of any post-operative complications, using the relevant code from the list given. 
*Tick SAE as Yes for any complications listed that met the definition of serious, i.e. are/were life-threatening, resulted in 
persistent or significant disability/incapacity, prolonged hospitalisation or resulted in death.  
Date/time of re-admission to CICU/HDU Date/time of re-admission to ward 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
Date/time of re-intubation Re-extubation  
N/A* 
Date/time of re-extubation 
*Patient died (24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
(24 hour clock) dd/mm/yyyy 
__ __ /__ __ /__ __ __ __  __ __ : __ __ 
 __ __ /__ __ /__ __ __ __ 
M=VF/VT requiring intervention, 
N=pacing,  
O=other arrhythmia,  
P=DVT,  
Q=pulmonary embolus, 
R=Other thromboembolic  
 complication  
S=low cardiac output requiring 
 management,  
T=wound dehiscence 
 
__ __ : __ __ 
 
__ __ : __ __ 
Re-op start time  Re-op end time  
(24 hour clock) (24 hour clock) 
 
__ __ / __ __ / __ __ __ __ 
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Appendix 5 Statistical analysis plan
For further information on the statistical analysis plan, please see Pike et al.34
List of abbreviations
Acronym Details
AE Adverse event
AKI Acute kidney injury
AKIN Acute kidney injury network
ARDS Acute respiratory distress syndrome
BMI Body mass index
CABG Coronary artery bypass graft
CCS Canadian cardiovascular society
CI Confidence interval
CICU Cardiac intensive care unit
CPAP Continuous positive airway pressure
CPB Cardiopulmonary bypass
CRF Case report form
CT Computed tomography
CVA Cerebrovascular accident
DOB Date of birth
eGFR Estimated glomerular filtration rate
FFP Fresh frozen plasma
GMR Geometric mean ratio
HDU High dependency unit
HR Hazard ratio
ICU Intensive care unit
IQR Inter quartile range
ITT Intention to treat
IV Intravenous
LIMA Left internal mammary artery
LV Left ventricular
MAR Missing at random
MD Mean difference
MI Myocardial infarction
MRI Magnetic resonance imaging
NYHA New York heart association 
OR Odds ratio
PH Proportional hazards
PIL Patient information leaflet
PT Preferred term
RBC Red blood cell
RCT Randomised controlled trial
RIMA Right internal mammary artery
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Acronym Details
RRT Renal replacement therapy
SAE Serious adverse event
SAP Statistical analysis plan
SD Standard deviation
SIRS Systemic inflammatory response syndrome
SOC System organ class
SVT Supraventricular tachycardia
TIA Transient ischaemic attack
TR Time ratio
VF Ventricular fibrillation
VT Ventricular tachycardia
WBC White blood cell
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1 INTRODUCTION TO SAP
1.1 Scope
This document details information regarding the statistical analysis of the TITRe2 trial and
covers all of the analysis of trial data outlined in the study protocol, with the exception of 
the health economic analyses.  
1.2 Editorial changes
Any changes made to this Statistical Analysis Plan (SAP) after approval must be clearly 
justified and documented as an amendment at the end of this document. The SAP should 
then be re-approved.
1.3 SAP document approval
The trial statistician should authorise this document.
2 STUDY BACKGROUND AND OBJECTIVES 
2.1 Study background
TITRe2 is a UK wide, multi-centre, open randomised controlled trial (RCT). 
Two thresholds for red blood cell (RBC) transfusion following cardiac surgery are 
compared: a “restrictive” threshold whereby transfusions are given if the haemoglobin (Hb) 
level is below 7.5g/dL (or haematocrit (Hct) < 22) and a “liberal” threshold whereby 
transfusions are given if the Hb < 9g/dL (or Hct < 27).
2.2 Study objectives
Objectives of the RCT are to: 
A. Estimate the difference in the risk of a post-operative infection or ischaemic event 
between restrictive and liberal transfusion thresholds.
B. Compare the effects of restrictive and liberal transfusion thresholds with respect to a 
range of secondary outcomes.
C. Estimate the cost-effectiveness of the restrictive compared to the liberal Hb transfusion 
threshold and describe this in terms of a cost-effectiveness acceptability curve.
This SAP covers objectives A and B.
2.3 Primary outcome
The primary outcome is a binary composite outcome of any serious infectious or ischaemic 
event in the first 3 months after randomisation.  The qualifying events listed below will be 
included, along with the manner in which they will be verified:
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Infectious events Definition / method of verification
Sepsis during index 
admission
Defined by the following two conditions, both of which must be satisfied for sepsis to be 
documented:
(a) Antibiotic treatment for suspected infection, and
(b) The presence of SIRS1 within 24 hours prior to start of antibiotic treatment
Wound infection ASEPSIS[1] score >20.  Wounds will be assessed at least once during a participant’s 
hospital stay and details of the ASEPSIS assessment added to the study CRF.  A 
questionnaire will be posted for self-completion, or will be administered by telephone, at 3 
months to identify wound infections arising after discharge.[2]
Ischaemic events Definition / method of verification
Permanent stroke Clinical report of brain imaging (computerised tomography (CT) or magnetic resonance 
imaging (MRI)), in association with new onset focal or generalised neurological deficit 
(defined as deficit in motor, sensory or co-ordination functions).
Myocardial infarction 
(MI)
Elevated post-operative peak serum Troponin I or T, verified by an adjudication committee. 
Further details are given on the following page. 
Acute kidney injury 
(AKI)
AKI Network criteria for AKI, stage 1, 2 or 3 (see below)[3]
Stage 1:
serum creatinine increase ≥0.3mg/dl (≥ 26.4μmol/l), OR 
>1.5 and ≤2-fold serum creatinine increase compared to the pre-operative serum creatinine 
(baseline) value, OR 
urine output <0.5ml/kg for 6 hours.
Stage 2:
>2 and ≤3-fold serum creatinine increase compared to the pre-operative serum creatinine 
(baseline) value, OR 
urine output <0.5ml/kg for >12 hours.
Stage 3: 
>3-fold serum creatinine increase compared to the pre-operative serum creatinine (baseline) 
value, OR 
serum creatinine ≥4.0 mg/dl (≥354 μmol/l) with an acute increase of at least 0.5 mg/dl (44 
μmol/l), OR 
urine output <0.3 ml/kg per hour for 24 hours or anuria for 12 hours, OR 
need for renal replacement therapy (RRT) irrespective of AKI stage at time of RRT.
The time of onset of AKI, used to determine whether the event occurred pre-randomisation, 
is the first time that the patient triggers for AKI regardless of whether this is due to urine 
output or serum creatinine. 
The AKI stage recorded is the highest stage reached by the patient post-operatively but pre-
1 SIRS - systemic inflammatory response syndrome.  SIRS is central to the diagnosis of infective complications.  It 
will be defined as ≥2 of the following conditions: temperature >38oC or <36oC; heart rate >90 beats/minute; 
respiratory rate >20 breaths/min or PaCO2 <32 mm Hg or PaCO2 <4.3 kPa; WBC count >12,000/mm3 or <4,000/mm3.
Blood test results and temperature will be classified using standard reference ranges.
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discharge. 
Gut infarction Laparotomy or post mortem
Events occurring post-discharge only contribute to the primary outcome if the potentially 
qualifying event resulted in admission to hospital or death.  The exception to this is post-
discharge wound infections, which are ascertained using the ASEPSIS post-discharge 
surveillance assessment. Other suspected infectious events treated in the community that 
did not cause readmission to hospital will not be recorded because they cannot be validated 
and are less serious than peri-operative infections. 
Events suspected to qualify for the primary outcome but not supported by objective 
evidence will be referred to an independent adjudication committee whose members will be 
blinded to the random allocation. In practice this will amount to MIs only, as for all other 
elements documentary objective evidence has been collated and verified by research nurses 
blinded to the random allocation at the co-ordinating centre. Therefore the adjudication 
committee will be required to reach a final decision about whether patients with a suspected 
MI have actually had an MI, based on patient history, Troponin levels and preoperative and 
postoperative ECGs. The adjudication committee will consist of three clinical specialists, 
and agreement between two of the three specialists will be required to reach a final 
decision. 
2.4 Secondary outcomes
Secondary outcomes are listed in the study protocol as:
- Units of RBCs and other blood components transfused during a participant’s hospital 
stay
- Proportion of patients experiencing an infectious event
- Proportion of patients experiencing an ischaemic event
- EQ5D [4]
- Duration of intensive care unit (ICU) / high dependency unit (HDU) post-operative 
stay
- Duration of post-operative hospital stay
- All-cause mortality
- Significant pulmonary morbidity, comprising (i) initiation of non-invasive ventilation 
(e.g. continuous positive airway pressure (CPAP) ventilation), (ii) re-
intubation/ventilation, or (iii) tracheostomy
- Cumulative resource use, cost, and cost-effectiveness
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The latter outcome listed above is not covered by this SAP.
2.5 Changes to the study objectives during the course of the study
Some minor changes have been made to the study over the course of the trial:
- A protocol amendment was made to include Troponin T in addition to Troponin I in 
defining MI, and remove the defined threshold for MI in the study protocol. The highest 
troponin level for all patients with a suspected MI is collected and a definitive definition 
of MI will be decided upon after blinded review by the adjudication committee (see 
section 2.3).
- One of the secondary outcomes (significant pulmonary morbidity) was added part way 
through the trial.
- In the study protocol one of the intended subgroup analyses is pre-operative renal 
impairment, defined by pre-operative creatinine ≤177 µmol/l vs creatinine >177 µmol/l. 
However during the course of the trial use of pre-operative creatinine for risk 
stratification has been totally superseded by estimated Glomerular Filtration Rate 
(eGFR). Therefore the subgroup analysis on renal impairment has been amended to 
eGFR ≤60ml/min vs eGFR >60ml/min (note this has not been covered by a protocol 
amendment). 
- The timings of all primary and secondary outcomes have been clarified as occurring 
post-randomisation, rather than post-operative. 
All required data for the changes/additions were already being collected.
3 STUDY POPULATION
The study population is all adult patients (aged 16 or over) undergoing non-emergency 
elective cardiac surgery (this includes non-emergency cases admitted from home or non-
emergency inpatient cases). Eligibility criteria are as inclusive as possible to promote the 
applicability of the evidence obtained during the trial. 
The planned sample size is 2000 randomised patients. A graph showing recruitment trends 
over time will be given as well as centre-specific screening data. 
3.1 Flow of participants
Participant flow will be described via a flowchart.
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3.1.1 Whilst in hospital
Participants consent to the study pre-surgery if they meet all of the pre-consent eligibility 
criteria and give written consent. They are then randomised if at any point post-surgery 
they meet the post-consent eligibility criteria (Hb falls below 9g/dL or Hct below 27%). 
This means that a significant proportion of patients (~45%) consent to the study but are not 
randomised.
For randomised patients the duration of intervention in the trial is the duration of the 
patient’s care under the consultant cardiac surgeon or a maximum of 3 months after the 
date of randomisation, whichever is shorter. Almost always, the duration of care under the 
cardiac surgeon will be the period of hospitalisation after surgery. The majority of data 
collection is undertaken whilst the participant is an in-patient.
3.1.2 Follow-up
After patients have been discharged from hospital they are followed up at further time 
points:
- At approximately six weeks post-operatively they are sent an EQ5D questionnaire.
- At approximately three months post-operatively they are contacted by telephone or 
post to complete a questionnaire including the following elements: a) adverse events 
(AEs) occurring after discharge; b) questions to identify surgical wound infections 
occurring after discharge (ASEPSIS post-discharge surveillance questionnaire)[1]; c) 
health economics / resource use questionnaire; d) questions determining whether a 
participant is aware of his/her random allocation. At this point they are also asked to 
complete a further EQ5D questionnaire.
- Patients that consent but are not randomised are also sent an EQ5D questionnaire at 
approximately three months post-operatively. 
The duration of follow-up in the trial is until the three month follow-up assessment 
questionnaires have been completed or until 3 months after randomisation if a participant 
does not complete the questionnaires.
3.1.3 Follow-up windows
Although the follow-up times are planned at six weeks and three months post-operatively, 
occasionally data collection is delayed. When this occurs the following rules will be used to 
determine whether data should be included in analyses:
- EuroQol EQ5D: to determine suitable time frames within which data will be used, the 
distribution of time between questionnaire completion and operation date will be 
examined by group, blinded to allocation, separately for each time point. If the 
DOI: 10.3310/hta20600 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 60
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
229
distributions differ between the groups, pre-specified windows will be used: a) for pre-
operative questionnaires a window of within 3 months pre-operatively; b) for the 6 
week assessment a window of 4-10 weeks after the operation date; c) for the 3 month 
assessment a window of 10-20 weeks after the operation date. If the distributions are 
balanced across the two groups, any times that appear to be extreme outliers (identified 
by eye) will be excluded but all other data collected will be used. 
- Three month telephone/postal questionnaire: the questionnaire specifically asks about 
the three month post-operative period and staff completing the telephone 
questionnaires are trained to only record information regarding this period, therefore 
data from all questionnaires will be used. Where dates of events are recorded (this is 
the case for AEs and the majority of resource use questions), any events inadvertently 
recorded that occurred more than three months post randomisation will not be included 
in any analyses. If dates are missing the event will be assumed to have occurred within 
the three month follow up period. 
3.2 Comparisons of patients characteristics 
3.2.1 Comparisons of non-consented and consented patients
The only characteristics available for patients that do not consent to the study are age and 
sex. These characteristics will be described for the following groups of patients:
- Non-consented (including PIL not sent, not approached, ineligible, did not consent and 
other reason for exclusion from study)
- Consented
This will only be done for sites known to have complete screening data; we anticipate these 
sites to be Bristol, Southampton and Leicester. Completeness of screening data is 
ascertained from knowledge about site-specific screening processes, and reflects whether 
the site screens the majority of patients admitted for cardiac surgery or predominantly those 
who are considered for inclusion in the trial. Screening log data for Bristol will be 
supplemented with data from institutional cardiac surgery databases, to identify any 
patients not recorded on the screening log but who could potentially have been considered 
for TITRe2. No formal statistical comparisons will be made.
3.2.2 Comparisons of non-randomised (but consented) and randomised patients
Characteristics that will be described include: all pre-operative characteristics, operation 
type, post-operative Hb/Hct values, blood products transfused, status (alive/dead) at end of 
surgery and hospital discharge, and EQ5D scores pre-operatively and at 3 months post-
operative. These characteristics will be described for the following groups of patients:
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- Consented patients considered for randomisation but not randomised (i.e. all consented 
patients including those randomised in error and excluding: patient/clinician 
withdrawals pre-surgery, patients who died pre-surgery or surgery was not performed, 
other reasons not considered for randomisation).
- Randomised patients included in the analysis population (i.e. all randomised patients, 
excluding: those randomised in error, or patients who withdrew and were unhappy for
data collected to be used).
In both groups of patients, the excluded patients do not have the relevant data collected and 
so cannot be included in the comparisons. 
No formal statistical comparisons will be made. Note that comparisons of resource use will
be carried out by the health economists and so is not covered in the scope of this SAP. 
3.3 Randomisation
Participants are randomised (1:1 allocation) to either the liberal or restrictive group using 
an internet-based system (Sealed Envelope Ltd). Cohort minimisation is used to minimise 
imbalance of: a) centre and b) operation type (classified as CABG, Valve, CABG+ Valve 
and Other).  
3.4 Withdrawals
There are two types of study withdrawal, which are documented on a specific case report 
form (CRF):
- Patient withdrawal: patients can withdraw from the study at any time (including post-
consent but prior to randomisation). Reasons for withdrawal are collected along with:
a) whether data already collected can be used
b) whether the patient is happy to participate in follow-up
- Clinician decision to discontinue treatment according to protocol: clinicians can decide 
to discontinue the patient’s treatment at any time (this can include post-consent but 
prior to randomisation, which may happen if a patient’s condition changes and the 
clinician feels decisions about the patient’s care should not depend upon the study 
protocol) . This does not constitute a withdrawal and data collection continues as 
planned (unless the patient also withdraws their consent) but transfusions are no longer 
required to be given according to the study protocol. 
Withdrawals and treatment discontinuations are summarised by treatment allocation, if 
applicable.
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Unless patients were unhappy for data collected to be used, data on all withdrawals or 
treatment discontinuations will be included in the study analyses on an intention to treat 
basis (ITT), see section 3.6.
3.5 Protocol deviations
3.5.1 Non-compliance with randomisation protocol
The following types of protocol deviation will be considered:
- Patient did not meet one or more of the pre-consent study eligibility criteria but was 
consented into the study.
- Patient did not meet the post-consent eligibility criteria (i.e. Hb did not drop below 
9g/dL or Hct below 27%) but was randomised.
- Patient was randomised more than 24 hours after meeting the post-consent inclusion 
criteria (i.e. randomised more than 24 hours after Hb dropping below 9g/dL or Hct 
below 27%).
- Patient consented and met the post-consent inclusion criteria (i.e. Hb dropped below 
9g/dL or Hct dropped below 27%) but was not randomised.
The frequency of each type of protocol deviation will be described.
3.5.2 Non-compliance with transfusion protocol
The following types of protocol deviation will be described:
- Patient received a RBC transfusion outside of protocol.
- Patient was not given a RBC transfusion that, according to the protocol, should have 
been given.
Such compliance will be assessed for the period from randomisation to hospital discharge. 
If patients withdraw or have their treatment discontinued, compliance after the time of 
withdrawal/discontinuation will not be assessed. For both of the above types of non-
compliance, instances will be classified into mild, moderate or severe dependent on the 
likely influence on transfusion rates, and therefore possible influence on study outcomes:
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Transfusion outside of protocol Transfusion according to protocol withheld
Mild N/A A transfusion took place, but more than 24 
hours after the relevant breach of the transfusion 
threshold
Moderate Patient transfused outside of protocol, but patient 
did breach the threshold for transfusion at some 
point post-operatively
Patient was not transfused following a breach, 
but the patient had previously had at least one 
post-randomisation transfusion
Severe Patient transfused outside of protocol, and patient 
did not breach the threshold for transfusion at any 
point post-operatively
Patient was not transfused following a breach, 
and patient had no post-randomisation 
transfusions
Note it may be possible for patients to be classified as a protocol deviation for more than 
one reason. 
The frequency of each type of deviation will be tabulated by treatment allocation. 
Additional analyses will be carried out looking at non-compliance with the transfusion 
protocol in further detail:
- The following characteristics of different non-compliance will be described by 
treatment group:
Reasons for deviations 
Number of deviations per patient
Hb/Hct levels at deviation
Day of week
Time of day (weekday, evening or weekend)
Time of year (split as Feb-Apr, May-Jul, Aug-Oct and Nov-Jan, to reflect the time 
of year when changes to junior medical staff are made) 
For withheld transfusions only:
Number of previous breaches of transfusion threshold for withheld transfusions 
Time from first breach of transfusion threshold to transfusion 
- Descriptive analyses will be carried out to investigate any differences in patient 
baseline and operative characteristics between those with and without non-compliance. 
This will be done separately for any non-compliance and any severe non-compliance, 
with patient characteristics compared within randomised group.
- The rates of non-compliance with the transfusion protocol across the sites will be 
described graphically. These will compare the proportions of patients with a) any non-
compliance and b) any severe non-compliance with the transfusion protocol. 
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- Finally, at the beginning of the trial sites were asked to give feedback on standard 
transfusion protocols to gauge how the trial protocol differed from standard 
procedures. At the end of the study this exercise will be repeated, with sites being 
asked additional information on how and when protocols have changed. This 
information will be summarised as part of the trial reporting.  
3.6 Analysis population
The analysis will consist of all randomised patients, excluding:
- Patients marked as “randomised in error”: this is a small number of patients (<10) for 
whom it is realised shortly after randomisation and prior to any intervention that are not 
eligible
- Patients withdrawn who were unhappy for data collected to be used.
All study analyses will be performed on a modified ITT basis. 
3.7 Safety population
Safety data will be analysed on an ITT basis, and will therefore be the same as the analysis 
population. Note that often safety data are analysed as the treatment received rather than on 
an ITT basis, however in this study that will not be feasible as protocol deviations do not 
constitute a “cross-over” between groups. In addition, as the primary outcome is a measure 
of risk and is analysed on an ITT basis, it will be consistent to also analyse safety data on 
an ITT basis.
4 DERIVATIONS
4.1 Primary outcome
The primary outcome is defined as follows:
Component 
event
Within index admission After hospital discharge
Sepsis
1 YES, if on CRF C5 there is at least one antibiotic course 
with:
- Date/time antibiotic course started≥date/time of 
randomisation, AND
- SIRS total2≥2
NO, if:
- Patient was not given any antibiotics in their post-
operative stay (excluding prophylaxis), OR
- For all courses of antibiotics, either:
o Date/time course started<date/time of 
YES, if a readmission form (X1) has 
been completed with:
- Infective complication=Yes, AND
- Date of admission is within 3 months 
of operation
NO, if the above conditions are not met 
and patient completed 3 month follow-
up/died
MISSING, otherwise
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randomisation, OR
o SIRS total=0 and SIRS missing2≤1
o SIRS total=1 and SIRS missing=0 
MISSING, otherwise
Wound 
infection
3
YES, If at least one wound with in-hospital asepsis score 
>20
NO, if all scored wounds have in-hospital asepsis score ≤
20, and no wounds have missing in-hospital asepsis scores
MISSING, otherwise
YES, if at least one wound with post-
discharge asepsis score >20
NO, if all scored wounds have post-
discharge asepsis score ≤ 20, and no 
wounds have missing post-discharge 
asepsis scores
MISSING, otherwise
Permanent 
stroke
1
YES, if on CRF C6:
- Stroke=Yes, AND
- Date/time of stroke≥date/time of randomisation, AND 
- Verified by CT=Yes or verified by MRI=Yes, or 
verification criteria missing
NO, if:
- Stroke=No, OR 
- Stroke=Yes and date/time of stroke<date/time of 
randomisation, OR
- Stroke=Yes and verified by CT=No and verified by 
MRI=No
MISSING, otherwise
YES, if a readmission form (X1) has 
been completed with:
- Stroke=Yes, AND
- Date of admission is within 3 months 
of operation, AND
- Verified by CT=Yes or verified by
MRI=Yes, or verification criteria 
missing
NO, if the above conditions are not met 
and patient completed 3 month follow-
up/died
MISSING, otherwise
MI YES, if on CRF C6:
- Suspected MI=Yes, AND
- Date/time of MI≥date/time of randomisation, AND 
- At least 2 out of 3 adjudication committee members 
agree that an MI has occurred
NO, if:
- Suspected MI=No, OR 
- Suspected MI=Yes and date/time of MI<date/time of 
randomisation, OR
- Suspected MI=Yes and at least 2 out of 3 adjudication 
committee members agree that an MI has not occurred
MISSING, otherwise
YES, if a readmission form (X1) has 
been completed with:
- Suspected MI=Yes, AND
- Date of admission is within 3 months 
of operation, AND
- At least 2/3 adjudication committee 
members agree that an MI has 
occurred 
NO, if the above conditions are not met 
and patient completed 3 month follow-
up/died
MISSING, otherwise
AKI
1 YES, if on CRF C6:
- AKI=Yes, AND
- Date/time of AKI≥date/time of randomisation, AND
- Acute Kidney Injury Network (AKIN) criteria stage 1, 
2 or 3=Yes or missing
YES, if a readmission form (X1) has 
been completed with:
- AKI=Yes, AND
- Date of admission is within 3 months 
of operation, AND
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NO, if:
- AKI=No, OR
- AKI=Yes and date/time of AKI<date/time of 
randomisation, OR
- AKI=Yes and AKIN criteria stage 1, 2 or 3=No
MISSING, otherwise
- AKIN criteria stage 1, 2 or 3=Yes or 
missing 
NO, if the above conditions are not met 
and patient completed 3 month follow-
up/died
MISSING, otherwise
Gut 
infarction1
YES, if on CRF C6:
- Gut infarction=Yes, AND
- Date/time of gut infarction≥date/time of 
randomisation, AND 
- Verified by laparotomy=Yes or verified by post 
mortem=Yes, or verification criteria missing
NO, if:
- Gut infarction=No, OR 
- Gut infarction =Yes and date/time of gut infarction 
<date/time of randomisation, OR
- Gut infarction =Yes and verified by laparotomy=No 
and verified by post mortem=No
MISSING, otherwise
YES, if a readmission form (X1) has 
been completed with:
- Gut infarction=Yes, AND
- Date of admission is within 3 months 
of operation, AND
- Verified by laparotomy=Yes or 
verified by post mortem=Yes, or 
verification criteria missing
NO, if the above conditions are not met 
and patient completed 3 month follow-
up/died
MISSING, otherwise
Notes:
1 For sepsis, stroke, AKI and gut infarction the event will default to NO if the documentary evidence does not 
support that the event occurred.
2SIRS elements are defined as:
- Temperature: YES if >38oC or <36oC, NO if 36-38 oC, MISSING otherwise
- Heart rate: YES if >90 beats/minute, NO if ≤90 beats/minute, MISSING otherwise
- Respiration: YES if respiratory rate >20 breaths/min OR PaCO2 <32 mm Hg or <4.3 kPa, NO if 
respiratory rate ≤20 breaths/min, MISSING otherwise
- White blood cell (WBC): YES if >12,000/mm3 or <4,000/mm3, NO if 4,000-12,000/mm3, MISSING 
otherwise
SIRS total = total of (temperature, heart rate, respiration, WBC), with YES=1, NO=0
SIRS missing = number of missing elements of (temperature, heart rate, respiration, WBC)
3 For details of how to derive in-hospital and post-discharge asepsis scores see Supplementary Material.
Separately for pre- and post-discharge, the composite primary outcome is defined as:
- If any of the component events occurred, the composite primary outcome is classified 
as occurring.  
- If all of the component events did not occur (with no missing components), the 
composite primary outcome is classified as not occurring.
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- Otherwise (i.e. there is missing data for at least one of the component events, and all 
non-missing component events did not occur), the composite primary outcome is 
classified as missing.
Overall (at any time), the composite primary outcome is defined as:
- If the composite outcome occurred pre-hospital discharge and/or post-discharge, the 
overall composite outcome is classified as occurring.
- If the composite outcome did not occur either pre- or post-discharge, the overall 
composite outcome is classified as not occurring.
- Otherwise (i.e. the outcome is missing either pre- and/or post-discharge, and, if 
applicable, did not occur at the other time point), the composite outcome is classified as 
missing.
The time to primary outcome occurring is defined as follows:
Situation Time to primary outcome defined as
One or more of the components 
occur within the index admission
Time (in hours) from randomisation to the onset of the first event (note: the 
timing of asepsis is assumed to be either: a) the date of sepsis if sepsis is also 
reported, or b) the halfway point of the participant’s post-randomisation stay 
(i.e. halfway between the randomisation date and the date of discharge from
the cardiac surgery unit)
No components occur in the index 
admission, but one or more occur 
after discharge
Time (in days) from randomisation to the hospital admission where the event 
was reported (note: the timing of asepsis will be defined as either a) the date of 
sepsis if sepsis is also reported, or b) the halfway point between discharge date 
and 6 weeks post-operatively)
No components occur, patient 
completed 3 month follow-up
Censored as the time (in days) between randomisation and follow-up
No components occur, patient did 
not complete 3 month follow-up
Censored as the time (in days) between randomisation and hospital discharge 
(or death if the patient died prior to 3 month follow-up)
4.2 Secondary outcomes
The following secondary outcomes require derivations to be made:
Secondary outcome Rules
Infectious events YES, if sepsis=Yes, OR wound infection=Yes
NO, if sepsis=No AND wound infection=No
MISSING, otherwise
Ischaemic events YES, if stroke=Yes, OR MI=Yes, OR AKI=Yes, OR gut infarction=Yes
NO, if stroke=No, AND MI=No, AND AKI=No, AND gut infarction=No
MISSING, otherwise
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Secondary outcome Rules
RBC units transfused 
intra-operatively
Total number of units listed on CRF B2 with reason for transfusion=A
2
(intra-operative)
RBC units transfused 
during pre-randomisation 
re-operation
Total number of units listed on CRF B2 with reason for transfusion=B (re-operation) and 
date/time < date/time of randomisation 
RBC units transfused 
during post-randomisation 
re-operation
Total number of units listed on CRF B2 with reason for transfusion=B (re-operation) and 
date/time ≥ date/time of randomisation
RBC units transfused after 
treatment according to 
protocol discontinued
Total number of units listed on CRF B2 with reason for transfusion=C (treatment 
according to protocol discontinued)
RBC units transfused post-
operative but pre-
randomisation
Total number of units listed on CRF B2 with reason for transfusion=D (pre-
randomisation)
RBC units transfused in 
breach of protocol
Total number of units listed on CRF B2 with reason for transfusion=E (in breach of 
protocol)
RBC units transfused per 
protocol
Total number of units listed on CRF B2 with reason for transfusion=F (per protocol)
Total RBC units transfused Total number of RBC units listed on CRF B2
Total duration of post 
randomisation ICU/HDU 
stay (hours)
Calculated as the sum of the following components:
- Duration of initial cardiac intensive care unit (CICU)/HDU stay = Earliest of (ward 
admission date/time, general ICU date/time, discharge date) – Latest of 
(Randomisation date/time, CICU/HDU admission date/time)  * 24
- Duration of initial general ICU stay (if applicable) = (Date/time of next admission  
following general ICU admission) – Latest of (Randomisation date/time, Date/time 
of general ICU admission) * 24
- Duration of any readmissions to CICU/HDU/general ICU: (Date/time of next 
admission following relevant readmission) – Latest of (Randomisation date/time, 
Date/time of CICU/HDU/general ICU readmission) * 24
ICU/HDU censor variable YES if patient died during ICU/HDU stay
NO otherwise
Duration of post 
randomisation hospital 
stay
(Date of discharge from cardiac surgery unit or date of death) – (Randomisation date)
Postoperative hospital stay 
censor variable
YES if patient died during hospital stay
NO otherwise
2
Note: for early versions of the study CRFs, reasons for transfusions were not recorded and therefore will be derived 
from dates/times of transfusions, operation, re-operation, treatment discontinuation, randomisation and Hb/Hct levels 
at transfusions.
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Secondary outcome Rules
All-cause mortality YES, if either:
- Patient recorded as dead at discharge from hospital on CRF B1 and/or D1
- A SAE form (CRF F1) has been completed with either: reason for reporting 
SAE=patient died, OR outcome of SAE=death AND date of death is within 3 months 
of operation date
- NHS mortality tracing shows the patient died with a date of death within 3 months of 
operation date
NO, otherwise
Time to death (days) (Date of death – Randomisation date)
Significant pulmonary 
morbidity
YES, if:
EITHER, on CRF C7 any of the following are true: 
- Initiation of mask CPAP=Yes AND date/time ≥date/time of randomisation, OR
- Re-intubation/ventilation=Yes AND date/time ≥date/time of randomisation, OR
- Tracheostomy=Yes AND date/time is after date/time of randomisation
OR, a readmission form (X1) has been completed with date of admission within 3 
months of operation and any of the following are true:
- Initiation of mask CPAP=Yes, OR
- Re-intubation/ventilation=Yes, OR
- Tracheostomy=Yes
NO, if:
On CRF C7:
- Initiation of mask CPAP=No OR (Initiation of mask CPAP=Yes AND date/time 
<date/time of randomisation), AND
- Reintubation/ventilation=No OR (Reintubation/ventilation=Yes AND date/time 
<date/time of randomisation), AND
- Tracheostomy=No OR (Tracheostomy =Yes AND date/time <date/time of 
randomisation)
AND, patient completed 3 month follow-up/died and there is not a readmission form 
completed for initiation of mask CPAP, reintubation/ventilation or tracheostomy
MISSING, otherwise
EQ5D single summary 
index score
Five digit ‘state’ score is derived as: 10000*mobility score + 1000*self-care score + 
100*usual activities score + 10*pain/discomfort score + anxiety/depression score.
Each state score is then assigned a single summary index score according to reference 
scales.  These index scores are numerical and range from -0.59 to 1.00, with a score of 
1.00 denoting perfect health.
4.3 Protocol compliance
New variable Rules
Did not meet pre-consent YES, if consent=Yes but one or more of the eligibility criteria are not met
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New variable Rules
eligibility criteria but was 
consented 
NO, otherwise
Did not meet post-consent 
eligibility criteria but was 
randomised
YES, if randomisation date non-missing but Hb ≥9g/dL (Hct ≥27%) on all days post-
operatively
NO, otherwise
Randomised >24 hrs after 
meeting post-con sent 
eligibility criteria
YES, if either:
- First day that Hb <9g/dL (or Hct <27%) is 2 or more days before date of 
randomisation, OR
- (Randomisation date/time – Date/time threshold first breached) >1 day
NO, otherwise
Consented and met post-
consent eligibility criteria 
but not randomised
YES, if randomisation date missing but there is at least one day postoperatively when 
Hb <9g/dL (or Hct <27%), and patient is not withdrawn/treatment discontinued at time 
Hb <9g/dL
NO, otherwise
Any transfusion outside of 
protocol
Transfusions listed on CRF B2 prior to treatment discontinuation/patient withdrawal 
where one of the following is true:
- Reason for transfusion=E (outside of protocol)
- Reason for transfusion=F (per protocol) or missing and:
o CRF E1 (reason for giving transfusion outside of protocol) has been completed, 
OR
o Recorded Hb/Hct is above the relevant (treatment group specific) threshold, OR
o Transfusion is within 2 hours of a previous transfusion that had the same 
Hb/Hct (or missing). These are two units of blood given together without 
rechecking Hb/Hct
Moderate transfusion outside 
of protocol
Transfusion outside of protocol (i.e. identified from above) whereby patient breached 
relevant threshold for transfusion at some point post-randomisation
Severe transfusion outside of 
protocol
Transfusion outside of protocol (i.e. identified from above) whereby patient did not
breach the relevant threshold for transfusion at any point post-randomisation
Mild withheld transfusion Any instances that are more than 24 hours before the next per protocol transfusion 
whereby:
- A CRF E2 (withheld transfusion) was completed 
- According to CRF B1 the patient breached the relevant threshold on a day that was 
prior to the breach date for the next per-protocol transfusion, and no CRF E2 was 
completed or other type of transfusion given on that day
- According to CRF B2 the “number of breaches prior to trigger breach” is greater 
than 0, and these breaches have not been accounted for in the previous two steps
- According to CRF B2 the “number of breaches prior to trigger breach” is 0, no 
CRF E2s have been completed and the answer to the question “Was RBC
prescribed within 24h of breach” is No  
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New variable Rules
Moderate withheld 
transfusion
Any instances between the last per protocol transfusion received and discharge 
whereby the patient breached the relevant threshold for transfusion (identified either 
via a completed CRF E2 or via a breach on CRF B1). 
Severe withheld transfusion For patients who did not have any post-randomisation transfusions (including post 
withdrawal, in breach of protocol and per-protocol), any instances post-randomisation 
whereby the patient breached the relevant threshold for transfusion (identified either 
via a completed CRF E2 or via a breach on CRF B1). 
Any withheld transfusion YES, if mild withheld transfusion=Yes, OR moderate withheld transfusion=Yes, OR 
severe withheld transfusion=Yes
NO, otherwise
Any severe protocol 
deviation (transfusion 
protocol)
YES, if severe extra transfusion=Yes, OR severe withheld transfusion=Yes
NO, otherwise
Any protocol deviation 
(transfusion protocol)
YES, if any extra transfusion=Yes, OR any withheld transfusion=Yes
NO, otherwise
Threshold breaches that do 
not constitute a protocol 
deviation
Any instances where a CRF E2 has been completed that are within the 24 hour period 
prior to a per-protocol transfusion
4.4 Other variables
New variable Rules
Reason for exclusion from study Exclusion group defined as:
- PIL not sent: PIL sent=No, Approach is not Yes, Consent is not Yes
- Not approached: PIL sent=Yes, Approach=No, Consent is not Yes
- Ineligible: Eligible=No, Consent is not Yes
- Eligible but did not consent: Eligible=Yes, Consent=No
Age at randomisation (Randomisation date – date of birth (DOB))/365.25
Body mass index (BMI) Weight (kg) / Height (cm)
2
* 10,000
EuroSCORE For all patients start with Euroscore of zero and add points according to the 
following rules:
- Age: <60=0, 60-64=1, 65-69=2, 70-74=3, 75-79=4, 80-84=5, 85-90=6, >90=7
- Sex: Male=0, Female=1
- Chronic pulmonary disease: add 1
- Extracardiac arteriopathy, neurological dysfunction, Creatinine >200 µmol/l, 
unstable angina, pulmonary hypertension, recent MI, surgery other than isolated 
CABG: add 2 for each
- Previous cardiac surgery, active endocarditis, critical preoperative state, surgery 
on thoracic aorta: add 3 for each
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New variable Rules
- Postinfarct septal rupture: add 4
- LV function: Good (>50%)=0, Mod (30-50%)=1, Poor (<30%)=3
Day of randomisation (days 
post-op)
(Randomisation date – Operation date) 
Time between surgery and 
randomisation (hours)
(Randomisation date/time - Operation date/time) * 24
Day of withdrawal post-op for 
pre-randomisation withdrawals
(Withdrawal date – Operation date)
Day of withdrawal post-
randomisation for post-
randomisation withdrawals
(Withdrawal date – Randomisation date)
Day of treatment discontinuation 
(days post-randomisation)
(Treatment discontinuation date – Randomisation date) 
Duration of operation (hours) (Operation end time – Operation start time) * 24
Complication (on C7) occurred 
pre-randomisation
YES if complication (C7) occurred and date/time of onset<date/time of 
randomisation
NO otherwise
Complication (on C7) occurred 
post-randomisation
YES if complication (C7) occurred and date/time of onset≥date/time of 
randomisation
NO otherwise
Ventilation time (hours) Calculated as the sum of the following components: 
- (Extubation date/time – Randomisation date/time) * 24
- (Re-extubation date/time) – Latest of (Randomisation date/time, re-intubation 
date/time) * 24 (if applicable)
Duration of ward stay (hours) Calculated as the sum of the following components:
- Duration of initial ward stay = Earliest of (Date/time of next admission 
following ward admission) – Latest of (Randomisation date/time, Ward 
admission date/time) * 24
- Duration of any readmissions to ward: (Date/time of next admission following 
ward readmission) – Latest of (Randomisation date/time, Date/time of ward 
readmission) * 24
Ward censor variable YES if patient died during ward stay
NO otherwise
Timing of unexpected SAE Pre-discharge if SAE start date ≤ discharge date
Post-discharge if SAE start date > discharge date 
Maximum intensity of 
unexpected SAE
Maximum of intensity variable on initial SAE form and all follow-up SAE forms
Final outcome of unexpected 
SAE
Outcome (resolved without sequelae, resolved with sequelae, ongoing, died) 
according to last SAE form completed (may be initial report or follow-up)
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New variable Rules
Percentage decline in Hb (Pre-operative Hb (CRF A2) – minimum Hb post-operatively (B1)) / Pre-operative 
Hb * 100 
eGFR ([140–age] * Weight (A2) * [0.85 if female]) / (Pre-op creatinine (mg/dl) * 72) 
5 STATISTICAL ANALYSES
5.1 Descriptive data
Baseline (i.e. patient demography and past history) and intra-operative characteristics will 
be described by treatment group for patients in the analysis population. In addition post-
operative outcomes that are not study outcomes or AEs will be described by treatment 
group.
Continuous variables will be summarised using the mean and standard deviation (SD) (or 
median and inter quartile range (IQR) if the distribution is skewed), and categorical data 
will be summarised as a number and percentage. The summary statistic headings given are 
those we expect to use based on a-priori knowledge of the clinical measurements gained 
from previous studies. However, if distributional assumptions are not valid, changes will be 
made.  
Any imbalances in the characteristics of the patients will be described but statistical tests 
for imbalance will not be carried out. 
5.2 Primary and secondary outcome data 
All outcomes listed in the study protocol will be presented as follows:
5.2.1 Primary outcome
The primary outcome will be summarised as follows:
- The numbers and percentages of patients experiencing at least one element of the 
primary outcome at any time post-randomisation will be presented by treatment group. 
This outcome will be analysed as a binary outcome, see section 5.3.2.
- In addition, the numbers and percentages of patients experiencing: a) any infectious 
event, b) any ischaemic event and c) each of the individual primary outcome 
components will be given by treatment group.
- The frequency of each combination of component events will be described by deriving 
a 6-digit variable where each digit relates to one of the components, and takes the value 
“1” if the patient experienced the outcome, “0” if they did not and “.” if the component 
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is missing. The numbers of patients with each value of this variable will be described 
by treatment group. 
- The time from randomisation to the first occurrence of the primary outcome will also be 
analysed as a time to event outcome as a secondary analysis (see section 5.3.2). Patients 
that don’t experience the primary outcome will be censored at either:
Date of 3 month follow-up, for patients with 3 month follow-up completed
Date of death, for patients who die prior to 3 month follow-up.
Date of discharge from hospital, for patients who survive 3 months post-operatively 
but do not complete the follow-up questionnaire.
- Various sensitivity analyses will also be undertaken (see Section 5.5).
5.2.2 Secondary outcome: units of RBCs and other blood components transfused during a 
participant’s hospital stay
RBC transfusions
All RBCs transfused post-randomisation will be summarised by the median and IQR (or 
mean and SD if the data is not skewed, which is unlikely) number of units transfused in 
each treatment group. This outcome will be analysed as a continuous outcome (see section 
5.3.2).
In addition, a more detailed breakdown of the numbers of units transfused will be 
presented, and the above summary statistics will also be presented split into the four types 
of transfusion (re-operation transfusions, transfusions after treatment according to protocol 
has been discontinued, transfusions in breach of protocol, per protocol transfusions). 
However, no further comparisons between the groups will be made. The total RBC units 
transfused (both pre- and post-randomisation) will also be given, but no formal comparison 
made.
Fresh frozen plasma (FFP), platelets and cryoprecipitate transfusions
FFP, platelets and cryoprecipitate transfusions will be summarised by the median and IQR 
number of units transfused during a participant’s hospital stay for each group. All three 
outcomes will be analysed as continuous outcomes (see section 5.3.2). Note it is not 
possible to spilt such transfusions into pre- and post-randomisation due to how the data was 
collected. The numbers of units of RBC, FFP, platelets and cryoprecipate transfused will 
also be described graphically.
Use of Activated Factor VII and Beriplex
Activated Factor VII and Beriplex use will be summarised by the numbers and percentages 
of patients in each group for whom the blood product was used. Both outcomes will be 
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analysed as binary outcomes (see section 5.3.2). Note it is not possible to spilt such product 
use into pre- and post-randomisation due to how the data was collected.
Hb/Hct levels
The average nadir daily Hb and Hct levels in each group at each day post-randomisation 
will be described graphically by the mean and SD (or median and IQR if distributions are 
skewed) in each treatment group. Although no formal comparisons will be made, the 
Hb/Hct levels at day three post-randomisation (chosen because at this point the differing 
transfusions regimens will be likely to have had an effect on Hb/Hct levels, and most 
patients will still be in hospital and have readings available for comparison) in each group 
will be used as an overall summary measure.
5.2.3 Secondary outcome: proportion of patients experiencing an infectious/ischaemic event
The presentation of the proportion of patients experiencing infectious/ischaemic events is 
covered within the primary outcome table. Both outcomes will be analysed separately as 
binary outcomes (see section 5.3.2).
5.2.4 Secondary outcomes: other clinical outcomes 
For the presentation of other clinical outcomes (duration of post-operative ICU/HDU and 
hospital stay, all-cause mortality and significant pulmonary morbidity).
The duration of post-randomisation ICU/HDU and hospital stay, and the time to death (all-
cause mortality) will be summarised by the median and IQR in each treatment group. All 
outcomes will be analysed as time to event outcomes (see section 5.3.2), with censor 
variables as defined below:
Outcome Censor variable
Duration of post-randomisation ICU/HDU 
stay
Time of death in ICU/HDU
Duration of post-operative hospital stay Time of death in hospital
All-cause mortality Time of last follow-up (usually 3 months post-operation)
Significant pulmonary morbidity will be summarised as the numbers and percentages of 
patients in each treatment group experiencing the event. The outcome will be analysed as a 
binary outcome (see section 5.3.2).
5.2.5 Secondary outcome: EQ5D
The responses to each of the five EQ5D questions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) will be summarised as the numbers and 
percentages of patients in each treatment group choosing each response, at each time-point 
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(pre-operative, 6 weeks post-operative and 3 months post-operative). No formal statistical 
comparisons between the groups will be made.
The two continuous EQ5D outcomes (single summary index and visual analogue scale) 
will be summarised as means and SDs (or medians and IQRs if distributions are skewed) at 
each time point, in each treatment group. Both outcomes will be analysed as continuous 
longitudinal outcomes, see section 5.3.2.
Note that a summary figure will be produced summarising all the results from sections 
5.2.4 and 5.2.5.
5.3 Analysis models
5.3.1 Adjustment in models
The intention is to adjust all models for factors included in the cohort minimisation: 
operation type (coronary artery bypass graft (CABG) only, Valve only, CABG and valve, 
Other – with CABG only as the reference group) as a fixed effect and centre as a random 
effect (or a shared frailty term in time to event models). Occasionally operation type differs 
between the study database and the randomisation system as it has been entered incorrectly 
into the randomisation system. In this case the value from the study database will be used, 
as the operation type recorded on the database has been confirmed to be correct in such 
instances.
5.3.2 Models for different data types
General methods of assessing treatment effects are outlined below. For all treatment 
comparisons the liberal group will be the reference group. Details specific to each outcome 
are described as appropriate.
- Binary outcomes (primary outcome, proportions of infectious/ischaemic events, use of 
Activated Factor VII/Beriplex and significant pulmonary morbidity) will be compared 
between treatment groups using logistic regression. Formal statistical comparisons of 
treatment effects will only be performed if more than ten patients in total experience the 
outcome (with at least one event in each treatment group).  Treatment comparison 
estimates will be presented as adjusted odds ratios (OR) and 95% confidence intervals 
(95% CI).
- Continuous outcomes (units of RBCs, FFP, platelets and cryoprecipitate transfused) 
will be compared using linear regression. For untransformed data treatment 
comparisons will be presented as adjusted differences in means with 95% CI, and for 
logarithmically transformed data as adjusted ratios of geometric means with 95% CI. If 
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a logarithmic transformation is not satisfactory other analysis/presentation methods will 
be sought.
- Time to event outcomes (duration of ICU/HDU stay, duration of post-operative 
hospital stay and all-cause mortality) will be compared using Cox’s proportional 
hazards (PH) models, with treatment comparisons presented as hazard ratios (HR) and 
95% CI. Such models require an assumption of PH to be met. If such outcomes consist 
of more than one distinct time periods (e.g. the patient had two separate admission 
periods in ICU, or the patient was admitted to ICU after they were randomised) time 
periods may be “split” (e.g. by using the “stsplit” command in Stata) to account for this. 
Any patients with a time of zero will be included in analyses by assuming a time of half 
of the smallest non-zero time to event. 
- Continuous longitudinal outcomes (EQ5D single summary index and visual analogue 
scale scores) will be compared using linear mixed effects methodology with the 
treatment group and study design variables (see section 5.3.2) fitted as fixed effects, and 
patient terms as random effects. Separate parameter estimates will be incorporated into 
models for 1) the mean baseline response across both treatment groups and 2) at each 
post-intervention time point for each treatment (i.e. saturated model with time fitted as a 
categorical variable). This approach of “jointly” modelling the baseline and post-
intervention measurements avoids the necessity to either exclude cases with missing 
baseline measures or to impute missing baseline values. If the time x treatment 
interaction (post-intervention) is not statistically significant at the 10% level an overall 
treatment effect will be reported. If the interaction is statistically significant the changes 
in treatment effect with time will be described. Different variance/covariance structures 
will be explored, and the structure that provides the best fit in terms of information 
criteria such as AIC, BIC and likelihood ratio tests will be used. Treatment comparisons 
will be presented as adjusted differences in means with 95% CI. 
5.3.3 Statistical significance
For hypothesis tests two-tailed p-values<0.05 are considered statistically significant. 
Likelihood ratio tests will be used in preference to Wald tests for hypothesis testing. 
5.3.4 Model assumptions
For all methods outlined underlying assumptions will be checked using standard methods, 
e.g. residual plots, tests for PH, etc. If assumptions are not valid then alternative methods of 
analysis will be sought. If outlying observations are found which mean models do not fit 
the data adequately, such observations will be excluded from the main analyses and 
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comments made in footnotes. Sensitivity analyses may be performed to examine the effect 
on the study’s conclusions of excluding outlying observations. 
If there are any boundary problems for either of the EQ5D continuous scales (i.e. if there 
are an inflated number of patients scoring “perfect health”) then alternative analysis 
methods will be sought. Examples include: creating a binary endpoint from the continuous 
outcome and analysing using the methods outlined above. 
5.3.5 Multiple testing
No formal adjustment will be made for multiple testing. However, the following measures 
to try and avoid problems with over-interpretation will be taken: 1) formal statistical 
comparisons will not be made for outcomes with low event rates, and 2) only pre-specified 
subgroup analyses will be performed (see section 5.4), and a significance level of 5% will 
be used for the tests for interaction for subgroup analyses despite being low powered tests. 
Consideration will be taken in interpretation of results to reflect the number of statistical 
tests performed and the consistency, magnitude and direction of treatment estimates for 
different outcomes.
5.4 Subgroup analyses
There are seven pre-specified subgroup analyses stated in the study protocol:
- Operation type (isolated CABG vs other operation types)
- Age at operation (<75 years vs ≥75 years)
- Pre-operative diagnosis of diabetes (none vs diet, oral medication or insulin controlled)
- Pre-operative diagnosis of lung disease (none vs chronic pulmonary disease or asthma)
- Pre-operative renal impairment (eGFR ≤60ml/min vs eGFR >60ml/min)
- Sex (males vs females)
- Pre-operative ventricular function (good vs moderate or poor) 
Each subgroup analysis will be performed by adding a relevant interaction term to the 
primary outcome logistic regression model (e.g. for sex, a sex*treatment interaction term 
will be added to the model). The hypothesis for all subgroup analyses is that there will be 
no interaction. Results of the subgroup analyses will be presented in forest plots, (one for 
subgroup analyses with statistically significant tests for interaction, and one for those 
without significant interactions), with ORs and 95% CIs within each subgroup displayed 
alongside p-values from results of tests for interactions. P-values for treatment estimates 
within each subgroup will not be given. 
Note that for each of the subgroup analyses the first group listed in each set of brackets 
above will be the reference group (e.g. for age it will be the <75 years group). Also, for the 
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operation type subgroup analysis, operation type as a four-level variable will not be 
adjusted for as a fixed effect (see section 5.3.1). No further subgroup analyses will be 
performed.
5.5 Sensitivity analyses
The following sensitivity analyses have been identified, note these were not pre-specified in 
the study protocol:
- Examining treatment estimates for the primary outcome by site, ordering sites by rates 
of severe non-compliance with the transfusion protocol. This will be implemented by 
producing a forest plot of treatment estimates for each site, with the sites ordered by 
their rates of severe non-compliance with the transfusion protocol. The hypothesis is 
that the treatment effect should tend towards the null with increasing non-compliance. 
Any sites with no patients that experienced the primary outcome will be excluded from 
this analysis, although a footnote will be added indicating the severe non-compliance 
rates for such sites.
- Assessing the effect of the timing of randomisation and transfusions on the primary 
outcome. This will be implemented by two sensitivity analyses that re-analyse the 
primary outcome:
Excluding all events that occurred in the first 24 hours after randomisation. The 
justification for doing this is that such events occurring in the first 24 hours after 
randomisation are less likely to be attributable to the treatment regimen.
Excluding patients who were transfused prior to randomisation (either: intra-
operative, post-operative but pre-randomisation or during pre-randomisation re-
operations). The justification is that it may be these transfusions that lead to the 
primary outcome rather than any post-randomisation transfusions.
- Assessing the effect of AKI. In collecting AKI data, it was unfortunately overlooked that 
the creatinine rise required to trigger AKI should occur in a 48 hour period. However 
highest daily creatinine levels have been recorded separately, so the following 
sensitivity analyses have been planned that re-analyse the primary outcome:
Excluding patients identified with AKI who do not have an increase in creatinine 
over a 48 hour period or less, according to the daily highest creatinine levels 
collected (accepting that these patients may have triggered AKI anyway due to urine 
output or renal replacement therapy).
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Including patients that have not been identified as having AKI, but according to 
their daily highest creatinine levels have a rise in creatinine that would meet the 
criteria (and were not having haemofiltration or dialysis pre-operatively). 
- Serious primary outcome events. The interim analysis showed that the majority of the 
primary outcome events are either sepsis or AKI. Therefore the primary outcome will 
be re-analysed including only the more “serious” events. This will mean the following 
changes to the definitions of the primary outcome:
All MIs, gut infarctions and strokes will be included
Only AKI stage 3 events will be included 
All asepsis events will be excluded (the more serious wound infections will be 
identified via serious sepsis events)
For pre-discharge sepsis events: serious events will be identified via presence of 
sepsis plus organ failure (defined as: MI, stroke, AKI, laparotomy for gut infarction 
and one or more of reintubation, ARDS, low cardiac output and/or tracheostomy; 
for these latter events the event must meet the criteria of an SAE).
Post-discharge sepsis events will be included (as they require hospitalisation)
5.6 Pre-specified observational analyses
There are three pre-specified observational analyses in the study protocol:
1. Estimating the relationship between the number of RBC units transfused, and the risk 
of mortality and morbidity, stratified by trial arm. 
2. Investigating the relationship between percentage decline in Hb from the preoperative 
level and the risk of primary and secondary outcomes, taking into account the number 
of RBC units transfused.
3. Investigating whether RBC age is associated with the risk of primary and secondary 
outcomes.
Planned tables and figures for these analyses are not included in this SAP, as they are likely 
to vary dependent upon the final models used. However, in brief, tables of pre-operative 
and intra-operative characteristics will be presented by the (categorised) exposure of 
interest as well as tables reflecting the models fitted and variables adjusted for.
Some preliminary analysis techniques are outlined below; however the final techniques 
used are likely to change dependent upon the findings of a) exploratory analyses, and b) the 
analysis of the trial primary and secondary outcomes. This section of the SAP may 
therefore be reviewed and expanded once the main trial outcomes have been analysed.
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5.6.1 Analysis of number of RBC units transfused and percentage decline in Hb (analyses 1 
and 2)
Analyses 1 and 2 will be implemented by fitting logistic regression models, with an 
outcome of the primary outcome and/or all-cause mortality. Three separate models will be 
fitted to address the hypotheses posed by both analyses, with the following explanatory 
variables:
- Model 1: total number of RBC units transfused (either pre- or post-randomisation)
- Model 2: percentage decline in Hb 
- Model 3: total number of RBC units transfused and percentage decline in Hb
In all of these models the following variables will be adjusted for if found to be potential 
confounders: randomised allocation, operation type, centre (as a random effect), 
EuroSCORE, age and sex. 
Points of note:
- The total number of RBC units transfused will be fitted as either a continuous variable 
or an ordinal categorical variable, dependent upon model fit.
- The percentage decline in Hb will be defined as the percentage change from the pre-
operative value to the lowest Hb level reached post-operatively and prior to the primary 
outcome.
5.6.2 Age of blood analysis (analysis 3)
Analysis 3 will be achieved by linking the batch numbers of all RBCs transfused to a blood 
bank database. The age of each unit transfused will then be determined from the date of 
donation and date of transfusion. A logistic regression model will be fitted with an outcome 
of primary outcome and/or all-cause mortality as the outcome variable and the age of blood 
as the exposure.
For the primary analysis age of blood will be defined as the age of the ‘oldest’ unit of blood 
transfused at any time (i.e. including intra-operative, during re-operations, pre-
randomisation and post-randomisation). The following variables will be adjusted for if 
found to be potential confounders: number of RBC units transfused, blood group, 
EuroSCORE, age and sex.
Points of note:
- The sensitivity of fitting the model using the age of the ‘oldest’ unit of blood will be 
explored by refitting the model using other definitions of the exposure variable. This 
may include: the mean age of all RBC units, the use of any blood more than 14 days 
old, the number or percentage of RBC units given that are more than 14 days old, the 
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use of blood that is older than the median age of all RBC units transfused. There are 
known problems with all of these approaches, e.g.: the age of the ‘oldest’ unit of blood 
is likely to be confounded by the number of RBC units transfused, the use of any blood 
more than 14 days old is likely to be confounded by blood group and many of these 
methods will need to exclude patients not transfused any RBC units.
5.6.3 Points relevant to all analyses:
- Potential confounders are defined as: variables associated with both the exposure and 
the outcome that are not an intermediary step on the causal pathway between the 
exposure and outcome, that significantly contribute to the relevant multivariate model 
(defined as a likelihood ratio p-value <0.05 or by modifying the effect estimate by 
greater than 10%). 
- It may be sensible to restrict the analyses to only patients who did not receive a 
proportionately large number of RBC units (e.g. restrict to those who received five or 
less units).
- The instrumental variable method of controlling for confounding will be explored.
- In all of the analyses (with the exception of decline in Hb) there is a potential problem 
that some of the RBCs may be transfused after the outcome. Therefore fitting the 
models described above may not be appropriate due to the timing of the exposure 
relative to the outcome. If this proves to be the case then alternative approaches will be 
considered, including:
Nested matched case-control study: each patient with the primary outcome (i.e. 
case) will be matched to a control (by matching on at least centre and randomised
allocation, other factors may also be used). For both the case and the control any 
RBC units transfused after the time that the case first experienced the primary 
outcome will be excluded from analyses.
Time to event analyses with a time varying covariate of RBC units given: this would 
address the issue of exposure time (for cases the event would be the primary 
outcome event, and for controls the last follow-up), but would ignore any blood 
given after the occurrence of an outcome event.
5.7 Meta-analysis combining the results of TITRe2 with other studies
It is intended to perform a meta-analysis combining the primary outcome results from this 
study with any previous systematic reviews and studies.  This analysis will be performed 
using standard meta-analysis methods for binary outcomes, using a random effects model. 
Results will be presented in a forest plot. 
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Previous studies will be included in the meta-analysis if they fulfil the following criteria:
- The patient population was patients undergoing cardiac surgery.
- Restrictive and liberal RBC transfusion strategies are compared, although the actual 
Hb/Hct thresholds for transfusion can differ between studies.
- The outcomes included in the meta-analysis are post-operative morbidity or mortality –
if possible (i.e. there are sufficient numbers of studies) each component of the TITRe2 
primary outcome will be analysed separately.
Data from studies will be used individually if possible, i.e. aggregate data from previous 
systematic reviews/meta-analyses will only be used if individual study level data is not 
available. Also care will be taken to ensure that data from studies are included only once, 
i.e. data should not be included as part of a systematic review and then also from the study 
in its own right.
5.8 Post-hoc analyses
A secondary post-hoc analysis of severe in hospital events will be performed. This will 
involve refitting the primary outcome model with an outcome of: death, severe sepsis (as 
defined in section 5.5), ARDS, tracheostomy, low cardiac output, MI, AKI stage 3, gut 
infarction and/or stroke. 
5.9 Missing data
In all tables missing data will be indicated by footnotes. If the amount of missing data 
differs substantially between treatment groups potential reasons will be explored.
5.9.1 Missing predictor data
There will be no missing data for any of the randomisation factors (by design). All other 
potential predictors are preoperative measurements of continuous longitudinal outcomes, 
and due to the joint modelling approach described previously the handling of missing 
values for such data is considered in the context of missing longitudinal data (see below).
5.9.2 Missing continuous outcome data measured at one time point 
- If the proportion of missing data is less than 5% then complete case analysis will be 
performed (i.e. excluding cases with missing data). 
- If the proportion of missing data is between 5% and 15%, marginal mean imputation 
will be performed, i.e. imputing the overall median or mean for continuous data, or the 
most common category for binary or categorical data.
- If the proportion of missing data is between 15% and 25% conditional mean imputation 
methods will be used. This involves predicting the outcome from a regression model 
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from (linearly related) covariate(s). These covariates will include the design variables,
plus other potentially important covariates (e.g. age, gender, additive EuroSCORE).
- If the proportion of missing data is above 25% multiple imputation methods will be 
considered. A general imputation model that uses an iterative procedure to generate 
imputed values will be used to generate multiple complete data sets (e.g. using Stata’s 
mi impute). The model of interest will be the fitted to each of the complete data sets and 
effect estimates combined using Rubin’s rules. 
5.9.3 Missing longitudinal continuous outcome data
For continuous data measured at multiple time points preoperative values will be modelled 
jointly with those measured postoperatively, as described previously,  thereby allowing all 
cases with at least one observation to be included. If appropriate (the level of missingness is 
>20%) then any variables that are predictive of missingness will be identified, and if there 
is reason to suggest that an assumption of missing at random (MAR) given these variables 
is reasonable (especially likely if the variable was measured pre-operatively) then such 
variables will be adjusted for in the models of interest. These models can be shown to 
provide unbiased estimates of the treatment effect and moreover multiple imputation 
approaches would not be expected to recover any additional information.
5.9.4 Missing binary or categorical outcome data
No formal imputation techniques will be used for missing binary or categorical outcome 
data. The following approach will be followed for handling missing data will be used for 
the primary outcome: 
- The amounts of missing data in each treatment group will be described.
- The primary outcome element expected to have the highest amount of missing data is 
wound infection (asepsis scoring). If in-hospital asepsis scores are missing and the 
following are true the patient will be assumed to have no wound infection: 1) no 
antibiotics for suspected wound infection were prescribed in hospital, 2) follow-up is 
complete and the patient reported no problems with the healing of the wound at follow-
up.
- If after the above point has been implemented the level of missing data is greater than 
5%, this is likely to be mainly due to missing follow-up data. In this case separate 
treatment estimates will be made for: 1) primary outcome at hospital discharge, and 2) 
primary outcome at any time.
- Finally a sensitivity analysis will be carried out reanalysing the primary outcome twice: 
firstly assuming patients with missing data didn’t have the primary outcome and 
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secondly assuming patients with missing data had the primary outcome. Any impact on 
treatment difference estimates will be noted.
5.10 Safety data
AEs occurring in the study period for all patients in the safety population will be tabulated. 
No formal comparisons between treatment groups will be made.  
Tables will summarise expected AEs listed in the study protocol. Events occurring prior to 
hospital discharge will be summarised, with events that meet the serious criteria
3
indicated 
(serious adverse events, SAEs). Such events are captured via the study CRFs. After hospital 
discharge, only SAEs are collected and will be summarised. Finally the numbers of SAEs 
occurring at any time will be described (i.e. either pre or post hospital discharge).
Further tables will summarise unexpected SAEs, i.e. events that are not listed in the study 
protocol that meet the serious criteria. Such events are captured via separate SAE report 
forms and the event type will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA). System organ class (SOC) terms will be used to group events, with 
groupings further broken down into preferred terms (PTs) if necessary. 
A summary table of expected and unexpected events combined occurring at any time will 
also be produced.
5.11 Use of Hb/Hct
At most sites, Hct measurements are not used in treatment decisions. However at 
approximately a quarter of sites both Hb and Hct measurements are used; e.g. a patient in 
the liberal group would be transfused if their Hb fell below 9g/dL OR their Hct fell below 
27%.
In the presentation of the study results, Hb values are presented unless either: a) Hb is 
missing and Hct non-missing, b) the Hct is lower than the Hb. In either of these cases the 
Hct is converted to Hb (by dividing by three) and used in its place. 
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An event is classified as serious if it meets one or more of the following criteria: a) resulted in death, b) was life 
threatening, c) resulted in persistent or significant disability/incapacity, d) prolonged an ongoing hospitalisation or 
resulted in hospitalisation
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SUPPLEMENTARY MATERIAL: ASEPSIS SCORES
In-hospital asepsis scores
For each wound used in the operation (a minimum of one – chest – and a maximum of six – chest, 
left leg, right leg, left arm, right arm, other, per patient) a wound specific in-hospital asepsis score 
is derived using the following steps:
1. A daily score is derived for each of the days that the wound was scored (ideally scored on 
three separate occasions), from the following:
- If both filter questions (wound hot/wound wet) are “No” then the daily score is zero.
- Otherwise the daily score is derived from summing the points awarded as follows for the 
four proportions of wound affects answers given on the CRF:  
Proportion of wound affected: 0% <20% 20-39% 40-59% 60-79% >80%
Serous exudates 0 1 2 3 4 5
Erythema 0 1 2 3 4 5
Purulent exudates 0 2 4 6 8 10
Wound separation 0 2 4 6 8 10
Note: Any missing scores will be assumed to be 0, unless all four scores are missing and then the daily score 
will be set to be missing.
2. Data collection is ideally performed on days 3, 5 and 8 post-operatively. The following rules 
are used to determine if daily scores are valid:
- A two day window is allowed either side of the intended day, so for example the day 3 
score can be done between day 1 and day 5
4
.
- Any assessments done outside of these windows, after the date of discharge, or in an invalid 
order (e.g. day 5 done before day 3) are invalid and not used.
- A minimum of one daily score is required to proceed further. If this is not the case then the
in-hospital asepsis score for that wound is missing.
3. Scores for days 1 to 10 are calculated; scores for missing days are either propagated from the 
nearest score or interpolated between scores. Note that the actual day of assessment is used 
rather than the intended day. See the following examples:
4
Note the day 8 score is intended to be performed on day 8 or, if the patient discharged sooner, on the day of 
discharge.  Therefore if the patient is discharged prior to day 8 the allowed window will be within two days of 
discharge (for example if the patient is discharged on day 6 the window will be day 4 to day 6)
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EXAMPLE 1 EXAMPLE 2
Day (post-op) Score Rule Score Rule
1 3 Propagate 6 Propagate
2 3 Observed 6 Propagate
3 2.25 Interpolate 6 Observed
4 1.5 Interpolate 8 Interpolate
5 0.75 Interpolate 10 Observed
6 0 Observed 8 Interpolate
7 0 Propagate 6 Interpolate
8 0 Propagate 4 Interpolate
9 0 Propagate 2 Interpolate
10 0 Propagate 0 Observed
4. Any daily scores after day 7 are then discarded. The remaining scores are summed and then 
multiplied by 5/7 to give a single score representing five days’ worth of daily asepsis scores.
5. The final in-hospital asepsis score for the wound is then calculated from adding points to the 
score derived from point 4 if any of the following events occurred at any time in the post-
operative stay for that wound:
- Antibiotics given for wound infection: 10 points
- Isolation of bacteria: 10 points
- Drainage of pus under local anaesthetic: 5 points
- Drainage of pus under general anaesthetic: 10 points
- Length of hospital day >14 days: 5 points
Note: any missing elements will be assumed to be 0.
Post-discharge asepsis scores
Post-discharge asepsis scores are calculated by taking the in-hospital asepsis score for each wound 
and adding additional points if the patient has answered the questions on the 3-month follow-up
questionnaire for that wound as follows:
- Been given antibiotics for wound infection=Yes AND patient did not have antibiotics for 
wound infection in initial hospital admission: 10 points
- Doctor opened/drained an abscess=Yes AND patient did not have drainage of pus under 
local anaesthetic in initial hospital admission: 5 points
- Wound been opened and cleaned under general anaesthetic in hospital=Yes AND patient 
did not have drainage of pus under general anaesthetic in initial hospital admission: 10 
points
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- Wound discharged pus=Yes AND the purulent exudates question on the in-hospital 
questionnaire was no/missing at all time points: 5 points
- District nurse had to dress wound=Yes AND patient did not have drainage of pus under 
local anaesthetic in initial hospital admission: 5 points
Note: any missing elements will be assumed to be 0.
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